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List of abbreviations 
Ac acetyl 
All allyl 
aq. aqueous 
Ar aryl 
Arom aromatic 
BAIB (diacetoxyiodo)benzene 
Bn benzyl 
bs broad singlet 
Bu butyl 
Bz  benzoyl 
C  chair 
cat.  catalytic 
CBz  carboxybenzyl 
COSY  correlation spectroscopy 
CSA  camphor-10-sulfonic acid 
Cy  cyclohexyl 
δ  chemical shift (ppm) 
d  doublet 
DBU 1,8-diazabicyclo[5.4.0]undec-
7-ene 
DCE  1,2-dichloroethane 
DCM  dichloromethane 
dd  double doublet 
DFT  density function theory 
DIPEA  diisopropylethylamine 
DIPF N,N-diisopropylformamide 
DMA N,N-dimethylacetamide 
DMAP  4-dimethylaminopyridine 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DPSO diphenyl sulfoxide 
dq  double quartet 
dt  double triplet 
DTBMP  2,6-di-tert-butyl-4-
methylpyridine 
DTBS  di-tert-butylsilylidene 
eq.  molar equivalent 
Et  ethyl 
GATED  proton decoupling applied 
only during relaxation 
Gal  galactose 
Glc  glucose 
GlcA  glucuronic acid 
GlcN  glucosamine 
GlcN3  2-azido-2-deoxy glucose 
GlcNAc  N-acetyl glucosamine 
h  hour(s) 
HFIP  hexafluoro-iso-propanol 
HMBC  heteronuclear multiple-bond 
correlation spectroscopy 
HPLC  high performance liquid 
chromatography 
HRMS  high-resolution mass 
spectroscopy 
HSQC  heteronuclear single quantum 
coherence 
IR  infrared 
J  coupling constant 
KIE  kinetic isotope effect 
LC-MS  liquid chromatography-mass 
spectrometry 
LG  leaving group 
M  molar 
m  multiplet 
m/z  mass over charge ratio 
min  minutes 
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Man  mannose 
ManA  mannuronic acid 
Me  methyl 
MPF N-methyl-N-phenylformamide 
M.S.  molecular sieves 
Nap  2-methylnaphthyl 
NBS  N-bromosuccinimide 
NFM  N-formylmorpholine 
NFP N-formylpiperidine 
NIS  N-iodosuccinimide 
NMR  nuclear magnetic resonance 
NOESY  nuclear Overhauser effect 
spectroscopy Nu nucleophile 
p  para 
PG  protection group 
Ph  phenyl 
Phth  phthaloyl 
PMB 4-methoxybenzyl 
ppm  parts per million 
q  quartet 
rt  room temperature 
Rf  retention factor 
RRV  relative reactivity value 
s  singlet 
sat.  saturated 
SN1  uni-molecular nucleophilic 
substitution 
SN2 bi-molecular nucleophilic 
substitution 
SSIP  solvent-separated ion pair 
t  triplet 
TBAF  tetrabutylammonium fluoride 
TBAB tetrabutylammonium bromide 
TBAI  tetrabutylammonium iodide 
TBS  tert-butyldimethylsilyl 
TBDPS  tert-butyldiphenylsilyl 
TCA  trichloroacetyl 
TES  triethylsilyl 
TEMPO  2,2,6,6-tetramethylpiperidine 
TFA  trifluoroacetic acid 
THF tetrahydrofuran 
TLC  thin layer chromatography 
TMS  trimethylsilyl 
TMSI trimethylsilyl iodide 
TMU tetramethylurea 
Tol  tolyl; 4-methylphenyl 
td  triple doublet 
tt  triple triplet 
TTBP  2,4,6-tri-tert-butylpyrimidine 
UV  ultraviolet 
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Chapter 1 
Modulating Glycosylation with Additives 
and Its Application in Synthesis of 
Oligosaccharides 
1. Introduction 
Carbohydrates, polysaccharides and glycoconjugates are widely found in nature, and they play 
crucial roles in diverse biological processes such as cellular adhesion, migration, development, 
disease progression, pathogen detection, and immune response.[1] To better understand the 
mechanism of action of these biomolecules, well-defined oligosaccharides and glycoconjugate 
libraries need to be investigated.[2] However, extracting well defined oligosaccharides from 
natural sources can be extremely difficult, if not impossible, because of the heterogeneity of many 
naturally occurring oligosaccharides/glycoconjugates. Therefore, chemical synthesis has become 
an important method to provide these compounds. 
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The key step in oligosaccharide synthesis is the stereoselective formation of the glycosyl bond 
through the union of a donor and acceptor building blocks.[3] Even after 140 years from the first 
chemical glycosylation reaction, reported by Arthur Michael and Emil Fischer,[4] this step still 
presents a great challenge. In a glycosylation reaction, a new stereocenter is formed and while 
1,2-trans glycosides can generally be reliably formed using a participating protecting group (such 
as an acyl type protecting group), the stereoselective formation of 1,2-cis glycosides and linkages 
of 2-deoxy sugars still presents a great challenge.[5] To solve these problems, various strategies 
have been developed[6] including the use of participating solvents,[7] coordinating metal 
catalysts[8], organocatalysis,[6d, 9] remote participation by protecting groups placed at the C3, C4 
and/or C6 positions,[10] cyclic protecting group, such as benzylidene[11] and silylidene groups,[12] 
and chiral auxiliaries at the C2 position.[5c, d, 13] However, no general solution exists yet, for the 
stereoselective construction of all types of glycosidic bonds. One of the main reasons for the lack 
of a universal stereoselective glycosylation method is the varying reactivity of different donor-
acceptor glycoside combinations. The immense diversity in functional and protecting group 
patterns on the densely functionalized carbohydrate rings, creates an enormous diversity in 
reactivity in glycosylation systems and can make it difficult to translate a given glycosylation 
procedure from one system to another. In this regard, the introduction of nucleophilic additives 
to modulate the condensation reaction has been an important step forwards as this opens up the 
way to match donor and acceptor reactivity. This Thesis describes the use of additives for the 
stereoselective construction of 1,2-cis-glycosidic linkages, with a focus on glucosyl and 
galactosyl bonds in the context of oligosaccharide assembly. This introductory Chapter provides 
an overview of additive modulated glycosylations and glycosylation strategies developed to date.  
2. The proposed mechanism of additive mediated glycosylation reactions  
The first glycosylation reactions using nucleophilic additives to modulate the selectivity dates 
back to 1973 (Scheme 1).[14] West and Schuerch reported that the methanolysis of α-glucosyl 
bromide 1, modulated by dimethyl sulfide (Me2S), triethylamine (Et3N), and triphenyl phosphine 
(Ph3P) nucleophiles proceeded in a stereoselective manner to form the α-glycoside 2 through the 
intermediacy of the β-glucosyl sulfonium, ammonium and phosphonium adducts, respectively. 
West and Schuerch reasoned that the electropositive anomeric substituents would occupy an 
equatorial position for steric reasons. Then the direct SN2-type inversion of the anomeric leaving 
group should lead to the desired 1,2-cis-linked products. The reactions of the ammonium and 
phosphonium ions indeed proceeded in a stereoselective manner, while the sulfonium ion was 
proved to be somewhat less selective (α/β = 6:1). After these pioneering experiments, various 
nucleophilic additives have been probed, including sulfides, sulfoxides, phosphine and phosphine 
oxides, amides and formamides and iodide based reagents and several stereoselective 1,2-cis-
glycosylation procedures have been reported based on their use. 
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Scheme 1. Use of Me2S, Et3N, and Ph3P as additive modulate glycosylation. 
There isn’t one general reaction mechanism to describe all glycosylation reactions, as many 
factors affect the glycosylation reaction, including the nature of the substrates, reagents, solvent, 
concentration, temperature and pressure.[15] The mechanism of a glycosylation reaction can be 
described with the continuum of reaction pathways depicted in Scheme 2 (path A). Upon 
activation of the leaving group with an electrophilic activator the donor can be transformed into 
a series of reactive intermediates, including covalent species or contact/solvent-separated ion 
pairs. The nature of these species enables different reaction pathway ranging from SN1- to SN2-
type substitutions. In the presence of a nucleophilic additive, these intermediate species will react 
with the additive to form an intermediate adduct (Scheme 2, path B). In general, the axial adduct 
is formed predominantly (and can often be observed and characterize by spectroscopic techniques 
such as NMR). The use of (a large) excess of the external nucleophilic additive however allows 
for the formation of sufficient amounts of the more reactive equatorial adduct, which can react to 
provide the 1,2-cis-linked products.  
 
Scheme 2. Proposed continuum of reaction mechanisms in the presence or absence of external 
nucleophilic additives. 
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According to this mechanism, and the use throughout this Thesis, the “additive” in glycosylation 
reactions, is a nucleophilic reagent that plays an important role in the glycosylation mechanism, 
but that cannot activate (or catalyze) the glycosylation reaction independently. In the next sections 
different nucleophilic additives (or “modulators”) will be discussed, including amide, phosphate 
and sulfur reagents as well as quaternary ammonium halides. 
3. Glycosylations modulated with amide reagents 
3.1 N,N-dimethylacetamide (DMA) 
The first use of an amide regent to modulate glycosylation reactions can be traced to 1982, when  
Koto and coworkers reported DMA modulated glucosylations to proceed with good α-
selectivity.[16] They reported that reactions of 2,3,4,6-tetra-O-benzyl-α-D-glucopyranose 3 with 
secondary and primary glucosyl acceptors formed α-glycosides, when a four component active 
system consisting of p-nitrobenzenesulfonyl chloride (NsCl), silver trifluoromethanesulfonate 
(AgOTf), N,N-dimethylacetamide (DMA, 2.5 eq for secondary and 5.0 eq for primary alcohol 
acceptors), and triethylamine (Et3N) in dichloromethane (DCM), was used. The use of the 
corresponding ternary mixture (NsCl, AgOTf, Et3N) without DMA led to the predominant 
formation of β-glucosides. Koto and coworkers speculated that the stereochemical course of the 
reaction in the presence of DMA, was due to the intermediacy of the β-imidinium ion. Besides a 
small set of disaccharides they also generated a branched trisaccharide 12 using the NSDT-system 
(Scheme 3).[17]  
 
Scheme 3. Glucosylation with DMA. 
Next, Koto and coworkers explored the NSDT (NsCl, AgOTf, DMA and Et3N) and NST (NsCl, 
AgOTf, and Et3N) systems with more substrates[18] including 2-azido-sugar donors 13 and 14, in 
combination with glucosyl acceptors (15-18, Scheme 4).[19] The use of the NSDT system led to 
the formation of more α-product than the use of the NST system. The 1,2-cis-selectivity of the 
glycosylations involving the primary alcohol acceptors was generally lower than the 
glycosylations of the (less reactive) secondary alcohol acceptors. 
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3.2 N,N-dimethylformamide (DMF) 
N,N-dimethylformamide (DMF) is not only an excellent solvent for reactions involving polar 
reagents and reaction intermediates, it can also serve as the source for key reactive intermediates, 
such as the Vilsmeier-Haack reagent .[20] It has been widely used as an additive in glycosylation 
reactions, after Mong’s systematically study of its use as a glycosylation additive in 2011[21] 
owing to the good selectivity it provides. Dourtoglou and Gross were the first to describe the use 
of DMF in glycosylation reactions, when they explored the Vilsmeier-Haack reagent, formed 
from DMF and oxalyl choride, to effect glycosylation reactions.[22] They described the detection 
of α- and β-furanosyl imidinium adducts by NMR spectroscopy. In 1984, DMF was used as 
additive for the first time by Koto and coworkers, but only to serve as reference for the DMA 
system (vide supra).[17] Later glycosyl imidinium adducts were detected by NMR by Kobayashi 
in glycosylation reactions, in which lactol donors were activated using Appel reagents (Ph3P, 
CBr4).[23]  
 
Scheme 4. Glycosylations of 2-azido-donors and glucosyl acceptors using the NSDT and NST 
system. 
In 2009, Mong and co-workers noted that DMF (present as a contamination in the reaction 
originating from the donor glycoside) increased the α-selectivity of a Koening-Knorr 
glycosylation.[24] Inspired by these results, Mong and co-workers systematically evaluated the use 
of DMF as an additive in glycosylation reactions using thio-glycosyl donors and a pre-activation 
protocol as depicted in Scheme 5.[21]   
In this protocol, the thio-donor first mixed with DMF prior to the addition of NIS and TMSOTf. 
After complete activation of the thio-donor (1-1.5 h), the acceptor was added. The substrate scope 
of this protocol was shown to be quite broad with α-selectivity ranging from 5:1 to 49:1. The 
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authors only detected the α-glycosyl imidinium ion by NMR spectroscopy when reactive donor 
glycosides were used. In later research, Mong and co-workers also found β-glycosyl imidinium 
ions, when disarmed donors were used[25] (Scheme 6, 9 and 10) and corresponds to the results of 
Chapter 6. Based on these glycosylations, Mong and coworkers proposed the mechanism depicted 
in Scheme 5, in which an equilibrium is set up between α- and β-imidinium ions, in which the 
latter is more reactive than the former and thus substituted in a selective manner to provide the α-
glycoside products. They coined the term DMF-modulated glycosylations for thus type of 
reactions.  
 
Scheme 5. Glycosylations mediated by DMF. 
After this initial work, Mong and co-workers explored whether DMF can react with dioxonium 
ions, formed through neighboring group participation from a 2-acyl donor, to modulate the 
glycosylations of disarmed donors, giving trans-selectivity. They investigated the glycosylation 
of disarmed donors with armed acceptors in the presence of DMF (Scheme 6A).[25a] When 1.2 eq 
DMF was used, the desired products were obtained with good yield and complete trans-selectivity. 
In an NMR study, α- and β-glucosyl imidinium adducts, and β-glucosyl N-succinimide were 
detected with a ratio of 1:7:1. Although the β-adducts were shown to be the major species in the 
equilibrium, the trans-products were obtained exclusively. Therefore, the authors proposed the 
dioxolenium ion to be the key player in the glycosylation reaction. This “disarmed-armed” 
glycosylation strategy enables the synthesis of oligosaccharide in a one pot fashion, where the 
order of the coupling partners does not depend on decreasing reactivity as it does in “traditional” 
armed-disarmed one-pot glycosylation sequences. To prove the utility of the method, three 
trisaccharides were synthesized using the disarmed-armed glycosylation strategy (Scheme 6B).  
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Scheme 6. Disarmed donors glycosylate armed acceptors in the presence of DMF. 
Building on the application of DMF-modulation in pre-activation based glycosylation reactions, 
Mong and co-workers have developed iterative one-pot glycosylation methods to sequentially 
construct α,α-, β,α-, and α,β-linkages using one-pot glycosylation protocols.[26] Several 
saccharides were synthesized using DMF to modulate the stereoselectivity illustrating the 
applicability of their method in the synthesis of oligosaccharides (Scheme 7).[26] And a 
tetrasaccharide glycoglycerolipid from Meiothermus taiwanensis was assembled using a one-pot 
glycosylation protocol, in which the α-linked disaccharide building block was prepared using 
DMF-mediated reaction conditions.[27] 
 
Scheme 7. One-pot α-glycosylations with DMF modulation. 
In 2014, Mong’s group reported an α-selective glycosylation method for 2-deoxy- and 2,6-
dideoxythioglycoside donors based on DMF modulation (Scheme 8A).[28] As 2-deoxy-donors are 
more reactive than fully oxygenated donors, it is more challenging to control the selectivity to 
generate either α- or β-glycosides. In this study, the desired glycoside products were obtained 
with an excellent α:β ratio, ranging from 7:1 to α only. A tetrasaccharide composed of 2-
deoxyglucosides and a trisaccharide built up from 2-deoxygalactosides were assembled using 
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one-pot glycosylations modulated by DMF (Scheme 8B). 
 
Scheme 8. Glycosylation of 2-deoxy- and 2,6-dideoxythioglycosides modulated by DMF.  
Recently, Li and co-workers reported a glycosylation procedure to generate α-pseudaminic acid 
linkages, using DMF to modulate the reactivity and selectivity of the pseudaminic acid donors. 
The system was applied to a broad panel of acceptors, providing the disaccharides with excellent 
α-selectivity (Scheme 9).[29] 
 
Scheme 9. Glycosylation of pseudaminic acid donors modulated by DMF. 
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3.3 N-formylmorpholine (NFM) 
Although the scope of donors and acceptors is quite broad in glycosylations modulated by DMF, 
it presents limitation for highly reactive building blocks such as primary alcohol acceptors and 
donor glycosides that are less reactive, such as 2-azido-2-deoxyglycosides. To overcome the low 
reactivity of the latter systems, a new additive, N-formylmorpholine (NFM), was introduced by 
Mong’s group in 2013 (Scheme 10).[25b] Glycosylations of 2-azido-glucosyl and galactosyl donors 
60-62 were explored in combination with various additives, and the use of 16 equivalents of NMF 
proved to be the most effective to provide the desired products with optimal α-selectivity and 
yield. With NMR spectroscopy, both α- (major) and β-glycosyl (minor) imidium adducts were 
detected using DMF, NMF or di-iso-propylformamide (DIPF). 
 
Scheme 10. Glycosylation using NFM-modulation. 
Mong’s group found that DMF or NFM-modulation did not work well for glycosylations 
involving reactive acceptors like primary alcohols. Therefore they introduced the combination of 
NFM and TBAI in glycosylations of thio-donors with primary alcohol acceptors in 2017.[25c] 
Various building blocks including 2-azido-2-deoxyglycosyl donors were examined under these 
conditions and found to provide excellent α-selectivity. The mechanism of the reactions was 
explored using low temperature NMR to detect potential reactive species. Glycosyl iodides were 
formed after the glycosyl imidinium adducts were treated with TBAI and therefore they proposed 
the mechanism depicted in Scheme 11A. Glucosyl trisaccharide 76 was synthesized using these 
conditions (Scheme 11B). 
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Scheme 11. Proposed mechanism of glycosylations with NFM and TBAI.  
3.4 Other amide additives 
Other amide additives that have been used to steer the stereoselectivity of glycosylation reactions 
include N,N-diisopropylformamide (DIPF),[25b] tetramethylurea (TMU),[23b, 25b, 30] N-
formylpiperidine (NFP),[25b, 30a] and N-methyl-N-phenylformamide (MPF). They all play a similar 
role as DMF in the reported glycosylation reactions, but have been found to be less selective or 
provide lower yields.  
4. Glycosylations modulated with phosphine and phosphine oxide additives 
Many different phosphine reagents have been used in glycosylation reactions, as catalyst,[31] 
ligand[32] or additive to influence the stereochemistry. Here below, only phosphine or phosphine 
oxide reagents that have been used as additives are introduced. The use of (chiral) phosphoric 
acid catalysis and phosphine ligands in transition metal catalyzed glycosidic bond forming 
reactions has recently been reviewed.[6d] 
4.1 Phosphine reagents 
The use of phosphine additives was first reported in 1973, as described above (Scheme 1).[14] In 
this study per-benzyl protected glucosyl bromide was coupled with methanol in the presence of 
Ph3P to stereoselectively provide the α-product. Ye and co-workers explored various phosphine 
additives in glycosylations of glucosyl chlorides, activated by urea 77 (Scheme 12).[33] They 
found tri-(2,4,6-trimethoxyphenyl)-phosphine (TTMPP) 78 to be the best additive, providing 
glycosylation reactions with excellent α-selectivity (α:β = 8:1 to 20:1) as shown in Scheme 12. 
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Scheme 12. Glycosylations Modulated by TTMPP. 
4.2 Phosphine oxide reagents 
Phosphine oxide additives have been widely explored to synthesize 1,2-cis-glycosides. The first 
publication on the use of phosphine oxide as an additive dates back to 1997. Bogusiak and Szeja 
reported the glycosylation of N,N-diethyl S-(2,3,5-tri-O-benzyl-D-xylofuranosyl)-
dithiocarbamate and 1,6-anhydro-3,4-O-isopropylidene-β-D-galactopyranose using 
hexamethylphosphoric triamide (HMPA) as additive (Scheme 13).[30b] The desired disaccharide 
was obtained in 87% yield with good stereoselectivity (α:β = 10:1). When O-ethyl S-(2,3,5-tri-
O-benzyl-D-xylofuranosyl)-dithiocarbonate was used as donor, the selectivity decreased. 
 
Scheme 13. Glycosylations using HMPA as additive. 
Mukaiyama and co-workers also systematically studied the application of various phosphine 
oxide additives, including Ph2P(=O)Me, Bu3P=O, Ph3P=O, HMPA, tripyrrolidinophosphine 
oxide and (PhO)3P=O.[34] Three kinds of donor glycosides, iodides, bromides and acetates, were 
explored with different acceptors in the presence of the phosphine oxides. First, Mukaiyama’ 
group found that glucosyl iodides 94 could be coupled with 2,3,4-tri-O-benzyl-D-
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glucopyranoside in the presence of Ph2P(=O)Me to form the disaccharide with excellent α-
selectivity (Scheme 14A). Because glycosyl iodides are generally quite unstable, they switched 
to use the more stable glycosyl bromides. It was found that tripyrrolidinophosphine oxide 
performed best as a nucleophilic additive, promoting glycosylations to proceed with excellent 
yield and selectivity. Different building blocks were investigated and all found to react with 
excellent yield and selectivity (Scheme 14B). To further improve on the protocol, they explored 
glycosylations of glycosyl acetates 95 and 96, that were activated by TMSI, to provide the 
anomeric iodides in situ, in the presence of Ph3P=O (Scheme 14C). 
 
Scheme 14. Glycosylations of glycosyl acetate with phosphine oxide additives. 
Mukaiyama and co-workers also studied the mechanism of glycosylation modulated by TMSI-
Ph3P=O. The proposed mechanism is depicted in Scheme 15. First, a glycosyl iodide is formed 
from the glycosyl acetate donor and TMSI which is then treated with the phosphine oxide to form 
the intermediate adduct. In line with the general additive controlled glycosylation mechanism, 
described in Scheme 2, the incoming acceptor then attacks the more reactive β-adduct to afford 
the α-product. Mukaiyama and co-workers tried to detect the glycosyl phosphonium iodide as the 
key intermediate adduct, but were unable to find this by NMR spectroscopy. That may indicate 
that only a very small amount of the glycosyl phosphonium iodide is formed or that the phosphine 
oxide only serves as a catalyst to assist in the formation of a β-iodide species. 
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Scheme 15. Proposed mechanism for glycosylations modulated by TMSI-Ph3P=O. 
In 2014, Oka and co-workers applied TMSI-Ph3P=O in the glycosylation of 1-O-trimethylsilyl-
2,3,5-tri-O-benzyl-D-ribofuranose 101 to form α-ribofuranosides.[35] The desired products were 
obtained in excellent yield with good α-selectivity (Scheme 16). They compared the TMSI-
Ph3P=O conditions with the TMSI-TBAI conditions reported by Gervay in 1999[36] and found 
that both the yield and α-selectivity decreased using the TMSI-TBAI conditions. The authors also 
tried to detect the glycosyl phosphonium iodide but did not succeed. 
 
Scheme 16. Ribofuranosylation using TMSI-Ph3P=O activation. 
In 2016, Wang and co-workers reported glycosylations of glycals using TMSBr-Ph3P=O 
activation conditions to form α-2-deoxyglycosides.[37] They explored different additives, such as 
DMF, dimethyl sulfide (DMS), 2,4,6-tri-tert-butylpyridine (TTBP), triphenylphosphine (TPP), 
trimethyl phosphine oxide (TMPO) and Ph3P=O, and found Ph3P=O to be the best one. It was 
reported that armed and disarmed glucal and galactal acceptors could be used to provide the 
desired products with good yield and selectivity. 
Very recently, Wan and co-workers reported a β-selective glycosylation procedure for 3-amino-
2,3,6-trideoxy sugars, using gold catalysis and phosphine oxide additives (Scheme 17).[38] It was 
found that a nosyl protecting group was crucial to the outcome of the glycosylation reactions. The 
mechanism proposed by Wan and co-workers, differs from the TMSI-Ph3P=O system, as it 
invokes a hydrogen bond between the amino group and oxygen of Ph3P=O interacting with the 
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anomeric carbon on the α-face. The desired products were obtained with good selectivity (β:α = 
3.5:1 to 1:0) and yield. 
 
Scheme 17. Proposed mechanism of glycosylations of 3-amino-2,3,6-trideoxy sugars. 
5. Glycosylations modulated with sulfur additives 
5.1 Thio-ether additives 
As described above, the first glycosylation using a thio-ether as additive was reported by West 
and Schuerch in 1973 (Scheme 1).[14] Diethyl sulfide was applied in the glycosylation of glucosyl 
bromide 1 to afford methyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside 2 in 86% yield with a  
86:14 α:β ratio. After 34 years, Boons and coworkers reported on the glycosylation of 2-azido-2-
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deoxy-glucosyl trichloroacetimidates using PhSEt or thiophene as additive,[39] inspired by the 
success of sulfur based C2-chiral auxiliaries[13, 40] for 1,2-cis-glycosylations. The desired 
disaccharides were obtained with excellent yields and selectivity when using disarmed donors in 
the presence of PhSEt or thiophene (Table 1). The 2-azido-3,4,6-tri-O-benzyl-2-deoxy-D-
glucopyranosyl trichloroacetimidate donor 133 gave poor α-selectivity because of the high 
reactivity of this donor. It was shown that a β-substituted anomeric sulfonium ion was formed 
upon activation of donor in the presence of PhSEt. 
Table 1. Glycosylations of 2-azido-2-deoxy-glucosyl donors with PhSEt or thiophene. 
 
entry donor acceptor additive product yield % α:β 
1 
132a 134 
none 
137a 
92 8:1 
2 PhSEt 94 20:1 
3 thiophene 91 1:0 
4 
132a 135 
none 
138a 
85 10:1 
5 PhSEt 92 14:1 
6 thiophene 95 18:1 
7 
132a 136 
none 
139a 
87 2:1 
8 
 
PhSEt 92 5:1 
9 thiophene 95 14:1 
10 132a 82 none 140a 56 10:1 
11 thiophene 60 15:1 
12 132a 84 none 141a 40 1:0 
13 thiophene 43 1:0 
14 132b 134 none 137b 90 12:1 
15 thiophene 93 20:1 
16 none 95 10:1 
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17 132b 135 thiophene 138b 92 20:1 
18 132b 136 none 139b 98 10:1 
19 thiophene 96 15:1 
20 132b 82 none 140b 52 11:1 
21 thiophene 50 15:1 
22 132b 84 none 141b 35 1:0 
23 thiophene 34 1:0 
24 133 132 none 142 80 3:1 
25 thiophene 80 3:1 
26 133 134 none 143 83 3:1 
27 thiophene 81 4:1 
28 133 135 none 144 95 2:1 
29 thiophene 96 2:1 
30 133 82 none 85 45 2:1 
31 thiophene 48 1:1 
Encouraged by Boons’ aforementioned work, Yoshida and coworkers studied the role of Me2S in 
glycosylation reactions, in which the thioglycosides were electrochemically activated, using low 
temperature NMR (Scheme 18).[41] To this end, the glycosyl triflate formed from 2-azido-3,4,6-
tri-acetyl-glucosyl donor 145 was treated with Me2S in CD2Cl2. The intermediate sulfonium 
adduct was formed as a mixture of α:β-anomers in a 45:55 ratio. The anomeric composition did 
not change upon varying the temperature from -80 oC to 0 oC. When methanol was added to the 
solution at room temperature, the methyl glycoside 146 was obtained as an anomeric mixture (α:β 
= 41:59), indicating that the α-glycosyl sulfonium ion is somewhat more reactive than the β-
glycosyl sulfonium ion and that an in situ anomerisation scenario operates to some extent. 
Yoshida and coworkers also found that some glycosyl sulfonium ions, such as the ion made from 
a 2-N-phthalimide-3,4,6-tri-acetylglucosyl thio-donor and Me2S, can be stored as stable reagents 
for glycosylation.[42] 
 
Scheme 18. Mechanism of glycosylations involving Me2S. 
5.2 Diphenyl sulfoxide (DPSO) 
Diphenyl sulfoxide (DPSO) has been widely used in glycosylation reactions after the first 
dehydrative glycosylation using the DPSO-Tf2O reagent combination by Gin in 1997.[43] DPSO 
plays different roles in these glycosylations. It is part of the promoter system, but can also function 
as additive. In 2006, Crich and Li described that an excess of DPSO (3 eq) can be used in the 
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glycosylation of 2-thiosialic acid donors 147 to obtain the α-linked products with excellent yield 
and good α-selectivity.[44] It was shown that DPSO plays a crucial role in the glycosylation as 
adducts 149 were formed upon treatment of the glycosyl triflate 148 with an excess of DPSO 
(Scheme 19). 
 
Scheme 19. Glycosylation of 2-thiosialic acid donors with an excess of DPSO. 
5.3 Other sulfur containing additives 
Bennett and co-workers applied 2,3-bis(2,3,4-trimethoxyphenyl)-cyclopropene-1-thione 163 as 
additive in a synthesis of a branched trisaccharide fragment of the antibiotic saccharomicin B 
(Scheme 20).[45] Disaccharide 165 was synthesized from monosaccharides 162 and 164 in the 
presence of thione 163 as a single anomer. When the same conditions were used to synthesize 
trisaccharide 168, an α/β mixture was obtained (α:β = 1:4). Application of thio-donor 166 in 
combination with AgPF6 activation and the use of TTBP as an acid scavenger provided the desired 
trisaccharide 168 with excellent α-selectivity.  
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Scheme 20. Synthesis of trisaccharide 168. 
6 Glycosylations modulate with quaternary ammonium halide salt 
The mechanism of quaternary ammonium salts in glycosylations is different with the other 
additives aforementioned. There isn’t new intermediate species formed in the glycosylation 
modulated by quaternary ammonium salts. The halide ion (Br- or I-) from quaternary ammonium 
salt rebalance the glycosyl halide to offer more reactive β-anomer. That will be attacked by the 
acceptor to form α-glycosides. Originally quaternary ammonium salts were combined with 
glycosyl halides but have now been used as additives to many different types of glycosylations 
in the synthesis of 1,2-cis-oligasaccharides. 
6.1 Tetraethylammonium bromide (TEAB) and tetrabutylammonium bromide (TBAB) 
The first glycosylation mediated by quaternary ammonium bromide was reported by Lemieux 
and Hadd in 1975.[46] Tetraethylammonium bromide (TEAB) was used in glycosylation of 
glycosyl bromides to form α-glycosides.[46a] Two trisaccharides 174 and 175 were synthesized 
using this method, paving the way for more applications of quaternary ammonium salt in 
glycosylation reactions (Scheme 21).[46b, c] It should be noted, however, that this glycosylation 
system is quite unreactive (because of the neutral nature of the intermediates as opposed to the 
cationic species generated in the previously described protocols), and therefore requires long 
reaction times and reactive nucleophiles for productive glycosylation reactions.  
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Scheme 21. Glycosylation of glucopyranosyl bromide with TEAB. 
6.2 Tetrabutylammonium iodide (TBAI) 
Inspired by Lemieux method, and building on improved methods to generate glycosyl iodides[47]， 
Gervay and co-workers described the use of these donors in combination with 
tetrabutylammonium iodide (TBAI) in glycosylation reactions.[36] Compared to the TEAB-
glycosyl bromide system, the TBAI-glycosyl iodide system is more efficient with shorter reaction 
times and higher yields. Hadd and Gervay described various iodide donors and reported that they 
reacted with good yield and α-selectivity (Table 2).  
Table 2. TBAI modulate glycosylation of glycosyl iodide.  
 
entry donor acceptor solvent additive time (h) product yield % α:β 
1 94 179 DCM TBAI, DIEA 2 183 71 1:0 
2 176 179 DCM TBAI, DIEA 3 184 69 1:0 
3 177 179 DCM TBAI, DIEA 40 min 185 62 1:0 
4 176 180 DCM TBAI, DIEA 24 173 45 1:0 
5 176 180 benzene TBAI, DIEA 5.5 173 93 9:1 
6 177 180 benzene TBAI, DIEA 3 172 66 1:0 
7 178 179 benzene TBAI, DIEA - 186 - 1:1 
8 178 179 benzene DIEA - 186 - 1:1 
9 178 180 benzene DIEA 5.5 187 67 1:0 
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10 94 180 benzene TBAI, DIEA 1.5 170 44 1:0 
11 168 181 benzene TEAB 4 188 quant 1:0 
12 177 181 benzene TBAI, DIEA 4 189 quant 1:0 
13 177 182 DCM TBAI, DIEA 5.5 190 91 1:0 
In the same year, Hashimoto and co-workers applied TBAI in the glycosylation of glycosyl 
diethyl phosphites to construct 1,2-cis-glycosides.[48] In their research, 2,6-di-tert-
butylpyridinium iodide (DTBPI, 1.2 eq) was used as promoter and TBAI (1.2 eq) was used as 
additive, which transformed the glycosyl diethyl phosphites into the glycosyl iodide within 30 
minutes as determined by TLC and 1H-NMR. The desired products were obtained with excellent 
yield and α-selectivity (Table 3). 
Table 3. Glycosylation of glycosyl diethyl phosphites with TBAI. 
 
entry donor acceptor time (h) yield % product α:β 
1 191 30 48 85 7 92:8 
2 191 30 24 84 7 92:8 
3 191 84 48 59 87 95:5 
4 191 136 24 91 144 94:6 
5 191 180 48 81 170 92:8 
6 191 201 48 88 205 91:9 
7 191 204 48 89 206 90:10 
8 191 203 36 92 207 92:8 
9 192 30 24 88 208 95:5 
10 193 30 48 88 209 96:4 
11 194 30 48 91 210 96:4 
12 195 30 48 80 211 90:10 
13 196 30 48 85 89 95:5 
14 196 199 24 94 212 93:7 
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15 196 202 48 87 213 93:7 
16 197 30 3 82 214 88:12 
17 197 136 4 95 171 89:11 
18 198 30 4 87 215 95:5 
19 198 136 4 95 216 93:7 
Afterwards, Gervay and co-workers studied the application of the TBAI-glycosyl iodide system 
in the solution and solid phase synthesis of oligosaccharides.[49] Hexasaccharide 226 was 
assembled in solution using a [2+2+2] coupling strategy.[49a] The glycosylation reactions were 
performed in refluxing benzene for 4h using 5 equivalents of TBAI and 1.5 equivalents of DIPEA 
(Scheme 22). Next, a tetrasaccharide was assembled using a solid phase approach, using the same 
reaction conditions.[49b] Longer reaction times (up to 12 h) and more donor (7.5 equivalents in 
total) were needed to achieve good conversions. 
 
Scheme 22. TBAI-glycosyl iodide system in the synthesis of hexsaccharides. 
Gervay and co-workers also used his method to synthesize a C-analogue of the bacterial 
glycolipid BbGL2.[50] To this end a galactosyl iodide was generated from the galactosyl acetate 
by adding TMSI. The desired C-glycoside was obtained with good yield (79%) and α-selectivity 
(α:β = 12:1) from the galactosyl iodide and vinyl magnesium bromide using TBAI in refluxing 
toluene (Scheme 23A). Afterwards, they synthesized α-O-glycolipids from per-O-silylated 
galactosyl iodides using TBAI as additive (Scheme 23B).[51]  
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Scheme 23. Synthesis of glycolipid under influence of TBAI.  
Sergio Castillon and co-workers also reported the synthesis of α- and β-linked glycolipids using 
TBAI to modulate the reactivity of the glycosylations.[52] The glycosylation of the disarmed tetra-
O-acetyl-α-iodogalactose donor 234 with the tin ketal of the acceptor afforded the β-linked 
glycolipid, through direct displacement of the (relatively stable) α-iodide 234 (Scheme 24A). 
When the armed per-O-silylated galactosyl iodide donor 229 was used in combination with an 
excess TBAI (2 eq) and acceptor 237, the α-glycolipid 238 was formed (Scheme 24B). 
 
Scheme 24. Synthesis of glycolipid using TBAI condition. 
Bennett and co-workers developed a dehydrative glycosylation procedure for deoxy-sugar donors 
promoted by 3,3-dichloro-1,2-diphenylcyclopropene 239 (1.5 eq) and TBAI (5 eq) to form α-
glycosides.[53] The mechanism that was proposed by the authors is depicted in Scheme 25. Upon 
treatment of the deoxy-sugar with 3,3-dichloro-1,2-diphenylcyclopropene 239, the glycosyl 
chloride is formed, which is then treated with TBAI to form more reactivity glycosyl iodide. 
Acceptors attack the β-glycosyl iodide to give the α-glycosides. Various donors and acceptors 
were explored using these conditions. The desired products were obtained with good selectivity 
and yields. Later, they reported a new promoter 3,3-dibromo-1,2-diphenylcyclopropene 240 to 
further improve the α-selectivity.[54]  
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Scheme 25. Mechanism of 3,3-dichloro-1,2-diphenylcyclopropene mediated dehydrative 
glycosylation of deoxy-sugar, modulated by TBAI. 
In 2013, Bennett and co-workers reported a glycosylation protocol to construct 1,2-cis-glycosides 
from thio-donors.[55] Per-benzylated thio-donors were activated by Ph2SO and Tf2O, and then 
treated with TBAI to form the intermediate glycosyl iodide. They also found that the addition of 
N-methylmaleimide to the reaction increases the yield. Scheme 26 depicts the scope of acceptors 
studied with per-benzyl glucosyl and galactosyl donors 241 and 242. An 1,6-linked trisaccharide 
251 was synthesized to illustrate the potential of the method in oligosaccharide synthesis. 
 
Scheme 26. Glycosylations of thio-donors modulated by TBAI and N-methylmaleimide. 
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7 Conclusion 
Tremendous progress has been made in the synthesis of oligosaccharides over the past decades. 
The use of exogenous nucleophiles (“additives”) to modulate the selectivity has opened up a new 
avenue for the stereoselective synthesis of oligosaccharides. This Chapter has summarized 
different additives that have been developed to date and that have found most applications. The 
prime advantage of additive controlled glycosylations is the fact that one can rely on the reactivity 
of an external agent instead of using specialized building blocks, bearing a specific protecting 
group pattern to control the stereochemistry of the glycosylation.[56]  In addition, the use of an 
external additive for reaction modulation enables the flexible tuning of the reactivity of the system 
and matching of donor and acceptor reactivity. Although the first “additive controlled” 
glycosylations were reported many years ago, the approach has received relatively limited 
attention until better mechanistic insight was recently gained, and reactive intermediates could be 
characterized by spectroscopic techniques. Still, relatively few applications of the methodology 
in the assembly of large and complex, branched oligosaccharides have been reported.  
To date most additives have been used to afford α-selectivity, while the synthesis of β-glycosides 
modulated by additives has been only scarcely investigated, this could pose advantages for 
example in the context of the protecting group strategy followed. Besides applications in total 
synthesis of carbohydrates more insight is demanded into the reaction mechanism of additive 
controlled glycosylations and detailed kinetic studies are therefore required. In addition, 
knowledge of the reactivity of both coupling partners will enable better fine tuning of the reaction 
to optimally control the outcome of the reaction in terms of yield and stereoselectivity. The 
conception of an “additive toolbox” with modulators of known properties to match the reactivity 
of the donor and acceptor in a predictable manner will then be achievable. 
8 Outline of this Thesis 
This Thesis focuses on the development of additive controlled glycosylation and its use in 
assembly of biologically relevant oligosaccharides built up from 1,2-cis-linkages. 
Chapter 2 describes an additive controlled glycosylation strategy built on the use of TfOH-DMF 
and TMSI-Ph3P=O mediated glycosylation reactions of N-phenyltrifluoroacetamide donors. The 
different activator/additive combinations were used to match the reactivity of the donor and 
secondary and primary acceptor building blocks. To eliminate reactivity differences originating 
from different protecting groups, only benzyl type protecting groups (Bn, PMB, Nap) were used. 
To prove the utility of the devised synthesis strategy, a linear α-(1,4)-hexasaccharide and a 
branched α-glucan from Mycobacterium tuberculosis were assembled.  
Encouraged by the results of chapter 2, an α-(1,3)-linked octasaccharide from the Aspergillus 
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fumigatus fungal cell wall was prepared using the TfOH-DMF mediated conditions as described 
in Chapter 3. The synthesis of α-(1,2)-linked glucans (“kojioligosaccharides”) using additives to 
control the selectivity of the required glycosylations is described in Chapter 4. The synthesis of 
α-galactosides is introduced in Chapter 5, where it is described that TMSI-Ph3P=O conditions 
can be applied to a broad scope of substrates. 
In Chapter 6, a new additive, N-methyl(phenyl) formamide (MPF) is introduced for 
glycosylations to form 1,2-cis-2-azido glycosides. A linear α-glucosazide tetrasaccharide and a 
linear Pel hexsaccharide, containing both α-glucosamines and α-galactosamines were synthesized 
using MPF as additive. Chapter 7 provides a conclusion of this Thesis and an outlook for future 
research. 
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Introduction 
As described in chapter 1, there exists still no general solution for the stereoselective construction 
of challenging glycosidic bonds, such as 1,2-cis and 2-deoxy linkages.1 At the root of this 
persisting problem is the enormous variation in carbohydrate building blocks and the different 
mechanistic pathways that can be followed in the union of these.1 Most glycosylation reactions 
rely on the activation of a glycosyl donor using a (Lewis) acid catalyst to generate a strong 
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electrophile that can either be a covalent species, a close ion pair or a solvent separated ion pair, 
in which the glycosyl oxocarbenium ion and the counter ion are fully dissociated (See Figure 
1).2,3 Most often triflate-based activators are used and a multitude of covalently linked anomeric 
triflates has been described over the last two decades.3 These triflates may engage in a SN2 type 
substitution reaction, but more often they act as a reservoir for the more reactive glycosyl cation-
triflate ion pair, providing reactions with SN1-character. The equilibrium between the covalent 
species and ion pairs in combination with the reactivity of the incoming nucleophile -the acceptor- 
determines which pathway(s) will be followed. The reactivity of the donor building block 
depends on the nature and position of the functional groups on the carbohydrate ring and the 
different reactivity of donor glycosides has been called upon in reactivity based one-pot 
chemoselective glycosylation sequences.4 It is also well appreciated - but less well studied - that 
the reactivity of the acceptor alcohol can vary as a result of the protecting/functional group pattern 
on the ring and the intrinsic reactivity difference between primary and secondary alcohols often 
leads to a different stereochemical outcome when glycosylating these acceptors.5 It is a 
tremendous challenge to design a general glycosylation strategy that accommodates the varying 
reactivity of different donor-acceptor glycoside combinations and ensures a fully stereoselective 
glycosylation process. 
 
Figure 1. Additive controlled stereoselective glycosylations. The reactivity of the adducts of the 
different nucleophiles (Y and Z) are tuned to the reactivity of the incoming acceptor alcohol. 
An attractive way to modulate the reactivity of a glycosyl donor is through the use of an 
exogenous nucleophile that can be added to the coupling reaction. These nucleophilic additives 
or reactivity modulators react with the activated donor to form a new covalent species (See Figure 
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1).6 Like introduced in chapter 1, various additives have been probed over the years, including 
sulfides,7 sulfoxides,8 phosphine oxides,9 amides and formamides10 and iodide based reagents11 
and several stereoselective 1,2-cis-glycosylation procedures have been reported based on their 
use. The most often invoked mechanistic rationale to account for the observed stereoselectivity 
involves the generation of a stable α-covalent species (often identified and characterized by NMR 
spectroscopy), that is in equilibrium with its less stable and more reactive β-counterpart (often 
not detected by NMR), following an in situ anomerisation kinetic scenario as first introduced by 
Lemieux and co-workers.12 It is reasonable that modulation of donor reactivity through external 
nucleophiles would be very attractive to match the reactivity of acceptor alcohols of different 
nucleophilicity in order to achieve fully stereoselective glycosylation reactions with both partners. 
It is described here how a single type of donor glycoside can be used for the fully stereoselective 
glycosylation of both primary and secondary alcohol acceptors. Different additives have been 
used to accommodate the intrinsic reactivity difference between these two types of alcohols. Key 
to the success of the strategy is a protecting group strategy that ensures identical reactivity of the 
parent donor building blocks used, so that the reactivity of the system is under direct control of 
the activator/additive used. The applicability of this approach is showed in the assembly of 
Mycobacterium tuberculosis (Mtb) derived branched α-glucans. Mtb α-Glucans play an important 
role in allowing the bacterium to evade the human immune system, but the molecular details 
behind this process remain obscure.13 To unravel how α-glucans interact with our immune system, 
well-defined α-glucans fragments will be valuable tools. These structures represent excellent 
target molecules to test the proposed synthetic strategy, as they only contain 1,2-cis linkages and 
carry different branches, necessitating flexible building blocks and stereoselective glycosylation 
methodology for the construction of glycosidic linkages to both primary and secondary alcohol 
functions. 
Results and Discussion 
A glycosylation strategy was expected to be developed that is under full control of the used 
reagents and aimed to employ a single donor type, devoid of any stereodirecting protecting groups 
for the glycosylations of both the primary and secondary alcohol acceptors. Therefore, the used 
donors and acceptors were equipped solely with benzyl type protecting groups. This serves two 
purposes. Firstly, since all protecting groups on the building blocks are benzyl ethers, the 
reactivity of the building blocks is as similar as possible. The only factors influencing the relative 
reactivity of the acceptors are the intrinsic difference between the primary and secondary alcohols 
and the effect of the growing chain length on the reactivity of the acceptor. Secondly, global 
protection of the donor glycoside with benzyl ethers leads to a donor that is as reactive as possible. 
Previous reports employing nucleophilic additives in glycosylations have shown that this type of 
glycosylation is generally very slow.6 The reactive intermediates that are generated are relatively 
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stable necessitating long reaction times. The use of acyl type protecting groups would make the 
system less reactive leading to even longer reaction times. The target α-glucans of this study and 
the employed building blocks are depicted in Scheme 1. The most complex target, nonasaccharide 
1, features a hexa-α-glucan backbone with two different branches. This target saccharide was 
selected because its synthesis requires the introduction of all possible structural elements present 
in naturally occurring α-glucans. To be able to assemble this structure four different building 
blocks were designed: per-benzylated donor 2, a chain-terminating synthon; donor 3 to build the 
growing α-(1,4)-chains; donor 4, to build the branches; and finally, donor 5 to introduce the 
branches. The triad of benzyl ethers that was aimed to use include benzyl (Bn) ethers for 
permanent protection, only to remove at the end of the assembly; 2-methylnaphthyl (NAP) ethers 
that can be selectively removed with respect to the other benzyl ethers under acidic or oxidative 
conditions and finally the para-methoxybenzyl (PMB) ether that are the most labile of the three 
benzyl ethers and that can be selectively removed in the presence of the other two using mild 
acidic conditions, as described in recently publication of Volbeda etal.14 
 
Scheme 1. Synthetic strategy for the assembly of Mtb α-glucan 1. 
The stereoselective construction of the α-(1,4)-glucosyl linkages was paid to attention firstly. To 
this end the condensation of tetra-O-benzyl thioglucoside 2a and tri-O-benzyl-α-O-methyl 
glucose acceptor 6 were investigated using N-iodosuccinimide (NIS) and trimethylsilyl triflate 
(TMSOTf) activation.15 Following the seminal work of Mong and co-workers,10 several amides 
and formamide additives were explored, including N,N-dimethylformamide (DMF), N-
formylpiperidine (NFP), N-formylmorpholine (NFM), N,N-dimethylacetamide (DMA) and 
tetramethylurea (TMU) as reactivity modulators. Phosphine oxides (triphenylhosphine oxide, 
Ph3P=O) and sulfoxides (benzene sufinyl piperidine, BSP) also were probed. As shown in Table 
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1 (Entries 2-14), the stereoselectivity of the reactions with additives are better than the 
condensation reaction without nucleophilic additive (Entry 1), barred one: the reaction using 
Ph3P=O. In line with the findings of the Mong laboratory,10 the formamide additives performed 
best and the use of a larger excess of these additives generally gave better results in terms of 
stereoselectivity.  
Table 1. Glycosylations of perbenzylated glucose donors with secondary alcohols. 
 
entry donor acceptor promoter additives eq product yield  α:β 
1 2a 6 NIS, TMSOTf a - - 9 86% 2:1 c 
2 2a 6 NIS, TMSOTf a 
DMF 
6 9 91% 37:1 c 
3 2a 6 NIS, TMSOTf a 16 9 83% >50:1 c 
4 2a 6 NIS, TMSOTf a 
NFP 
6 9 72% 23:1 c 
5 2a 6 NIS, TMSOTf a 16 9 69% >30:1 c 
6 2a 6 NIS, TMSOTf a 
NFM 
6 9 91.5% 15:1 c 
7 2a 6 NIS, TMSOTf a 16 9 94% 19:1 c 
8 2a 6 NIS, TMSOTf a 
DMA 
6 9 83% 9:1 c 
9 2a 6 NIS, TMSOTf a 16 9 90% 19:1 c 
10 2a 6 NIS, TMSOTf a 
TMU 
6 9 32% 4:1 c 
11 2a 6 NIS, TMSOTf a 16 9 49% 3.5:1 c 
12 2a 6 NIS, TMSOTf a 
BSP 
3 9 61% 3:1 c 
13 2a 6 NIS, TMSOTf a 6 9 39% 3:1 c 
14 2a 6 NIS, TMSOTf a Ph3P=O 6 9 60% 2:1 c 
15 2b 6 TfOHb DMF 16 9 94% >20:1 d 
16 3b 6 TfOHb DMF 16 10 91% >20:1 d 
17 2b 7 TfOHb DMF 16 11 85% >20:1 d 
18 2b 8 TfOHb DMF 16 12 90% >20:1 d 
aDCM, 0 oC, 24h. bDCM, -78-0 oC, 24h. cThe α:β ratio was determined by chiral HPLC analysis. dThe α:β ratio was 
determined by 1H-NMR. 
It was observed that the reactions with TMU and the phosphine oxide proceeded slower than the 
formamide and amide mediated condensations, resulting in diminished yields. This likely reflects 
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the greater stability of the formed covalent intermediates generated with these additives. As 
shown in Table 1, DMF performed best as additive and this reagent was further studied and the 
use of imidate donors was also explored as these represent a very powerful class of glycosylating 
agents.16 Where the in situ transformation of thioglycosides into reactive covalent species has 
been widely applied in glycosylation chemistry, the use of imidate donors for this purpose has 
not been explored. Gratifyingly, the additive controlled condensation of imidate donor 2b and 
acceptor 6 proceeded in excellent yield and stereoselectivity to provide the desired disaccharide 
9 (Table 1, entry 15). To test whether the acid labile naphthyl ether in donor 3b is compatible with 
the developed reaction conditions, which employ a stoichiometric amount of TfOH, donor 3b 
was next coupled with acceptor 6. This glycosylation delivered the protected maltoside 10 in 
similar yield and with comparable stereoselectivity as the condensation of per-benzyl donor 2b 
and acceptor 6 (Table 1, entry 16), showing that the Nap ether well tolerates the glycosylation 
conditions. The scope of the established conditions was briefly explored with two other secondary 
carbohydrate alcohols. Acceptors 7 and 8 could be glucosylated at the C-3 and C-2 OH, 
respectively, in good yield and with excellent stereoselectivity (Table 1, entries 17 and 18). 
To probe the robustness of the established methodology, a longer α-glucan was assembled, as 
depicted in Scheme 2. To this end, the Nap-protecting group was removed from maltoside 10 
using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to furnish acceptor 13. Compound 13 
was glycosylated with donor 3b using the DMF-conditions to give the desired trisaccharide 14 in 
81% yield. Repetition of the deprotection and glycosylation reactions then provided the 
tetrasaccharide 16, pentasaccharide 18 and hexasaccharide 20. All through this reaction sequence 
the yields and stereoselectivity of the condensations did not erode showcasing the reliability of 
the methodology.  
 
a) DMF, TfOH, DCM, -78 - 0 oC, 8: 82%; 14: 81%; 16: 82%; 18: 80%; 20: 79%. b) DDQ, DCM/H2O, 13: 78%; 15: 
78%; 17: 84%; 19: 81%. c) Pd(OH)2/C, H2, THF:H2O:t-BuOH, 3.5 atm, 80%. 
Scheme 2. Synthesis of α-(1,4)-hexasaccharide 21. 
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Then the attention was turned to the condensations of the primary acceptor. For this model 
acceptor 22 was used in combination with thioglycoside 2a and the panel of additives described 
above. The higher reactivity of the primary alcohol 22 with respect to its secondary alcohol 
counterpart 6 leads to significant erosion of the stereoselectivity, when identical condensation 
conditions are used (Table 2, entries 1-5). It was surprised to see that the condensation using the 
phosphine oxide actually led to the formation of more β- than α-linked product. Cognizant of the 
work of Mukaiyama and co-workers on the use of phosphine oxides in highly stereoselective 
condensation reactions of perbenzylated glucosyl pyranosyl iodides,9 it was switched to the use 
of imidate donor 2b that was transformed in situ into the anomeric iodide using 
trimethylsilyliodide (TMSI).17 Under these conditions, the disaccharide 23 was formed with 
moderate α-selectivity and in rather poor yield (Table 2, entry 6). The addition of 1.2 equivalent 
of diphenylmethyl phosphine oxide, as advocated by Mukaiyama and co-workers, led to a 
significant improvement of the stereoselectivity (α/β = 6:1, Table 2, entry 7).  
Table 2. Glycosylations of primary alcohol 22. 
 
entry donor promoter additive eq T  
pro
duct 
t(h) yield  α: β a 
1 2a NIS, TMSOTf DMF 16 0 oC 23 12 90% 2.7:1 
2 2a NIS, TMSOTf NFM 16 0 oC 23 24 83% 2.1:1 
3 2a NIS, TMSOTf DMA 16 0 oC 23 24 69% 1:1.3 
4 2a NIS, TMSOTf TMU 6 0 oC 23 24 82% 1:1.1 
5 2a NIS, TMSOTf Ph3P=O 6 0 oC 23 24 70% 1:3 
6 2b TMSI - - rt 23 24 41% 2:1 
7 2b TMSI Ph2(Me)P=O 1.2 rt 23 24 46% 6:1 
8 4b TMSI Ph2(Me)P=O 3 rt 24 24 82% 16:1 
9 4b TMSI Ph2(Me)P=O 6 rt 24 24 76% 20:1 
10 4b TMSI Ph2(Me)P=O 10 rt 24 24 73% 20:1 
11 4b TMSI Ph2(Me)P=O 16 rt 24 24 70% 20:1 
12 4b TMSI Ph3P=O 6 rt 24 24 78% 25:1 
13 2b TMSOTf Ph2(Me)P=O 6 rt 23 24 84% 3:2 
aThe α:β ratio was determined by 1H-NMR. 
As planned to use this activation system in combination with a donor glucoside bearing a relative 
acid labile PMB group, these conditions were explored for the coupling of donor 4b and acceptor 
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22. The amount of phosphine oxide was increased to ensure that sufficient Lewis-basic reagent 
was present to protect the labile PMB. As displayed in Table 2, entry 8, the desired disaccharide 
24 was obtained in good yield with improved stereoselectivity and the PMB group proved to be 
completely stable to the conditions used. Increasing the amount of the phosphine oxide additive 
to 6 equivalents led to a further increase in stereoselectivity (Table 2, entry 9). More phosphine 
oxide did not further improve the stereoselectivity (Table 2, entries 10 and 11). Triphenyl 
phosphine oxide performed equally well as an additive and the use of 6 equivalents of this reagent 
proved optimal for the condensation of donor 3b and acceptor 22 (Table 2, entry 12). 
To explore the necessity of the intermediate iodide, the activation of imidate donor 2b with 
TMSOTf instead of TMSI in the presence of 6 equivalents phosphineoxide was executed (Table 
2, entry 13). This led to formation of the diglucoside 23 in good yield, but very poor selectivity, 
indicating that the anomeric iodide plays an important role in the coupling mechanism. To shed 
further light on the reactive intermediates formed with the TMSI-phosphine oxide reagent 
combination, the activation of donor 2b was studied by NMR spectroscopy. When donor 2b was 
activated with TMSI in CDCl2 in the absence of a phosphine oxide additive, a mixture of two 
products was formed. The products were tentatively assigned as α-iodide 26 (Scheme 3, H-1:  = 
6.82 ppm; C-1:  = 81.04 ppm; See SI for NMR spectra) and its β-counterpart 25 (H-1:  = 5.68 
ppm; C-1:  = 61.42 ppm).18 In time (± 45 min), the β-iodide 25 isomerized into its more stable 
α-congener 26.  Alternatively, treatment of a mixture of donor 2b and Ph2(Me)PO in CDCl3 with 
TMSI, showed a clean conversion of the imidate into the anomeric α-iodide 26. The β-iodide 25 
was not observed, nor could be detected the presence of any anomeric phosphonium species. 
Given the importance of the phosphine oxide for the stereoselectivity of the reaction (compare 
Table 2, entries 6 and 9), it is suggested that the anomeric α-iodide serves a reservoir for the more 
reactive β-phosphonium iodide 25, which is the actual glycosylating species (See Scheme 3). The 
phosphine oxide also catalyzes the transformation of the β-iodide 25 into α-iodide 26. 
 
Scheme 3. Proposed mechanism for the activation and glyosylation of imidate donors with TMSI 
and phosphineoxides. 
Having identified the required reagents and conditions to stereoselectively construct cis-
glucosidic linkages with both primary and secondary acceptor glucosyl alcohols, the attention 
was turned to assemble nonaglucoside 1 using the strategy outlined in Scheme 4.19 First 3-
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azidopropanol was condensed with donor 4b using the Ph3PO mediated glycosylation conditions 
to deliver monosaccharide 27 in 91% yield and 11:1 α/β selectivity (Scheme 4).  
 
a) TMSI, Ph3P=O, DCM, rt, 27: 91%, α:β = 11:1; 32: 68%, α:β > 20:1; 44: 67%, α:β > 20:1. b) 0.2M HCl/HFIP, 
DCM/HFIP, 28: 85%; 31: 85%; 33: 83%; 43: 88%. c) TMSOTf, DMF, 0 ℃, 30: 81%, α:β > 20:1. d) TfOH, DMF, 0 ℃, 
34: 81%, α:β > 20:1; 36: 91%, α:β > 20:1; 38: 93%, α:β > 20:1; 40: 91%, α:β > 20:1; 42: 80%, α:β > 20:1. e) DDQ, 
DCM/H2O, 35: 84%; 37: 75%; 39: 66%; 41: 70%. f) Pd(OH)2/C, H2 (3.5 atm), THF:H2O:t-BuOH, yield 61%. 
Scheme 4. Stereoselective synthesis of branched alpha nonasaccharide 1. 
The spacer-equipped glucoside 27 was then treated with a catalytic amount of HCl in a mixture 
of hexafluoro-iso-propanol (HFIP) and dichloromethane (DCM) to remove the PMB protecting 
group and liberate the C-4-alcohol. Acceptor 28 was then reacted with “branching” donor 5b 
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using the DMF-mediated glycosylation conditions to provide disaccharide 30 in 81% yield and 
excellent α-selectivity.20,21 The PMB ether in disaccharide 30, was chemoselectively removed 
using the aforementioned HCl/HFIP conditions. Of note, the Nap-ether at the C-4’ position was 
completely stable under these acidic conditions. Disaccharide 31 was then elongated at its C-6’-
OH with C-4-PMB-donor 4b using the TMSI-Ph3PO reagent combination to stereoselectively 
provide the trisaccharide 32. Liberation of the C-4”-OH, again using HCl/HFIP, then set the stage 
for the elongation of the branching arm with perbenzyl donor 2b under the aegis of TfOH and 
DMF. Having completed the first arm, it was continued to grow the α-(1,4)-backbone. To this end 
the Nap ether was oxidatively removed and the resulting secondary alcohol coupled to C-4-Nap 
donor 3b with TfOH-DMF to give pentasaccharide 36. Reiteration of this deprotection-coupling 
cycle let to hexasaccharide 38 and heptasaccharide 40 in a completely stereoselective fashion. To 
introduce the second α-(1,6)-arm the C-4-OH was unmasked and the heptasaccharide acceptor 41 
was coupled to branching glucoside 5b to deliver octamer 42. Liberation of the primary alcohol 
was then followed by the final TMSI-Ph3PO-condensation leading to the fully protected 
nonasaccharide 44. Global deprotection of the nonasaccharide was accomplished in a single 
hydrogenation event to complete the total synthesis of branched α-glucan 1. 
Conclusion 
In conclusion, a strategy was described to assemble α-glucans in a fully stereoselective manner, 
using a single type of donor, relying solely on the activating agents and additives to control the 
stereoselectivity of the glycosylation reactions. The reactivity of the donor building blocks was 
matched to the intrinsically different reactivity of primary and secondary alcohols through the 
use of different activator/additive combinations (TfOH or TMSOTf/DMF and TMSI/Ph3PO). To 
keep the reactivity of all donor synthons on par, it was introduced the triad of benzyl, 2-
methylnaphthyl and para-methoxybenzyl ethers, as a set of semi-orthogonal protecting groups 
that can be used to differentiate the hydroxyl groups on the building blocks that need permanent 
protection, that have to be extended to form the glycan backbone or removed to introduce 
branching.22 The applicability of the strategy has been illustrated by the fully stereoselective 
assembly of an Mtb nonasaccharide α-glycan, bearing two different branches. Matching the 
reactivity of both donor and acceptor through the use of external nucleophiles as reactivity 
moderators presents an important step towards the generation of a general glycosylation reaction. 
Increasing our insight into the reactivity of donor and acceptor building blocks in combination 
with the development of tailor made additives, covering a broad range of reactivity, will likely 
allow the fine tuning of many glycosylation systems in the future. Besides the stereoselective 
construction of cis-glycosidic linkages in a reagent controlled manner, it should be feasible to 
conceive nucleophilic additives that allow for the stereoselective formation of trans-glycosidic 
bonds using the same donor/acceptor pair, further broadening the scope of the methodology. 
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Experimental Section 
Standard procedure for glycosylation of secondary alcohols with thiodonors (2a-5a) (procedure A) 
The donor (1.0 eq, co-evaporated with toluene) was dissolved in dry DCM (see experimental description below for 
concentrations) under nitrogen and stirred over fresh flame-dried molecular sieves 3A, after which DMF (16 eq) was 
added to the solution. The solution was cooled to 0℃, after which NIS (1.0 eq) and TMSOTf (1.0 eq) were added. After 
1 h, the pre-activation was complete as indicated by TLC-analysis. Then acceptor (0.7 eq, see experimental description 
below for concentrations) was added to the solution. The reaction was stirred at 0 oC until TLC-analysis showed complete 
conversion of the acceptor. The reaction mixture was diluted and the reaction was quenched with saturated Na2S2O3. The 
organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The 
products were purified by size exclusion (eluent (50/50) MeOH/DCM and silica gel column chromatography (See 
experimental description below for eluent system). 
Standard procedure for glycosylation of secondary alcohols with imidate donors (2b-5b) (procedure B) 
The donor (1.0 eq, co-evaporated with toluene) was dissolved in dry DCM (see experimental description below for 
concentrations) under nitrogen and stirred over fresh flame-dried molecular sieves 3A, after which DMF (16 eq) was 
added to the solution. The solution was cooled to -78 oC, after which TfOH (1.0 eq) was added. After 30 min, the pre-
activation was complete as indicated by TLC-analysis. Acceptor (0.7 eq, see experimental description below for 
concentrations) was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until 
TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The products were purified by size exclusion (eluent (50/50) MeOH/DCM and silica gel column 
chromatography (See experimental description below for eluent system). 
Standard procedure for the glycosylation of primary alcohols (procedure C) 
A mixture of donor (1.0 eq), acceptor (0.7 eq) was co-evaporated with toluene three times and together with Ph3P=O (6 
eq) dissolved in dry DCM (see experimental description below for concentrations) and stirred over fresh flame-dried 
molecular sieves 3A under nitrogen. Then TMSI (1.0 eq) was added slowly in the mixture. The reaction was stirred at 
room temperature until TLC-analysis indicated the reaction to be complete. The solution was diluted and the reaction 
quenched with saturated Na2S2O3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, 
filtered and concentrated in vacuo. The products were purified by size exclusion (eluent (50/50) MeOH/DCM and silica 
gel column chromatography (See experimental description below for eluent system). 
General procedure for deprotection of the Nap protecting group (general procedure D) 
The starting material (1.0 eq) was dissolved in CH2Cl2 (DCM):H2O (10:1, 0.1 M). DDQ (1.1 eq) was added to the mixture. 
The reaction stirred until TLC-analysis indicated full consumption of the starting material (± 2h). Then the mixture was 
diluted with DCM and the reaction quenched with saturated Na2S2O3. The organic phase was washed with water and brine, 
dried with anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified by silica gel column 
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chromatography (See experimental description below for eluent system). 
General procedure for deprotection of the PMB protecting group (general procedure E) 
The starting material (1.0 eq) and triethylsilane (1.0 eq) were dissolved in DCM:HFIP (hexafluoro-iso-propanol) (1:1, 0.1 
M). Then 0.2M HCl in HFIP (0.1 eq) was added to the mixture. The reaction was stirred until TLC-analysis indicated 
complete consumption of the starting material (± 30 min.). Then the mixture was diluted with DCM and the reaction 
quenched with saturated Na2CO3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, 
filtered and concentrated in vacuo. The product was purified by silica gel column chromatography (See experimental 
description below for eluent system). 
Experimental Procedures and Characterization Data of Products 
For the synthesis procedure and data of known compounds 2a 23, 2b 24,32, 3a 25, 4a 26, 627,28, 727,29, 827,30, 9 32, 1132, 1232, 
2227,31, 2332 see references. We used "a", "b", "c", "d", "e", "f", "g", “h” and “i” to specify the H-1 and C-13 NMR signals 
of sugar rings from the “reducing” to the “non-reducing” end and “°” to specify the H-1 and C-13 NMR signals of the 
spacer. 
Scheme S1. Preparation of 3b and 4b 
 
N-phenyl trifluoroacetimidate glucose donor 3b 
Compound 3a (8.0 g, 11.7 mmol) was dissolved in acetone:H2O (10:1, 120 mL). N-Iodosuccinimide (NIS) (5.27 g, 23.4 
mmol) was added in one portion and the reaction was stirred at room temperature for 2 hours. The solution was diluted 
with DCM and the reaction was quenched with saturated aqueous Na2S2O3, then the organic layer was washed with water 
and brine. The organic layer was dried with anhydrous MgSO4, filtered and concentrated in vacuo, and the product purified 
by column chromatography (PE:EA = 2:1). Compound SI-1 (6.37 g, 92% yield) was obtained as a white solid. Next, 
compound SI-1 (6.37 g, 10.8 mmol) was dissolved in acetone:H2O (10:1, 110 mL). Cs2CO3 (5.27 g, 16.2 mmol) and 2,2,2-
trifluoro-N-phenylacetimidoyl chloride (2.62 ml, 16.2 mmol) were added to the solution respectively. The reaction stirred 
overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product was purified by column 
chromatography (PE:EA = 50:1-20:1). Compound 3b (7.89 g, 96% yield, mixture of α and β, PE:EA = 10:1, Rf = 0.45-
0.55) was obtained as yellow syrup. 1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.77-6.72(m, aromatic H), 6.46 (bs, 1 H, H-1α), 
5.61 (bs, 1 H, H-1β), 5.00-4.71 (m, CHH), 4.58-4.43 (m, CHH), 4.06 (t, J = 9.0 Hz, 1 H, H-α), 3.99 (bd, 1 H, H-α), 3.80-
3.68 (m), 3.42 (bs, 1 H). 13 C-APT (CDCl3, 125 MHz, 60℃) δ 143.93, 143.73, 143.42, 138.94, 138.72, 138.32, 138.22, 
138.14, 138.12, 135.91, 135.82, 133.57, 133.54, 133.28, 133.26 (aromatic C), 129.42, 128.81, 128.58, 128.55, 128.49, 
128.46, 128.21, 128.17, 128.06, 128.05, 127.98, 127.94, 127.90, 127.80, 127.94, 127.90, 127.80, 127.74, 127.71, 127.68, 
126.72, 126.70, 126.42, 126.17, 126.06, 126.00, 124.44, 124.30, 120.75, 119.66, 119.59 (aromatic CH), 116.50 (q, CF3), 
97.65 (C-1β), 93.95 (C-1α), 84.76 (β), 81.77 (α), 81.25 (β), 79.73 (α), 77.61 (β), 77.34 (α), 76.06 (β), 75.79, 75.60, 75.32, 
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75.07, 75.05, 73.72, 73.64, 73.57 (α), 73.52, 68.69 (C-6α and β). HR-MS: Calculated for C43H42F3O7N [M-
[O(C=NPh)CF3]+OH+Na]
+: 593.2510, found:593.2516.  
N-phenyl trifluoroacetimidate glucose donor 4b 
Compound 4a (10 g, 15.1 mmol) was dissolved in acetone:H2O (10:1, 150 mL). N-Iodosuccinimide (NIS) (6.79 g, 30.2 
mmol) was added in one portion and the reaction was stirred at room temperature for 2 hours. The solution was diluted 
with DCM and the reaction was quenched with saturated aqueous Na2S2O3, then the organic layer was washed with water 
and brine. The organic layer was dried with anhydrous MgSO4, filtered and concentrated in vacuo, and the product purified 
by column chromatography (PE:EA = 2:1). Compound SI-2 (7.40 g, 86% yield) was obtained as a white solid. Next, 
compound SI-2 (7.40 g, 10.8 mmol) was dissolved in acetone:H2O (10:1, 110 mL). Cs2CO3 (6.34 g, 19.4 mmol) and 
2,2,2-trifluoro-N-phenylacetimidoyl chloride (3.15 ml, 19.4 mmol) were added to the solution respectively. The reaction 
stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product was purified by column 
chromatography (PE:EA = 50:1-20:1). Compound 4b (9.14 g, 95% yield, mixture of α and β, PE:EA = 10:1, Rf = 0.34) 
was obtained as yellow syrup. 1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.79-6.70 (m, aromaticH), 6.44 (bs, 1 H, H-1α), 5.57 
(bs, 1 H, H-1β), 4.97-4.70 (m, CHH), 4.60-4.47 (m, CHH), 4.01 (t, J = 9.5 Hz, 1 H, H-α), 3.94 (bd, 1 H, H-α), 3.75-3.61 
(m), 3.36 (bs, 1 H). 13 C-APT (CDCl3, 125 MHz, 60℃) δ 159.66, 143.94, 143.73, 139.00, 138.78, 138.38, 138.28, 138.14, 
130.67, 130.57 (aromatic C), 129.68, 129.64, 129.46, 128.80, 128.57, 128.54, 128.51, 128.48, 128.46, 128.18, 127.96, 
127.92, 127.80, 127.78, 127.74, 127.70, 127.66, 126.46, 124.43, 124.27, 120.78, 119.65, 119.58 (aromatic CH), 116.48 
(q, CF3), 114.12, 114.10 (aromatic CH), 97.64 (C-1β), 93.91 (C-1α), 84.78, 81.78, 81.25, 79.70, 77.32, 77.07, 76.07, 
75.75, 75.58, 75.06, 74.95, 74.70, 73.72, 73.64, 73.56, 73.52, 68.71 (C-6), 68.69 (C-6), 55.39 (OCH3), 55.38 (OCH3). 
HR-MS: Calculated for C46H42F3O6N [M-[O(C=NPh)CF3]+OH+Na]
+: 613.2561, found: 613.2562. 
Scheme S2. Preparation of 5b. 
 
CF3COOH was added to the solution of SI-3 (16.9 g, 31.2 mmol) in wet DCM (160 mL). After TLC-analysis showed 
complete consumption of the starting material, the reaction was quenched with Et3N. Then the mixture was diluted with 
DCM, washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The product SI-4 
(10.6 g, 75% yield) was purified by column chromatography (PE:EA = 2:1). Compound SI-4 (10.6 g, 23.4 mmol) was 
dissolved in pyridine (60 mL). TBDPS-Cl (6.08 ml, 23.4 mmol) was added to the solution. After TLC-analysis showed 
complete consumption of the starting material, the reaction was quenched with saturated NaHCO3. The mixture was 
diluted with DCM, washed with H2O and brine, dried with anhydrous MgSO4, filtered, concentrated in vacuo, purified 
by column chromatography (PE:EA = 20:1). Compound SI-5 (12.9 g, 80% yield) was obtained as colorless solid. The 
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compound SI-5 (12.9 g, 18.7 mmol) was dissolved in DMF (75 mL). Sodium hydride (1.34g, 56 mmol) and NapBr (5.37 
g, 24.3 mmol) were added to the mixture at 0 oC under N2. The reaction was stirred at room temperature until TLC-
analysis showed complete consumption of the starting material. The mixture was poured in cold water, diluted with Et2O, 
washed with H2O and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The compound SI-6 (14.4 
g, 93% yield) was obtained as yellow syrup. Compound SI-6 (14.4g, 17.3 mmol) was treated with 1M TBAF in THF 
(52.0 ml, 52.0 mmol). After TLC-analysis showed complete consumption of the starting material, the reaction was 
quenched with saturated NaHCO3. The mixture was diluted with DCM, washed with H2O and brine, dried with anhydrous 
MgSO4, filtered and concentrated in vacuo. The crude compound SI-7 was dissolved in DMF (70 mL). Sodium hydride 
(1.25 g, 52 mmol) and PMBCl (3.52 ml, 26.0 mmol) were added to the mixture at 0 oC under N2. The reaction was stirred 
at room temperature until TLC-analysis showed complete consumption of the starting material. The mixture was poured 
in cold water, diluted with Et2O, washed with H2O and brine, dried with anhydrous MgSO4, filtered and concentrated in 
vacuo. The crude compound was crystallization from EtOH. Compound 5a (9.70g, 78% yield over two steps, PE:EA = 
4:1, Rf = 0.63, melting point 90.4-91 oC) was obtained as a white solid. [α]D
20 +0.9 (c=1, CHCl3). IR (neat, cm
-1) ν 696, 
744, 818, 1029, 1066, 1084, 1125, 1247, 1363, 1512, 1612, 2860, 2920. 1H-NMR (CDCl3, 400 MHz) δ 7.78-7.71 (m, 3 
H, aromatic H), 7.602-7.57 (m, 3 H, aromatic H), 7.45-7.38 (m, 4 H, aromatic H), 7.33-7.20 (m, 14 H, aromatic H), 6.84-
6.79 (m, 2 H, aromatic H), 4.96-4.84 (m, 4 H, 4 CHH), 4.75-4.67 (m, 3 H, H-1, 2 CHH), 4.54 (d, J = 11.6 Hz, 1 H, CHH), 
4.42 (d, J = 11.6 Hz, 1 H, CHH), 3.77-3.69 (m, 7 H), 3.56-3.51 (m, 2 H). 13C-APT (CDCl3, 100 MHz,) δ 159.18, 138.49, 
138.08, 135.60, 133.98, 133.26, 132.99 (aromatic C), 131.88 (aromatic CH), 130.29 (aromatic C), 129.43, 128.94, 128.58, 
128.47, 128.45, 128.25, 128.15, 127.95, 127.89, 127.78, 127.70, 127.69, 127.43, 126.61, 126.11, 125.96, 125.93, 113.91, 
113.76 (aromatic CH), 87.54 (C-1), 86.79, 80.91, 79.12, 77.79, 75.82, 75.44, 75.04, 73.08, 68.61, 64.83 (C-6), 55.19 
(OCH3). HR-MS: Calculated for C45H44O6S [M+Na]
+: 735.2751, found: 735.2760. 
Compound 5a (9.63g, 13.5 mmol) was dissolved in acetone:H2O (10:1, 135 mL). NIS (6.08 g, 27.0 mmol) was added in 
a portion. The reaction was stirred at room temperature for 2 hours, after which the solution was diluted with DCM and 
the reaction quenched with saturated Na2S2O3. Then the organic layer was washed with water and brine, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography 
(PE:EA = 3:1). Compound SI-8 (7.30 g, 87% yield) was obtained as white solid. Then compound SI-8 (7.30 g, 11.7 mmol) 
was dissolved in acetone:H2O (10:1, 120 mL). Cs2CO3 (5.75g, 17.6 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl 
chloride (2.86 mL, 17.6 mmol) were added to the solution respectively. The reaction was stirred overnight, then quenched 
with Et3N, filtered and concentrated in vacuo. The product was purified by column chromatography (PE:EA = 50:1-20:1). 
Compound 5b (8.50 g, 91% yield, mixture of α and β, PE:EA = 10:1, Rf = 0.25-0.36) was obtained as yellow syrup. 1H-
NMR (CDCl3, 500 MHz, 60 ℃) δ 7.78-6.72 (m, aromatic H), 6.46 (bs, 1 H, H-1α), 5.60 (bs, 1 H, H-1β), 4.98-4.37 (m, 
CHH), 4.05 (t, J = 9.5 Hz, 1 H, H-α), 3.97 (bd, 1 H, H-α), 3.78-3.64 (m), 3.40 (bs, 1 H). 13 C-APT (CDCl3, 125 MHz, 
60℃)δ 159.63, 159.59, 143.95, 143.75, 143.44, 138.97, 138.74, 138.15, 138.13, 135.95, 135.86, 133.58, 133.55, 133.28, 
133.27, 130.41, 130.29 (aromatic C), 129.62, 129.56, 129.46, 128.81, 128.59, 128.55, 128.48, 128.46, 128.19, 128.08, 
128.07, 127.98, 127.95, 127.80, 127.76, 127.71, 127.67, 126.66, 126.45, 126.16, 126.04, 125.99, 124.44, 124.30, 120.75, 
119.68, 119.60 (aromatic CH), 116.50 (q, CF3), 114.10, 114.08 (aromatic CH), 97.65 (C-1β), 93.97 (C-1α), 84.78, 81.78, 
81.26, 79.71, 77.62, 77.34, 76.06, 75.79, 75.61, 75.30, 75.07, 75.05, 73.54, 73.52, 73.33, 73.27, 68.25 (C-6), 68.22 (C-6), 
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55.31 (OCH3). HR-MS: Calculated for C47H44F3O7N [M-[O(C=NPh)CF3]+OH+Na]
+: 643.2666, found: 643.2676. 
Activation of donor 4b using TMSI with or without Ph2MeP=O.   
TMSI (10 μL, 0.07 mmol) was added to a solution of donor 4b (51 mg, 0.07 mmol), with or without Ph2MeP=O (91 mg, 
0.42 mmol) in CDCl3 (0.6 mL) in a normal NMR tube under N2 at room temperature. Spectra were recorded every 10 
min. 
Figure S1. Activation study of donor 4b using NMR (for full NMR spectra: see below). 
 
The following NMR spectra were obtained (from bottom to top): Starting donor; Activation with TMSI (after 5 min); 
Activation with TMSI and Ph2MeP=O (after 55 min)  
 
Synthesis of diglucoside 9 using NIS/TMSOTf 
The donor 2a (102 mg, 0.16 mmol) and acceptor 6 (50 mg, 0.11 mmol) were co-evaporated with toluene 3 times, then 
dissolved in dry DCM (2 mL) under nitrogen and stirred over fresh flame-dried molecular sieves 3A. The solution was 
cooled to 0 oC, after which NIS (36 mg, 0.16 mmol) and TMSOTf (29 μL, 0.16 mmol) were added. The reaction was 
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stirred at 0 oC until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with saturated 
Na2S2O3, then the organic layer was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated 
in vacuo. The crude product was purified by size exclusion (DCM:MeOH = 1:1). Compound 9 (91mg, 86% yield, α:β= 
2:1, PE:EA = 4:1, Rf = 0.32) was obtained as a colorless syrup. 
Synthesis of diglucoside 9 using NIS/TMSOTf + DMF 
The donor 2a (102 mg, 0.16 mmol, co-evaporated with toluene 3 times) was dissolved in dry DCM (1 mL) under nitrogen 
and stirred over fresh flame-dried molecular sieves 3A, after which DMF (202 μL, 2.56 mmol) was added to the solution. 
The solution was cooled to 0 oC, after which NIS (36 mg, 0.16 mmol) and TMSOTf (29 μL, 0.16 mmol) were added. 
After 30 min, the pre-activation was complete as indicated by TLC-analysis. Acceptor 6 (50 mg, 0.11 mmol, dissolved in 
a little DCM and washed 2 times with DCM (totally 1 mL) was added to the solution. The reaction was stirred at 0 oC 
until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with saturated Na2S2O3, then 
the organic layer was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The 
crude product was purified by size exclusion (DCM:MeOH = 1:1). Compound 9 (88 mg, 83% yield, α:β> 50:1) was 
obtained as a colorless syrup. 
Synthesis of diglucoside 10: The reaction was carried out according to the standard 
procedure B at -78 - 0 oC. The donor 3b (1.34g, 1.96 mmol, co-evaporated with toluene 3 
times) was dissolved in dry DCM (20 mL) under nitrogen and stirred over fresh flame-dried 
molecular sieves 3A, after which DMF (2.47 mL, 31.4 mmol) was added to the solution. 
The solution was cooled to -78 oC, after which TfOH (173μL, 1.96 mmol) was added. After 30 min, the pre-activation 
was complete as indicated by TLC-analysis. Acceptor 6 (608mg, 1.31 mmol, dissolved in a little DCM and washed 3 
times with DCM, totally 6 mL) was added to the solution and the mixture was placed in an ice bath. The reaction was 
stirred at 0 oC until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, 
filtered and concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 10 
(1113mg, 82% yield, α:β> 20:1, PE:EA = 4:1, Rf = 0.48) was obtained as a colorless syrup. [α]D
20 +34.8 (c=1, CHCl3). 
IR (neat, cm-1) ν 696, 735, 820, 857, 910, 1028, 1045, 1093, 1156, 1207, 1261, 1273, 1363, 1453, 1496, 2860, 3030.1H-
NMR (CDCl3, 400MHz) δ 7.81-7.79 (m, 1 H, aromatic H), 7.74-7.70 (m, 2 H, aromatic H), 7.50 (bs, 1 H, aromatic H), 
7.47-7.43 (m, 2 H, aromatic H), 7.30-7.18 (m, 31 H, aromatic H), 5.73 (d, J = 3.6Hz, 1 H, H-1b), 5.05 (d, J = 11.6 Hz, 1 
H, CHH), 4.91 (d, J = 10.8 Hz, 1 H, CHH), 4.81 (d, J = 10.8 Hz, 1 H, CHH), 4.70 (d, J = 12.0 Hz, 1 H, CHH), 4.63-
4.49(m, 8 H, 7 CHH, H-1a), 4.23 (d, J = 12.0 Hz, 1 H, CHH), 4.13-4.05 (m, 2 H, H-3a, H-4a), 3.94 (t, J = 9.2 Hz, 1 H, 
H-3b), 3.87-3.82 (m, 2 H, H-5a, H-6aa), 3.73-3.59 (m, 4 H, H-5a, H-4b, H-2a, H-6ab), 3.54-3.50 (m, 2H, H-2b, H-6ba), 
3.40-3.37 (m, 4 H, H-6bb). 
13C-APT (CDCl3, 100 MHz,) δ 139.01, 138.88, 138.22, 138.05, 137.96, 136.00, 139.29, 132.99 
(aromatic C), 128.54, 128.45, 128.41, 128.35, 128.32, 128.31, 128.20, 128.04, 127.96, 127.88, 127.82, 127.78, 127.74, 
127.69, 127.61, 127.46, 127.29, 127.21, 126.86, 126.61, 126.15, 126.10, 125.93 (aromatic CH), 97.86 (C-1a), 96.72 (C-
1b), 82.19 (C-3b), 82.15 (C-3a), 80.28 (C-2a), 79.52 (C-2b), 77.65 (C-4b), 75.66, 75.11, 74.54, 73.54, 73.49, 73.35, 73.20 
(7 CH2), 72.17 (C-4a), 71.03 (C-5a), 69.57 (C-5b), 69.05 (C-6a), 68.12 (C-6b), 55.25 (OCH3). HR-MS: Calculated for 
C66H68O11 [M+Na]
+: 1059.4654 found: 1059.4681. 
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Synthesis of diglucoside 11: The reaction was carried out according to the standard 
procedure B at -78 - 0 oC. The donor 2b (106 g, 0.15 mmol, co-evaporated with toluene 
3 times) was dissolved in dry DCM (1 mL) under nitrogen and stirred over fresh flame-
dried molecular sieves 3A, after which DMF (188 μL, 2.39 mmol) was added to the solution. The solution was cooled to 
-78 oC, after which TfOH (13 μL, 0.15 mmol) was added. After 30 min, the pre-activation was complete as indicated by 
TLC-analysis. Acceptor 7 (46 mg, 0.10 mmol, dissolved in a little DCM and washed 2 times with DCM, totally 1 mL) 
was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 11 (83 mg, 85% yield, α:β> 20:1, PE:EA = 
4:1, Rf = 0.32) was obtained as a colorless syrup. 
Synthesis of diglucoside 12: The reaction was carried out according to the standard procedure 
B at -78 - 0 oC. The donor 2b (106 g, 0.15 mmol, co-evaporated with toluene 3 times) was 
dissolved in dry DCM (1 mL) under nitrogen and stirred over fresh flame-dried molecular sieves 
3A, after which DMF (188 μL, 2.39 mmol) was added to the solution. The solution was cooled 
to -78 oC, after which TfOH (13 μL, 0.15 mmol) was added. After 30 min, the pre-activation was complete as indicated 
by TLC-analysis. Acceptor 7 (46 mg, 0.10 mmol, dissolved in a little DCM and washed 2 times with DCM, totally 1 mL) 
was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 12 (88 mg, 90% yield, α:β> 20:1, PE:EA = 
4:1, Rf = 0.22) was obtained as a colorless syrup. 
Synthesis of diglucoside 13: The reaction was carried out according to the general procedure 
D, using 12 (750mg, 0.73 mmol, 0.1 M in DCM:H2O) and DDQ (180 mg, 0.80 mmol). The 
product was purified by silica gel column chromatography (PE:EA = 6:1). Compound 13 
(510mg, 78% yield, PE:EA = 4:1, Rf = 0.20) was obtained as a colorless syrup. [α]D
20 +38.4 
(c=1, CHCl3), IR (neat, cm
-1) ν 696, 735, 764, 910, 1027, 1046, 1093, 1153, 1208, 1456, 2867, 2923. 1H-NMR (CDCl3, 
400 MHz) δ 7.34-7.17 (m, 30 H, aromatic H), 5.71 (d, J = 3.6Hz, 1 H, H-1b), 5.05 (d, J = 11.6 Hz, 1 H, CHH), 4.90 (d, J 
= 11.6 Hz, 1 H, CHH), 4.71 (d, J = 11.6 Hz, 1 H, CHH), 4.69 (d, J = 11.6 Hz, 1 H, CHH), 4.61 (d, J = 3.6Hz, 1 H, H-1a), 
4.59-4.47(m, 6 H, 6 CHH), 4.43 (d, J = 12.0 Hz, 1 H, CHH), 4.32 (d, J = 12.0 Hz, 1 H, CHH), 4.12-4.03 (m, 2 H, H-3a, 
H-4a), 3.88-3.83 (m, 2 H), 3.77-3.58 (m, 5 H), 3.54-3.51 (m, 2H), 3.46-3.42 (m, 2 H), 3.38 (s, 3 H, OCH3). 
13C-APT 
(CDCl3, 100 MHz,) δ138.97, 138.81, 138.25, 137.97, 137.94, 137.90 (aromatic C), 128.51, 128.48, 128.38, 128.36, 
128.30, 128.25, 128.13, 127.99, 127.90, 127.76, 127.69, 127.43, 127.36, 127.16, 126.75 (aromatic CH), 97.77 (C-1a), 
96.58 (C-1b), 82.09 (C-3a), 81.30 (C-3b), 80.21 (C-2a), 79.02 (C-2b), 75.35, 74.43, 73.56, 73.38, 73.19, 73.12 (6 CH2), 
72.27 (C-4a), 71.48 (C-4b), 70.57 (C-5a), 69.77 (C-5b), 69.56 (C-6a), 69.03 (C-6b), 55.21 (OCH3). HR-MS: Calculated 
for C55H60O11 [M+Na
+]: 919.4028; found: 919.4058. 
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Synthesis of triglucoside 14: The reaction was carried out according to the 
standard procedure B. The donor 3b (1.04g, 1.53 mmol, co-evaporated with 
toluene 3 times) was dissolved in dry DCM (10 mL) under nitrogen and stirred 
over fresh flame-dried molecular sieves 3A, after which DMF (1.90 mL, 24.4 
mmol) was added to the solution. The solution was cooled to -78 oC, after which 
TfOH (134 μL, 1.52 mmol) was added. After 30 min, the pre-activation was complete as indicated by TLC-analysis. 
Acceptor 13 (680 mg, 0.76 mmol) dissolved in a little DCM and washed 3 times with DCM (totally 5 mL) was added to 
the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed 
complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The 
product was purified by size exclusion (DCM:MeOH = 1:1).  Compound 14 (906mg, 81% yield, α:β> 20:1, PE:EA = 
4:1, Rf = 0.42) was obtained as a colorless syrup.[α]D
20 +49.4(c=1, CHCl3). IR (neat, cm
-1) ν 696, 749, 764, 1028, 1043, 
1094, 1154, 1275, 2870, 3030.1H-NMR (CDCl3, 400 MHz) δ 7.81-7.78 (m, 1 H, aromatic H), 7.74-7.68 (m, 2 H, aromatic 
H), 7.50 (bs, 1 H, aromatic H), 7.47-7.43 (m, 2 H, aromatic H), 7.30-7.09 (m, 46 H, aromatic H), 5.71 (d, J = 3.6 Hz, 1 
H, H-1b), 5.59 (d, J = 3.6 Hz, 1 H, H-1c), 5.04 (d, J = 11.6 Hz, 1 H, CHH), 4.93 (d, J = 11.6 Hz, 1 H, CHH), 4.91 (d, J = 
10.8 Hz, 1 H, CHH), 4.85-4.68 (m, 5 H, 5 CHH), 4.60-4.40 (m, 12 H), 4.24 (d, J = 12.0 Hz, 1 H, CHH), 4.11-4.02 (m, 4 
H), 3.95-3.83 (m, 4 H), 3.74-3.50 (m, 9 H), 3.40-3.37 (m, 4 H). 13C-APT (CDCl3, 100 MHz,) δ 139.12, 138.95, 138.89, 
138.42, 138.30, 138.12, 138.01, 137.85, 136.06, 133.31, 133.00 (aromatic C), 128.55, 128.42, 128.38, 128.36, 128.34, 
128.31, 128.29, 128.19, 128.05, 127.97, 127.96, 127.78, 127.76, 127.7, 127.64, 127.62, 127.60, 127.55, 127.46, 127.22, 
127.13, 126.89, 126.71, 126.59, 126.15, 126.12, 125.94 (aromatic CH), 97.90 (C-1a), 96.83 (C-1b), 96.37 (C-1c), 82.23, 
82.01, 81.83 (3 C-3), 80.09, 79.71, 79.67 (3 C-2), 77.66 (C-4), 75.55, 75.11, 74.57, 74.15, 73.57, 73.48, 73.32, 73.12, 
73.08 (CH2), 73.03, 72.47 (2 C-4), 71.03, 70.83, 69.65 (3 C-5), 68.98, 68.87, 68.16 (3 C-6), 55.31 (OCH3). HR-MS: 
Calculated for C93H96O16 [M+Na
+]: 1491.6591; found: 1491.6603. 
Synthesis of triglucoside 15: The reaction was carried out according to the general 
procedure D, using 14 (800mg, 0.54 mmol, 0.1 M in DCM:H2O) and DDQ (136 mg, 
0.60 mmol). The product was purified by silica gel column chromatography (PE:EA 
= 6:1). Compound 15 (564mg, 78% yield, PE:EA = 4:1, Rf = 0.20) was obtained as 
a colorless syrup. [α]D
20+41.0(c=1, CHCl3). IR (neat, cm
-1) ν696, 735, 1028, 1042, 
1077, 1081, 1094, 1125, 1132, 1154, 1364, 1453, 2854, 2930. 1H-NMR (CDCl3, 400 
MHz) δ 7.28-7.06 (m, 45 H, aromatic H), 5.71 (d, J = 3.6 Hz, 1 H, H-1b), 5.60 (d, J = 3.2 Hz, 1 H, H-1c), 5.05 (d, J = 
11.6 Hz, 1 H, CHH), 4.96 (d, J = 11.6 Hz, 1 H, CHH), 4.85-4.62 (m, 2 H, 2 CHH), 4.77-4.39 (m, 13 H), 4.33 (d, J = 12.0 
Hz, 1 H, CHH), 4.13-4.03 (m, 5 H), 3.91-3.85 (m, 3 H), 3.77-3.52 (m, 9 H), 3.47-3.42 (m, 2 H) 3.38 (s, 3 H, OCH3). 
13C-
APT (CDCl3, 125 MHz,) δ 139.19, 138.97, 138.95, 138.51, 138.24, 138.21, 138.17, 137.05, 137.88 (aromatic C), 128.56, 
128.55, 128.48, 128.39, 128.35, 128.32, 128.05, 127.99, 127.85, 127.79, 127.78, 127.75, 127.70, 127.67, 127.60, 127.54, 
127.48, 127.23, 127.17, 127.92, 126.72(aromatic CH), 97.95, 96.64, 96.37 (3 C-1), 82.01, 81.83, 81.47, 80.13, 79.74, 
79.25, 75.32, 74.58, 74.08, 73.70, 73.49, 73.35, 73.27, 73.08, 72.94, 72.39, 7169, 70.88, 70.53, 69.95, 69.73, 69.03, 68.93, 
55.33 (OCH3). HR-MS: Calculated for C82H88O16 [M+Na
+]: 1351.5965; found: 1351.6018. 
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Synthesis of tetraglucoside 16: The reaction was carried out according to the 
standard procedure B. The donor 3b (620 mg, 0.91 mmol, co-evaporated with 
toluene 3 times) was dissolved in dry DCM (5 mL) under nitrogen and stirred over 
fresh flame-dried molecular sieves 3A, after which DMF (1.13 mL, 14.5 mmol) 
was added to the solution. The solution was cooled to -78 oC, after which TfOH 
(80 μL, 0.91 mmol) was added. After 30 min, the pre-activation was complete as indicated by TLC-analysis. Acceptor 15 
(680 mg, 0.76 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 3 mL) was added to the solution 
and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed complete conversion 
of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by 
size exclusion (DCM:MeOH = 1:1).  Compound 16 (661mg, 82% yield, α:β> 20:1, PE:EA = 4:1, Rf = 0.33) was obtained 
as a colorless syrup. [α]D
20 +64.8 (c=1, CHCl3). IR (neat, cm
-1) ν 696, 735, 1028, 1040, 1095, 1155, 1208, 1275, 1456, 
2865, 3031, 3064.1H-NMR (CDCl3, 400 MHz) δ 7.81-7.78 (m, 1 H, aromatic H), 7.74-7.68 (m, 2 H, aromatic H), 7.51 
(bs, 1 H, aromatic H), 7.46-7.42 (m, 2 H, aromatic H), 7.30-7.09 (m, 61 H, aromatic H), 5.71 (d, J = 3.6 Hz, 1 H, H-1b), 
5.60 (m, 2 H, H-1c, H-1d), 5.04 (d, J = 11.6 Hz, 1 H, CHH), 4.94-4.69 (m, 9 H, 9 CHH), 4.61 (d, J = 3.6 Hz, 1 H, H-1b), 
4.60-4.37 (m, 15 H), 4.23 (d, J = 12.0 Hz, 1 H, CHH), 4.14-4.01 (m, 6 H), 3.96 (t, J = 9.2 Hz, 1 H), 3.90-3.85 (m, 4 H), 
3.79-3.71 (m, 4 H), 3.66-3.50 (m, 8 H), 3.40-3.37 (m, 4 H). 13C-APT (CDCl3, 100 MHz,) δ 139.09, 138.97, 138.93, 138.87, 
138.42, 138.23, 138.14, 138.12, 138.09, 138.02, 137.96, 137.87, 136.02, 133.28, 132.97 (aromatic C), 128.49, 128.37, 
128.27, 128.25, 128.22, 128.20, 128.14, 128.00, 127.98, 127.91, 127.73, 127.71, 127.66, 127.62, 127.58, 127.54, 127.48, 
127.40, 127.16, 127.10, 127.02, 126.87, 126.73, 126.58, 126.12, 126.07, 125.90 (aromatic CH), 97.87 (C-1a), 96.94 (C-
1b), 96.45, 96.32 (2 C-1), 82.19, 81.97, 81.85, 81.59 (4 C-3), 80.04, 79.79, 79.57, 79.42 (4 C-2), 77.67 (C-4), 75.52, 75.09, 
74.56, 74.11, 74.05, 73.52, 73.41, 73.35, 73.31, 73.25 (CH2), 73.18, 73.14 (2 C-4), 73.06, 73.02, 72.87 (CH2), 72.53 (C-
4), 70.99, 70.88, 70.81, 69.66 (4 C-5), 68.90, 68.84, 68.78, 68.15 (4 C-6), 55.26 (OCH3). HR-MS: Calculated for 
C120H124O21 [M+H
+]: 1901.8708; found: 1901.8695. 
Synthesis of tetraglucoside 17: The reaction was carried out according to the general 
procedure D, using 16 (590 mg, 0.31 mmol, 0.05 M in DCM:H2O) and DDQ (80 mg, 
0.35 mmol). The product was purified by silica gel column chromatography (PE:EA 
= 5:1). Compound 17 (460 mg, 84% yield, PE:EA = 4:1, Rf = 0.18) was obtained as 
a colorless syrup. [α]D
20+59.2 (c=1, CHCl3). IR (neat, cm
-1) ν 695, 733, 747, 764, 
910, 1027, 1039, 1094, 1152, 1207, 1260, 1456, 2855, 3923, 3031.1H-NMR (CDCl3, 400 MHz) δ 7.29-7.10 (m, 60 H, 
aromatic H), 5.70 (d, J = 3.2 Hz, 1 H, H-1b), 5.61 (bd, 2 H, H-1c, H-1d), 5.05 (d, J = 11.6 Hz, 1 H, CHH), 4.94-4.78 (m, 
5 H, 5 CHH), 4.73-4.37 (m, 18 H), 4.31 (d, J = 12.0 Hz, 1 H, CHH), 4.14-4.01 (m, 6 H), 3.90-3.86 (m, 4 H), 3.78-3.39 
(m, 17 H). 13C-APT (CDCl3, 100 MHz,) δ 139.19, 139.05, 138.98, 138.95, 138.54, 138.34, 138.24, 138.20, 138.12, 138.07, 
138.04, 137.97 (aromatic C), 128.57, 128.55, 128.48, 128.40, 128.35, 128.33, 128.29, 128.05, 127.99, 127.85, 127.83, 
127.79, 127.77, 127.75, 127.72, 127.70, 127.67, 127.61, 127.59, 127.52, 127.47, 127.23, 127.17, 127.12, 126.97, 126.92, 
126.81, 126.73, 126.64 (aromatic CH), 97.97, 96.79, 96.56, 96.34 (4 C-1), 82.03, 81.91, 81.63, 81.50 (4 C-3), 80.14, 
79.86, 79.50, 79.17 (4 C-2), 75.36, 74.65, 74.15, 73.69, 73.50, 73.45 (C-4), 73.41, 73.38, 73.33 , 73.27 (C-4), 72.93, 72.90, 
72.40, 71.72 (C-4), 70.95, 70.91, 70.50 (3 C-5), 69.95 (C-6), 69.77 (C-5), 68.97, 68.88 (3 C-6), 55.35 (OCH3). HR-MS: 
Chapter 2 
54 
Calculated for C109H116O21 [M+Na
+]: 1783.7901; found: 1783.7969. 
Synthesis of pentaglucoside18: The reaction was carried out according to the 
standard procedure B. The donor 3b (380 mg, 0.56 mmol, co-evaporated with 
toluene 3 times) was dissolved in dry DCM (2 mL) under nitrogen and stirred over 
fresh flame-dried molecular sieves 3A, after which DMF (700 μL, 8.90 mmol) 
was added to the solution. The solution was cooled to -78 oC, after which TfOH 
(49 μL, 0.55 mmol) was added. After 30 min, the pre-activation was complete as indicated by TLC-analysis. Acceptor 15 
(680 mg, 0.76 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 3 mL) was added to the solution 
and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed complete conversion 
of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by 
size exclusion (DCM:MeOH = 1:1). Compound 18 (410mg, 80% yield, α:β> 20:1, PE:EA = 4:1, Rf = 0.26) was obtained 
as a colorless syrup. [α]D
20 +92.7 (c=1, CHCl3). IR (neat, cm
-1) ν695, 734, 820, 857, 910, 1027, 1037, 1094, 1154, 1207, 
1363, 1453, 2862, 2927, 3031. 1H-NMR (CDCl3, 400 MHz) δ 7.81-7.79 (m, 1 H, aromatic H), 7.74-7.69 (m, 2 H, aromatic 
H), 7.50 (bs, 1 H, aromatic H), 7.46-7.44 (m, 2 H, aromatic H), 7.29-7.04 (m, 76 H, aromatic H), 5.72 (bs, 1 H, H-1), 5.63 
(bs, 1 H, H-1) , 5.59 (bs, 2 H, 2 H-1), 5.04 (d, J = 11.6 Hz, 1 H, CHH), 4.93-4.70 (m, 11 H, 11 CHH), 4.60-4.37 (m, 20 
H), 4.22 (d, J = 12.0 Hz, 1 H, CHH), 4.11-3.47 (m, 29 H), 3.38-3.35 (m, 4 H). 13C-APT (CDCl3, 100 MHz,) δ 139.14, 
139.00, 138.95, 138.89, 138.44, 138.28, 138.27, 138.14, 138.08, 137.99, 137.94, 137.90, 136.06, 133.30, 133.00 
(aromatic C), 128.52, 128.40, 128.33, 128.21, 128.17, 128.02, 128.00, 127.94, 127.81, 127.77, 127.74, 127.71. 127.65, 
127.59, 127.53, 127.50, 127.42, 127.18, 127.13, 127.05, 126.91, 126.77, 126.66, 126.59, 126.57, 126.15, 126.10, 125.93 
(aromatic CH), 97.91 (C-1a), 97.01, 96.52, 96.46, 96.34 (4 C-1), 82.24, 81.98, 81.89, 81.68 (5 C-3), 80.05, 79.75, 79.57, 
79.49 (5 C-2), 77.69 (C-4), 75.54, 75.12, 74.60, 74.12, 74.06, 73.55, 73.45, 73.41, 73.33, 73.29 (CH2), 73.17 (2 C-4), 
73.06 (CH2), 72.95 (C-4), 72.91, 72.85 (CH2), 72.50 (C-4), 71.02, 70.90, 70.85, 69.69 (5 C-5), 68.92, 68.86, 68.80, 68.73, 
68.16 (5 C-6), 55.29 (OCH3). MALDI-TOF: Calculated for C147H152O26 [M+H
+]: 2356.0; found: 2357.9. 
Synthesis of pentaglucoside 19: The reaction was carried out according to the 
general procedure D, using 18 (590 mg, 0.25 mmol, 0.05 M in DCM:H2O) and DDQ 
(63 mg, 0.28 mmol). The product was purified by silica gel column chromatography 
(PE:EA = 5:1). Compound 19 (415mg, 81% yield, PE:EA = 4:1, Rf = 0.16) was 
obtained as a colorless syrup. [α]D
20 +73.0 (c=1, CHCl3). IR (neat, cm
-1) ν695, 733, 
746, 763, 937, 1027, 1037, 1092, 1153, 1207, 1275, 1363, 1454, 2860, 2920, 3030, 3064. 1H-NMR (CDCl3, 400 MHz) δ 
7.31-7.02 (450m, 75 H, aromatic H), 5.71 (d, J = 3.6 Hz, 1 H, H-1), 5.64 (d, J = 3.6 Hz, 1 H, H-1), 5.60 (bd, 2 H, 2 H-1), 
5.05 (d, J = 11.6 Hz, 1 H, CHH), 4.95-4.36 (m, 29 H), 4.30 (d, J = 12.0 Hz, 1 H, CHH), 4.13-3.98 (m, 8 H), 3.91-3.86 (m, 
5 H), 3.80-3.50 (m, 15 H), 3.45-3.37 (m, 5 H). 13C-APT (CDCl3, 100 MHz,) δ 139.56, 139.19, 139.03, 138.99, 138.95, 
138.92, 138.50, 138.33, 138.20, 138.17, 138.11, 138.10, 138.00, 137.94 (aromatic C), 128.63, 128.53, 128.52, 128.45, 
128.37, 128.31, 128.29, 128.27, 128.25, 128.22, 128.01, 127.96, 127.84, 127.80, 127.76, 127.30, 127.70, 127.69, 127.62, 
127.55, 127.48, 127.44, 127.20, 127.15, 127.07, 126.94, 126.80, 126.69, 126.57 (aromatic CH), 97.95 (C-1a), 96.81, 
96.55, 96.41, 96.36 (4 C-1), 81.99, 81.90, 81.68, 81.66, 81.50 (5 C-3), 80.10, 79.77, 79.58, 79.53, 79.13, 75.32, 74.62, 
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74.12, 74.04, 73.98, 73.66, 73.51, 73.46, 73.41, 73.37, 73.33, 73.22, 73.08, 73.02, 72.93, 72.91, 72.82, 72.35, 71.71, 70.93, 
70.91, 70.46, 69.92, 69.74, 68.91, 68.77, 55.31 (OCH3). MALDI-TOF: Calculated for C136H144O26 [M+Na
+]: 2216.0; 
found: 2220.0. 
Synthesis of hexaglucoside 20: The reaction was carried out according to the 
standard procedure B. The donor 3b (95 mg, 0.14 mmol, co-evaporated with 
toluene 3 times) was dissolved in dry DCM (1 mL) under nitrogen and stirred over 
fresh flame-dried molecular sieves 3A, after which DMF (175 μL, 2.25 mmol) 
was added to the solution. The solution was cooled to -78 oC, after which TfOH 
(12 μL, 0.14 mmol) was added. After 30 min, the pre-activation was complete as indicated by TLC-analysis. Acceptor 15 
(680 mg, 0.76 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 3 mL) was added to the solution 
and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed complete conversion 
of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by 
size exclusion (DCM:MeOH = 1:1). Compound 20 (104mg, 81% yield, α:β> 20:1, PE:EA = 4:1, Rf = 0.21) was obtained 
as a colorless syrup. [α]D
20 +72.6 (c=1, CHCl3). IR (neat, cm
-1) ν696, 738, 749, 764, 1028, 1039, 1095, 1154, 1208, 1261, 
1456, 2859, 2922, 3031. 1H-NMR (CDCl3, 400 MHz) δ 7.82-7.79 (m, 1 H, aromatic H), 7.74-7.67 (m, 2 H, aromatic H), 
7.50 (bs, 1 H, aromatic H), 7.47-7.43 (m, 2 H, aromatic H), 7.29-7.02 (m, 91 H, aromatic H), 5.71 (d, J = 3.6 Hz, 1 H, H-
1), 5.64 (d, J = 3.2 Hz, 1 H, H-1) , 5.61 (bt, 2 H, 2 H-1), 5.58 (d, J = 3.6 Hz, 1 H, H-1), 5.04 (d, J = 11.6 Hz, 1 H, CHH), 
4.93-4.69 (m, 13 H, 11 CHH), 4.61-4.34 (m, 24 H), 4.21 (d, J = 12.0 Hz, 1 H, CHH), 4.13-3.46 (m, 35 H), 3.38-3.35 (m, 
4 H). 13C-APT (CDCl3, 100 MHz,) δ 139.16, 138.98, 138.96, 138.91, 138.46, 138.30, 138.27, 138.16, 138.07, 138.00, 
137.95, 137.92, 136.08, 133.32, 133.01 (aromatic C), 128.54, 128.41, 128.23, 128.19, 128.02, 127.97, 127.83, 127.80, 
127.76, 127.73, 127.60, 127.58, 127.54, 127.50, 127.43, 127.21, 127.15, 127.06, 126.94, 126.79, 126.67, 126.64, 126.60, 
126.58, 126.17, 126.11, 125.94 (aromatic CH), 97.93 (C-1a), 97.02, 96.55, 96.47, 96.34 (5 C-1), 82.25, 82.00, 81.92, 
81.77, 81.73, 81.65 (6 C-3), 80.07, 79.77, 79.65, 79.58, 79.50, 77.71, 75.55, 75.13, 74.63, 74.07, 73.98, 73.56, 73.47, 
73.37, 73.34, 73.30, 73.08, 72.99, 72.91, 72.63, 72.48, 71.02, 70.91, 70.85, 69.71, 68.88 (C-6), 68.72 (C-6), 68.18 (C-6), 
55.31 (OCH3). MALDI-TOF: Calculated for C174H180O31 [M+Na
+]: 2788.2; found: 2790.1. 
Synthesis of hexaglucoside 21: Compound 20 (31 mg, 0.011 mmol) was dissolved 
in THF/H2O/tert-BuOH (4 ml/4 ml/1.6 ml) before a catalytic amount of Pd(OH)2/C 
was added. The reaction mixture was stirred for 3 days under a H2 atmosphere (3.5 
bar), filtered and concentrated in vacuo. A white powder was obtained, which was 
purified by gel filtration (HW-40, 0.15M NH4OAc in H2O) to provide 21 (9mg, 
80%).1H-NMR (CDCl3, 400 MHz) δ5.37-5.36 (m, 5 H, 5 H-1), 4.77 (d, J = 4.0 Hz, 1 H, H-1a), 3.94-3.53 (m, 35 H), 3.41-
3.35 (m, 4 H). 13C-APT (CDCl3, 100 MHz,) δ 96.68, 96.53, 99.40, 99.07 (6 C-1), 76.71, 76.64, 76.55, 73.50, 73.29, 72.81, 
72.66, 71.68, 71.50, 71.12, 71.01, 70.00, 69.26, 60.41 (C-6), 60.34 (C-6), 55.04 (OCH3). HR-MS: Calculated for 
C37H64O31 [M+Na
+]: 1027.3324; found: 1027.3348. 
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Synthesis of diglucoside 23 using NIS/TMSOTf+DMF: The donor 2a (102 mg, 0.16 mmol, 
co-evaporated with toluene 3 times) was dissolved in dry DCM (1 mL) under nitrogen and 
stirred over fresh flame-dried molecular sieves 3A, after which DMF (202 μL, 2.56 mmol) 
was added to the solution. The solution was cooled to 0 oC, after which NIS (36 mg, 0.16 
mmol) and TMSOTf (29 μL, 0.16 mmol) were added. After 30 min, the pre-activation was complete as indicated by TLC-
analysis. Acceptor 22 (50 mg, 0.11 mmol, dissolved in a little DCM and washed 2 times with DCM (totally 1 mL) was 
added to the solution. The reaction was stirred at 0 oC until TLC-analysis showed complete conversion of the acceptor. 
The reaction was quenched with saturated Na2S2O3, then the organic layer was washed with water and brine, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by size exclusion (DCM:MeOH = 
1:1). Compound 23 (88 mg, 83% yield, α:β = 2.7:1, PE:EA = 4:1, Rf = 0.32) was obtained as a colorless syrup. 
Synthesis of diglucoside 24 (α:β = 3:1): The donor 4b  (123 mg, 0.16 mmol) and acceptor 
22 (70 mg, 0.15 mmol, co-evaporated with toluene 3 times) was dissolved in dry DCM (2 
mL) under nitrogen and stirred over fresh flame-dried molecular sieves 3A, after which DMF 
(50 μL, 0.64 mmol) was added to the solution. Then TMSOTf (10 μL, 0.05 mmol) was added. 
The reaction was stirred at rt until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched 
with Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). 
Compound 24 (144 mg, 94% yield, α:β = 3:1) was obtained as a white solid. 
Synthesis of diglucoside 24: The reaction was carried out according to the standard 
procedure C, using 4b (90 mg, 0.15 mmol), 22 (40 mg, 0.09 mmol, 0.1 M in DCM), Ph3P=O 
(143 mg, 0.51 mmol) and TMSI (19 μL, 0.12 mmol). The product was purified by size 
exclusion (DCM:MeOH = 1:1). Compound 24 (79 mg, 90% yield, α:β = 25:1, PE:EA = 4:1, 
Rf = 0.34, melting point 117.5-118.6 oC) was obtained as a white solid. IR (neat, cm-1) ν696, 737, 747, 821, 1028, 1052, 
1072, 1084, 1137, 1159, 1249, 1363, 1456, 1515, 1855, 2924, 3030.1H-NMR (CDCl3, 400 MHz) δ 7.33-7.22 (m, 30 H, 
aromatic H), 7.04-7.01 (m, 2 H, aromatic H), 6.79-6.76 (m, 2 H, aromatic H), 4.99-4.89 (m, 4 H, 3 CHH, H-1), 4.82-4.54 
(m, 10 H, 10 CHH), 4.43-4.37 (m, 2 H, CHH, H-1), 4.00-3.92 (m, 2 H), 3.84-3.52 (m, 12 H), 3.43 (dd, J1 = 3.6 Hz, J2= 
9.6 Hz, 1 H), 3.34 (s, 3 H). 13C-APT (CDCl3, 100 MHz,) δ 159.22, 138.98, 138.93, 138.55, 138.27, 138.10, 130.72 
(aromatic C), 129.54, 128.51, 128.46, 128.25, 128.11, 128.07, 128.00, 127.95, 127.87, 127.74, 127.72, 127.67, 127.59, 
113.78 (aromatic CH), 98.04 (C-1), 97.35 (C-1), 82.22, 81.80, 80.22, 80.07, 77.85, 77.42, 75.81, 75.57, 75.08, 74.68, 
73.49, 73.48, 72.45, 70.47, 70.35, 68.56, 66.10, 55.35, 55.25. HR-MS: Calculated forC63H68O12[M+Na
+]: 1039.4603; 
found: 1039.4642. 
Synthesis of glucoside 27 (α:β = 1:1): The donor 4b  (123 mg, 0.16 mmol) and 3-
aminopropanol (30 μL, 0.32 mmol, co-evaporated with toluene 3 times) was dissolved in 
dry DCM (2 mL) under nitrogen and stirred over fresh flame-dried molecular sieves 3A. 
Then TMSOTf (5 μL, 0.03 mmol) was added. The reaction was quenched with Et3N after 3 h, filtered and concentrated 
in vacuo. The product was purified by silica gel column chromatography (PE:EA = 10:1). Compound 27 (53 mg, 49% 
yield, α:β = 1:1) was obtained as a colorless syrup. 
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Synthesis of glucoside 27: The reaction was carried out according to the standard procedure 
C, using 4b (1.95 g, 2.63mmol, 0.1 M in DCM), 3-aminopropanol (369 μL, 3.94mmol), 
Ph3P=O (4.39 g, 15.8 mmol) and TMSI (413 μL, 2.89 mmol). The product was purified by 
silica gel column chromatography (PE:EA = 10:1). Compound 27 (1530 mg, 91% yield, α:β = 11:1, PE:EA = 4:1, Rf = 
0.48) was obtained as a colorless syrup. An analytical sample of the pure α-anomer was obtained by careful silica gel 
column chromatography (PE:EA = 10:1). [α]D
20 +24.6 (c=1, CHCl3). IR (neat, cm
-1) ν697, 749, 764, 823, 1014, 1028, 
1040, 1071, 1158, 1249, 1257, 1456, 2096, 2867, 2910, 2923, 3031. 1H-NMR (CDCl3, 400 MHz) δ 7.33-7.22 (m, 15 H, 
aromatic H), 7.03 (d, J = 8.6 Hz, 2 H, aromatic H), 6.78 (d, J = 8.6 Hz, 2 H, aromatic H), 4.98 (d, J = 11.0 Hz, 1 H, CHH), 
4.83 (d, J = 11.0 Hz, 1 H, CHH), 4.79-4.72 (m, 3 H, 2 CHH, H-1), 4.63 (d, J = 12.0 Hz, 1 H, CHH), 4.61 (d, J = 12.0 Hz, 
1 H, CHH), 4.47 (d, J = 12.0 Hz, 1 H, CHH), 4.39 (d, J = 12.0 Hz, 1 H, CHH), 3.94 (t, J1 = J2 = 9.2 Hz, 1 H, H-3), 3.76 
(s, 3 H, CH3), 3.74-3.68 (m, 3H, H-5, H-6a, H-1°a), 3.64-3.59 (m, 2H, H-6b, H-4), 3.55 (dd, J1 = 3.6 Hz, J2 = 9. 6Hz, 1 
H, H-2), 3.48-3.33 ( m, 3 H, H-1°b, H-3°), 1.95-1.77 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz,) δ 159.33, 138.96, 
138.32, 137.99, 130.39 (5 aromatic C), 129.73, 128.55, 128.48, 128.46, 128.09, 128.01, 127.99, 127.94, 127.79, 127.66, 
113.86 (19 aromatic CH), 97.30 (C-1), 82.12 (C-3), 80.13 (C-2), 77.41 (C-4), 75.74, 74.85, 73.55, 73.38 (4 PhCH2), 70.41 
(C-5), 68.49 (C-6), 64.79 (C-1°), 55.33 (OCH3), 48.38 (C-3°), 28.93 (C-2°). HR-MS: Calculated for C38H43O7N3[M+Na
+]: 
676.2993; found: 676.3008. 
Synthesis of glucoside 28: The reaction was carried out according to the general procedure E, 
using 27 (1605 mg, 2.51 mmol, 0.1 M in DCM:HFIP), triethylsilane (400 μL, 2.52 mmol) and 
0.2M HCl/HFIP (1.3 ml, 0.26 mmol). The product was purified by silica gel column 
chromatography (PE:EA = 6:1). Compound 28 (1138 mg, 85% yield, PE:EA = 2:1, Rf = 0.49) was obtained as a colorless 
syrup. [α]D
20 +30.0 (c=1, CHCl3). IR (neat, cm
-1) ν697, 749, 764, 1000, 1028, 1053, 1080, 1152, 1261, 1275, 1456, 2096, 
2874, 2916, 3032. 1H-NMR (CDCl3, 400 MHz) δ 7.33-7.21 (m, 15 H, aromatic H), 4.99 (d, J = 11.4 Hz, 1 H, CHH), 4.76-
4.71 (m, 3 H, 2 CHH, H-1), 4.61 (d, J = 12.0 Hz, 1 H, CHH), 4.58 (d, J = 12.0 Hz, 1 H, CHH), 4.52 (d, J = 12.0 Hz, 1 H, 
CHH), 3.81-3.66 (m, 5 H, H-6, H-5, H-1°a), 3.60 (dt, J1 = 2.2 Hz, J2 = 9.2 Hz, 1 H, H-4), 3.52 (dd, J1 = 3.6 Hz, J2 = 9. 
6Hz, 1 H, H-2), 3.47-3.33 ( m, 3 H, H-1°b, H-3°), 2.46 (d, J = 2.2 Hz, 1 H, OH), 1.94-1.82 (m, 2 H, H-2°). 13C-APT 
(CDCl3, 100 MHz,) δ138.85, 138.18, 138.02 (3 aromatic C), 128.59, 128.52, 128.04, 128.02, 127.98, 127.94, 127.84, 
127.68, 127.64 (15 aromatic CH), 97.21 (C-1), 82.42 (C-3), 79.80 (C-2), 75.39, 73.59, 73.07 (3 PhCH2), 70.77 (C-4), 
70.20 (C-5), 69.49 (C-6), 64.78 (C-1°), 48.35 (C-3°), 28.86 (C-2°). HR-MS: Calculated for C30H35O6N3 [M+Na
+]: 
556.2418; found: 556.2771. 
Characterization of anhydroglucose 29: Compound 29 was obtained in the glycosylation reaction of 5b 
and 28 as a side product. Compound 29 was obtained as a colorless syrup. [α]D
20-21.1 (c=1, CHCl3). IR 
(neat, cm-1) ν 697, 736, 819, 857, 898, 925, 953, 1027, 1071, 1089, 1173, 1197, 1315, 1337, 1454, 1718, 
2858, 2895, 2922, 2956, 3060. 1H-NMR (CDCl3, 400 MHz) δ 7.85-7.78 (m, 3 H, aromatic H), 7.74 (s, 1 H, aromatic H), 
7.51-7.46 (m, 3 H, aromatic H), 7.33-7.27 (m, 8 H, aromatic H), 7.20-7.17 (m, 2 H, aromatic H), 5.47 (s, 1 H, H-1), 4.47 
(d, J = 12.4 Hz, 1 H, CHH), 4.71 (d, J = 12.4 Hz, 1 H, CHH), 4.62 (d, J = 5.4 Hz, 1 H, H-5), 4.58 (d, J = 12.4 Hz, 1 H, 
CHH), 4.54 (d, J = 12.4 Hz, 1 H, CHH), 4.42 (d, J = 12.4 Hz, 1 H, CHH), 4.37 (d, J = 12.4 Hz, 1 H, CHH), 3.89 (dd, J1 
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= 0.8 Hz, J2 = 7.2 Hz, 1 H, H-6a), 3.62 (dd, J1 = 5.4 Hz, J2 = 7.2Hz, 1 H, H-6b), 3.61 (bs, 1 H, H-3), 3.36 (bd, 2 H, H-4, 
H-2),. 13C-APT (CDCl3, 100 MHz,) δ137.93, 135.47, 133.27, 133.16 (aromatic C), 128.56, 128.55, 128.45, 128.09, 127.98, 
127.96, 127.94, 127.83, 127.71, 126.78, 126.35, 126.15, 125.92 (aromatic CH), 100.69 (C-1), 76.71 (C-4), 76.06 (C-3), 
776.04 (C-2), 74.51 (C-5), 72.08, 71.90, 71.47 (3 CH2), 65.469 (C-6). HR-MS: Calculated for C31H30O5 [M+Na
+]: 
505.1985; found: 505.1999. 
Synthesis of diglucoside 30: The reaction was carried out according to the standard 
procedure B. The donor 5b (2.60 g, 3.28 mmol, co-evaporated with toluene 3 times) 
was dissolved in dry DCM (35 mL) under nitrogen and stirred over fresh flame-dried 
molecular sieves 3A, after which DMF (2.80 mL, 35.5 mmol) was added to the 
solution. The solution was cooled to -78 oC, after which TMSOTf (600 μL, 3.35 mmol) was added. After 60 min, the pre-
activation was complete as indicated by TLC-analysis. Acceptor 28 (1.19 g, 2.23 mmol, dissolved in a little DCM and 
washed 3 times with DCM, totally 10 mL) was added to the solution and the mixture was placed in an ice bath. The 
reaction was stirred at 0 oC until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched 
with Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). 
Compound 30 (2.05 g, 81% yield, α:β> 20:1, Toluene (Tol):EA = 12:1, Rf = 0.55) was obtained as a colorless syrup. 
[α]D
20 +44.5 (c=1, CHCl3). IR (neat, cm
-1) ν697, 750, 764, 1014, 1029, 1038, 1093, 1156, 1261, 2096, 2868, 2925.1H-
NMR (CDCl3, 400 MHz) δ 7.81-7.78 (m, 1 H, aromatic H), 7.73-7.68 (m, 2 H, aromatic H), 7.47-7.42 (m, 3 H, aromatic 
H), 7.29-7.10 (m, 28 H, aromatic H), 6.76-6.72 (m, 2 H, aromatic H), 5.73 (d, J = 3.6Hz, 1 H, H-1b), 5.05 (d, J = 11.6 
Hz, 1 H, CHH), 4.92 (d, J = 10.8 Hz, 1 H, CHH), 4.88 (d, J = 11.2 Hz, 1 H, CHH), 4.83 (d, J = 11.6 Hz, 1 H, CHH), 4.81 
(d, J = 11.2 Hz, 1 H, CHH), 4.74 (d, J = 3.6 Hz, 1 H, H-1a), 4.67 (d, J = 12.0 Hz, 1 H, CHH), 4.61-4.46 (m, 7 H, 7 CHH), 
4.16 (d, J = 12.0 Hz, 1 H, CHH), 4.11-4.05 (m, 2 H, H-3a, H-4a), 3.93 (t, J = 8.8 Hz, 1 H, H-3b), 3.86-3.82 (m, 2 H, H-
5a, H-6aa), 3.76-3.61 (m, 8H, H-5b, H-4b, H-2a, H-1°a, H-6ab, OCH3), 3.55-3.49 (m, 2H, H-2b, H-6ba), 3.48-3.34 (m, 4 
H, H-1°b, H-6bb, H-3°), 1.92-1.85 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) δ 159.25, 139.02, 138.89, 138.23, 138.11, 
137.98, 135.99, 133.26, 132.96 (aromatic C), 129.91 (aromatic CH), 129.88 (aromatic C), 128.52, 128.40, 128.36, 128.32, 
128.29, 128.15, 128.00, 127.94, 127.93, 127.87, 127.80, 127.68, 127.55, 127.44, 127.27, 127.17, 126.79, 126.47, 126.04, 
125.88, 113.72 (aromatic CH), 96.88 (C-1a), 96.84 (C-1b), 82.09 (C-3b), 81.97 (C-3a), 80.48 (C-2a), 79.42 (C-2b), 77.63 
(C-4b), 75.59, 75.03, 74.36, 73.30, 73.25, 73.18, 73.07 (7 CH2), 72.34 (C-4a), 71.01 (C-5b), 69.84 (C-5a), 69.02 (C-6a), 
67.52 (C-6b), 64.86 (C-1°), 55.12 (OCH3), 48.36 (C-3°), 28.90 (C-2°). HR-MS: Calculated forC69H73O12N3[M+Na
+]: 
1158.5086; found: 1158.5112. 
Synthesis of diglucoside 31: The reaction was carried out according to the general 
procedure E, using 30 (1.78 g, 1.57 mmol, 0.1 M in DCM:HFIP), triethylsilane (250 
μL, 1.57 mmol) and 0.2M HCl/HFIP (0.8 ml, 0.16mmol). The product was purified 
by silica gel column chromatography (Tol:EA = 20:1). Compound 31 (1.36 g, 85% yield, Tol:EA = 12:1, Rf = 0.21) was 
obtained as a colorless syrup. [α]D
20 +30.4 (c=1, CHCl3). IR (neat, cm
-1) ν696, 735, 748, 818, 1027, 1047, 1072, 1089, 
1155, 1208, 1261, 1275, 1355, 1363, 1456, 2096, 2862, 2871, 2918, 2924, 3031.1H-NMR (CDCl3, 400 MHz) δ 7.82-7.74 
(m, 3 H, aromatic H), 7.68 (bs, 1 H, aromatic H), 7.48-7.43 (m, 2 H, aromatic H), 7.39 (dd, J1 = 1.6 Hz, J2 = 8.4 Hz, 1 H, 
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aromatic H), 7.30-7.19 (m, 25 H, aromatic H), 5.63 (d, J = 3.6 Hz, 1 H, H-1b), 5.04 (d, J = 11.2 Hz, 1 H, CHH), 5.00 (d, 
J = 10.8 Hz, 1 H, CHH), 4.93 (d, J = 10.8 Hz, 1 H, CHH), 4.82 (d, J = 10.8 Hz, 1 H, CHH), 4.80 (d, J = 10.8 Hz, 1 H, 
CHH), 4.77 (d, J = 11.2 Hz, 1 H, CHH), 4.74 (d, J = 3.6 Hz, 1 H, H-1a), 4.68 (d, J = 12.0 Hz, 1 H, CHH), 4.61-4.50 (m, 
5 H, 5 CHH), 4.09-4.04 (m, 2 H, H-3a, H-4a), 3.96  (t, J = 8.8 Hz, 1 H, H-3b), 3.86-3.82 (bd, 2 H, H-5a, H-6aa), 3.76-
3.51 (m, 7H, H-6b, H-5b, H-4b, H-6ab, H-2a, H-1°a), 3.48-3.37 (m, 4 H, H-2b, H-1°b, H-3°), 1.93-1.87 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) δ 139.01, 138.79, 138.10, 137.99, 137.95, 135.77, 133.32, 133.07 (aromatic C), 128.58, 
128.48, 128.47, 128.40, 128.38, 128.28, 128.19, 128.08, 128.01, 127.94, 127.86, 127.83, 127.80, 127.67, 126.85, 126.71, 
126.23, 126.12, 126.07 (aromatic CH), 96.90 (C-1a), 96.53 (C-1b), 82.00 (C-3a), 81.85 (C-3b), 80.41 (C-2a), 79.60 (C-
2b), 77.59 (C-4b), 75.64, 75.31, 74.40, 73.50, 73.35 (6 CH2), 72.31 (C-4a), 71.71 (C-5b), 69.91 (C-5a), 68.70 (C-6a), 
64.94 (C-1°), 64.68 (C-6b), 48.41 (C-3°), 28.93 (C-2°). HR-MS: Calculated for C62H67O11N3 [M+Na
+]: 1038.4511; found: 
1038.4543. 
Synthesis of triglucoside 32: The reaction was carried out according to the 
standard procedure C, using 4b (1.80 g, 2.43 mmol), 31 (1.28 g, 1.26 mmol, 
0.1 M in DCM), Ph3P=O (4.00g, 14.4 mmol) and TMSI (382 μL, 2.67 
mmol). The product was purified by size exclusion (DCM:MeOH = 1:1). 
Compound 32 (1.34 g, 68% yield, α:β> 20:1, Tol:EA = 12:1, Rf = 0.52) was 
obtained as a colorless syrup. [α]D
20 +58.1 (c=1, CHCl3). IR (neat, cm
-1) ν697, 749, 764, 820, 1028, 1051, 1073, 1084, 
1156, 1208, 1251, 1261, 1275, 1465, 2096, 2868, 2923, 3031.1H-NMR (CDCl3, 400 MHz) δ 7.78-7.68 (m, 4 H, aromatic 
H), 7.46-7.37 (m, 3 H, aromatic H), 7.32-7.10 (m, 40 H, aromatic H), 7.01 (bd, 2 H, aromatic H), 6.75-6.72 (m, 2 H, 
aromatic H), 5.63 (d, J = 3.6 Hz, 1 H, H-1b), 5.07 (d, J = 3.6 Hz, 1 H, H-1c), 5.03 (d, J = 12.0 Hz, 1 H, CHH), 5.02 (d, J 
= 11.6 Hz, 1 H, CHH), 4.93 (d, J = 10.8 Hz, 1 H, CHH), 4.88 (d, J = 10.8 Hz, 1 H, CHH), 4.80-4.72 (m, 6 H, H-1a, 5 
CHH), 4.65-4.46 (m, 7 H, 7 CHH), 4.41-4.34 (m, 4 H, 4 CHH), 4.07-4.03 (m, 2 H, H-4a, H-3a), 3.96-3.56 (m, 17 H), 
3.53 (dd, J1 = 3.2 Hz, J2 = 9.6 Hz, 1 H, H-2c), 3.48-3.37 (m, 4 H, H-6c, H-3°), 3.26 (dd, J1 = 3.6 Hz, J2 = 9.6 Hz, 1 H, H-
2b), 1.91-1.85 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz,) δ 159.20, 134.14, 139.03, 138.96, 138.54, 138.17, 138.13, 
138.11, 138.03, 136.20, 133.36, 133.01, 130.77 (aromatic C), 129.62, 128.57, 128.45, 128.39, 128.36, 128.33, 128.22, 
128.15, 128.05, 128.04, 127.80, 127.75, 127.70, 127.55, 127.50, 127.47, 127.38, 127.21, 126.61, 126.53, 126.15, 126.08, 
125.87, 113.76 (aromatic CH), 97.20 (C-1c), 96.90 (C-1a), 96.29 (C-1b), 82.12 (C-3a), 81.98 (C-3b), 81.81 (C-3c), 80.38 
(C-2a), 80.21 (C-2c), 80.00 (C-2b), 77.65 (C-4b), 77.31 (C-4c), 75.58, 75.50, 75.22, 74.77, 74.09, 73.54, 73.34, 73.29 
(CH2), 71.94 (C-4a), 71.84 (CH2), 71.70 (C-5b), 70.27 (C-5c), 69.79 (C-5a), 69.14 (C-6a), 68.39 (C-6c), 65.24 (C-6b), 
64.91 (C-1°), 55.33 (OCH3), 48.41 (C-3°), 28.93 (C-2°).HR-MS: Calculated for C62H67O11N3 [M+Na
+]: 1591.7162; found: 
1591.6997. 
Synthesis of triglucoside 33: The reaction was carried out according to the 
general procedure E, using 30 (1.90 g, 1.21 mmol, 0.1 M in DCM:HFIP), 
triethylsilane (302 μL, 1.90 mmol) and 0.2M HCl/HFIP (0.95 ml, 0.19 mmol). 
The product was purified by silica gel column chromatography (Tol:EA = 
25:1). Compound 33 (1456mg, 83% yield, Tol:EA = 12:1, Rf = 0.33) was 
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obtained as a colorless syrup. [α]D
20 +47.7 (c=1, CHCl3). IR (neat, cm
-1) ν696, 737, 749, 764, 820, 857, 911, 1027, 1051, 
1081, 1091, 1141, 1155, 1208, 1261, 1275, 2097, 2867, 2923.1H-NMR (CDCl3, 400 MHz) δ 7.82-7.70 (m, 4 H, aromatic 
H), 7.49-7.39 (m, 3 H, aromatic H), 7.31-7.12 (m, 40 H, aromatic H), 5.64 (d, J = 3.6 Hz, 1 H, H-1b), 5.06-5.03 (m, 3 H, 
H-1c, 2 CHH), 4.94 (d, J = 11.6 Hz, 1 H, CHH), 4.89 (d, J = 10.8 Hz, 1 H, CHH), 4.81-4.35 (m, 15 H, H-1a, 14 CHH), 
4.09-4.03 (m, 2 H, H-4a, H-3a), 3.93-3.32 (m, 19 H), 3.26 (dd, J1 = 3.6 Hz, J2 = 10.0 Hz, 1 H, H-2b), 1.91-1.85 (m, 2 H, 
H-2°). 13C-APT (CDCl3, 100 MHz,) δ 139.04, 138.92, 138.42, 134.14, 138.09, 137.99, 136.15, 133.35, 133.02 (aromatic 
C), 128.55, 128.45, 128.40, 128.36, 128.32, 128.20, 128.17, 128.10, 128.05, 128.01, 127.82, 127.79, 127.69, 127.58, 
127.53, 127.46, 127.38, 127.32, 127.23, 126.65, 126.59, 126.14, 125.93 (aromatic CH), 97.17 (C-1c), 96.85 (C-1a), 96.16 
(C-1b), 82.15 (C-3a), 81.99 (C-3b), 80.86 (C-3c), 80.39 (C-2a), 80.01 (C-2b), 79.76 (C-2c), 77.71 (C-4b), 77.48, 77.16, 
76.84, 75.52, 75.17, 74.12, 73.58, 73.33, 73.28 (CH2), 71.69 (C-4a), 71.65 (C-5b), 71.58 (CH2), 70.62 (C-5c), 70.70 (C-
4c), 69.75 (C-5a), 69.36 (C-6a), 69.07 (C-6c), 65.34 (C-6b), 64.90 (C-1°), 48.38 (C-3°), 28.90 (C-2°). HR-MS: Calculated 
for C62H67O11N3 [M+H
+]: 1448.6629; found: 1448.6653. 
Synthesis of tetraglucose 34: The reaction was carried out according 
to the standard procedure B. The donor 2b (1.05 g, 1.47 mmol, co-
evaporated with toluene 3 times) was dissolved in dry DCM (10 mL) 
under nitrogen and stirred over fresh flame-dried molecular sieves 
3A, after which DMF (1.86 mL, 23.6 mmol) was added to the 
solution. The solution was cooled to -78 oC, after which TfOH (130 
μL, 1.47 mmol) was added. After 30 min, the pre-activation was complete as indicated by TLC-analysis. Acceptor 33 
(1.07 g, 0.74 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 5 mL) was added to the solution 
and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed complete conversion 
of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by 
size exclusion (DCM:MeOH = 1:1). Compound 34 (1.18 g, 81% yield, α:β> 20:1, Tol:EA = 12:1, Rf = 0.57) was obtained 
as a colorless syrup.[α]D
20 +60.7 (c=1, CHCl3). IR (neat, cm
-1) ν696, 734, 749, 764, 819, 856, 909, 1027, 1047, 1072, 
1091, 1155, 1207, 1261, 1275, 1363, 1456, 2090, 2095, 2863, 2923, 3031. 1H-NMR (CDCl3, 400MHz) δ 7.78-7.73 (m, 4 
H, aromatic H), 7.48-7.37 (m, 3 H, aromatic H), 7.28-7.03 (m, 60 H, aromatic H), 5.73 (d, J = 3.6 Hz, 1 H, H-1d), 5.64 
(d, J = 3.6 Hz, 1 H, H-1b), 5.20 (d, J = 3.6 Hz, 1 H, H-1c), 5.08-5.00 (m ,3 H, 3 CHH), 4.90-4.29 (m, 23 H, H-1a, 22 
CHH), 4.22 (d, J = 12.4 Hz, 1 H, CHH), 4.11-4.03 (m, 4 H, H-5b, H-4c, H-3a, H-3c), 3.95-3.31 (m, 23 H), 3.23 (dd, J1 = 
3.6 Hz, J2 = 9.2 Hz, 1 H, H-2b), 1.91-1.85 (m, 2 H, H-2°).
13C-APT (CDCl3, 100 MHz,) δ 139.05, 139.04, 139.02, 138.85, 
138.64, 138.38, 138.21, 138.07 138.04, 138.01, 137.98, 136.24, 133.38, 133.05 (aromatic C), 128.57, 128.41, 128.35, 
128.32, 128.31, 128.26, 128.21, 128.12, 128.06, 128.03, 127.93, 127.80, 127.76, 127.68, 127.63, 127.50, 127.46, 127.34, 
127.24, 127.06, 126.93, 126.75, 126.54, 126.35, 126.08. 125.85 (aromatic CH), 96.90 (C-1a), 96.71 (2 C, C-1c and 1d), 
96.18 (C-1b), 82.15 (2 C, C-3a and 3d), 81.88 (C-3b), 81.71 (C-3c), 80.38 (C-2a), 80.22 (C-2c), 79.98 (C-2b), 79.38 (C-
2d), 77.65 (2 C, C-4b and 4d), 75.51, 75.41, 75.27, 74.99, 74.07, 74.01, 73.49, 73.43, 73.34, 73.23, 72.96 (CH2), 72.06 
(C-4a), 71.97 (C-4c), 71.54 (CH2), 71.40 (C-5b), 70.91 (C-5d), 69.83 (C-5c), 69.70 (C-5a), 68.95 (2 C, C-6a and 6c), 
68.15 (C-6d), 64.90 (C-1°), 64.55 (C-6b), 48.36 (C-3°), 28.90 (C-2°). HR-MS: Calculated for C122H127O21N3 [M+H
+]: 
1970.9035; found: 1970.9066. 
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Synthesis of tetraglucoside 35: The reaction was carried out 
according to the general procedure D, using 34 (1.20 g, 0.61 mmol, 
0.05 M in DCM:H2O) and DDQ (152 mg, 0.67 mmol). The product 
was purified by silica gel column chromatography (Tol:EA = 25:1). 
Compound 35 (928mg, 84% yield, Tol:EA = 12:1, Rf = 0.28) was 
obtained as a colorless syrup. [α]D
20 +64.3 (c=1, CHCl3). IR (neat, 
cm-1) ν695, 733, 747, 764, 911, 1026, 1044, 1092, 1155, 1208, 1261, 1275, 1355, 1363, 1456, 2095, 2868, 2926, 3031, 
3064.1H-NMR (CDCl3, 400MHz) δ7.43-7.09 (m, 60 H, aromatic H), 5.70 (d, J = 3.6 Hz, 1 H, H-1d), 5.67 (d, J = 3.6 Hz, 
1 H, H-1b), 5.04 (d, J = 12.0 Hz, 1 H, CHH), 4.99 (d, J = 11.6 Hz, 1 H, CHH), 4.89-4.39 (m, 23 H, H-1a, H-1c, 21 CHH), 
4.25 (d, J = 12.4 Hz, 1 H, CHH), 4.11-3.97 (m, 4 H, H-4a, H-4c, H-3a, H-3c), 3.88-3.33 (m, 24 H), 1.93-1.86 (m, 2 H, H-
2°). 13C-APT (CDCl3, 100 MHz,) δ 139.09, 138.98, 138.86, 138.62, 138.19, 138.10, 138.06, 138.00, 137.97 (aromatic C), 
128.77, 128.57, 128.51, 128.44, 128.43, 128.37, 128.35, 128.29, 128.20, 128.15, 128.05, 127.92, 127.90, 127.84, 127.79, 
127.74, 127.70, 127.66, 127.64, 127.60, 127.54, 127.44, 127.23, 127.12, 126.75, 126.69 (aromatic CH), 97.53 (C-1a), 
96.90 (C-1c), 96.82 (C-1d), 96.52 (C-1b), 82.06 (C-3d and 3c), 81.96 (C-3a), 81.37 (C-3b), 80.44 (C-2c), 80.04 (C-2a), 
79.40 (C-2d), 79.26 (C-2b), 77.69 (C-4d), 75.63, 75.53, 75.02, 74.22, 73.54, 73.32, 73.27, 72.57 (CH2), 72.03 (C-4a), 
71.92 (C-4c), 71.72 (C-4b), 71.06 (C-5b), 70.94 (C-5d), 69.84 (C-5c and 5a), 68.92 (C-6a), 68.83 (C-6c), 68.17 (C-6d), 
67.73 (C-6b), 64.90 (C-1°), 48.40 (C-3°), 28.93 (C-2°). HR-MS: Calculated for C111H119O21N3 [M+H
+]: 1830.8409; found: 
1830.8458. 
Synthesis of pentaglucoside 36: The reaction was carried out according 
to the standard procedure B. The donor 3b (1.20 g, 1.57 mmol, co-
evaporated with toluene 3 times) was dissolved in dry DCM (6 mL) under 
nitrogen and stirred over fresh flame-dried molecular sieves 3A, after 
which DMF (1.98 mL, 25.1 mmol) was added to the solution. The 
solution was cooled to -78 oC, after which TfOH (139 μL, 1.57 mmol) 
was added. After 30 min, the pre-activation was complete as indicated by 
TLC-analysis. Acceptor 35 (860 mg, 0.47 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 3 mL) 
was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 36 (1.04 g, 91% yield, α:β> 20:1, Tol:EA = 
12:1, Rf = 0.64) was obtained as a colorless syrup.[α]D
20 +60.5 (c=1, CHCl3). IR (neat, cm
-1) ν696, 749, 765, 1297, 1275, 
2094, 2868, 2925, 3012. 1H-NMR (CDCl3, 400MHz) δ 7.69-7.62 (m, 3 H, aromatic H), 7.51 (s, 1 H, aromatic H), 7.39-
7.36 (m, 2 H, aromatic H), 7.28-7.02 (m, 74 H, aromatic H), 6.97-6.95 (m, 2 H, aromatic H), 5.72-5.71 (bt, 2 H, H-1d, H-
1e), 5.54 (d, J = 3.6 Hz, 1 H, H-1b), 5.35 (d, J = 3.6 Hz, 1 H, H-1c), 5.05 (d, J = 11.6 Hz, 1 H, CHH), 4.96-3.56 (m, 59H), 
3.47-3.30 (m, 6H), 3.20 (dd, J1 = 3.6 Hz, J2 = 9.6 Hz, 1 H, H-2b), 1.91-1.85 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) 
δ 139.12, 138.98, 138.89, 138.87, 138.72, 138.51, 138.25, 138.18, 138.16, 138.11, 138.07, 138.04, 137.72, 135.91, 133.29, 
133.01 (aromatic C), 128.58, 128.43, 128.36, 128.34, 128.32, 128.27, 128.20, 128.18, 128.15, 128.12, 128.06, 127.98, 
127.94, 127.90, 127.77, 127.72, 127.68, 127.65, 127.56, 127.47, 127.43, 127.31, 127.24, 127.04, 126.94, 126.79, 126.75, 
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126.61, 126.24, 126.05, 125.88 (aromatic CH), 97.14 (C-1a), 96.95 (C-1e), 96.63 (C-1d), 96.51 (C-1c), 95.80 (C-1b), 
82.13 (C-3a), 81.98 (2 C, C-3d, C-3e), 81.78 (C-3c), 81.08 (C-3b), 80.34 (C-2a), 80.20 (2 C, C-2c, C-2d), 79.46 (C-2b), 
79.25 (C-2e), 77.69 (C-4d), 77.57 (C-4e), 75.49, 75.24, 75.01, 74.43 (CH2), 74.24 (C-4b), 74.12, 73.68, 73.49, 73.35, 
73.24, 73.11, 72.89 (CH2), 72.38 (C-4a), 72.24 (C-5e), 72.11 (C-5b), 71.76 (CH2), 71.60 (C-4c), 70.99 (C-5d), 69.90 (C-
5c), 69.80 (C-5a), 68.98 (C-6e), 68.80 (2 C, C-6a, C-6c), 68.20 (C-6d), 64.91 (C-1°), 64.30 (C-6b), 48.38 (C-3°), 28.91 
(C-2°). MALDI-TOF: Calculated for C149H155O26N3 [M+H
+]: 2403.1; found: 2397.7. 
Synthesis of pentaglucoside 37: The reaction was carried out according to 
the general procedure D, using 36 (1.10 g, 0.46 mmol, 0.05 M in DCM:H2O) 
and DDQ (125 mg, 0.55 mmol). The product was purified by silica gel 
column chromatography (Tol:EA = 20:1). Compound 37 (777mg, 75% yield, 
Tol:EA = 12:1 =, Rf = 0.36) was obtained as a colorless syrup. [α]D
20 +79.6 
(c=1, CHCl3). IR (neat, cm
-1) ν697, 749, 764, 1028, 1045, 1098, 1155, 1261, 
1275, 2098, 2855, 2923, 3031.1H-NMR (CDCl3, 400MHz) δ 7.28-6.98 (m, 
75 H, aromatic H), 5.74(d, J = 3.2 Hz, 1 H, H-1d), 5.63 (d, J = 3.2 Hz, 1 H, H-1e), 5.56 (d, J = 3.2 Hz, 1 H, H-1b), 5.32 
(d, J = 3.2 Hz, 1 H, H-1c), 5.06 (d, J = 12.0 Hz, 1 H, CHH), 4.93-3.36 (m, 63H), 3.21 (dd, J1 = 3.2 Hz, J2 = 9.6 Hz, 1 H, 
H-2b), 1.92-1.86 (m, 2 H, H-2°). 13C-APT (CDCl3, 12 MHz,) δ139.02, 138.96, 138.92, 138.82, 138.55, 138.43, 138.34, 
138.21, 138.17, 138.08, 138.03, 137.96, 137.59 (aromatic C), 128.53, 128.38, 128.28, 128.15, 128.08, 128.03, 127.88, 
127.84, 127.76, 127.70, 127.68, 127.57, 127.45, 127.42, 127.38, 127.31, 127.20, 127.09, 127.02, 126.93, 126.79, 126.55 
(aromatic CH), 96.90 (C-1a), 96.87 (C-1e), 96.55 (C-1c), 95.72 (C-1d), 95.68 (C-1b), 82.15 (C-3a), 82.00 (C-3e), 81.59 
(C-3c), 81.41 (C-3d), 81.26 (C-3b), 80.14 (C-2a), 80.09 (C-2c), 79.74 (C-2b), 79.60 (C-2d ), 79.31 (C-2e), 77.65 (C-4d), 
75.50, 75.21, 74.92, 74.20, 74.08, 73.89, 73.76, 73.44, 73.29, 73.20, 73.07, 73.02, 72.96, 72.74, 72.64, 71.84, 71.79, 71.47 
(CH2), 71.44 (C-4b), 71.84 (2 C, C-4e, C-4a), 71.79 (2 C, C-5b, C-5d), 71.47 (CH2), 71.44 (C-4c), 70.98 (C-4c), 70.85 
(C-5e), 69.83 (C-5c), 69.76 (C-6), 69.70 (C-5a), 68.91, 68.60, 68.21 (3 C-6), 64.86 (C-1°), 64.20 (C-6b), 48.31 (C-3°), 
28.87 (C-2°). MALDI-TOF: Calculated for C138H147O26N3 [M+H
+]: 2263.0; found: 2259.9. 
Synthesis of hexasaccharide 38: The reaction was carried out according to 
the standard procedure B. The donor 3b (860 mg, 1.13 mmol, co-
evaporated with toluene 3 times) was dissolved in dry DCM (3 mL) under 
nitrogen and stirred over fresh flame-dried molecular sieves 3A, after 
which DMF (1.30 mL, 16.5 mmol) was added to the solution. The solution 
was cooled to -78 oC, after which TfOH (100 μL, 1.13 mmol) was added. 
After 30 min, the pre-activation was complete as indicated by TLC-analysis. 
Acceptor 37 (620 mg, 0.27 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 3 mL) was added to 
the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed 
complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The 
product was purified by size exclusion (DCM:MeOH = 1:1). Compound 38 (717mg, 93% yield, α:β> 20:1, Tol:EA = 12:1 
=, Rf = 0.64) was obtained as a colorless syrup. [α]D
20 +62.6 (c=1, CHCl3).IR (neat, cm
-1) ν696, 749, 764, 1028, 1042, 
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1094, 1144, 1155, 1208, 1261, 1275, 1456, 2096, 2860, 2923, 3031.1H-NMR (CDCl3, 400 MHz) δ 7.80-7.77 (m, 1 H, 
aromatic H), 7.71-7.67 (m, 2 H, aromatic H), 7.46-7.42 (m, 3 H, aromatic H), 7.34-6.92 (m, 91 H, aromatic H), 5.78 (d, 
J = 3.6 Hz, 1 H, H-1d), 5.74 (d, J = 3.6 Hz, 1 H, H-1e), 5.58 (d, J = 3.6 Hz, 1 H, H-1b), 5.48 (d, J = 3.6 Hz, 1 H, H-1f), 
5.33 (d, J = 3.6 Hz, 1 H, H-1c), 5.14 (d, J = 10.8 Hz, 1 H, CHH), 5.04 (d, J = 11.6 Hz, 1 H, CHH), 4.91-3.30 (m, 75 H), 
3.25 (dd, J1 = 3.6 Hz, J2 = 10.0 Hz, 1 H, H-2b), 1.90-1.84 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) δ 139.37, 139.25, 
139.00, 138.89, 138.78, 138.53, 138.40, 138.26, 138.23, 138.11, 138.08, 137.98, 137.93, 136.10, 133.35, 133.05 (aromatic 
C), 129.17, 128.59, 128.05, 127.71, 127.68, 127.41, 127.23, 127.04, 126.96, 126.75, 126.72, 126.58, 126.25, 126.11, 
125.95, 125.43 (aromatic CH),96.99 (C-1a, 1e, 1f), 96.84 (C-1d), 96.70 (C-1c), 96.28 (C-1b), 82.29, 82.16, 82.00, 81.87, 
81.56 (5 C-3), 80.62 (C-2), 80.48 (C-3), 80.42, 80.35. 79.52, 79.25, 78.88 (5 C-2), 78.49, 77.78 (2 C-4), 75.58, 75.34, 
75.17, 74.98, 74.30, 74.01, 73.58, 73.55, 73.44, 73.35, 73.29, 73.07 (CH2), 72.90 (C-4), 72.81 (C-5), 72.64, 72.16 (CH2), 
72.02, 71.85 (2 C-4), 71.28, 71.08, 71.00, 70.04, 70.00 (5 C-5), 69.28, 69.11, 69.00, 68.26, 68.16 (5 C-6), 64.94 (C-1°), 
64.83 (C-6b), 48.44 (C-3°), 28.95 (C-2°). MALDI-TOF: Calculated for C176H183O31N3 [M+H
+]: 2835.3; found: 2833.2. 
Synthesis of hexaglucoside 39: The reaction was carried out according to the 
general procedure D, using 38 (700 g, 0.25 mmol, 0.05 M in DCM:H2O) and 
DDQ (67 mg, 0.30 mmol). The product was purified by silica gel column 
chromatography (PE:EA = 20:1). Compound 39 (440 mg, 66% yield, Tol:EA 
= 12:1, Rf = 0.38) was obtained as a colorless syrup. [α]D
20 +67.8 (c=1, 
CHCl3). IR (neat, cm
-1) ν 696, 732, 734, 1016, 1028, 1050, 1094, 1152, 1363, 
1453, 2093, 2872, 2927. 1H-NMR (CDCl3, 400 MHz) δ 7.30-6.93 (m, 90 H, 
aromatic H), 5.78 (d, J = 3.6 Hz, 1 H, H-1d), 5.73 (d, J = 3.6 Hz, 1 H, H-1e), 5.58 (d, J = 3.6 Hz, 1 H, H-1b), 5.53 (d, J = 
3.2 Hz, 1 H, H-1f), 5.36 (d, J = 3.6 Hz, 1 H, H-1c), 5.09 (d, J = 11.2 Hz, 1 H, CHH), 5.05 (d, J = 12.0 Hz, 1 H, CHH), 
4.91-3.31 (m, 75 H), 3.25 (dd, J1 = 3.6 Hz, J2 = 9.6 Hz, 1 H, H-2b), 1.92-1.86 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) 
δ 139.28, 139.19, 138.92, 138.86, 138.70, 138.49, 138.42, 138.17, 138.04, 137.95, 137.82 (aromatic C), 128.59, 128.51, 
128.23, 128.18, 128.06, 128.01, 127.93, 127.86, 127.84, 127.82, 127.75, 127.59, 127.50, 127.45, 127.40, 127.34, 127.24, 
127.04, 126.97, 126.69, 126.60, 126.55 (aromatic CH), 97.06 (C-1e), 96.96 (C-1a), 96.75 (C-1f), 96.64 (C-1c, 1d), 96.19 
(C-1b), 82.09, 82.00, 81.83, 81.65, 81.58, 80.59 (6 C-3), 80.52, 80.36, 80.29, 79.13, 78.89 (6 C-2), 77.69 (2 C-4), 75.55, 
75.29, 75.15, 74.99, 74.27, 74.02, 73.93, 73.60, 73.51, 73.37, 73.32, 73.25, 73.06, 72.98, 72.79, 72.65, 72.05, 71.91, 71.68, 
71.57, 71.22, 70.59, 70.51, 69.98, 69.93, 69.69, 69.14, 68.96, 68.16, 64.92 (C-1°), 64.63 (C-6b), 48.41 (C-3°), 28.93 (C-
2°). MALDI-TOF: Calculated for C165H175O31N3 [M+H
+]: 695.2; found: 2692.7. 
Synthesis of heptaglucoside 40: The reaction was carried out according to 
the standard procedure B. The donor 3b (550 mg, 0.72 mmol, co-evaporated 
with toluene 3 times) was dissolved in dry DCM (1 mL) under nitrogen and 
stirred over fresh flame-dried molecular sieves 3A, after which DMF (900 
μL, 11.4 mmol) was added to the solution. The solution was cooled to -78 
oC, after which TfOH (63 μL, 0.71 mmol) was added. After 30 min, the pre-
activation was complete as indicated by TLC-analysis. Acceptor 39 (360 mg, 
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0.13 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 3 mL) was added to the solution and the 
mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed complete conversion of the 
acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by size 
exclusion (DCM:MeOH = 1:1). Compound 40 (397 mg, 91% yield, α:β> 20:1, Tol:EA = 12:1, Rf = 0.67) was obtained 
as a colorless syrup. [α]D
20 +67.5 (c=1, CHCl3). IR (neat, cm
-1) ν 696, 733, 1027, 1035, 1078, 1082, 1093, 1132, 1141, 
1145, 1155, 1361, 1453, 1496, 2098, 2864, 2928. 1H-NMR (CDCl3, 400 MHz) δ 7.80-7.78 (m, 1 H, aromatic H), 7.73-
7.68 (m, 2 H, aromatic H), 7.50 (s, 1 H, aromatic H), 7.46-7.40 (m, 2 H, aromatic H), 7.28-6.88 (m, 106 H, aromatic H), 
5.75 (d, J = 3.2 Hz, 1 H, H-1), 5.73 (d, J = 3.6 Hz, 1 H, H-1), 5.69 (d, J = 3.2 Hz, 1 H, H-1), 5.61 (d, J = 3.2 Hz, 1 H, H-
1b), 5.49 (d, J = 2.8 Hz, 1 H, H-1), 5.34 (d, J = 3.2 Hz, 1 H, H-1c), 5.22 (d, J = 10.8 Hz, 1 H, CHH), 5.07 (d, J = 11.6 Hz, 
1 H, CHH), 4.97-3.32 (m, 88 H), 3.25 (dd, J1 = 3.6 Hz, J2 = 10.0 Hz, 1 H, H-2b), 1.90-1.84 (m, 2 H, H-2°). 
13C-APT 
(CDCl3, 100 MHz,) δ 139.25, 139.13, 138.97, 138.89, 138.84, 138.78, 138.65, 138.45, 138.17, 138.12, 138.10, 138.08, 
138.03, 137.95, 137.82, 137.78, 137.63, 136.03, 133.25, 132.93 (aromatic C), 128.51, 128.35, 128.30, 128.25, 128.21, 
128.18, 128.12, 128.03, 127.97, 127.96, 127.89, 127.85, 127.82, 127.79, 127.67, 127.60, 127.54, 127.51, 127.47. 127.36, 
127.26, 127.17, 127.03, 126.98, 126.88, 126.83, 126.66, 126.63, 126.53, 126.38, 126.10, 126.04, 125.87 (aromatic CH), 
97.04, 96.89, 96.85, 96.77, 96.64, 96.25, 96.15 (7 C-1), 82.18, 82.07, 81.93, 81.84, 81.77, 81.26, 80.63, 80.34, 80.26, 
80.20, 79.58, 79.52, 79.21, 78.79, 78.64, 77.64, 77.36, 75.55, 75.46, 75.05, 74.92, 74.22, 74.02, 73.93, 73.86, 73.48, 73.45, 
73.40, 73.30, 73.24, 73.04, 72.97, 72.53, 72.46, 72.26, 72.19, 72.00, 71.84, 71.14, 70.92, 70.80, 69.90, 68.99, 68.85, 68.71, 
68.08, 64.81 (C-1°), 64.69 (C-6b), 48.29 (C-3°), 28.83 (C-2°). MALDI-TOF: Calculated for C203H211O36N3 [M
+]: 3266.5; 
found: 3266.2. 
Synthesis of heptaglucoside 41: The reaction was carried out according to the 
general procedure D, using 40 (260 g, 0.080mmol, 0.05 M in DCM:H2O) and 
DDQ (20 mg, 0.09 mmol). The product was purified by silica gel column 
chromatography (Tol:EA = 20:1). Compound 41 (175mg, 70% yield, Tol:EA 
= 12:1, Rf = 0.40) was obtained as a colorless syrup. [α]D
20 +70.1 (c=1, CHCl3). 
IR (neat, cm-1) ν 695, 731, 1026, 1036, 1092, 1135, 1152, 1207, 1363, 1453, 
1496, 2098, 2857, 2923.1H-NMR (CDCl3, 500 MHz) δ 7.29-6.89 (m, 105 H, 
aromatic H), 5.73 (d, J = 3.0 Hz, 1 H, H-1), 5.67 (bd, 2 H, H-1), 5.59 (d, J = 3.0 Hz, 1 H, H-1b), 5.48 (bs, 1 H, H-1), 5.32 
(bs, 1 H, H-1c), 5.19 (d, J = 11.0 Hz, 1 H, CHH), 5.04 (d, J = 11.5 Hz, 1 H, CHH), 4.93 (d, J = 11.5 Hz, 1 H, CHH), 4.88-
3.32 (m, 86 H), 3.27 (bd, 1 H, H-2b), 2.52 (s, 1 H, OH), 1.89-1.88 (m, 2 H, H-2°). 13C-APT (CDCl3, 125 MHz,) δ 139.34, 
139.24, 139.08, 139.00, 138.97, 138.95, 138.89, 138.78, 138.56, 138.52, 138.24, 138.22, 138.20, 138.16, 138.11, 138.07, 
138.03, 137.93, 137.88, 137.72 (aromatic C), 128.60, 128.53, 128.46, 128.44, 128.39, 128.37, 128.34, 128.29, 128.26, 
128.19, 128.12, 128.05, 127.98, 127.93, 127.90, 127.86, 127.81, 127.78, 127.71, 127.64, 127.60, 127.55, 127.52, 127.46, 
127.38, 127.37, 127.24, 127.14, 127.04, 126.97, 126.91, 126.74, 126.61, 126.49 (aromatic CH), 97.12 (C-1), 97.00 (C-
1), 96.85 (C-1), 96.76 (2 C-1), 96.38 (C-1), 96.21 (C-1),82.16, 81.99, 81.88, 81.50, 81.34, 80.68, 80.43, 80.38, 80.30, 
79.66, 79.35, 79.13, 78.79, 77.77, 75.63, 75.58, 75.00, 74.32, 74.02, 73.92, 73.67, 73.56, 73.47, 73.39, 73.35, 73.33, 73.12, 
73.03, 73.00, 72.87, 72.75, 72.64, 72.43, 72.29, 72.11, 71.99, 71.70, 71.24, 71.03, 70.90, 70.45, 70.04, 70.01, 69.90 (C-
6), 69.13 (C-6), 69.02 (C-6), 68.98 (C-6), 68.78 (C-6), 68.25 (C-6), 64.94 (C-1°), 64.81 (C-6b), 48.43 (C-3°), 28.96 (C-
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2°). MALDI-TOF: Calculated for C192H203O36N3 [M
+]: 3126.4; found: 3126.1. 
Synthesis of octaglucoside 42: The reaction was carried out according 
to the standard procedure B. The donor 5b (285 mg, 0.36 mmol, co-
evaporated with toluene 3 times) was dissolved in dry DCM (1 mL) 
under nitrogen and stirred over fresh flame-dried molecular sieves 3A, 
after which DMF (455 μL, 5.78 mmol) was added to the solution. The 
solution was cooled to -78 oC, after which TfOH (31 μL, 0.35 mmol) 
was added. After 30 min, the pre-activation was complete as indicated 
by TLC-analysis. Acceptor 15 (680 mg, 0.76 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 3 
mL) was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in 
vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 42 (135 mg, 80% yield, α:β> 20:1, 
Tol:EA = 12:1, Rf = 0.64) was obtained as a colorless syrup. [α]D
20 +69.7 (c=1, CHCl3). IR (neat, cm
-1) ν697, 734, 1028, 
1035, 1074, 1077, 1082, 1093, 1095, 1154, 1363, 2093, 2863, 2928. 1H-NMR (CDCl3, 400 MHz) δ 7.80-7.78 (m, 1 H, 
aromatic H), 7.72-7.68 (m, 2 H, aromatic H), 7.45-7.42 (m, 3 H, aromatic H), 7.30-6.86 (m, 118 H, aromatic H), 6.73-
6.71 (m, 2 H, aromatic H), 5.75-5.71 (m, 3H, 3 H-1), 5.71 (bt, 2 H, 2 H-1), 5.46 (d, J = 3.2 Hz, 1 H, H-1), 5.33 (d, J = 3.2 
Hz, 1 H, H-1), 5.21 (d, J = 10.8 Hz, 1 H, CHH), 5.05 (d, J = 11.6 Hz, 1 H, CHH), 4.92-3.24 (m, 104 H), 1.90-1.83 (m, 2 
H, H-2°). 13C-APT (CDCl3, 125 MHz,) δ 159.29, 139.33, 139.23, 139.04, 139.01, 138.98, 138.85, 138.56, 138.32, 138.21, 
138.12, 138.09, 138.06, 138.01, 137.89, 137.86, 137.74, 136.17, 133.34, 133.02, 130.01 (aromatic C), 129.95, 128.60, 
128.42, 128.39, 128.36, 128.34, 128.30, 128.26, 128.20, 128.12, 128.06, 128.00, 127.97, 127.94, 127.90, 127.88, 127.84, 
127.74, 127.70, 127.65, 127.59, 127.56, 127.54, 127.47, 127.42, 127.36, 127.25, 127.14, 127.05, 126.96, 126.90, 126.75, 
126.72, 126.69, 126.61, 126.49, 126.46, 126.11, 125.92, 113.78 (aromatic CH), 97.07 (C-1), 96.99 (2 C-1), 96.73 (2 C-
1), 96.34 (2 C-1), 96.16 (C-1), 82.27, 82.17, 82.01, 81.97, 81.88, 81.74, 81.38, 80.87, 80.40, 80.28, 79.82, 79.56, 79.43, 
79.32, 78.87, 78.73, 77.76, 77.70, 75.64, 75.54, 75.08, 75.02, 74.30, 74.01, 73.88, 73.56, 73.44, 73.40, 73.35, 73.31, 73.14, 
73.09, 73.03, 72.84, 72.75, 72.64, 72.52, 72.23, 72.11, 71.99, 71.79, 71.25, 71.00, 70.93, 70.02, 69.98, 69.12, 69.02, 68.94, 
68.61, 68.22, 67.62, 64.91 (C-1°), 64.76 (C-6b), 55.21 (OCH3), 48.41 (C-3°), 28.94 (C-2°). MALDI-TOF: Calculated for 
C231H241O42N3 [M
+]: 3728.7; found: 3728.9. 
Synthesis of octaglucoside 43: The reaction was carried out according 
to the general procedure E atrt about 1 h, using 42 (70 mg, 0.019 mmol, 
0.01 M in DCM:HFIP),triethylsilane (3 μL, 0.018 mmol) and 0.1M 
HCl/HFIP (20 μL, 0.19 mmol). The product was purified by silica gel 
column chromatography (Tol:EA = 20:1). Compound 43 (60 mg, 88% 
yield, Tol:EA = 12:1, Rf = 0.29) was obtained as a colorless syrup. 
[α]D
20 +79.3 (c=1, CHCl3). IR (neat, cm
-1) ν 696, 735, 1027, 1039, 
1042, 1078, 1094, 1138, 1155, 1363, 1454, 2097, 2858, 2927. 1H-NMR (CDCl3, 400 MHz) δ 7.81-7.72 (m, 3 H, aromatic 
H), 7.67 (s, 1 H, aromatic H), 7.46-7.38 (m, 3 H, aromatic H), 7.30-6.86 (m, 115 H, aromatic H), 5.75 (d, J = 3.6 Hz, 1 
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H, H-1), 5.73 (d, J = 3.6 Hz, 1 H, H-1), 5.65 (d, J = 3.6 Hz, 1 H, H-1), 5.61 (d, J = 3.6 Hz, 1 H, H-1b), 5.56 (d, J = 3.6 
Hz, 1 H, H-1), 5.48 (d, J = 3.2 Hz, 1 H, H-1), 5.34 (d, J = 3.2 Hz, 1 H, H-1c), 5.22 (d, J = 11.6 Hz, 1 H, CHH), 5.06 (d, J 
= 12.0 Hz, 1 H, CHH), 4.99 (d, J = 11.2 Hz, 1 H, CHH), 4.94 (d, J = 11.6 Hz, 1 H, CHH), 4.90-3.31 (m, 97 H), 3.27 (dd, 
J1 = 3.6 Hz, J2 = 10.0 Hz, 1 H, H-2b), 1.90-1.84 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) δ 139.29, 139.18, 138.98, 
138.94, 138.80, 138.77, 138.72, 138.52, 138.26, 138.17, 138.13, 138.08, 138.03, 138.00, 137.93, 137.94, 137.81, 137.66, 
135.80, 133.32, 133.07 (aromatic C), 128.59, 128.45, 128.42, 128.37, 138.31, 128.26, 128.20, 128.10, 128.06, 128.00, 
127.94, 127.89, 127.87, 127.85, 127.80, 127.75, 127.71, 127.64, 127.62, 127.54, 127.46, 127.32, 127.24, 127.16, 127.11, 
127.04, 126.95, 126.83, 126.71, 126.68, 126.64, 126.61, 126.41, 126.23, 126.11, 126.06 (aromatic CH), 97.07 (C-1), 
96.97 (C-1), 96.68 (3 C-1), 96.29 (C-1), 96.17 (C-1), 96.10 (C-1), 82.15, 82.02, 81.96, 81.847, 81.36, 80.88, 80.36, 80.23, 
79.61, 79.47, 79.26, 78.83, 78.66, 77.72, 77.65, 75.64, 75.53, 75.32, 75.01, 74.28, 74.10, 74.01, 73.88, 73.63, 73.53, 73.44, 
73.39, 73.32, 73.27, 73.15, 73.06, 72.82, 72.41, 72.07, 71.87, 71.66, 71.21, 70.97, 70.86, 70.82, 69.96, 69.07, 68.89, 68.52, 
68.37, 68.14, 64.88 (C-1°), 64.67 (C-6b), 61.73 (C-6), 48.38 (C-3°), 28.92 (C-2°). MALDI-TOF: Calculated for 
C223H233O41N3 [M+H
+]: 3609.6; found: 3604.8.  
Synthesis of nonaglucoside 44: The reaction was carried out according 
to the standard procedure C, using 4b (100 mg, 0.13 mmol), 43 (40 
mg, 0.011 mmol, 0.005 M in DCM), Ph3P=O (225 mg, 0.81 mmol) 
and TMSI (30 μL, 0.21 mmol). The product was purified by size 
exclusion (DCM:MeOH = 1:1). Compound 44 (31 mg, 67% yield, α:β> 
20:1, Tol:EA = 12:1, Rf = 0.65) was obtained as a colorless syrup. 
[α]D
20 +86.6 (c=1, CHCl3). IR (neat, cm
-1) ν 696, 734, 1008, 1028, 
1049, 1084, 1091, 1154, 1362, 2097, 2858, 2924. 1H-NMR (CDCl3, 
500 MHz) δ 7.75 (bd, 1 H, aromatic H), 7.70 (bd, 1 H, aromatic H), 7.67-7.64 (m, 3 H, aromatic H), 7.43-7.36 (m, 3 H, 
aromatic H), 7.29-6.87 (31mg, 132 H, aromatic H), 6.76-6.73 (m, 2 H, aromatic H), 5.74 (d, J = 3.5 Hz, 1 H, H-1), 5.71 
(d, J = 3.5 Hz, 1 H, H-1), 5.65 (d, J = 3.5 Hz, 1 H, H-1), 5.61 (d, J = 3.5 Hz, 1 H, H-1), 5.60 (d, J = 3.5 Hz, 1 H, H-1), 
5.47 (d, J = 3.5 Hz, 1 H, H-1), 5.32 (d, J = 3.5 Hz, 1 H, H-1), 5.20 (d, J = 11.0 Hz, 1 H, CHH), 5.09 (d, J = 3.5 Hz, 1 H, 
H-1), 5.02 (bt, 2 H, CHH), 4.92-3.31 (m, 113 H), 3.27 (dd, J1 = 3.5 Hz, J2 = 9.0 Hz, 1 H, H-2), 3.23-3.20 (m, 1 H, H-2), 
1.89-1.84 (m, 2 H, H-2°). 13C-APT (CDCl3, 125 MHz,) δ 159.24, 139.34, 139.24, 139.09, 139.05, 139.01, 138.87, 138.78, 
138.58, 138.39, 138.32, 138.28, 138.24, 138.21, 138.19, 138.14, 138.12, 138.08, 137.96, 137.91, 137.87, 137.77, 136.42, 
133.41, 133.04, 130.86 (aromatic C), 129.65, 128.60, 128.46, 128.44, 128.40, 128.34, 128.30, 128.21, 128.19, 128.12, 
128.06, 128.04, 127.99, 127.97, 127.95, 127.90, 127.88, 127.80, 127.76, 127.74, 127.72, 127.69, 127.65, 127.61, 127.57, 
127.54, 127.47, 127.42, 127.37, 127.35, 127.25, 127.15, 127.09, 127.05, 126.97, 126.91, 126.76, 126.74, 126.72, 126.48, 
126.38, 126.19, 126.07, 125.84, 113.81 (aromatic CH), 97.25 (C-1), 97.08 (C-1), 97.00 (C-1), 96.76 (2 C-1), 96.33 (2 C-
1), 96.20 (2 C-1), 82.14, 82.01, 81.89, 81.74, 81.38, 80.86, 80.42, 80.30, 80.25, 80.16, 79.78, 79.43, 79.36, 78.88, 78.76, 
77.79, 77.54, 77.34, 75.64, 75.54, 75.35, 75.19, 75.02, 74.77, 74.31, 73.99, 73.88, 73.68, 73.57, 73.44, 73.38, 73.33, 73.15, 
73.10, 72.83, 72.71, 72.66, 72.61, 72.13, 72.05, 71.84, 71.71, 71.27, 71.03, 70.91, 70.78, 70.35, 70.04, 70.01, 69.15, 69.02, 
68.97, 68.85, 68.62, 68.45, 68.26, 65.05, 64.92 (C-1°), 64.79 (C-6), 55.38 (OCH3), 48.42 (C-3°), 28.96 (C-2°). MALDI-
TOF: Calculated for C258H269O47N3 [M+H
+]: 4161.8; found: 4161.7. 
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Synthesis of nonaglucoside 1: Compound 40 (20 mg, 0.0048 mmol) 
was dissolved in THF/H2O/tert-BuOH (4 ml/4 ml/1.6 ml) before a 
catalytic amount of Pd(OH)2/C was added. The reaction mixture was 
stirred for 3 days under a H2 atmosphere (3.5 bar), filtered and 
concentrated in vacuo. A white powder 1 was obtained, which was 
purified by gel filtration (HW-40, 0.15M NH4OAc in H2O) to yield 1 
(4.7 mg, 61%).1H-NMR (CDCl3, 500 MHz) δ 5.40-5.38 (m, 3 H, 3 H-
1), 5.35 (bt, 2 H, 2 H-1), 5.32 (d, J = 4.0 Hz, 1 H, H-1), 4.96-4.93 (m, 
3 H, 3 H-1), 4.02-3.54 (m, 53 H), 3.49 (t, J = 9.5 Hz, 1 H), 3.44-3.39 (m, 2 H), 3.20-3.10 (m, 2 H), 2.02-1.97 (m, 2 H). 
13C-APT (CDCl3, 125 MHz,) δ 100.03, 99.94, 99.83, 99.63, 99.56, 98.60, 98.11 (9 C-1), 78.86, 77.94, 77.57, 77.16, 76.78, 
73.44, 73.02, 72.98, 72.79, 71.87, 71.83, 71.69, 71.53, 71.38, 71.31, 70.90, 70.57, 71.42, 70.23, 69.54, 69.41, 69.33, 67.55, 
65.93, 60.79, 60.54, 60.49, 60.44, 37.85, 26.60. HR-MS: Calculated for C57H99O46N [M+H
+]: 1534.5511; found: 
1534.5779. 
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Reagent Controlled Stereoselective 
Assembly of α-(1,3)-Glucans 
Published in: Liming Wang, Herman S. Overkleeft, Gijsbert A. van der Marel, and Jeroen D. C. Codée*, Eur. J. Org. 
Chem. 2019, 10, 1994-2003. 
Introduction 
The stereoselective construction of 1,2-cis-glycosidic bonds continues to be a great challenge in 
the assembly of oligosaccharides and glycoconjugates, and no general solution exists for the 
construction of these linkages.[1] The large panel of diastereoisomeric monosaccharides in 
combination with the plethora of different functional and protecting group schemes generate a 
humongous diversity in carbohydrate building blocks. [1] The structural variation translates to 
varying reactivity of both the donor glycoside [2] and acceptor glycoside [3] because of the large 
differences in the reactivity of both coupling partners it is often difficult to translate a productive 
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glycosylation reaction from one glycosylation couple to another. The introduction of nucleophilic 
additives to modulate the coupling reaction has been an important step forwards as this opens up 
the way to match donor and acceptor reactivity.[4] Chapter 2 describes the fully stereoselective 
assembly of a Mycobacterium tuberculosis derived α-glucan 1, built up from a 1,4-linked-hexa-
α-glucose backbone, bearing a mono- and disaccharide α-glucose branch.[5] The assembly of this 
nonasaccharide was accomplished using additive controlled glycosylation reactions and built on 
the following design parameters: 1) Only a single type of N-phenyltrifluoroimidate building block 
was used, bearing a uniform protecting group pattern, solely relying on the use of benzyl type 
ethers; 2) A triad of benzyl ethers (namely the benzyl (Bn), para-methoxybenzyl (PMB) and 2-
methylnaphthyl (Nap) ether) was used to discriminate the alcohol groups that required permanent 
protection or needed to be removed to introduce the branches or grow the α-(1,4)-backbone. 3) 
The intrinsic differences in reactivity between the primary and secondary alcohol acceptors was 
accommodated for in the coupling reaction using two different activator/additive couples: 
Trifluoromethanesulfonic acid (TfOH) in conjunction with dimethylformamide (DMF) for the 
condensation of the secondary alcohols and trimethylsilyliodide (TMSI) in combination with 
triphenylphosphine oxide for the coupling to the more reactive primary alcohols (See Figure 1). 
Besides the fact that all building blocks were of nearly identical reactivity, as a result of the chosen 
protecting group strategy, the use of solely benzyl ether-type protecting groups is beneficial at the 
stage of building block assembly - the benzyl ethers used are very robust and easily introduced - 
and at the final stage of the synthesis, as unmasking all groups can be achieved under mild 
condition in a single hydrogenation event. The successful assembly of the 1,4-α-glucan 
nonasaccharide was an incentive to explore the above described synthesis strategy for the 
assembly of the related α-(1,3)-glucans. These compounds are prominent components of fungal 
cell walls[6] and they have been shown to interact with our immune system, through as yet 
undefined receptor(s).[7] Nifantiev and co-workers recently reported the synthesis of an 
Aspergillus fumigatus α-(1,3)-glucan pentasaccharide, employing a long-range participation 
approach to ensure the stereoselective construction of the cis-glucosidic linkages.[8] The spacer-
equipped pentasaccharide was used for the generation of a BSA-conjugate vaccine and the 
polyclonal mouse serum raised with the conjugate could recognize α-(1,3)-glucan-expressing A. 
fumigatus. 
This chapter describes the synthesis of the largest synthetic α-(1,3)-glucan to date, i.e. the 
assembly of octasaccharide 2 (Figure 1). To streamline the synthesis of large oligosaccharides 
using a nucleophilic additive glycosylation based on approach being further optimized the 
coupling protocol by showing that pre-activation of the donor glycoside can be omitted allowing 
for a much-simplified experimental procedure. 
Results and Discussion 
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In line with the strategy outlined above, the synthetic approach is built on the use per-benzylated 
donor and acceptor building blocks. To temporarily mask the C-3-OH a 2-methylnaphthyl (Nap)-
ether[9] was used (building block 3, See Figure 1). The assembly of the required building block 
for this study is depicted in Scheme 1A. The free alcohol in 1,2;5,6-di-O-isopropylidene-α-D-
glucofuranose was used to introduce the Nap ether at this position. Acidic hydrolysis of both 
acetone ketals, ensuing acetylation, introduction of an anomeric thiophenol group and 
benzylation of the alcohols at C-2, C-4 and C-6 then delivered glucoside 5. The anomeric thio 
acetal in this building block was hydrolyzed using N-iodosuccinimide in acetone/water to liberate 
the anomeric hydroxyl group, which could then be turned into the required N-
phenyltrifluoroimidate 3.  
 
Figure 1. Schematic syntheses of branched 1,4-α-glucans (previously reported) and 1,3-α-glucans. 
The strategy hinges on the use of building blocks carrying solely benzyl-type protecting groups 
in combination with different activator/additive systems for glycosylations of primary (more 
reactive) or secondary (less reactive) alcohols. 
With the required building block in hand, a series of glycosylations was performed to probe the 
feasibility of the DMF-mediated glycosylation conditions for the construction of the α-(1,3)-
glucosyl bond (Scheme 1B). It was recently established by Van der Vorm that the glucosyl C-3-
OH is somewhat more nucleophilic than its C-4-OH counterpart, which could impact the 
stereoselectivity of the projected glycosylation reactions.[3a, 3c] Thus, donor 6 was activated at -78 
oC using an equimolar amount of TfOH in the presence of 16 equivalents of DMF, as originally 
prescribed by Mong co-workers.[4k] After 30 minutes C-3-OH acceptor 7 was added and the 
mixture warmed to 0 oC.  
This protocol installed the desired α-glucosyl linkage with excellent stereoselectivity and 
generated diglucoside 8 in 85% yield. To allow for an operationally simpler protocol, it was 
examined whether the donor and acceptor could be premixed. Indeed, addition of TfOH to a 
mixture containing donor 6, acceptor 7 and DMF at -78 oC and subsequent warming to 0 oC 
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proved feasible as the yield and stereoselectivity of the condensation remained excellent (See 
Scheme 1B). Especially in the generation of larger oligomers, using large and expensive acceptor 
building blocks (vide infra) this simpler protocol represents a significant improvement, as less 
manipulations are required on the side of the acceptor. It was also explored whether a 
chemoselective glycosylation could be achieved under these conditions, and to this end donor 6 
and thioglucoside 9, obtained by removal of the Nap ether in 5, were coupled using TfOH/DMF 
to provide diglucoside 10 in 91%, again with excellent stereoselectivity. The resulting 
thiodisaccharide could be turned into N-phenyltrifluoroimidate donor 11 and used in a subsequent 
glycosylation event. In the event disaccharide imidate 11 and acceptor 7 were pre-mixed with 
DMF in dichloromethane (DCM), after which the activator was added and the mixture warmed 
to 0 oC. Trisaccharide 12 was obtained as a single anomer in 63 % yield. 
 
a) 1) NIS, acetone:H2O = 10:1; 2) 2,2,2-trifluoro-N-phenylacetimidoyl chloride, Cs2CO3, acetone, 3: 90%; 11: 80%. b) 
DMF, TfOH, DCM, -78-0 ℃, 8: α:β > 20:1; 10: 91%, α:β > 20:1; 12: 63%, α:β > 20:1. 
Scheme 1. A) Synthesis of building block 3 and B) model glycosylations. 
Next the attention was turned to the assembly of a longer and spacer-functionalized α-(1,3)-
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glucan as depicted in Scheme 2. Firstly, the azidopropanol spacer was introduced. To this end 
donor 3 was activated using a combination of TMSI and Ph3P=O (6 equivalents). As described in 
chapter 2, these conditions work well to install the α-glucosidic linkage on reactive primary 
alcohols and also in this case the desired azidopropyl glucoside 13 was obtained in good yield 
and stereoselectivity (α/β = 10:1). Deprotection of the C-3-O-Nap ether under oxidative 
conditions (dichlorodicyanobenzoquinone (DDQ) in DCM/H2O, 10 : 1 v/v) proceeded 
uneventfully and set the stage for elongation of the aziopropyl glucoside which was purified with 
silica gel column chromatography to get pure α-anomer 14.  
 
a) TMSI, Ph3P=O, DCM, rt, 13: 80%, α:β = 10:1. b) DDQ, DCM/H2O, 14: 80%; 16: 90% (with two steps); 18: 95%; 20: 
80%; 22: 75%; 24: 70%; 26: 51%. c) DMF, TfOH, DCM, -78-0 ℃, 15: >90%, α:β > 20:1; 17: 81%, α:β > 20:1; 19: 84%, 
α:β > 20:1; 21: 81%, α:β > 20:1; 23: 90%, α:β > 20:1; 25: 90%, α:β > 20:1; 27: 98%, α:β > 20:1. d) Pd(OH)2, H2 (40 bar), 
THF/H2O/t-BuOH, 40%. 
Scheme 2. Assembly of an A. fumigatus α-(1,3)-octaglucan. 
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Activation of donor 3 with the TfOH/DMF combination and coupling with acceptor 14 delivered 
the desired disaccharide 15 as the sole anomer. The only side product that was detected was a 
1,1’-coupled trehalose. Unfortunately, this side product was difficult to remove form the 
disaccharide product and therefore it was continued with the deprotection of 15 to give 
disaccharide alcohol 16, which was now readily purified and obtained in 90% over the two steps. 
Elongation of the diglucoside proceeded smoothly and gave the trisaccharide 17 in 81% yield. 
Oxidative deprotection of the C-3”’-O-Nap ether and subsequent elongation with another copy 
of donor 3 delivered the tetrasaccharide 19. Repetition of the deprotection-coupling cycle then 
generated pentasaccharide 21 and hexasaccharide 23. Deprotection of the Nap ether again 
proceeded uneventfully to set the stage for the next glycosylation. From this stage on employing 
the donor-acceptor pre-mixing strategy and using the above described protocol, heptasaccharide 
25 was generated as the sole anomer in 90% yield. De-naphthylation gave heptasaccharide 
alcohol 26, which was elongated in a final glucosylation event, again under the donor-acceptor 
pre-mixing conditions, to give the all-cis octaglucoside 27 in 98% yield. Deprotection of the 
octasaccharide was accomplished in a single hydrogenation event to give 2 in 40% yield and 
complete the synthesis. 
Conclusion 
In summary the synthesis of a spacer-equipped octa-α-(1,3)-glucan was described using a strategy 
that is built on the use of benzyl ether protected building blocks in combination with appropriate 
activator-additive reagent combinations to install the desired glucosidic linkages. To 
stereoselectively install the linker on the first building block, the TMSI-Ph3P=O reagent was used 
combination, while all other glycosylations, generating linkages to secondary alcohols, were 
promoted by the TfOH-DMF reagent system. It was shown that a pre-activation strategy, which 
encompasses the activation of the donor glycoside in the absence of the acceptor, is not required 
to achieve high yielding stereoselective glycosylation reactions. This has allowed the 
development of an effective α-glucosylation protocol that is operationally easier and requires less 
manipulation of (expensive) acceptor alcohols. Extension of the here reported glycosylation 
strategy to other cis-glycans is described in Chapter 4 and 5. The generated octasaccharide can 
be used as a synthetic antigen to raise antibodies at A. fumigatus 
Experimental Section 
General experimental procedures  
All reagents were of commercial grade and used as received. All moisture sensitive reactions were performed under an 
argon atmosphere. DCM used in the glycosylation reactions was dried with flamed 4Å molecular sieves before being 
used. Reactions were monitored by TLC analysis with detection by UV (254 nm) and where applicable by spraying with 
20% sulfuric acid in EtOH or with a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% 
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sulfuric acid (aq.) followed by charring at ~150 °C. Column chromatography was carried out using silica gel (0.040-0.063 
mm). Size-exclusion chromatography was carried out using Sephadex LH-20. High resolution mass (HRMS) was 
performed on a Thermo Finnigan LTQ Orbitrap mass spectrometer equipped with an electrospray ion souce in positive 
ion mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 °C) resolution R= 60.000 at m/z 400 
(mass range of 150-4000) and dioctylphtalate(m/z=391.28428) as lock mass, or on a Waters Spynat G2-Si(OTF) equieped 
with an electrospary ion souce in positive mode (source voltage 3.5kV) and LeuEnk (m/z = 556.2771). 1 μl of 2,5-
dihydroxybenzoic acid (2,5-DHB; Bruker Daltonics) matrix (20 mg/mL in ACN/water; 50:50 (v/v)) was applied on a 
384-MTP target plate (Bruker Daltonics, Bremen, Germany) and air-dried. Subsequently, 1 μl of xxx solution was spotted 
on the plate and the spots were left to dry prior MALDI-TOF analysis. An Ultraflextreme MALDI-TOF (Bruker 
Daltonics), with Smartbeam-II laser was used to measure the samples in reflectron positive ion mode. The MALDI-TOF 
was calibrated using a peptide calibration standard prior to measurement. 1H and 13C spectra were recorded on a Bruker 
AV 400 and Bruker AV 500 in CDCl3 or D2O. Chemical shifts (δ) are given in ppm relative to tetramethylsilane as internal 
standard (1H NMR in CDCl3) or the residual signal of the deuterated solvent. Coupling constants (J) are given in Hz. All 
13C spectra are proton decoupled. NMR peak assignments were made using COSY and HSQC experiments, where 
applicable Clean TOCSY, HMBC and GATED experiments were used to further elucidate the structure. The anomeric 
product ratios were analyzed through integration of proton NMR signals. IR spectra were recorded on a Shimadzu FTIP-
8300 IR spectrometer and are reported in cm Specific rotations were measured on a Propol automatic polarimeter or an 
Anton-Paar MCP 100 modular circular polarineter at 589 nm unless otherwise stated. 
Standard procedure A for glycosylation of secondary alcohols: The donor (1.0 eq, co-evaporated with toluene) was 
dissolved in dry DCM under nitrogen and stirred over fresh flame-dried molecular sieves 3A, after which DMF (16 eq) 
was added to the solution. The solution was cooled to -78 ℃, after which TfOH (1.0 eq) was added. After 30 min, the 
pre-activation was complete as indicated by TLC-analysis. Acceptor (0.7 eq) was added to the solution and the mixture 
was placed in an ice bath. The reaction was stirred at 0 ℃ until TLC-analysis showed complete conversion of the acceptor. 
The reaction was quenched with Et3N, filtered and concentrated in vacuo. The products were purified by size exclusion 
and silica gel column chromatography. 
Standard procedure B for glycosylation of secondary alcohols: A mixture of donor (1.0 eq), acceptor (0.7 eq) (donor 
and acceptor co-evaporated with toluene three times), DMF (6 eq) in dry DCM were stirred over fresh flame-dried 
molecular sieves 3A under nitrogen. The solution was cooled to -78 ℃, after which TfOH (1.0 eq) was added. After 30 
min, the mixture was placed in an ice bath. The reaction was stirred at 0 ℃ until TLC-analysis showed complete 
conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The products were 
purified by size exclusion and silica gel column chromatography. 
Standard procedure C for the glycosylation of primary alcohols: A mixture of donor (1.0 eq), acceptor (0.7 eq) (donor 
and acceptor co-evaporated with toluene three times), Ph3P=O (6 eq) in dry DCM were stirred over fresh flame-dried 
molecular sieves 3A under nitrogen. Then TMSI (1.0 eq) was added slowly in the mixture. The reaction was stirred at 
room temperature until TLC-analysis indicated the reaction to be complete. The solution was diluted and the reaction 
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quenched with saturated Na2S2O3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, 
filtered and concentrated in vacuo. The products were purified by size exclusion and silica gel column chromatography.  
Standard procedure D for deprotection of the Nap protecting group: The starting material (1 eq) was dissolved in 
DCM:H2O (10:1, 0.1 M). DDQ (1.1 eq) was added to the mixture. The reaction stirred until TLC-analysis indicated full 
consumption of the starting material (± 2h). Then the mixture was diluted with DCM and the reaction quenched with 
saturated Na2S2O3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and 
concentrated in vacuo. The product was purified by silica gel column chromatography. 
Experimental Procedures and Characterization Data of Products 
For the synthesis procedure and data of known compounds 6, 8 see reference 5. We used "a", "b", "c", "d", "e", "f", "g", 
and “h” to specify the H-1 and C-13 NMR signals of sugar rings from the “reducing” to the “non-reducing” end and “°” 
to specify the H-1 and C-13 NMR signals of the spacer. 
Phenyl 2,4,6-tri-O-benzyl-3-O-(naphthalen-2-ylmethyl)-1-thio-β-D-glucopyranoside (5): [α]D
20 
+8.1, c=1, CHCl3. 
1H-NMR (CDCl3, 400 MHz) δ 7.81-7.70 (m, 4 H, aromatic H), 7.61-7.59 (m, 2 
H, aromatic H), 7.46-7.16 (m, 21 H, aromatic H), 5.05 (d, J = 11.2 Hz, 1 H, CHH), 4.99 (d, J = 11.2 Hz, 1 H, CHH), 4.91 
(d, J = 10.8 Hz, 1 H, CHH), 4.85 (d, J = 10.8 Hz, 1 H, CHH), 4.75 (d, J = 10.8 Hz, 1 H, CHH), 4.69 (d, J = 9.6 Hz, 1 H, 
H-1), 4.61 (bd, 2 H, CHH), 4.54 (d, J = 12.0 Hz, 1 H, CHH), 3.81-3.67 (m, 4 H), 3.57-3.51 (m, 2 H). 13C-APT (CDCl3, 
100 MHz,) δ 137.97, 137.73, 135.56, 133.52, 133.01, 132.65 (aromatic C), 131.62, 128.62, 128.14, 128.06, 127.91, 
127.88, 127.63, 127.61, 127.57, 127.51, 127.38, 127.28, 127.14, 126.18, 125.78, 125.59, 125.55 (aromatic CH), 87.15 
(C-1), 86.45, 80.53, 78.79, 77.49, 75.55 (PhCH2), 75.16 (PhCH2), 74.78 (PhCH2), 73.11 (PhCH2), 68.69 (C-6). HR-MS: 
Calculated for C44H42O5S [M+Na]
+: 705.2645; found: 705.2657. 
2,4,6-Tri-O-benzyl-3-O-(naphthalen-2-ylmethyl)-α/β-D-glucopyranosyl N-
phenyltrifluoroacetimidate (3): Compound 5 (9.5 g, 13.9 mmol) was dissolved in acetone:H2O 
(10:1, 140 mL). N-Iodosuccinimide (NIS) (6.2 g, 27.6 mmol) was added in one portion and the 
reaction was stirred at room temperature for 2 hours. The solution was diluted with DCM and the reaction was quenched 
with saturated aqueous Na2S2O3. Then the organic layer was washed with water and brine. The organic layer was dried 
with anhydrous MgSO4, filtered and concentrated in vacuo, and the product purified by column chromatography (pentane : 
ethyl acetate (EA) = 3:1). The lactol (7.4 g, 90% yield) was obtained as a white solid. Next, the lactol (7.4 g, 12.5 mmol) 
was dissolved in acetone (120 mL). Cs2CO3 (6.1 g, 18.7 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (3.0 mL, 
18.7 mmol) were added to the solution respectively. The reaction was stirred overnight, then quenched with Et3N, filtered 
and concentrated in vacuo. The product was purified by column chromatography (pentane:EA = 40:1-20:1). Compound 
3 (9.1 g, 95% yield, α:β = 1:1.2, pentane:EA = 10:1, Rf = 0.45-0.55) was obtained as yellow syrup. 1H-NMR (CDCl3, 500 
MHz, 60℃) δ 7.79-6.72(m, aromatic H), 6.47 (bs, 1 H, H-1α), 5.60 (bs, 1 H, H-1β), 5.11-4.74 (m, CHH), 4.61-4.48 (m, 
CHH), 4.08 (t, J = 9.0 Hz, 1 H, H-α), 3.97 (bd, 1 H, H-α), 3.78-3.68 (m), 3.40 (bs, 1 H). 13 C-APT (CDCl3, 125 MHz, 
60℃) δ 143.97, 143.76, 138.48, 138.39, 138.38, 138.27, 138.65, 138.15, 136.45, 136.20, 133.69, 133.65, 133.29 
(aromatic C), 129.52, 128.84, 128.63, 128.59, 128.54, 128.51, 128.21, 128.18, 128.12, 128.11, 128.00, 127.95, 127.85, 
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127.78, 126.69, 126.56, 126.51, 126.19, 126.18, 126.13, 125.99, 125.93, 124.47, 124.32, 120.77, 119.70, 119.63 
(aromatic CH), 116.50 (q, CF3), 97.69, 93.94, 84.77, 81.85, 81.29, 79.76, 77.67, 77.40, 76.09, 75.89, 75.69, 75.34, 75.11, 
75.09, 73.78, 73.69, 73.60, 73.56, 68.73, 68.71.  
Phenyl 2,4,6-tri-O-benzyl-1-thio-β-D-glucopyranoside (9): The reaction was carried out 
according to the general procedure D, using 5 (235 mg, 0.35 mmol, 0.1 M in DCM:H2O) and DDQ 
(89 mg, 0.39 mmol). The product was purified by silica gel column chromatography (pentane:EA = 15:1). Compound 9 
(168 mg, 87% yield, pentane:EA = 8:1, Rf = 0.44) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.60-
7.56 (m, 2 H, aromatic H), 7.41-7.22 (m, 18 H, aromatic H), 4.95 (d, J = 11.2 Hz, 1 H, CHH), 4.78 (d, J = 11.2 Hz, 1 H, 
CHH), 4.68-4.59 (m, 4 H, 3 CHH, H-1), 4.54 (d, J = 11.6 Hz, 1 H, CHH), 3.81-3.70 (m, 3 H, H-6, H-3), 3.56-3.46 (m, 2 
H, H-4, H-5), 3.37 (dd, J1 = 8.8 Hz, J2 = 9.6 Hz, 1 H, H-2), 2.42 (d, J = 2.4 Hz, 1 H, OH). 
13C-APT (CDCl3, 100 MHz,) 
δ 138.35, 138.33, 138.19, 133.94 (aromatic C), 131.89, 129.05, 128.73, 128.62, 128.48, 128.35, 128.20, 128.08, 128.00, 
127.84, 127.72, 127.57 (aromatic CH), 87.18 (C-1), 80.70 (C-2), 878.91, 78.75, 77.48 (C-4), 75.25 (PhCH2), 74.77 
(PhCH2), 73.55 (PhCH2), 68.17 (C-6).  
Phenyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-1- 
thio-β-D-glucopyranoside (10): The reaction was carried out according to the standard 
procedure B, using 6 (330 mg, 0.46 mmol), 9 (168 mg, 0.31 mmol, 0.1 M in DCM), 
DMF (580 μL, 7.38 mmol) and TfOH (41 μL, 0.46 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed 
complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The 
product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 10 (301 mg, 91% yield, α:β> 
20:1, pentane:EA = 8:1, Rf = 0.46) was obtained as a colorless syrup. [α]D
20 +31.0, c=1, CHCl3. IR (neat, cm
-1) ν 696, 
745, 1028, 1071, 1090, 1361, 1454, 1497, 2862, 2910, 3030, 3063. 1H-NMR (CDCl3, 500 MHz) δ 7.60-7.57 (m, 2 H, 
aromatic H), 7.45 (bd, 2 H, aromatic H), 7.37-7.01 (m, 36 H, aromatic H), 5.68 (d, J = 3.5 Hz, 1 H, H-1b), 4.97-4.89 (m, 
4 H, 3 CHH), 4.81 (d, J = 10.5 Hz, 1 H, CHH), 4.72-4.48 (m, 8 H, H-1a, 7 CHH), 4.40 (d, J = 10.5 Hz, 1 H, CHH), 4.11 
(d, J = 11.5 Hz, 1 H, CHH), 4.14 (bd, 1 H), 4.10-4.04 (m, 2 H, ), 3.85 (t, J = 9.5 Hz, 1 H), 3.75-3.65 (m, 3 H), 3.59-3.56 
(m, 2H, H-6), 3.50-3.48 (m, 2 H), 3.33-3.27 (m, 2 H). 13C-APT (CDCl3, 125 MHz,) δ 138.72, 138.58, 138.27, 138.14, 
137.95, 137.80, 137.55, 133.81 (aromatic C), 131.81, 129.01, 128.87, 128.37, 128.33, 128.28, 128.25, 128.12, 127.94, 
127.91, 127.76, 127.72, 127.60, 127.58, 127.53, 127.46, 127.39, 126.77 (aromatic CH), 97.30 (C-1b), 87.66 (C-1a), 79.42, 
79.25, 78.95, 78.84, 78.20, 75.55, 75.20, 75.12, 73.91, 73.36, 73.31, 70.01, 68.73, 68.01.  
2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-1-thio-
β-D-glucopyranosyl N-phenyltrifluoroacetimidate (11): Compound 10 (265 mg, 
0.25 mmol) was dissolved in acetone:H2O (10:1, 3.3 mL). N-Iodosuccinimide (NIS) 
(112 mg, 0.50 mmol) was added in one portion and the reaction was stirred at room temperature for 2 hours. The solution 
was diluted with DCM and the reaction was quenched with saturated aqueous Na2S2O3, then the organic layer was washed 
with water and brine. The organic layer was dried with anhydrous MgSO4, filtered and concentrated in vacuo, and the 
product purified by column chromatography (pentane:EA = 2:1). Compound Di-glucose alcohol (185 mg, 76% yield) 
was obtained as a white solid. Next, compound Di-glucose alcohol (185 mg, 0.19 mmol) was dissolved in acetone (2 mL). 
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Cs2CO3 (93 mg, 0.28 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (50 μl, 0.28 mmol) were added to the 
solution respectively. The reaction stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. The 
product was purified by column chromatography (pentane:EA = 50:1-20:1). Compound 11 (170 mg, 80% yield, α:β = 
1.1:1) was obtained as yellow syrup. 1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.31-7.01 (m, aromatic H), 6.77 (d, J = 13.0 
Hz, 2 H), 6.68 (d, J = 13.0 Hz, 2 H), 6.48 (bs, 1 Hα), 5.65 (bs, 1 H), 5.55 (d, J = 3.5 Hz, 1 H), 5.51 (d, J = 3.5 Hz, 1 H), 
4.99 (d, J = 11.5 Hz, 1 H), 4.92-4.68 (m, CHH), 4.61-4.42 (m, CHH), 4.36-4.28 (m), 4.18 (bd, 1 H), 4.10-3.43 (m). 13 C-
APT (CDCl3, 125 MHz, 60℃) δ 143.83, 143.73, 139.16, 139.07, 139.02, 138.91, 138.53, 138.49, 138.48, 138.41, 138.38, 
138.37, 138.33, 138.20, 137.88, 137.71 (aromatic C), 128.81, 128.77, 128.52, 128.50, 128.46, 128.41, 128.38, 128.37, 
128.35, 128.29, 128.22, 128.02, 128.00, 127.94, 127.90, 127.86, 127.83, 127.79, 127.72, 127.64, 127.62, 127.60, 127.58, 
127.53, 127.48, 127.24, 127.16, 124.45, 124.31, 119.70, 119.61 (aromatic CH), 115.31 (q, CF3), 97.78, 97.71, 97.61, 
93.35, 82.49, 82.33, 80.31, 80.25, 79.83, 78.57, 78.55, 78.35, 78.20, 78.18, 76.24, 75.66, 75.56, 75.51, 75.10, 74.94, 74.73, 
74.04, 73.89, 73.85, 73.77, 73.71, 73.64, 73.60, 73.46, 73.18, 70.90, 70.74, 68.96, 68.87, 68.63, 68.55.  
Methyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl-(1→3)-2,4,6-tri-O-
benzyl-α-D-glucopyranosyl-(1→3)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (12): The reaction was carried out according to the 
standard procedure B, using 11 (78 mg, 0.07 mmol), 7 (33 mg, 0.07 mmol, 0.1 M in DCM), DMF (87 μL, 1.12 mmol) 
and TfOH (7 μL, 0.07 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed complete conversion of the 
acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by size 
exclusion chromatography (DCM:MeOH = 1:1). Compound 12 (65 mg, 63% yield, α:β> 20:1, pentane:EA = 4:1, Rf = 
0.50) was obtained as a colorless syrup. [α]D
20 +60.1, c=1 (10mg), CHCl3. IR (neat, cm
-1) ν 696, 735, 1028, 1072, 1157, 
1362, 1454, 1497, 2864, 2916, 3031. 1H-NMR (CDCl3, 400 MHz) δ 7.39-6.87 (m, 50 H, aromatic H), 5.66 (bd, J = 3.6 
Hz, 2 H, 2 H-1), 4.90-4.21 (m, 24 H), 4.08 (d, J = 12.0 Hz, 1 H, CHH), 4.01 (t, J = 9.6 Hz, 1 H), 3.85 (t, J = 9.6 Hz, 1 H), 
3.74-3.48 (m, 10 H), 3.30-3.24 (m, 5 H). 13C-APT (CDCl3, 100 MHz) δ 138.90, 138.71, 138.43, 138.18, 138.09, 137.90, 
137.86 (aromatic C), 128.77, 128.51, 128.49, 128.39, 128.38, 128.32, 128.29, 128.24, 128.22, 128.18, 128.17, 128.11, 
128.04, 127.99, 127.91, 127.83, 127.69, 127.62, 127.52, 127.44, 127.32, 127.13, 126.67 (aromatic CH), 97.70 (C-1), 
97.43 (C-1), 96.21 (C-1), 82.35, 79.55, 79.24, 79.00, 78.90, 78.59, 78.12, 77.05, 75.76, 75.50, 74.71, 73.64, 73.60, 73.52, 
73.37, 73.28, 73.09, 70.11 (C-5), 69.98 (C-5), 69.15 (C-a), 68.62 (2 C-6), 68.416 (C-6), 55.16 (CH3). 
3-Azidopropyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside (13): The reaction was carried 
out according to the standard procedure C, using 3 (2500 mg, 3.28 mmol, 0.1 M in DCM), 3-
aminopropanol (399 μL, 4.27 mmol), Ph3P=O (5.48 g, 19.7 mmol) and TMSI (516 μL, 3.61 
mmol). The product was purified by silica gel column chromatography (pentane:EA = 15:1). Compound 13 (1716 mg, 
80 % yield, α:β = 10:1, pentane:EA = 4:1, Rf = 0.74) was obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 820, 
1072, 1085, 1363, 1454, 2095, 2868, 2917, 3030. 1H-NMR (CDCl3, 400 MHz) δ 7.81-7.70 (m, 4 H, aromatic H), 7.48-
7.39 (m, 3 H, aromatic H), 7.36-7.21 (m, 13 H, aromatic H), 7.13-7.10 (m, 4 H, aromatic H), 5.13 (d, J = 11.2 Hz, 1 H, 
CHH), 4.97 (d, J = 11.2 Hz, 1 H, CHH), 4.85 (d, J = 10.4 Hz, 1 H, CHH), 4.78 (d, J = 8.4 Hz, 1 H, CHH), 4.77 (s, 1 H, 
H-1), 4.65 (d, J = 8.4 Hz, 1 H, CHH), 4.60 (d, J = 12.0 Hz, 1 H, CHH), 4.49 (d, J = 10.4 Hz, 1 H, CHH), 4.47 (d, J = 12.0 
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Hz, 1 H, CHH), 4.03 (t, J = 9.2 Hz, 1 H, H-3), 3.78-3.57 (m, 6 H), 3.48-3.30 (m, 3H), 1.94-1.79 (m, 2 H, H-2°). 13C-APT 
(CDCl3, 100 MHz,) δ 138.21, 138.15, 137.85, 136.32, 133.34, 132.92 (aromatic C), 128.47, 128.37, 128.06, 128.00, 
127.92, 127.88, 127.71, 127.66 (aromatic CH), 97.18 (C-1), 82.04 (C-3), 80.07 (C-2), 77.65 (C-4), 75.69, 75.11, 73.47, 
73.24 (4 PhCH2), 70.34 (C-5), 68.42 (C-6), 64.72 (C-1°), 48.26 (C-3°), 28.83 (C-2°). HR-MS: Calculated for C41H43O6N3 
[M+Na+]: 696.3044; found: 696.3059. 
3-Azidopropyl 2,4,6-tri-O-benzyl-α-D-glucopyranoside (14): The reaction was carried out 
according to the general procedure D, using 13 (1.67 g, 2.53 mmol, 0.1 M in DCM:H2O) and 
DDQ (632 mg, 2.78 mmol). The product was purified by silica gel column chromatography 
(pentane:EA = 8:1). Compound 14 (1.08 g, 80% yield, pentane:EA = 4:1, Rf = 0.33) was obtained as a colorless syrup. 
[α]D
20 +69.8, c=1 (10mg), CHCl3. IR (neat, cm
-1) ν 697, 734, 1028, 1070, 1154, 1453, 2096, 2869, 2918, 3031. 1H-NMR 
(CDCl3, 400 MHz) δ 7.31-7.19 (m, 15 H, aromatic H), 4.86 (d, J = 11.2 Hz, 1 H, CHH), 4.74 (s, J = 3.6 Hz, 1 H, H-1), 
4.68 (d, J = 12.0 Hz, 1 H, CHH), 4.60 (d, J = 12.0 Hz, 1 H, CHH), 4.59 (d, J = 12.4 Hz, 1 H, CHH), 4.51 (d, J = 11.2 Hz, 
1 H, CHH), 4.46 (d, J = 12.4 Hz, 1 H, CHH), 4.06 (t, J = 9.2 Hz, 1 H, H-3), 3.72-3.53 (m, 5 H), 3.41-3.28 (m, 4 H), 2.69 
(bs, 1 H, OH), 1.86-1.75 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz,) δ 138.33, 137.99, 137.86 (aromatic C), 128.53, 
128.35, 128.01, 127.91, 127.68 (aromatic CH), 96.58 (C-1), 79.62 (C-3), 77.35 (C-2), 74.61, 73.43 (2 PhCH2), 73.42 (C-
4), 72.92 (PhCH2), 69.94 (C-5), 68.41 (C-6), 64.55 (C-1°), 48.17 (C-3°), 28.80 (C-2°). HR-MS: Calculated for 
C30H35O6N3 [M+Na
+]: 556.2418; found: 556.2423. 
3-Azidopropyl 2,4,6-tri-O-benzyl-3-O-(naphthalen-2-ylmethyl)-α-D- 
glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-α-D-glucopyranoside (15): The 
reaction was carried out according to the standard procedure A at -78 - 0 oC. The 
donor 3 (2.18 g, 2.86 mmol, co-evaporated with toluene 3 times) was dissolved in 
dry DCM (24 mL) under nitrogen and stirred over fresh flame-dried molecular sieves 3A, after which DMF (2.50 mL, 
31.7 mmol) was added to the solution. The solution was cooled to -78 oC, after which TfOH (173μL, 1.96 mmol) was 
added. After 30 min, the pre-activation was complete as indicated by TLC-analysis. Acceptor 14 (910 mg, 1.70 mmol, 
dissolved in a little DCM and washed 3 times with DCM, totally 10 mL) was added to the solution and the mixture was 
placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis showed complete conversion of the acceptor. 
The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion 
chromatography (DCM:MeOH = 1:1). Crude compound 15 (α:β> 20:1, pentane:EA = 4:1, Rf = 0.62) was obtained as a 
colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.79-7.64 (m, 4 H, aromatic H), 7.43-7.01 (m, 34 H, aromatic H), 5.62 (d, 
J = 3.6 Hz, 1 H, H-1b), 5.07 (d, J = 11.2 Hz, 1 H, CHH), 5.00 (d, J = 11.2 Hz, 1 H, CHH), 4.97 (d, J = 11.6 Hz, 1 H, 
CHH), 4.84-4.80 (bt, 2 H, H-1a, CHH), 4.72-4.57 (m, 5 H, 5 CHH), 4.51-4.32 (m, 6 H, 5 CHH, H-5), 4.28 (dd, J1 = 8.4 
Hz, J2 = 9.2 Hz, 1 H, H-3a), 4.12 (t, J = 9.2 Hz, 1 H, H-3b), 3.84-3.56 (m, 8 H), 3.50-3.44 (m, 2H, H-6), 3.41-3.30 (m, 3 
H, H-1°a, H-3°), 1.85-1.79 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) δ 138.70, 138.36, 138.07, 138.04, 137.96, 137.85, 
136.32, 133.33 (aromatic C), 128.55, 128.40, 128.30, 128.24, 128.23, 128.11, 128.04, 128.00, 127.95, 127.93, 127.87, 
127.76, 127.67, 127.65, 127.61, 127.47, 127.43, 127.29, 126.89, 126.57, 126.52, 126.48, 126.40, 126.12, 126.08, 125.98, 
125.95, 125.74 (aromatic CH), 97.40 (C-1b), 96.64 (C-1a), 82.33 (C-3b), 79.70 (C-2b), 78.77 (C-2a), 78.57 (C-4a), 78.20 
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(C-4b), 76.47 (C-3a), 75.51, 74.83, 73.67, 73.63, 73.52, 73.34, 73.01 (7 CH2), 70.10 (C-5), 69.98 (C-5), 68.43 (C-6), 
68.31 (C-6), 64.59 (C-1°), 48.28 (C-3°), 28.85 (C-2°).  
3-Azidopropyl 2,4,6-tri-O-benzyl-α-D-glucopyranosyl-(1→3)-2,4,6-tri-O- 
benzyl-α-D-glucopyranoside (16): The reaction was carried out according to the 
general procedure D, using crude 15 (2 g, 1.81 mmol, 0.1 M in DCM:H2O) and 
DDQ (451 mg, 1.99 mmol). The product was purified by silica gel column 
chromatography (pentane:EA = 8:1-5:1). Compound 15 (1.53 g, 90% yield with two steps, pentane:EA = 4:1, Rf = 0.32) 
was obtained as a colorless syrup. [α]D
20 +78.6, c=1, CHCl3. IR (neat, cm
-1) ν 696, 734, 1028, 1070, 1089, 1149, 1453, 
1497, 2097, 2867, 2918, 3030. 1H-NMR (CDCl3, 400 MHz) δ 7.31-7.07 (m, 30 H, aromatic H), 5.59 (d, J = 3.6 Hz, 1 H, 
H-1b), 4.91 (d, J = 11.6 Hz, 1 H, CHH), 4.78 (d, J = 3.6 Hz, 1 H, H-1a), 4.71 (d, J = 11.2 Hz, 1 H, CHH), 4.62-4.55 (m, 
4 H, 4 CHH), 4.48-4.40 (m, 5 H, 5 CHH), 4.32 (d, J = 12.0 Hz, 1 H, CHH), 4.28-4.23 (m, 2 H, H-3a, H-5b), 4.13 (t, J = 
11.6 Hz, 1 H, H-3b), 3.79-3.51 (m, 7 H), 3.46-3.29 (m, 6 H), 2.34 (d, J = 1.6 Hz, 1 H, OH), 1.84-1.78 (m, 2 H, H-2°). 
13C-APT (CDCl3, 100 MHz,) δ 138.67, 138.27, 137.94, 137.84, 137.82 (aromatic C), 128.48, 128.34, 128.32, 128.23, 
128.20, 128.10, 127.89, 127.85, 127.79, 127.69, 127.67, 127.57, 127.47, 127.25, 126.72 (aromatic CH), 96.86 (C-1b), 
96.58 (C-1a), 79.14 (C-2b), 78.65 (C-2a), 78.53 (C-4a), 77.90 (C-4b), 76.28 (C-3a), 74.33 (CH2), 73.68 (C-3b), 73.51, 
73.43, 73.27, 73.09, 72.95 (5 CH2), 69.92 (C-5a), 69.46 (C-5b), 68.32 (C-6), 68.18 (C-6), 64.50 (C-1°), 48.19 (C-3°), 
28.77 (C-2°). HR-MS: Calculated for C57H63O11N3 [M+Na
+]: 988.4355; found: 988.4391. 
Synthesis of trisaccharide 17: The reaction was carried out according 
to the standard procedure A at -78 - 0 oC. The donor 3 (1.78 g, 2.34 
mmol, co-evaporated with toluene 3 times) was dissolved in dry 
DCM (20 mL) under nitrogen and stirred over fresh flame-dried 
molecular sieves 3A, after which DMF (2.94 mL, 37.4 mmol) was added to the solution. The solution was cooled to -78 
oC, after which TfOH (210 μL, 2.38 mmol) was added. After 30 min, the pre-activation was complete as indicated by 
TLC-analysis. Acceptor 16 (1.47 g, 1.52 mmol, dissolved in a little DCM and washed 3 times with DCM, totally 10 mL) 
was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 17 (1.81 g, 81%, α:β> 20:1, 
pentane:EA = 4:1, Rf = 0.58) was obtained as a colorless syrup. [α]D
20 +56.8, c=1, CHCl3. IR (neat, cm
-1) ν 697, 750, 
1028, 1072, 1088, 1155, 1364, 1454, 2096, 2865, 2927, 3030. 1H-NMR (CDCl3, 400 MHz) δ 7.77-7.62 (m, 4 H, aromatic 
H), 7.47-7.06 (m, 42 H, aromatic H), 6.99-6.94 (m, 4 H, aromatic H), 6.90-6.88 (m, 2 H, aromatic H), 5.69 (d, J = 3.6 Hz, 
1 H, H-1c), 5.65 (d, J = 3.6 Hz, 1 H, H-1b), 5.01 (d, J = 11.2 Hz, 1 H, CHH), 4.94 (d, J = 11.2 Hz, 1 H, CHH), 4.90 (d, J 
= 12.0 Hz, 1 H, CHH), 4.81-4.23 (m, 21 H, H-1a, H-3a, H-3b, 2 H-5, 16 CHH), 4.12-4.05 (m, 2 H, 1 CHH, H-3c), 3.85 
(t, J = 9.6 Hz, 1 H, H-4), 3.78-3.45 (m, 11 H), 3.39-3.24 (m, 5 H), 1.87-1.77 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz) 
δ 138.81, 138.61, 138.34, 138.15, 138.08, 138.05, 138.00, 137.83, 137.80, 136.28, 133.30, 132.86 (aromatic C), 128.50, 
128.42, 128.32, 128.25, 128.21, 128.19, 128.15, 128.11, 128.06, 128.03, 127.96, 127.93, 127.87, 127.82, 127.77, 127.63, 
127.55, 127.47, 127.37, 127.34, 127.23, 127.01, 126.60, 126.46, 126.04, 125.90, 125.70 (aromatic CH), 97.35 (C-1c), 
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96.60 (C-1a), 96.25 (C-1b), 82.18 (C-3c), 79.52, 79.21, 78.95, 78.91, 78.47, 78.01, 76.99 (C-3a), 75.75 (C-3b), 75.43, 
74.62, 73.55, 73.46, 73.36, 73.23, 73.19, 73.15, 73.07, 69.93 (C-5b), 69.88 (C-5c), 69.54 (C-5a), 68.50 (C-6), 68.46 (C-
6), 68.32 (C-6), 64.60 (C-1°), 48.29 (C-3°), 28.83 (C-2°). HR-MS: Calculated for C95H99O16N3 [M+Na
+]: 1560.6918; 
found: 1560.6923. 
Synthesis of trisaccharide acceptor 18: The reaction was carried out 
according to the general procedure D, using 17 (1.40 g, 0.95 mmol, 
0.1 M in DCM:H2O) and DDQ (238 mg, 1.05 mmol). The product 
was purified by silica gel column chromatography (pentane:EA = 8:1-
5:1). Compound 18 (1.27 g, 95% yield, pentane:EA = 4:1, Rf = 0.32) was obtained as a colorless syrup. [α]D
20 +80.0, c=1, 
CHCl3. IR (neat, cm
-1) ν 696, 735, 1029, 1071, 1089, 1153, 1454, 1497, 2095, 2868, 2921, 3030. 1H-NMR (CDCl3, 400 
MHz) δ7.33-7.07 (m, 39 H, aromatic H), 7.02-7.00 (m, 4 H, aromatic H), 6.88-6.86 (m, 2 H, aromatic H), 5.67 (d, J = 3.6 
Hz, 1 H, H-1c), 5.62 (d, J = 3.6 Hz, 1 H, H-1b), 4.84-4.75 (m, 3 H, 2 CHH, H-1a), 4.68 (d, J = 11.2 Hz, 1 H, CHH), 4.81-
4.05 (m, 20 H, H-3c, H-3a, H-3b, 2 H-5, 15 CHH), 3.82-3.18 (m, 17 H), 2.25 (s, 1 H, OH), 1.87-1.77 (m, 2 H, H-2°). 13C-
APT (CDCl3, 100 MHz) δ 138.79, 138.57, 138.28, 138.03, 137.96, 137.79, 137.76 (aromatic C), 128.44, 128.40, 128.36, 
128.30, 128.24, 128.18, 128.10, 128.02, 127.86, 127.79, 127.76, 127.73, 127.67, 127.61, 127.59, 127.53, 127.33, 127.30, 
127.21, 127.10, 126.88, 126.51 (aromatic CH), 96.87 (C-1c), 96.56 (C-1a), 96.23 (C-1b), 79.19, 79.06, 78.87, 78.83, 
78.49, 77.83, 76.82, 76.68, 74.18, 73.57, 73.54, 73.38, 73.34, 73.24, 73.09, 73.03, 73.01, 69.82 (C-5), 69.53 (C-5), 69.34 
(C-5), 68.48 (C-6), 68.40 (C-6), 68.27 (C-6), 64.58 (C-1°), 48.28 (C-3°), 28.81 (C-2°). HR-MS: Calculated for 
C84H91O16N3 [M+Na
+]: 1420.6292; found: 1420.6320. 
Synthesis of tetrasaccharide 19: The reaction was carried out 
according to the standard procedure A at -78 - 0 oC. The donor 3 
(1.10 g, 1.45 mmol, co-evaporated with toluene 3 times) was 
dissolved in dry DCM (10 mL) under nitrogen and stirred over fresh 
flame-dried molecular sieves 3A, after which DMF (1.83 mL, 23.2 mmol) was added to the solution. The solution was 
cooled to -78 oC, after which TfOH (128 μL, 1.45 mmol) was added. After 30 min, the pre-activation was complete as 
indicated by TLC-analysis. Acceptor 18 (1.01 g, 0.73 mmol, dissolved in a little DCM and washed 3 times with DCM, 
totally 5 mL) was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until 
TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 19 
(1.20 g, 84%, α:β> 20:1, pentane:EA = 4:1, Rf = 0.46) was obtained as a colorless syrup. [α]D
20 +70.4, c=1, CHCl3. IR 
(neat, cm-1) ν 697, 734, 1028, 1071, 1087, 1155, 1363, 1454, 1497, 2093, 2867, 2924, 3031. 1H-NMR (CDCl3, 400 MHz) 
δ7.62-6.80 (m, 67 H, aromatic H), 5.71 (d, J = 3.6 Hz, 1 H, H-1), 5.61 (bd, 2 H, 2 H-1), 4.95 (d, J = 11.2 Hz, 1 H, CHH), 
4.87 (d, J = 11.2 Hz, 1 H, CHH), 4.80-4.18 (m, 30 H), 4.11 (d, J = 12.0 Hz, 1 H, CHH), 3.99 (t, J = 9.6 Hz, 1 H, H-3), 
3.83-3.22 (m, 21 H), 1.85-1.80 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz) δ 138.91, 138.71, 138.56, 138.32, 138.21, 
138.12, 138.07, 138.05, 137.91, 137.89, 137.84, 136.35, 133.34, 132.91 (aromatic C), 128.52, 128.50, 128.48, 128.39, 
128.32, 128.27, 128.25, 128.22, 128.12, 128.08, 128.04, 127.99, 127.97, 127.95, 127.87, 127.75, 127.68, 127.61, 127.59, 
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127.41, 127.38, 127.19, 127.13, 127.03, 126.92, 126.50, 126.45, 126.11, 125.92, 125.73 (aromatic CH), 97.33 (C-1), 
96.63 (C-1), 96.33 (C-1), 96.12 (C-1), 82.21, 79.48, 79.36, 78.98, 78.95, 78.82, 78.72, 78.45, 78.04, 77.01, 75.64, 75.45, 
74.56, 73.64, 73.50, 73.46, 73.37, 73.28, 73.13, 72.87, 72.72, 69.85 (C-5), 69.72 (C-5), 69.59 (2 C-5), 68.53 (3 C-6), 
68.40 (C-6), 64.66 (C-1°), 48.37 (C-3°), 28.91 (C-2°). HR-MS: Calculated for C122H127O21N3 [M+Na
+]: 1992.8854; found: 
1992.8793. 
Synthesis of tetrasaccharide acceptor 20: The reaction was carried 
out according to the general procedure D, using 19 (1.20 g, 0.61 
mmol, 0.1 M in DCM:H2O) and DDQ (152 mg, 0.67 mmol). The 
product was purified by silica gel column chromatography 
(pentane:EA = 5:1). Compound 20 (890 mg, 80% yield, pentane:EA = 4:1, Rf = 0.21) was obtained as a colorless syrup. 
[α]D
20 +87.8, c=1, CHCl3. IR (neat, cm
-1) ν 697, 735, 1028, 1091, 1154, 1364, 1453, 1497, 2098, 2866, 2924, 3029. 1H-
NMR (CDCl3, 400 MHz) δ7.35-6.78 (m, 60 H, aromatic H), 5.68 (d, J = 3.6 Hz, 1 H, H-1c), 5.61 (d, J = 3.6 Hz, 1 H, H-
1b), 5.60 (d, J = 3.6 Hz, 1 H, H-1d), 4.79-4.76 (m, 2 H, H-1a, CHH), 4.72-4.18 (m, 28 H), 4.11 (bd, 2 H, 2 CHH), 4.00 
(t, J = 9.2 Hz, 1 H, H-3d), 3.83-3.20 (m, 21 H), 2.19 (s, 1 H, OH), 1.86-1.80 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz) 
δ 138.85, 138.67, 138.49, 138.31, 138.09, 138.01, 137.88, 137.87, 137.82 (aromatic C), 128.40, 128.38, 128.23, 128.19, 
128.18, 128.04, 127.99, 127.94, 127.84, 127.78, 127.75, 127.70, 127.65, 127.60, 127.48, 127.41, 127.33, 127.30, 127.28, 
127.17, 127.08, 127.01, 126.96, 126.56, 126.40, 126.34 (aromatic CH), 96.86 (C-1d), 96.60 (C-1a), 96.29 (C-1b), 96.11 
(C-1c), 79.35, 79.00, 78.91, 78.72, 78.68, 78.45, 77.85, 76.97, 75.53, 75.35, 74.11, 73.62, 73.56, 73.49, 73.40, 73.25, 
73.11, 73.09, 72.95, 72.88, 72.67, 69.69 (C-5), 69.58 (C-5), 69.54 (C-5), 69.23 (C-5), 68.53 (C-6), 68.48 (2 C-6), 68.34 
(C-6), 64.65 (C-1°), 48.35 (C-3°), 28.89 (C-2°). HR-MS: Calculated for C111H119O21N3 [M+Na
+]: 1852.8228; found: 
1852.8154. 
Synthesis of pentasaccharide  21: The reaction was carried out 
according to the standard procedure A at -78 - 0 oC. The donor 3 
(587 mg, 0.77 mmol, co-evaporated with toluene 3 times) was 
dissolved in dry DCM (4 mL) under nitrogen and stirred over fresh 
flame-dried molecular sieves 3A, after which DMF (970 mL, 12.3 mmol) was added to the solution. The solution was 
cooled to -78 oC, after which TfOH (68 μL, 0.77 mmol) was added. After 30 min, the pre-activation was complete as 
indicated by TLC-analysis. Acceptor 20 (705 mg, 0.38 mmol, dissolved in a little DCM and washed 3 times with DCM, 
totally 4 mL) was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until 
TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 21 
(750 mg, 81%, α:β> 20:1, pentane:EA = 4:1, Rf = 0.36) was obtained as a colorless syrup. [α]D
20 +77.8, c=1, CHCl3. IR 
(neat, cm-1) ν 697, 734, 1029, 1071, 1089, 1154, 1364, 1454, 1497, 2097, 2864, 2923, 3030. 1H-NMR (CDCl3, 400 MHz) 
δ7.75-6.64 (m, 82 H, aromatic H), 5.69 (d, J = 3.2 Hz, 1 H, H-1c), 5.65 (d, J = 3.2 Hz, 1 H, H-1d), 5.61 (d, J = 3.6 Hz, H, 
H-1b), 5.57 (d, J = 3.2 Hz, 1 H, H-1e), 4.95 (d, J = 11.2 Hz, 1 H, CHH), 4.86 (d, J = 11.2 Hz, 1 H, CHH), 4.80-4.09 (m, 
39 H), 3.97 (t, J = 9.6 Hz, 1 H, H-3e), 3.83-3.20 (m, 25 H), 1.88-1.81 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz) δ 
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139.28, 138.87, 138.68, 138.50, 135.35, 138.26, 138.17, 138.06, 138.03, 137.99, 137.90, 137.84, 137.77, 136.31, 133.29, 
132.84 (aromatic C), 128.48, 128.44, 128.42, 128.33, 128.27, 128.25, 128.20, 128.14, 128.06, 127.98, 127.95, 127.93, 
127.90, 127.80, 127.72, 127.70, 127.63, 127.61 127.55, 127.50, 127.33, 127.29, 127.26, 127.19, 127.10, 127.00, 126.77, 
126.51, 126.44, 126.34, 126.22, 126.06, 126.86, 125.66 (aromatic CH), 97.21 (C-1e), 96.54 (C-1a), 96.26 (C-1b), 96.11 
(C-1c), 95.99 (C-1d), 82.10 (C-3e), 79.40, 79.20, 79.13, 78.91, 78.86, 78.78, 78.56, 78.51, 78.42, 77.98, 76.87, 75.53, 
75.36, 75.06, 74.46, 75.58, 73.44, 73.31, 73.09, 72.99, 72.93, 72.70, 72.64, 72.51, 69.73 (C-5), 69.55 (C-5), 69.49 (2 C-
5), 69.36 (C-5), 68.48 (2 C-6), 68.43 (2 C-6), 68.33 (C-6), 64.60 (C-1°), 48.29 (C-3°), 28.85 (C-2°). HR-MS: Calculated 
for C149H155O26N3 [M+H
+]: 2403.0972; found: 2403.0933. 
Synthesis of pentasaccharide acceptor 22: The reaction was carried 
out according to the general procedure D, using 21 (520 mg, 0.22 
mmol, 0.1 M in DCM:H2O) and DDQ (54 mg, 0.24 mmol). The 
product was purified by silica gel column chromatography (Tol:EA 
= 20:1). Compound 22 (370 mg, 75% yield, pentane:EA = 4:1, Rf = 0.20) was obtained as a colorless syrup. [α]D
20 +98.6, 
c=1, CHCl3. IR (neat, cm
-1) ν 696, 734, 1028, 1071, 1088, 1153, 1453, 1497, 2092, 2864, 2923, 3031. 1H-NMR (CDCl3, 
400 MHz) δ 7.34-6.60 (m, 75 H, aromatic H), 5.69 (d, J = 3.6 Hz, 1 H, H-1c), 5.61 (bt, 2 H, H-1b, H-1d), 5.54 (d, J = 3.6 
Hz, 1 H, H-1e), 4.79 (d, J = 3.6 Hz, 1 H, H-1a), 4.76 (d, J = 11.6 Hz, 1 H, CHH), 4.69-4.07 (m, 37 H), 3.98 (t, J = 9.6 Hz, 
1 H, H-3e), 3.83-3.17 (m, 25 H), 2.17 (s, 1 H, OH), 1.87-1.80 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz) δ 138.85, 
138.67, 138.52, 138.47, 138.28, 138.06, 138.01, 137.91, 137.86, 137.85, 137.79 (aromatic C), 128.49, 128.47, 128.45, 
128.36, 128.29, 128.23, 128.23, 128.16, 128.11, 128.09, 128.05, 127.99, 127.96, 127.92, 127.82 127.80, 127.73, 127.67, 
127.63, 127.57, 127.44, 127.29, 127.20, 127.01, 126.85, 126.79, 126.49, 126.27, 126.15 (aromatic CH), 96.79 (C-1e), 
96.56 (C-1a), 96.28 (C-1), 96.10 (C-1), 96.01 (C-1), 79.22, 79.15, 78.95, 78.87, 78.77, 78.55, 78.44, 77.81, 76.87, 75.50, 
75.02, 74.04, 73.61, 73.49 (C-3e), 73.47, 73.42, 73.38, 73.35, 73.30, 73.09, 73.01, 72.83, 72.69, 72.50, 69.57 (C-5), 69.48 
(2 C-5), 69.37 (C-5), 69.14 (C-5), 68.51 (2 C-6), 68.44 (2 C-6), 68.31 (C-6), 64.63 (C-1°), 48.33 (C-3°), 28.88 (C-2°). 
HR-MS: Calculated for C138H147O26N3 [M+H
+]: 2263.0346; found: 2263.0291. 
Synthesis of hexasaccharide 23: The reaction was carried out 
according to the standard procedure A at -78 - 0 oC. The donor 3 
(310 mg, 0.41 mmol, co-evaporated with toluene 3 times) was 
dissolved in dry DCM (1 mL) under nitrogen and stirred over fresh 
flame-dried molecular sieves 3A, after which DMF (512 μL, 6.56 mmol) was added to the solution. The solution was 
cooled to -78 oC, after which TfOH (36 μL, 0.41 mmol) was added. After 30 min, the pre-activation was complete as 
indicated by TLC-analysis. Acceptor 22 (260 mg, 0.12 mmol, dissolved in a little DCM and washed 3 times with DCM, 
totally 1 mL) was added to the solution and the mixture was placed in an ice bath. The reaction was stirred at 0 oC until 
TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 23 
(293 mg, 90%, α:β> 20:1, pentane:EA = 4:1, Rf = 0.32) was obtained as a colorless syrup. [α]D
20 +78.7, c=1, CHCl3. IR 
(neat, cm-1) ν 697, 734, 1029, 1072, 1089, 1154, 1363, 1454, 1497, m2097, 2863, 2926, 3029. 1H-NMR (CDCl3, 400 
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MHz) δ 7.75-6.58 (m, 97 H, aromatic H), 5.68 (d, J = 3.2 Hz, 1 H, H-1), 5.63-5.60 (m, 3 H, 3 H-1), 5.55 (d, J = 3.2 Hz, 
1 H, H-1f), 4.94 (d, J = 11.2 Hz, 1 H, CHH), 4.86 (d, J = 11.2 Hz, 1 H, CHH), 4.79 (d, J = 3.6 Hz, 1 H, H-1a), 4.76-4.08 
(m, 46 H), 3.96 (t, J = 9.6 Hz, 1 H, H-3f), 3.83-3.18 (m, 29 H), 1.85-1.81 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz) δ 
138.87, 138.68, 138.51, 138.48, 135.35, 138.26, 138.17, 138.03, 137.87, 137.84, 137.82, 137.77, 136.31, 133.28, 132.83 
(aromatic C), 128.48, 128.42, 128.33, 128.28, 128.26, 128.25, 128.21, 128.15, 128.14, 128.07, 128.06, 128.05, 128.01, 
128.99, 127.96, 127.92, 127.89, 127.79, 127.75, 127.70, 127.64, 127.61, 127.54, 127.49, 127.32, 127.27, 127.24, 127.02, 
126.83, 126.74, 126.69, 126.45, 126.43, 126.31, 126.29, 126.13, 126.05, 125.96, 125.85, 125.66 (aromatic CH), 97.19 
(C-1f), 96.53 (C-1a), 96.23 (C-1), 96.08 (C-1), 96.02 (C-1), 95.93 (C-1), 82.10 (C-3f), 79.38, 79.20, 79.08, 79.03, 78.87, 
78.74, 78.48, 78.39, 77.96, 76.91, 75.52, 75.44, 75.35, 75.13, 75.02, 74.44, 73.58, 73.44, 73.37, 73.30, 73.28, 73.00, 72.83, 
72.73, 72.66, 72.52, 72.36, 69.69 (C-5), 69.53 (C-5), 69.46 (C-5), 69.41 (C-5), 69.32 (C-5), 69.15 (C-5), 68.46 (5 C-6), 
68.29 (C-6), 64.60 (C-1°), 48.29 (C-3°), 28.84 (C-2°). MALDI-TOF: Calculated for C176H183O31N3 [M+H
+]: 2835.3; 
found: 2832.9. 
Synthesis of hexasaccharide acceptor 24: The reaction was carried 
out according to the general procedure D, using 21 (480 mg, 0.17 
mmol, 0.1 M in DCM:H2O) and DDQ (46 mg, 0.20 mmol). The 
product was purified by silica gel column chromatography (Tol:EA 
= 20:1). Compound 24 (320 mg, 70% yield, Tol:EA = 9:1, Rf = 0.26) was obtained as a colorless syrup. [α]D
20 +79.4, c=1, 
CHCl3. IR (neat, cm
-1) ν 697, 735, 1029, 1070, 1089, 1155, 1364, 1453, 1497, 2098, 2868, 2923, 3029. 1H-NMR (CDCl3, 
500 MHz) δ 7.33-6.56 (m, 90 H, aromatic H), 5.68 (d, J = 3.5 Hz, 1 H, H-1), 5.62 (bt, 2 H, 2 H-1), 5.57 (d, J = 4.0 Hz, 1 
H, H-1), 5.53 (d, J = 3.5 Hz, 1 H, H-1f), 4.78 (bt, 2 H, H-1a, CHH), 4.69-4.06 (m, 45 H), 3.97 (t, J = 9.5 Hz, 1 H, H-3f), 
3.82-3.16 (m, 29 H), 2.16 (bs, 1 H, OH), 1.87-1.78 (m, 2 H, H-2°). 13C-APT (CDCl3, 125 MHz) δ 138.86, 138.68, 138.53, 
138.50, 138.29, 138.04, 138.02, 137.90, 137.87, 137.81 (aromatic C), 128.46, 128.43, 128.42, 128.33, 128.28, 128.26, 
128.20, 128.13, 128.08, 128.03, 128.01, 127.96, 127.89, 127.78, 127.76, 127.69, 127.62, 127.59, 127.53, 127.42, 127.28, 
127.22, 127.21, 127.04, 126.84, 126.81, 126.70, 126.49, 126.29, 126.28, 126.10 (aromatic CH), 96.75 (C-1f), 96.55 (C-
1a), 96.23 (C-1), 96.07 (C-1), 95.99 (C-1), 95.93 (C-1), 79.23, 79.13, 79.07, 78.97, 78.92, 78.52, 78.44, 78.37, 77.82, 
75.46, 75.13, 74.99, 74.00, 73.59, 73.48, 73.45, 73.38, 73.35, 73.32, 73.28, 73.01, 72.83, 72.79, 72.66, 72.58, 72.51, 72.37, 
69.57 (C-5), 69.49 (C-5), 69.43 (C-5), 69.35 (C-5), 69.18 (C-5), 69.13 (C-5), 68.49 (5 C-6), 68.31 (C-6), 64.63 (C-1°), 
48.31 (C-3°), 28.86 (C-2°). MALDI-TOF: Calculated for C165H175O31N3 [M+K
+]: 2733.2; found: 2732.9. 
Synthesis of heptasaccharide 25: The reaction was carried out 
according to the standard procedure B, using 3 (275 mg, 0.36 mmol), 
24 (330 mg, 0.12 mmol, 0.05 M in DCM), DMF (455 μL, 5.78 
mmol) and TfOH (32 μL, 0.36 mmol). The reaction was stirred at -
78-0 oC until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered 
and concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 
25 (360 mg, 90% yield, α:β > 20:1, pentane:EA = 4:1, Rf = 0.24) was obtained as a colorless syrup. [α]D
20 +83.8, c=1, 
CHCl3. IR (neat, cm
-1) ν 697, 734, 1029, 1071, 1089, 1155, 1454, 2096, 2858, 2924, 3031. 1H-NMR (CDCl3, 500 MHz) 
Reagent Controlled Stereoselective Assembly of α-(1,3)-Glucans 
87 
δ 7.74-6.58 (m, 112 H, aromatic H), 5.69 (d, J = 3.5 Hz, 1 H, H-1), 5.63-5.55 (m, 5 H, 5 H-1), 4.93 (d, J = 11.5 Hz, 1 H, 
CHH), 4.85 (d, J = 11.5 Hz, 1 H, CHH), 4.79-4.09 (m, 55 H), 3.96 (t, J = 9.0 Hz, 1 H, H-3g), 3.83-3.19 (m, 33 H), 1.85-
1.79 (m, 2 H, H-2°). 13C-APT (CDCl3, 125 MHz) δ 138.84, 138.65, 138.49, 138.46, 128.23, 128.15, 138.03, 138.00, 
137.84, 137.80, 137.74, 136.29, 133.24, 132.79 (aromatic C), 128.39, 128.38, 128.36, 128.27, 128.22, 128.21, 128.19, 
128.14, 128.08, 128.03, 127.98, 127.96, 127.90, 127.86, 127.83, 127.72, 127.70, 127.64, 127.55, 127.48, 127.42, 127.32, 
127.27, 127.21, 127.17, 127.04, 126.97, 126.78, 126.59, 126.64, 126.45, 126.37, 126.28, 126.24, 126.20, 126.11, 126.00, 
125.79, 125.60 (aromatic CH), 97.11 (C-1g), 96.48 (C-1a), 96.17 (C-1), 95.99 (C-1), 95.92 (2 C-1), 95.87 (C-1), 82.03 
(C-3g), 79.40, 79.17, 79.05, 79.00, 78.85, 78.75, 78.47, 78.38, 78.32, 77.95, 76.83, 75.46, 75.42, 75.28, 75.05, 74.94, 
74.39, 73.52, 73.38, 73.31, 73.25, 73.22, 72.98, 72.93, 72.75, 72.61, 72.47, 72.35, 72.27, 69.67 (C-5), 69.52 (C-5), 69.43 
(C-5), 69.36 (C-5), 69.30 (C-5), 69.11 (C-5), 69.06 (C-5), 68.44 (6 C-6), 68.29 (C-6), 64.56 (C-1°), 48.22 (C-3°), 28.79 
(C-2°). MALDI-TOF: Calculated for C203H211O36N3 [M+K
+]: 3305.4; found: 3306.1. 
Synthesis of heptasaccharide acceptor 26: The reaction was carried 
out according to the general procedure D, using 25 (300 mg, 0.09 
mmol, 0.05 M in DCM:H2O) and DDQ (23 mg, 0.10 mmol). The 
product was purified by silica gel column chromatography (Tol:EA 
= 20:1). Compound 26 (145 mg, 51% yield, Tol:EA = 9:1, Rf = 0.25) was obtained as a colorless syrup. [α]D
20 +129.9, 
c=1, CHCl3. IR (neat, cm
-1) ν 696, 733, 1028, 1071, 1089, 1153, 1364, 1454, 1497, 2096, 2863, 2926, 3031. 1H-NMR 
(CDCl3, 500 MHz) δ 7.33-6.54 (m, 105 H, aromatic H), 5.68 (d, J = 3.5 Hz, 1 H, H-1), 5.61 (bt, 2 H, 2 H-1), 5.58 (d, J = 
3.5 Hz, 1 H, H-1), 5.55 (d, J = 3.5 Hz, 1 H, H-1), 5.52 (d, J = 3.5 Hz, 1 H, H-1g), 4.78 (bt, 2 H, H-1a, CHH), 4.69-4.06 
(m, 53 H), 3.96 (t, J = 9.5 Hz, 1 H, H-3g), 3.82-3.15 (m, 33 H), 2.15 (bs, 1 H, OH), 1.84-1.80 (m, 2 H, H-2°). 13C-APT 
(CDCl3, 125 MHz) δ 138.88, 138.70, 138.55, 138.52, 138.29, 138.07, 138.04, 138.03, 137.96, 137.88, 137.82 (aromatic 
C), 128.47, 128.45, 128.43, 128.34, 128.29, 128.27, 128.21, 128.16, 128.14, 128.10, 128.05, 128.02, 127.97, 127.94, 
127.89, 127.80, 127.77, 127.71, 127.63, 127.60, 127.54, 127.43, 127.39, 127.33, 127.30, 127.21, 127.14, 127.12, 127.05, 
126.84, 126.81, 126.77, 126.68, 126.61, 126.51, 126.29, 126.28, 126.23, 126.08 (aromatic CH), 96.75 (C-1f), 96.56 (C-
1a), 96.23 (C-1), 96.05 (C-1), 96.00 (C-1), 95.95 (2 C-1), 79.24, 79.10, 79.06, 78.97, 78.44, 78.41, 78.30, 77.82, 75.48, 
75.11, 74.97, 74.01, 73.60, 73.46, 73.39, 73.36, 73.34, 73.29, 73.02, 72.79, 72.74, 72.65, 72.56, 72.51, 72.38, 72.31, 69.58 
(C-5), 69.49 (C-5), 69.40 (C-5), 69.36 (C-5), 69.16 (C-5), 69.12 (2 C-5), 68.49 (6 C-6), 68.31 (C-6), 64.64 (C-1°), 48.33 
(C-3°), 28.88 (C-2°). MALDI-TOF: Calculated for C192H203O36N3 [M+K
+]: 3165.4; found: 3165.0. 
Synthesis of octasaccharide 27: The reaction was carried out 
according to the standard procedure B, using 3 (110 mg, 0.14 mmol), 
24 (120 mg, 0.038 mmol, 0.025 M in DCM), DMF (182 μL, 2.31 
mmol) and TfOH (13 μL, 0.15 mmol). The reaction was stirred at -
78-0 oC until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered 
and concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 
27 (140 mg, 98% yield, α:β> 20:1, pentane:EA = 4:1, Rf = 0.17) was obtained as a colorless syrup. [α]D
20 +97.1, c=1, 
CHCl3. IR (neat, cm
-1) ν 697, 734, 1028, 1071, 1154, 1208, 1364, 1455, 1497, 2097, 2864, 2925, 3030. 1H-NMR (CDCl3, 
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400 MHz) δ 7.75-6.56 (m, 127 H, aromatic H), 5.69 (d, J = 3.5 Hz, 1 H, H-1), 5.63-5.54 (m, 6 H, 6 H-1), 4.93 (d, J = 11.2 
Hz, 1 H, CHH), 4.85 (d, J = 11.2 Hz, 1 H, CHH), 4.809-4.08 (m, 63 H), 3.95 (t, J = 9.2 Hz, 1 H, H-3h), 3.83-3.15 (m, 37 
H), 1.84-1.80 (m, 2 H, H-2°). 13C-APT (CDCl3, 100 MHz) δ 139.17, 138.87, 138.67, 138.52, 138.49, 138.48, 138.34, 
138.25, 138.17, 138.06, 138.02, 137.86, 137.80, 137.76, 136.32, 133.27, 132.82 (aromatic C), 128.47, 128.44, 128.42, 
128.33, 128.27, 128.21, 128.17, 128.12, 128.07, 128.06, 128.03, 127.99, 127.95, 127.89, 127.80, 127.74, 127.71, 127.61, 
127.53, 127.47, 127.38, 127.31, 127.27, 127.22, 127.16, 127.08, 127.04, 127.01, 126.83, 126.72, 126.46, 126.42, 126.28, 
126.25, 126.17, 126.09, 126.05, 125.84, 125.65 (aromatic CH), 97.17 (C-1), 96.528 (C-1), 96.22 (C-1), 96.03 (C-1), 95.95 
(4 C-1), 82.09 (C-3h), 79.37, 79.19, 79.02, 78.86, 78.73, 78.44, 78.39, 78.28, 77.95, 76.89, 75.51, 75.43, 75.35, 75.05, 
74.97, 74.84, 74.43, 73.58, 73.44, 73.37, 73.30, 73.26, 72.99, 72.77, 72.64, 72.57, 72.46, 72.29, 69.67 (C-5), 69.52 (C-5), 
69.45 (C-5), 69.35 (C-5), 69.31 (C-5), 69.10 (C-5), 69.03 (2 C-5), 68.41 (7 C-6), 68.29 (C-6), 64.60 (C-1°), 48.29 (C-3°), 
28.84 (C-2°). MALDI-TOF: Calculated for C230H239O41N3 [M+K
+]: 3737.6; found: 3737.5. 
Synthesis of octasaccharide 2: Compound 27 (20 mg, 0.0054 mmol) 
was dissolved in THF/H2O/tert-BuOH (2 mL/2 mL/1 mL) before a 
catalytic amount of Pd(OH)2/C was added. The reaction mixture 
was stirred for 2 days under a H2 atmosphere (40 bar), filtered and 
concentrated in vacuo. A white powder 2 was obtained, which was purified by gel filtration (HW-40, 0.15M NH4OAc in 
H2O) to yield 1 (2.9 mg, 40%). 
1H-NMR (CDCl3, 500 MHz) δ 5.35 (bd, 7 H, 7 H-1), 4.91 (d, J = 3.5 Hz, 1 H, H-1), 4.02-
3.53 (m, 53 H), 3.41 (t, J = 10.0 Hz, 1 H), 3.14-3.00 (m, 2 H), 1.96-1.91 (m, 2 H). 13C-APT (CDCl3, 125 MHz) δ 99.39, 
99.23, 98.47, 79.94, 79.89, 79.75, 72.89, 71.84, 71.73, 71.62, 70.39, 69.93, 69.86, 69.74, 69.51, 65.91, 60.51, 60.39, 60.30, 
37.88, 27.60. HR-MS: Calculated for C51H89O41N [M+H
+]: 1372.4983; found: 1372.5005. 
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Chapter 4 
Synthesis of Teichoic Acid α-(1,2)-Glucans 
Introduction 
α-Glucans, polysaccharides composed of glucose monosaccharides connected through α-
glycosidic linkages, are widely found in natural products.[1] The most abundant α-glucans are the 
α-(1,4)-glucans, that occur as starch and glycogen, and can be found as extracellular 
polysaccharides surrounding bacteria, such as Mycobacterium tuberculosis.[2] α-(1,3)-Glucans are 
prominent members of the fungal cell wall and they have been implicated to play an important 
role in the interaction between the pathogenic fungus Aspergillus fumigatus and the host immune 
system.[3] α-(1,2)-Glucans, also referred to as kojioligosaccharides, are the rarest member of the 
α-glucan family, but kojibiose and higher kojioligosaccharides have been found in koji extract, 
sake, beer and honey and they have also been encountered in bacterial cell walls.[4] Kojibiose, 
kojitriose and kojitetraose have been found as part of the lipoteichoic acid (LTA) of Enterococcus 
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faecalis, which is a Gram-positive commensal bacterium.[5] Although this bacterium is generally 
of low virulence, it is the causative agent of many life-threatening infections in 
immunocompromised patients and one of the most prominent hospital bacteria.[6] LTA is an 
anionic polymer that is linked to the cell wall of the bacteria through a glycolipid anchor, and that 
is built up from glycerol phosphate repeating units, which can be substituted by glycans and D-
alanine esters at the C2 position of the glycerols.[7] Kojibiose is a prominent appendage of E. 
faecalis LTA (Figure 1), where it can be decorated with D-alanine esters at both C6-hydroxyl 
groups of the disaccharide.[7] D-Alanylation plays a critical role in the virulence of the bacteria 
and it renders the bacteria less susceptible to (cationic) antimicrobial peptides. E. faecalis LTA 
fragments, containing a single α-glucosyl substituent have previously been explored as 
components in synthetic vaccine conjugates, and antibodies raised by these conjugates have been 
shown to be opsonophagocytic and capable of inducing killing of the bacteria in both active and 
passive immunization strategies.[8] The microheterogeneity of naturally occurring LTA makes it 
challenging -if not impossible- to establish clear structure-activity relationships for these 
molecules, and therefore organic synthesis is the method of choice for the generation of well-
defined single LTA molecules.  
 
Figure 1. The structure of E. faecalis LTA. 
Only few chemical syntheses of α-(1,2)-glucans have been reported. Takeo and Suzuki reported 
a procedure to assemble kojitriose, kojitetraose and kojipentaose based on the use of Koenings-
Knorr-type glycosylations, using anomeric chlorides under the activation of silver perchlorate.[9] 
Hogendorf et al. relied on Crich’s α-glucosylation protocol which involved the use of benzylidene 
glucose donors for the synthesis of a kojibiose glycerol building block.[8] The work described in 
Chapter 2 and 3 has shown that additive controlled glycosylations of per-benzylated glucosyl 
donors can be used effectively for the introduction of α-(1,4)- and a α-(1,3)-glucosyl linkages,[10] 
and it thus represents an attractive strategy for the assembly of α-(1,2)-linkages. This Chapter 
explores the use of additive controlled glycosylation methodology for the construction of α-(1,2)-
glucans and the methodology is applied for, in combination with the triad of benzyl ether type 
protecting groups introduced in Chapter 2, the preparation of a D-Ala-kojibiose functionalized 
LTA (fragment of building block, depending on how far we get with the synthesis). 
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Results and Discussion 
First the assembly of a spacer functionalized kojioligosaccharide was explored. To achieve this 
aim, donor 6 was designed and assembled, bearing three permanent benzyl ethers to mask the C3, 
C4 and C6 hydroxyls and a 2-methylnaphthyl (Nap) ether as a temporary protecting group at the 
C2-OH. The synthesis of this building block used benzylidene protected glucose building block 
1 as starting compound. Selective protection of the C3-OH with benzyl ether was achieved 
through the formation of an intermediate tin ketal which was treated with benzyl bromide and 
cesium fluoride to give compound 2. Protection of the remaining C2-OH with a Nap ether then 
provided compound 3. Selective opening the benzylidene and protection of the liberated primary 
alcohol provided the fully benzylated thio donor 5. The anomeric thio acetal in this building block 
was hydrolyzed using N-iodosuccinimide (NIS) in acetone/water to liberate the anomeric 
hydroxyl group, which could then be turned into the required N-phenyltrifluoroimidate 6. 
 
a) 1) Bu2SnO, toluene, 120 
oC; 2) CsF, BnBr, 76%. b) NapBr, NaH, DMF, 91%. c) BF3
.Et2O, TES, DCM, 72%. d) BnBr, 
NaH, DMF, 88%. e) 1) NIS, acetone:H2O = 10:1 (v:v); 2) 2,2,2-trifluoro-N-phenylacetimidoyl chloride, Cs2CO3, acetone, 
81% over two steps. 
Scheme 1. The synthesis of donor 6. 
With the required donor 6 in hand, the assembly of kojioligosaccharides was explored as depicted 
in Scheme 2. Firstly, the donor 6 was glycosylated with azidopropanol under the TMSI-Ph3P=O 
condition to form the desired azidopropyl glucoside 7 in good yield and stereoselectivity (α:β = 
10:1), in line with the results described previously. Deprotection of the C2-O-Nap ether under 
oxidative condition (dichlorodicyanobenzoquinone (DDQ) in DCM/H2O, 10:1 v/v) provided 
alcohol 8 which was purified by silica gel column chromatography to deliver the pure α-anomer. 
Next the secondary alcohol acceptor 8 was glycosylated with donor 6 under the agency of 
TMSOTf and DMF to form the disaccharide 9 in 95% yield and a 15:1α:β-ratio. Deprotection of 
the C2-O-Nap ether by DDQ to give disaccharide acceptor 10 proceeded in somewhat lower yield 
than the deprotection of the monosaccharide 8 (49% vs 75% yield). The third glycosylation, again 
performed under DMF mediated glycosylation conditions, then provided trisaccharide 11. The 
stereoselectivity of this glycosylation, however, diminished slightly and 11 was formed as a 10:1 
α:β mixture. The erosion of stereoselectivity developed further upon elongation of the 
trisaccharide. Thus, the DMF-mediated glycosylation of acceptor 12, obtained after DDQ 
treatment of 11, with per-benzyl donor 13 delivered tetrasaccharide 14 as a 2:1 α:β-mixture. 
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Possibly the overall structure of the twisted oligosaccharide is at the root of the erosion of 
stereoselectivity, with increasing steric demands leading to lower yields and poorer selectivity, 
indicating a limitation of the current glycosylation protocol. 
 
a) TMSI, Ph3P=O, DCM, 36 h, 75%, α:β = 10:1. b) DDQ, DCM:H2O = 10:1 (v:v), 8: 75%; 10: 49%; 12: 47%. c) DMF, 
TfOH, DCM, 9: 95%, α:β = 15:1; 11: 67%, α:β = 10:1; 14: 67%, α:β = 2:1. 
Scheme 2. The assembly of α-(1,2)-tetrasaccharide. 
Although, the limitations of the DMF-mediated glycosylation protocol have come forward in the 
above described kojitetraose assembly, the synthesis also showed that the additive controlled 
glycosylation approach can provide a rapid entry into the assembly of kojibiose derivatives. 
Therefore, the assembly of an E. faecalis D-Ala-kojibiose LTA fragment was next explored. The 
synthesis of D-Ala-kojibiose LTAs requires the availability of compound 19 featuring the 
kojibiose, decorated with two D-alanine esters at both primary alcohols, attached to the glycerol 
through an α-bond with (Scheme 3). This intermediate compound 19 can be assembled from four 
building blocks: two benzyl type protected glucosyl donors, 15 and 16, glycerol 17 protected with 
a benzoyl ester (Bz), allyl ether and N-benzyloxycarbonyl protected D-alanine 18 (Scheme 3). 
The glucosyl donors are protected with solely benzyl type ethers protecting group to keep the 
reactivity of these building blocks uniform throughout the assembly. The triad of benzyl, para-
methoxybenzyl (PMB), and 2-methylnaphthyl ethers was used to discriminate the alcohol groups 
that required permanent protection or needed to be removed to introduce the next glucose residue 
of introduce the D-alanine esters.  
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Scheme 3. The required building blocks for synthesis of D-Ala kojibiose functionalized LTA-
fragments of Enterococcus faecalis. 
The synthesis of the required building blocks is depicted in Scheme 4. Firstly, donor 15 was 
synthesized from compound 1 by benzylation of the C2 and C3-hydroxyls, regioselective opening 
of the benzylidene acetal and protection of the liberated primary alcohol with a Nap-ether, to give 
thio donor 22. Hydrolysis of the thioacetal and introduction of the 2,2,2-trifluoro-N-
phenylacetimidate formed the desired donor 15. Donor 16 was obtained from compound 2 
following a similar sequence of reactions: Protection of the C2-OH with a PMB-ether, 
regioselective opening of the benzylidene acetal and installation of the C6-O-Nap ether provided 
thioacetal 25, which was transformed into the corresponding imidate donor 16. 
 
a) BnBr, NaH, DMF, 20: 96%. b) BH3
.THF, Cu(OTf)2, 21: 80%; 24: 76%. c) NapBr, NaH, DMF, 22: 91%; 25: 93%. d) 1) 
NIS, acetone:H2O = 10:1 (v:v); 2) 2,2,2-trifluoro-N-phenylacetimidoyl chloride, Cs2CO3, acetone, yield 15: 86%; 16: 
84%. e) PMBCl, NaH, DMF, 94%.  
Scheme 4. Synthesis of donor 15 and 16. 
With all the required building blocks available, the target kojibiose glycerol building block 19 
was assembled as depicted in Scheme 5. Donor 15 was glycosylated with glycerol 17, of which 
the primary alcohol groups were protected by a benzoate ester and an allyl ether, using the TMSI-
Ph3P=O activation condition to give the compound 26 in good yield and excellent selectivity. 
Next, the C2-O-PMB was selectively removed using a catalytic amount of HCl in a mixture of 
hexafluoro-iso-propanol (HFIP) and DCM to give C2-OH acceptor 27 in 95% yield.[11] All other 
benzyl ethers remained unaffected under these conditions.  
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a) TMSI, Ph3P=O, DCM, 36 h, 76%, α:β > 20:1. b) TES, HCl/HFIP, DCM:HFIP = 1:1 (v:v), 93%. c) DMF, TfOH, 24 h, 
95%, α:β > 10:1. d) CH3ONa, DCM:CH3OH = 1:1 (v:v), 92%. e) TBDPSCl, imidozole, DMF, 99%. f) DDQ, DCM:H2O 
= 10:1 (v:v), 77%. g) PyBOP, NMI, DCM, 90%. h) 1) Ir(COD)(Ph2MeP)2PF6, H2, THF, 2) I2, NaHCO3, 85%. i) DMTrCl, 
DIPEA, DCM, 95%. j) HF-pyridine, THF/pyridine, 86%. 
Scheme 5. Synthesis of 6,6-di-alanyl-α-kojibiose 19. 
Acceptor 27 was then glycosylated with donor 15 using the DMF-mediated glycosylation 
condition to form the disaccharide 28 with good selectivity and excellent yield. To set the stage 
for the introduction of the D-alanyl esters, first the glycerol benzoate was replaced by a TBDPS 
ether, after which the two C-6-O-Nap ethers were removed to give diol 31. The introduction of 
the two D-Ala esters was accomplished using PyBOP as a condensing agent to form 6,6-di-alanyl-
α-kojibiose 32 in 90% yield. To transform this building block into a synthon suitable for the 
assembly of LTA-fragments, the allyl ether was replaced by a 4,4′-dimethoxytrityl (DMTr) group. 
To this end the allyl group was isomerized to the corresponding enol ether using an iridium 
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catalyst, which was subsequently hydrolyzed using I2 in combination with sodium bicarbonate. 
The liberated primary alcohol was treated with DMTrCl in DCM to give compound 34. Finally 
compound 34 was treated with HF-pyridine to give the 6,6-di-alanyl-α-kojibiose 19 in 86% yield. 
Conclusion 
In conclusion, this Chapter deals with DMF-mediated glycosylations for the construction of α-
(1,2)-glucosyl linkages. After the successful construction of α-(1,3)-glucosyl and α-(1,4)-glucosyl 
linkages, reported in Chapter 3 and 2, respectively, it is shown that the developed conditions 
(activation of a per-benzylated glucosyl imidate donor with stoichiometric TfOH in the presence 
of an excess DMF) can be profitably used for the construction of kojibiosyl linkages. However, 
the assembly of a linear kojitetraose has revealed that the stereoselectivity of the glycosylation 
reactions decreases with growing chain length. A kojibiose was assembled with excellent 
stereoselectivity (α:β = 15:1) and elongation of this disaccharide proceeded with good selectivity 
(α:β = 10:1), but extension of the trisaccharide with a fourth residue led to an unproductive 
anomeric mixture (α:β = 2:1). Likely the secondary structure adopted by the trisaccharide 
acceptor caused this drop in selectivity. Using the methodology and building on a triad of benzyl-
type protecting groups, a D-Ala-kojibiose functionalized LTA from the E. faecalis cell wall was 
synthesized. The generation of this structure will enable its evaluation as synthetic antigen for the 
generation of a synthetic vaccine, directed at this important nosocomial pathogen. 
Experimental Section 
General experimental procedures 
All reagents were of commercial grade and used as received. All moisture sensitive reactions were performed under an 
argon atmosphere. DCM used in the glycosylation reactions was dried with flamed 4Å molecular sieves before being 
used. Reactions were monitored by TLC analysis with detection by UV (254 nm) and where applicable by spraying with 
20% sulfuric acid in EtOH or with a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% 
sulfuric acid (aq.) followed by charring at ~150 °C. Column chromatography was carried out using silica gel (0.040-0.063 
mm). Size-exclusion chromatography was carried out using Sephadex LH-20. 1H and 13C spectra were recorded on a 
Bruker AV 400 and Bruker AV 500 in CDCl3 or D2O. Chemical shifts (δ) are given in ppm relative to tetramethylsilane 
as internal standard (1H NMR in CDCl3) or the residual signal of the deuterated solvent. Coupling constants (J) are given 
in Hz. All 13C spectra are proton decoupled. NMR peak assignments were made using COSY and HSQC experiments, 
where applicable Clean TOCSY, HMBC and GATED experiments were used to further elucidate the structure. The 
anomeric product ratios were analyzed through integration of proton NMR signals. 
Standard procedure 
Procedure A for the glycosylation of secondary alcohols: 
A mixture of donor (1.0 eq), acceptor (0.7 eq) (donors and acceptors co-evaporated with toluene three times), DMF (16 
Chapter 4 
98 
eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. The solution was cooled to -
78 ℃, after which TfOH (1.0 eq) was added. After 30 min, the reaction was stirred at 0 or -10 ℃ until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The products were purified by size exclusion and silica gel column chromatography. 
Standard procedure B for the glycosylation of primary alcohols: A mixture of donor (1.0 eq), acceptor (0.7 eq) (donor 
and acceptor co-evaporated with toluene three times), Ph3P=O (6 eq) in dry DCM were stirred over fresh flame-dried 
molecular sieves 3A under nitrogen. Then TMSI (1.0 eq) was added slowly in the mixture. The reaction was stirred at 
room temperature until TLC-analysis indicated the reaction to be complete. The solution was diluted and the reaction 
quenched with saturated Na2S2O3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, 
filtered and concentrated in vacuo. The products were purified by size exclusion and silica gel column chromatography. 
Procedure C for deprotection of the PMB protecting group: 
The starting material (1 eq) was dissolved in DCM:HFIP (1:1, 0.1 M). TES (1.0 eq) and 0.1M HCl/HFIP (0.1eq) were 
added to the mixture. The reaction stirred until TLC-analysis indicated full consumption of the starting material (15min-
2h). Then the mixture was diluted with DCM and the reaction quenched with saturated NaHCO3. The organic phase was 
washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified 
by silica gel column chromatography. 
Standard procedure D for deprotection of the Nap protecting group:  
The starting material (1 eq) was dissolved in DCM:H2O (10:1, 0.1 M). DDQ (1.1 eq) was added to the mixture. The 
reaction stirred until TLC-analysis indicated full consumption of the starting material (± 2h). Then the mixture was diluted 
with DCM and the reaction quenched with saturated Na2S2O3. The organic phase was washed with water and brine, dried 
with anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified by silica gel column chromatography. 
Experimental Procedures and Characterization Data of Products 
We used "a", "b", "c" and "d" to specify the H-1 and C-13 NMR signals of sugar rings from the “reducing” to the “non-
reducing” end and “°” to specify the H-1 and C-13 NMR signals of the spacer. 
Phenyl 4,6-O-benzelidine-2-O-(naphthalen-2-ylmethyl)-3-O-benzyl-1-thio-β-D- 
glucopyranoside 3: 1H-NMR (CDCl3, 400 MHz) δ 7.80-7.77 (m, 4 H, aromatic H), 7.55-7.22 (m, 
18 H, aromatic H), 5.54 (s, 1 H), 5.02-4.94 (m, 3 H, 3 CHH), 4.79-4.76 (m, 2 H, H-1, 1 CHH), 4.35 (dd, J1 = 4.8 Hz, J2 
= 10.4 Hz, 1 H, H-6a), 3.86-3.66 (m, 3 H, H-6, H-4, H-3), 3.56 (t, J = 8.4 Hz, 1 H, H-2), 3.47-3.41 (m, 1 H, H-5). 
13C-
APT (CDCl3, 100 MHz,) δ 138.34, 137.29, 135.56, 133.29, 133.18, 133.08 (aromatic C), 132.31, 129.05, 128.99, 128.41, 
128.28, 128.12, 128.99, 128.87, 127.78, 127.73, 126.90, 126.26, 126.07, 126.03, 125.94 (aromatic CH), 101.08 (PhCH), 
88.27 (C-1), 82.99 (C-3), 81.45 (C-4), 80.48 (C-2), 75.92, 75.28 (CH2), 70.22 (C-5), 68.67 (C-6). 
Phenyl 3,4,6-tri-O-benzyl-2-O-(naphthalen-2-ylmethyl)-1-thio-β-D-glucopyranoside 5: 1H-
NMR (CDCl3, 400 MHz) δ 7.81-7.75 (m, 4 H, aromatic H), 7.62-7.18 (m, 23 H, aromatic H), 5.04 
(d, J = 10.4 Hz, 1 H, 1 CHH), 4.93-4.82 (m, 4 H, 4 CHH), 4.71 (d, J = 9.6 Hz, 1 H, H-1), 4.62-4.52 
(m, 3 H, 3 CHH), 3.81-3.65 (m, 4 H, H-6, H-4, H-3), 3.60-3.50 (m, 2 H, H-2, H-5). 13C-APT (CDCl3, 100 MHz,) δ 138.49, 
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138.37, 138.11, 135.62, 133.94, 133.37, 133.16 (aromatic C), 132.01, 129.02, 128.55, 128.45, 128.25, 128.07, 128.04, 
127.92, 127.85, 127.79, 127.76, 127.67, 127.54, 127.00, 126.34, 126.12, 126.00 (aromatic CH), 87.57 (C-1), 86.86 (C-
3), 80.92 (C-2), 79.18 (C-4), 77.89 (C-5), 75.93, 75.59, 75.16, 73.50 (CH2), 69.08 (C-6).  
3,4,6-Tri-O-benzyl-2-O-(naphthalen-2-ylmethyl)-α/β-D-glucopyranosyl N-
phenyltrifluoroacetimidate 6: Compound 5 (11.5 g, 16.8 mmol) was dissolved in acetone (200 
mL). N-Iodosuccinimide (NIS) (7.5 g, 33.6 mmol) was added in one portion and the reaction 
was stirred at room temperature for 2 hours. The solution was diluted with DCM and the reaction was quenched with 
saturated aqueous Na2S2O3. Then the organic layer was washed with water and brine. The organic layer was dried with 
anhydrous MgSO4, filtered and concentrated in vacuo, and the product purified by column chromatography. The lactol 
(8.7 g, 90% yield) was obtained as a white solid. Next, the lactol (8.7 g, 15.1 mmol) was dissolved in acetone (150 mL). 
Cs2CO3 (7.4 g, 22.6 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (3.5 mL, 25.1 mmol) were added to the 
solution respectively. The reaction was stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. 
The product was purified by column chromatography (pentane:EA = 40:1-20:1). Compound 6 (9.6 g, 92% yield, α:β = 
1:1) was obtained as yellow syrup. 1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.79-7.74 (m, aromatic H), 7.49- 7.01 (m, 
aromatic H), 6.83-6.73 (m, aromatic H), 6.40 (bs, 1 H, H-1α), 5.58 (bs, 1 H, H-1β), 4.96-4.53 (m), 4.02-3.95 (m), 3.79-
3.59 (m), 3.40 (bs, 1 H). 13 C-APT (CDCl3, 125 MHz, 60℃) δ 159.77, 159.73, 143.96, 143.73, 143.42, 138.99, 138.77, 
138.38, 138.31, 135.81, 135.70, 133.57, 133.32, 130.33, 130.26 (aromatic C), 129.86, 129.43, 128.80, 128.46, 128.43, 
128.33, 128.28, 128.06, 127.98, 127.94, 127.91, 127.84, 127.78, 127.69, 127.65, 127.60, 126.78, 126.72, 126.22, 126.20, 
126.01, 125.97, 124.41, 124.28, 119.69, 119.58, 114.20, 114.17 (aromatic CH), 117.62 (q, CF3), 97.71, 94.00, 84.78, 
81.75, 80.86, 79.41, 77.61, 77.36, 76.06, 75.31, 75.63, 75.55, 75.27, 75.02, 74.72, 73.82, 73.73, 73.48, 73.24, 68.73, 68.66, 
55.83, 55.36. HR-MS: Calculated for C46H42F3NO6 [M-[O(C=NPh)CF3]+OH+NH4]
+: 608.30066, found: 608.29853. 
Synthesis of 7: The reaction was carried out according to the standard procedure B, using 6 
(2000 mg, 2.6 mmol, 0.1 M in DCM), 3-aminopropanol (370 μL, 3.9 mmol), Ph3P=O (4.4 g, 
15.8 mmol) and TMSI (371 μL, 2.6 mmol). The product was purified by silica gel column 
chromatography (pentane:EA = 10:1). Compound 7 (1300 mg, 75 % yield, α:β = 10:1) was obtained as a colorless syrup. 
IR (neat, cm-1) ν 697, 735, 818, 1027, 1155, 1358, 1454, 2095, 2866, 2922. 1H-NMR (CDCl3, 400 MHz) δ 7.83-7.74 (m, 
4 H, aromatic H), 7.49-7.12 (m, 18 H, aromatic H), 5.02 (d, J = 11.2 Hz, 1 H, 1 CHH), 4.92 (d, J = 12.4 Hz, 1 H, 1 CHH), 
4.86-4.77 (m, 3 H, 3 CHH), 4.74 (d, J = 3.6 Hz, 1 H, H-1), 4.59 (d, J = 11.6 Hz, 1 H, 1 CHH), 4.48-4.41 (m, 2 H, 2 CHH), 
3.99 (t, J = 9.2 Hz, 1 H, H-2), 3.75-3.59 (m, 6 H, H-6, H-5, H-4, H-2, H-1ºa), 3.48-3.35 (m, 3 H, H-3º, H-1ºb), 1.97-1.81 
(m, 2 H, H-2º). 13C-APT (CDCl3, 100 MHz,) δ 138.93, 138.25, 138.14, 127.98, 135.72, 133.29, 133.17 (aromatic C), 
128.52, 128.49, 128.46, 128.40, 128.06, 128.00, 127.84, 127.79, 127.70, 127.03, 126.29, 126.13, 126.06 (aromatic CH), 
97.31 (C-1), 82.10 (C-3), 80.10 (C-2), 77.75 (C-4), 75.81, 75.24, 73.57, 73.53 (CH2), 70.43 (C-5), 68.50 (C-6), 64.83 (C-
1º), 48.41 (C-3º), 28.96 (C-2º). HR-MS: Calculated for C41H43N3O6 [M+NH4]
+: 691.34901, found: 691.34807. 
Synthesis of 8: The reaction was carried out according to the general procedure D, using 7 (1.3 
g, 1.93 mmol, 0.1 M in DCM:H2O) and DDQ (482 mg, 2.1 mmol). The product was purified 
by silica gel column chromatography. Compound 8 (770 mg, 75% yield) was obtained as a 
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colorless syrup. [α]D
20 +90.5 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 735, 1027, 1066, 1038, 1359, 1454, 1497, 2095, 2870, 
2923. 1H-NMR (CDCl3, 400 MHz) δ 7.39-7.13 (m, 15 H, aromatic H), 4.94-4.80 (m, 4 H, H-1, 3 CHH), 4.63 (d, J = 12.4 
Hz, 1 H, 1 CHH), 4.52-4.48 (m, 2 H, 2 CHH), 3.85-3.61 (m, 7 H, H-6, H-5, H-4, H-3, H-2, H-3ºa), 3.56-3.51 (m, 1 H, H-
3ºb), 3.43-3.32 (m, 2 H, H-1º), 2.18 (d, J = 7.6 Hz, 1 H, OH), 1.94-1.82 (m, 2 H, H-2º). 
13C-APT (CDCl3, 100 MHz,) δ 
138.69, 138.11, 137.93 (aromatic C), 128.50, 128.47, 128.02, 127.97, 127.96, 127.84, 127.80, 127.77 (aromatic CH), 
98.66 (C-1), 83.31 (C-3), 77.46 (C-4), 75.43, 75.11, 73.59 (CH2), 72.94 (C-2), 70.82 (C-5), 68.47 (C-6), 65.15 (C-1º), 
48.53 (C-3º), 28.86 (C-2º). HR-MS: Calculated for C30H35N3O6 [M+NH4]
+: 551.28641, found: 551.28604. 
Synthesis of 9: The reaction was carried out according to the standard procedure B, using 6 
(845 mg, 1.11 mmol), 8 (455 mg, 0.85 mmol, 0.05 M in DCM), DMF (1.4 mL, 17.7 mmol) 
and TfOH (98 μL, 1.11 mmol). The reaction was stirred at -78-0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered 
and concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 
9 (1160 mg, 95% yield, α:β = 15:1) was obtained as a colorless syrup. [α]D
20 +75.4 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 
736, 1029, 1069, 1359, 1454, 1497, 2098, 2866, 2922. 1H-NMR (CDCl3, 400 MHz) δ 7.83-7.71 (m, 4 H, aromatic H), 
7.49-7.45 (m, 3 H, aromatic H), 7.34-7.21 (m, 23 H, aromatic H), 7.16-7.03 (m, 7 H, aromatic H), 5.07 (d, J = 3.2 Hz, 1 
H, H-1b), 5.05 (d, J = 3.2 Hz, 1 H, H-1a), 5.01-4.79 (m, 8 H, 8 CHH), 4.63-4.39 (m, 5 H, 5 CHH), 4.31 (d, J = 12.4 Hz, 
1 H, 1 CHH), 4.11 (t, J = 91.6 Hz, 1 H, H-3b), 4.06-3.99 (m, 2 H, H-3a, H-5a), 3.83 (dd, J1 = 3.2 Hz, J2 = 9.6 Hz, 1 H, H-
2a), 3.78-3.61 (m, 7 H, H-6, H-5b, H-4b, H-4a, H-2b, H-3ºa), 3.55-3.39 (m, 3 H, H-6, H-3ºb), 3.29-3.19 (m, 2 H, H-1º), 
1.84-1.70 (m, 2 H, H-2º). 13C-APT (CDCl3, 100 MHz,) δ 138.81, 138.72, 138.32, 138.25, 138.00, 137.98, 135.69, 133.29, 
133.11 (aromatic C), 128.49, 128.43, 128.42, 128.39, 128.29, 128.09, 128.03, 128.01, 127.97, 127.90, 127.81, 127.80, 
127.71, 127.66, 127.62, 127.52, 126.87, 126.33, 126.12, 125.89 (aromatic CH), 96.06 (C-1a), 94.72 (C-1b), 82.17 (C-3b), 
80.79 (C-3a), 79.14 (C-2b), 78.07 (C-4), 77.68 (C-4), 76.18, 75.71 (CH2), 75.45 (C-2a), 75.20, 74.95, 73.60, 73.45, 72.99 
(CH2), 70.61 (C-5b), 70.44 (C-5a), 68.52 (C-6), 68.04 (C-6), 65.15 (C-1º), 48.36 (C-3º), 28.02 (C-2º). HR-MS: Calculated 
for C68H71N3O6 [M+NH4]
+: 1123.54269, found: 1123.54104. 
Synthesis of 10: The reaction was carried out according to the general procedure D, using 9 
(970 mg, 0.88 mmol, 0.1 M in DCM:H2O) and DDQ (217 mg, 0.96 mmol). The product was 
purified by silica gel column chromatography. Compound 10 (416 mg, 49% yield) was 
obtained as a colorless syrup. [α]D
20 +90.8 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 735, 1027, 
1050, 1132, 1361, 1454, 2098, 2866, 2929. 1H-NMR (CDCl3, 400 MHz) δ 7.38-7.06 (m, 30 H, aromatic H), 5.02-4.97 
(m, 3 H, H-1a, H-1b, 1 CHH), 4.87-4.75 (m, 5 H, 5 CHH), 4.63-4.44 (m, 5 H, 5 CHH), 4.32 (d, J = 12.0 Hz, 1 H, 1 CHH), 
3.94-3.65 (m, 11 H), 3.53-3.33 (m, 5 H, H-6), 1.91-1.84 (m, 2 H, H-2º). 13C-APT (CDCl3, 100 MHz,) δ 138.69, 138.61, 
137.97, 137.86, 737.83 (aromatic C), 128.41, 128.39, 128.34, 128.30, 128.28, 128.16, 128.08, 127.97, 127.95, 127.87, 
127.82, 127.78, 127.72, 127.65, 127.60, 127.55, 127.41 (aromatic CH), 96.21 (C-1b), 85.58 (C-1a), 83.28 (C-3b), 80.50 
(C-3a), 77.79 (C-4), 76.94 (C-4), 76.00 (CH2), 75.37 (C-2a), 75.12, 74.75, 73.48, 73.29 (CH2), 72.79 (C-2b), 70.62 (C-
5), 70.58 (C-5), 68.28 (C-6), 67.86 (C-6), 64.83 (C-1º), 48.33 (C-3º), 28.62 (C-2º). HR-MS: Calculated for C68H71N3O11 
[M+NH4]
+: 983.48003, found: 983.47815. 
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Synthesis of 11: The reaction was carried out according to the standard procedure B, using 
6 (547 mg, 0.72 mmol), 10 (347 mg, 0.36 mmol, 0.05 M in DCM), DMF (900 μL, 11.4 
mmol) and TfOH (64 μL, 0.72 mmol). The reaction was stirred at -78-0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with 
Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion 
chromatography (DCM:MeOH = 1:1). Compound 11 (372 mg, 67% yield, α:β = 10:1) was 
obtained as a colorless syrup. [α]D
20 +75.4 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 736, 1029, 1069, 1359, 1454, 1497, 2098, 
2866, 2922. [α]D
20 +96.5 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 735, 1029, 1069, 1359, 1454, 1497, 2098, 2845, 2921. 1H-
NMR (CDCl3, 400 MHz) δ 7.82 (s, 1 H, aromatic H), 7.71-7.62 (m, 3 H, aromatic H), 7.52-7.50 (m, 1 H, aromatic H), 
7.41-7.37 (m, 1H, aromatic H), 7.32-6.96 (m, 46 H, aromatic H), 5.49 (d, J = 3.6 Hz, 1 H, H-1c), 5.41 (d, J = 3.6 Hz, 1 
H, H-1b), 5.23 (d, J = 2.0 Hz, 1 H, H-1a), 5.16 (d, J = 12.0 Hz, 1 H, 1 CHH), 4.99-4.34 (m, 18 H, 18 CHH), 44.18-3.52 
(m, 21 H), 3.31-3.22 (m, 2 H, H-3º), 1.93-1.82 (m, 2 H, H-2º). 13C-APT (CDCl3, 100 MHz,) δ 138.78, 138.76, 138.74, 
138.45, 138.26, 138.16, 138.09, 137.98, 137.90, 136.09, 133.35, 132.94 (aromatic C), 128.72, 128.45, 128.44, 128.40, 
128.38, 128.29, 128.26, 128.13, 128.06, 128.04, 127.93, 127.79, 127.72, 127.65, 127.60, 127.56, 127.51, 127.46, 126.11, 
125.84, 125.77, 125.55 (aromatic CH), 95.84 (C-1c), 92.77 (C-1b), 92.09 (C-1a), 81.96 (C-3c), 81.45 (C-3a), 80.99 (C-
3b), 79.97 (C-2c), 77.37 (2 C-4), 77.05 (C-4), 76.08, 75.99, 75.65, 74.94, 74.84 (CH2), 74.71 (C-2), 74.60 (C-2), 73.58, 
73.50, 71.60 (CH2), 70.94 (C-5), 70.80 (C-5), 70.61 (C-5), 68.61 (C-6), 68.34 (C-6), 68.07 (C-6), 65.16 (C-1º), 48.31 (C-
3º), 29.20 (C-2º). HR-MS: Calculated for C95H99N3O16 [M+NH4]
+: 1555.73636, found: 1555.73599. 
Synthesis of 12: The reaction was carried out according to the general procedure D, using 
11 (700 mg, 0.45 mmol, 0.1 M in DCM:H2O) and DDQ (140 mg, 0.6 mmol). The product 
was purified by silica gel column chromatography. Compound 12 (300 mg, 47% yield) 
was obtained as a colorless syrup. [α]D
20 +90.8 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 735, 
1027, 1050, 1132, 1361, 1454, 2098, 2866, 2929. [α]D
20 +122.1 (c=1, CHCl3). 
1H-NMR 
(CDCl3, 400 MHz) δ 7.37-6.98 (m, 45 H, aromatic H), 5.18 (d, J = 3.2 Hz, 1 H, H-1b), 
5.06 (d, J = 3.2 Hz, 1 H, H-1a), 5.00-4.90 (m, 3 H, H-1a, 2 CHH), 4.84-4.30 (m, 16 H, 16 CHH), 4.01-3.34 (m, 22 H), 
2.41 (s, 1 H, OH), 2.06-1.85 (m, 2 H, H-2º). 13C-APT (CDCl3, 100 MHz,) δ 138.89, 138.85, 138.56, 138.24, 138.22, 
138.02, 137.96, 137.95, 137.89 (aromatic C), 128.56, 128.53, 128.51, 128.50, 128.42, 128.38, 128.36, 128.28, 128.08, 
128.07, 127.86, 127.82, 127.79, 127.74, 127.67, 127.63, 127.60, 127.50 (aromatic CH), 96.03 (C-1c), 95.04 (C-1a), 91.66 
(C-1b), 83.42 (C-3c), 80.90 (C-3a), 80.62 (C-3b), 77.89 (C-4), 77.73 (C-4), 76.84 (C-4), 76.30, 76.25, 75.20, 75.15, 74.94, 
74.92 (CH2), 74.67 (C-2b), 74.00 (C-2a), 73.65, 73.59, 73.45 (CH2), 72.67 (C-2c), 70.69 (C-5), 70.64 (C-5), 70.57 (C-5), 
68.38 (C-6), 68.00 (C-6), 67.97 (C-6), 64.50 (C-1º), 48.51 (C-3º), 28.77 (C-2º). HR-MS: Calculated for C84H91N3O16 
[M+NH4]
+: 1415.67376, found: 1415.67378. 
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Synthesis of 14: The reaction was carried out according to the standard procedure B, 
using 13 (190 mg, 0.27 mmol), 12 (70 mg, 0.05 mmol, 0.05 M in DCM), DMF (78 μL, 
0.99 mmol) and TfOH (23 μL, 0.27 mmol). The reaction was stirred at -78-0 oC until 
TLC-analysis showed complete conversion of the acceptor. The reaction was quenched 
with Et3N, filtered and concentrated in vacuo. The product was purified by size 
exclusion chromatography (DCM:MeOH = 1:1). Compound 14 (64 mg, 67% yield, α:β 
= 2:1) was obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1069, 1359, 
1454, 1497, 2098, 2866, 2922. IR (neat, cm-1) ν 695, 734, 1027, 1069, 1209, 1359, 1454, 1497, 1729, 2096, 2859, 2923. 
HR-MS: Calculated for C118H125N3O21 [M+NH4]
+: 1937.91438, found: 1937.91440. 
Synthesis of 15: Compound 22 (1.0 g, 1.46 mmol) was dissolved in acetone:H2O (10:1, 15 mL). 
N-Iodosuccinimide (NIS) (660 mg, 2.93 mmol) was added in one portion and the reaction was 
stirred at room temperature for 2 hours. The solution was diluted with DCM and the reaction 
was quenched with saturated aqueous Na2S2O3. Then the organic layer was washed with water and brine. The organic 
layer was dried with anhydrous MgSO4, filtered and concentrated in vacuo, and the product purified by column 
chromatography. The lactol was obtained as a white solid. Next, the lactol was dissolved in acetone (15 mL). Cs2CO3 (713 
mg, 2.19 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (355 μL, 2.19 mmol) were added to the solution 
respectively. The reaction was stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product 
was purified by column chromatography. Compound 15 (959 mg, 86% yield over two steps, α:β = 1:1) was obtained as 
yellow syrup. IR (neat, cm-1) ν 695, 734, 1027, 1073, 1153, 1208, 1314, 1454, 1597, 1716, 2869, 2915. 1H-NMR (CDCl3, 
400 MHz) δ 7.82-6.50 (m, aromatic H), 6.53 (bs, 1 H, H-1), 5.67 (bs, 1 H, H-1), 5.00-4.61 (m), 4.52-4.46 (m), 4.06-3.97 
(m), 3.81-3.66 (m). 13 C-APT (CDCl3, 125 MHz) δ 143.78, 143.55, 138.67, 138.64, 137.92, 137.83, 135.45, 135.28, 133.35, 
133.19, 133.16 (aromatic C), 129.51, 128.82, 128.64, 128.61, 128.57, 128.55, 128.49, 128.43, 128.36, 128.33, 128.13, 
128.05, 127.99, 127.92, 127.88, 127.84, 127.81, 127.78, 127.00, 126.88, 126.49, 126.30, 126.26, 126.10, 126.08, 126.05, 
124.39, 120.57, 119.44 (aromatic CH), 84.64, 81.62, 81.04, 79.37, 77.27, 76.94, 75.91, 75.82, 75.74, 75.44, 75.31, 75.17, 
73.76, 73.65, 73.44, 73.19, 68.12. 
Synthesis of 16: Compound 25 (4.8 g, 6.73 mmol) was dissolved in acetone:H2O (10:1, 77 mL). 
N-Iodosuccinimide (NIS) (3.0 g, 13.3 mmol) was added in one portion and the reaction was 
stirred at room temperature for 2 hours. The solution was diluted with DCM and the reaction 
was quenched with saturated aqueous Na2S2O3. Then the organic layer was washed with water and brine. The organic 
layer was dried with anhydrous MgSO4, filtered and concentrated in vacuo, and the product purified by column 
chromatography. The lactol was obtained as a white solid. Next, the lactol was dissolved in acetone (70 mL). Cs2CO3 (6.3 
g, 19.5 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (3.2 mL, 19.5 mmol) were added to the solution 
respectively. The reaction was stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product 
was purified by column chromatography. Compound 16 (4.48 g, 84% yield over two steps, α:β = 1:1) was obtained as 
yellow syrup. 1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.79-7.74 (m, aromatic H), 7.49- 7.01 (m, aromatic H), 6.83-6.73 (m, 
aromatic H), 6.40 (bs, 1 H, H-1α), 5.58 (bs, 1 H, H-1β), 4.96-4.53 (m), 4.02-3.95 (m), 3.79-3.59 (m), 3.40 (bs, 1 H). 13 C-
APT (CDCl3, 125 MHz, 60℃) δ 159.77, 159.73, 143.96, 143.73, 143.42, 138.99, 138.77, 138.38, 138.31, 135.81, 135.70, 
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133.57, 133.32, 130.33, 130.26 (aromatic C), 129.86, 129.43, 128.80, 128.46, 128.43, 128.33, 128.28, 128.06, 127.98, 
127.94, 127.91, 127.84, 127.78, 127.69, 127.65, 127.60, 126.78, 126.72, 126.22, 126.20, 126.01, 125.97, 124.41, 124.28, 
119.69, 119.58, 114.20, 114.17 (aromatic CH), 117.62 (q, CF3), 97.71, 94.00, 84.78, 81.75, 80.86, 79.41, 77.61, 77.36, 
76.06, 75.31, 75.63, 75.55, 75.27, 75.02, 74.72, 73.82, 73.73, 73.48, 73.24, 68.73, 68.66, 55.83, 55.36. HR-MS: 
Calculated for C47H44F3NO7 [M-[O(C=NPh)CF3]+OH+Na]
+: 643.26662, found: 643.26659. 
(S)-3-(allyloxy)-2-hydroxypropyl benzoate 17: 1H-NMR (CDCl3, 400 MHz) δ 8.07-8.04 (m, 2 H, 
aromatic H), 7.58-7.53 (m, 1 H, aromatic H), 7.45-7.41 (m, 2 H, aromatic H), 5.95-5.85 (m, 1 H, 
H-5), 5.31-5.17 (m, 2 H, H-6), 4.45-4.36 (m, 2 H, H-1), 4.19-4.14 (m, 1 H, H-2), 4.05-4.03 (m, 2 H, H-4), 3.63-3.53 (m, 
2 H, H-3), 3.01 (bs, 1 H, OH). 13C-APT (CDCl3, 100 MHz,) δ 166.69 (C=O), 134.30, 133.18 (aromatic CH), 129.87 
(aromatic C), 129.80 (aromatic CH), 128.43 (C-5), 117.54 (C-6), 772.43, 71.02, 68.93 (C-2), 66.07. HR-MS: Calculated 
for C13H16O4 [M+Na]
+: 259.0941, found: 259.0948. 
Synthesis of 26: The reaction was carried out according to the standard procedure B, using 15 
(1.5 g, 1.9 mmol), 17 (410 mg, 1.74 mmol, 0.1 M in DCM), Ph3P=O (3.16 g, 11.4 mmol) and 
TMSI (270 μL, 1.9 mmol). The product was purified by silica gel column chromatography. 
Compound 26 (1100 mg, 76 % yield, α:β > 20:1) was obtained as a colorless syrup. [α]D
20 +38.9 
(c=1, CHCl3). IR (neat, cm
-1) ν 698, 713, 820, 1037, 1072, 1095, 1249, 1272, 1452, 1513, 1720, 2865, 2912. 1H-NMR 
(CDCl3, 400 MHz) δ 7.99-7.97 (m, 2 H, aromatic H), 7.76-7.63 (m, 4 H, aromatic H), 7.46-7.08 (m, 16 H, aromatic H), 
6.92 (bd, 2 H, aromatic H), 6.85-6.82 (m, 2 H, aromatic H), 5.93-5.84 (m, 1 H, H-5º), 5.31-5.25 (m, 1 H, H-6ºa), 5.19-
5.16 (m, 2 H, H-1a, H-6ºb), 4.99 (d, J = 10.8 Hz, 1 H, CHH), 4.81-4.77 (m, 2 H, 2 CHH), 4.70-4.63 (m, 3 H, 3 CHH), 
4.57 (dd, J1 = 3.6 Hz, J2 = 11.6 Hz, 1 H, H-1ºa), 4.45-4.35 (m, 3 H, 2 CHH, H-1ºb), 4.28-4.24 (m, 1 H, H-2º), 4.04-3.99 
(m, 4 H, H-3a, H-5a, H-4º), 3.74 (s, 3 H, OCH3), 3.73-3.58 (m, 4 H, H-2a, H-4a, H-3º), 3.50 (dd, 1 H, J1 = 2.8 Hz, J2 = 
11.8 Hz, H-6aa), 3.37 (dd, 1 H, J1 = 2.0 Hz, J2 = 10.4 Hz, H-6ab). 
13C-APT (CDCl3, 100 MHz,) δ 166.19 (C=O), 159.30, 
138.91, 138.22, 135.16 (aromatic C), 134.38 (C-5º), 133.11, 132.96 (aromatic C), 132.88 (aromatic CH), 130.27, 129.84 
(aromatic C), 129.62, 129.60, 128.31, 128.28, 128.11, 127.85, 127.82, 127.67, 127.48, 127.44, 126.80, 126.03, 125.97, 
125.83 (aromatic CH), 117.19 (C-6º), 113.78 (aromatic CH), 96.13 (C-1a), 81.83 (C-5a), 79.26 (C-2a), 77.47 (C-4a), 
75.59, 74.83 (CH2), 73.59 (C-2º), 73.52, 72.43 (CH2), 72.35 (C-4º), 70.23 (C-3a), 69.59 (C-3º), 67.97 (C-6a), 65.01 (C-
1º), 55.16 (OCH3). HR-MS: Calculated for C52H54O10 [M+Na]
+: 861.3609, found: 861.3647. 
Synthesis of 27: The reaction was carried out according to the general procedure C, using 26 
(1000 mg, 1.19 mmol, 0.1 M in DCM:HFIP), triethylsilane (190 μL, 1.19 mmol) and 0.1M 
HCl/HFIP (1.2 ml, 0.12 mmol). The product was purified by silica gel column chromatography 
(PE:EA = 6:1). Compound 27 (800 mg, 93% yield) was obtained as a colorless syrup. [α]D
20 
+73.0 (c=1, CHCl3). IR (neat, cm
-1) ν 710, 713, 738, 1027, 1070, 1095, 1272, 1452, 1721, 2866, 2915. 1H-NMR (CDCl3, 
400 MHz) δ 8.02-8.00 (m, 2 H, aromatic H), 7.78-7.66 (m, 4 H, aromatic H), 7.49-7.09 (m, 14 H, aromatic H), 6.96-6.94 
(m, 4 H, aromatic H), 5.93-5.84 (m, 1 H, H-5º), 5.32-5.26 (m, 1 H, H-6ºa), 5.23-5.19 (m, 1 H, H-6ºb), 5.12 (d, J = 3.2 Hz, 
1 H, H-1a), 4.99 (d, J = 11.2 Hz, 1 H, 1 CHH), 4.81 (d, J = 11.2 Hz, 1 H, 1 CHH), 4.78 (d, J = 11.2 Hz, 1 H, 1 CHH), 
4.69 (d, J = 12.4 Hz, 1 H, 1 CHH), 4.49-4.38 (m, 4 H, 3 CHH, H-1º),4.24-4.18 (m, 1 H, H-2º), 4.07-3.98 (m, 2 H, H-4º), 
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3.97-3.93 (m, 1 H, H-3a), 3.80-3.73 (m, 2 H, H-2a, H-5a), 3.68-3.57 (m, 4 H, H-3º, H-4a, H-6aa), 3.42 (dd, 1 H, J1 = 2.0 
Hz, J2 = 10.4 Hz, H-6ab), 2.77 (d, 1 H, J = 8.0 Hz, OH). 
13C-APT (CDCl3, 100 MHz,) δ 166.29 (C=O), 138.93, 138.25, 
135.30 (aromatic C), 134.03 (C-5º), 133.24 (aromatic C), 133.18 (aromatic CH), 133.07, 129.83 (aromatic C), 129.75, 
128.47, 128.41, 128.26, 127.99, 127.94, 127.80, 127.77, 127.61, 127.59, 126.86, 126.16, 126.05, 125.95 (aromatic CH), 
117.92 (C-6º), 99.40 (C-1a), 83.53 (C-5a), 77.02 (C-4a), 76.14 (C-2º), 75.33, 74.95, 73.65 (CH2), 73.44 (C-2a), 72.46 (C-
4º), 71.08 (C-3a), 69.23 (C-3º), 68.11 (C-6a), 64.80 (C-1º). HR-MS: Calculated for C44H46O9 [M+Na]
+: 741.3034, found: 
741.3062. 
Synthesis of 28: The reaction was carried out according to the standard procedure B, using 
15 (1210 mg, 1.59 mmol), 27 (760 mg, 1.05 mmol, 0.1 M in DCM), DMF (1.3 mL, 16.8 
mmol) and TfOH (140 μL, 1.59 mmol). The reaction was stirred at -78-0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with 
Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion 
chromatography (DCM:MeOH = 1:1). Compound 28 (2.06 g, 95% yield, α:β > 10:1) was obtained as a colorless syrup. 
[α]D
20 +75.1 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 713, 820, 1046, 1070, 1095, 1272, 1359, 1454, 1721, 2863, 2919. 1H-
NMR (CDCl3, 400 MHz) δ 8.00-7.81 (m, 2 H, aromatic H), 7.78-7.63 (m, 8 H, aromatic H), 7.44-6.91 (m, 34 H, aromatic 
H), 5.81-5.76 (m, 1 H, H-5º), 5.46 (d, J = 3.6 Hz, 1 H, H-1a), 5.29 (d, J = 3.6 Hz, 1 H, H-1b), 5.22-5.10 (m, 2 H, H-6º), 
4.98-4.67 (m, 10 H, 10 CHH), 4.56-4.33 (m, 6 H, 4 CHH, H-1º), 4.29-4.23 (m, 1 H, H-2º), 4.14-4.04 (m, 4 H, H-5a, H-
5b, H-3a, H-3b), 3.91-3.88 (m, 3 H, H-3a, H-4º), 3.80-3.43 (m, 9 H, H-3º, H-2b, H-4a, H-4b, H-6a, H-6b). 13C-APT 
(CDCl3, 100 MHz,) δ 166.23 (C=O), 138.69, 138.46, 138.34, 138.31, 138.27, 135.33, 135.22 (aromatic C), 134.27 (C-
5º), 133.18, 133.15, 133.01, 132.99 (aromatic C), 132.91 (aromatic CH), 129.92 (aromatic C), 129.62, 128.41, 128.38, 
128.35, 128.31, 128.19, 128.17, 128.15, 128.09, 127.92, 127.87, 127.74, 127.69, 127.63, 127.54, 127.51, 127.46, 127.43, 
127.34, 126.88, 126.80, 126.09, 126.06, 125.98, 125.85, 125.84 (aromatic CH), 117.41 (C-6º), 99.70 (C-1b), 94.53 (C-
1a), 82.10 (C-5b), 80.73 (C-5a), 79.35 (C-2b), 77.80 (C-4), 77.56 (C-4), 76.03, 75.54 (CH2), 75.39 (C-2a), 74.85, 74.82, 
73.54, 73.53 (CH2), 73.14 (C-2º), 72.36, 72.22 (CH2), 70.46 (C-3a and 3b), 69.23 (C-3º), 68.98 (C-6a and 6b), 64.96 (C-
1º). HR-MS: Calculated for C82H82O14 [M+Na]
+: 1313.5597, found: 1313.5624. 
Synthesis of 29: Compound 28 (1100 mg, 0.85 mmol) was dissolved in DCM:CH3OH 
(1:1/v:v, 8.5 mL) stirring at room temperatura. Then 5 drops of solution of CH3ONa in 
CH3OH (5.4 M) was added in the mixture. The reaction was stirred at rt until TLC-analysis 
showed complete conversion of the starting martial (3 h). Then the mixture was diluted 
with DCM. The organic phase was washed with water and brine, dried with anhydrous 
MgSO4, filtered and concentrated in vacuo. The product was purified by silica gel column chromatography. Compound 
29 (930 mg, 92% yield) was obtained as a colorless syrup. [α]D
20 +69.4 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 737, 818, 
1069, 1209, 1359, 1454, 2865, 2921. 1H-NMR (CDCl3, 400 MHz) δ 7.83-7.69 (m, 8 H, aromatic H), 7.49-7.09 (m, 25 H, 
aromatic H), 7.03-6.92 (m, 6 H, aromatic H), 5.86-5.76 (m, 1 H, H-5º), 5.31 (d, J = 3.6 Hz, 1 H, H-1b), 5.22-5.10 (m, 3 
H, H-6º, H-1a), 4.94-4.35 (m, 14 H, 14 CHH), 4.09-3.98 (m, 4 H, H-5a, H-5b, H-3a, H-3b), 3.89-3.45 (m, 14 H). 13C-
APT (CDCl3, 100 MHz,) δ 138.73, 138.52, 138.31, 138.21, 137.98135.41, 135.20 (aromatic C), 134.56 (C-5º), 133.33, 
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133.29, 133.18, 133.12 (aromatic C), 128.60, 128.45, 128.42, 128.31, 128.22, 128.07, 128.04, 128.01, 127.95, 127.84, 
127.81, 127.78, 127.74, 127.67, 127.64, 127.49, 126.98, 126.26, 126.19, 126.06, 126.04, 125.97 (aromatic CH), 117.25 
(C-6º), 95.62 (C-1b), 95.08 (C-1a), 82.22 (C-5a), 80.73 (C-5b), 79.24 (C-2b), 78.89 (C-2b), 78.28 (C-4), 77.71 (C-4), 
76.15 (CH2), 75.73 (C-2º), 75.69, 75.16, 74.99, 73.70, 73.61, 72.86 (CH2), 72.34 (C-4º), 70.86 (C-3b), 70.59 C-3a), 69.67 
(C-3º), 68.64, 68.08 (C-6a and 6b), 63.61 (C-1º). HR-MS: Calculated for C75H78O13 [M+Na]
+: 1209.5335, found: 
1209.5356. 
Synthesis of 30: Compound 29 (350 mg, 0.3 mmol) was dissolved in DMF (6 mL) 
stirring at room temperature. Then TBDPSCl (153 μL, 0.6 mmol) and imidazole (120 
mg, 1.8 mmol) were added in the mixture. The reaction was stirred at rt until TLC-
analysis showed complete conversion of the starting martial. Then the mixture was 
diluted with DCM. The organic phase was washed with water and brine, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified by silica gel column chromatography. 
Compound 29 (423 mg, 99% yield) was obtained as a colorless syrup. [α]D
20 +62.1 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 
738, 818, 1047, 1070, 1361, 1454, 2858, 2928. 1H-NMR (CDCl3, 400 MHz) δ 7.80-7.62 (m, 12 H, aromatic H), 7.48-
7.06 (m, 31 H, aromatic H), 6.97-6.94 (m, 6 H, aromatic H), 5.87-5.77 (m, 1 H, H-5º), 5.48 (d, J = 3.2 Hz, 1 H, H-1a), 
5.34 (d, J = 3.2 Hz, 1 H, H-1b), 5.22-5.10 (m, 2 H, H-6º), 4.95-4.35 (m, 14 H, 14 CHH), 4.11-4.00 (m, 4 H, H-5a, H-5b, 
H-3a, H-2º), 3.89-3.84 (m, 4 H, H-3b, H-2a, H-4º), 3.78-3.40 (m, 11 H), 1.01 (s, 9 H, 3 CH3). 
13C-APT (CDCl3, 100 MHz,) 
δ 138.86, 138.70, 138.58, 138.54, 138.44 (aromatic C), 135.68 (aromatic CH), 135.52 (aromatic C), 134.70 (C-5º), 133.44, 
133.43, 133.32, 133.13 (aromatic C), 129.77, 129.76, 128.68, 128.43, 128.40, 128.38, 128.31, 128.23, 128.19, 128.13, 
128.05, 128.01, 127.98, 127.86, 127.84, 127.73, 127.60, 127.58, 127.45, 127.41, 126.98, 126.89, 126.23, 126.21, 126.15, 
125.98, 125.93 (aromatic CH), 117.33 (C-6º), 94.22 (C-1a), 93.60 (C-1b), 82.16 (C-5b), 81.01 (C-5a), 79.44 (C-2b), 77.76 
(C-4), 77.57 (C-4), 76.29, 75.67 (CH2), 75.12 (C-2º), 74.94, 74.85 (CH2), 74.79 (C-2a), 73.70, 72.28, 71.91 (CH2), 70.43 
(C-3b), 70.34 (C-3a), 69.29, 68.22, 63.77 (CH2), 27.00 (3 CH3), 19.30. HR-MS: Calculated for C91H96O13Si [M+Na]
+: 
1447.6512, found: 1447.6539. 
Synthesis of 31: The reaction was carried out according to the general procedure D, using 
30 (460 mg, 0.32 mmol, 0.1 M in DCM:H2O) and DDQ (170 mg, 0.75 mmol). The product 
was purified by silica gel column chromatography. Compound 31 (280 mg, 77% yield, 
pentane:EA = 4:1, Rf = 0.33) was obtained as a colorless syrup. [α]D
20 +72.3 (c=1, CHCl3). 
IR (neat, cm-1) ν 698, 737, 1027, 1072, 1209, 1361, 1454, 2858, 2929. 1H-NMR (CDCl3, 
400 MHz) δ 7.66-7.63 (m, 4 H, aromatic H), 7.41-7.07 (m, 31 H, aromatic H), 5.88-5.78 (m, 1 H, H-5º), 5.44 (d, J = 3.2 
Hz, 1 H, H-1a), 5.34 (d, J = 3.6 Hz, 1 H, H-1b), 5.23-5.13 (m, 2 H, H-6º), 4.99-4.58 (m, 10 H, 10 CHH), 4.11-4.00 (m, 3 
H, H-5a, H-5b, H-2º), 3.92-3.88 (m, 3 H, H-3b, H-4º), 3.76-3.51 (m, 14 H), 1.76 (s, 1 H, OH), 1.64 (s, 1 H, OH), 1.04 (s, 
9 H, 3 CH3). 
13C-APT (CDCl3, 100 MHz,) δ 138.69, 138.58, 138.44, 138.38, 138.35 (aromatic C), 135.62, 135.61 
(aromatic CH), 134.52 (C-5º), 133.27, 133.24 (aromatic C), 129.81, 128.46, 128.44, 128.41, 128.38, 128.36, 128.05, 
127.87, 127.84, 127.77, 127.70, 127.67, 127.62, 127.58 (aromatic CH), 117.28 (C-6º), 94.19 (C-1a), 93.40 (C-1b), 81.80 
(C-5b), 80.69 (C-5a), 79.65 (C-2b), 77.31 (C-4), 77.25 (C-4), 76.09, 75.57 (CH2), 75.04 (C-2º), 74.93 (CH2), 74.90 (C-
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2a), 72.24, 71.93 (CH2), 71.25 (C-3b), 70.94 (C-3a), 69.84, 63.67, 61.68, 61.50 (CH2), 26.93 (3 CH3), 19.22. HR-MS: 
Calculated for C69H80O13Si [M+Na]
+: 1167.5260, found: 1167.5280. 
Synthesis of 32: Compound 31 (650 mg, 0.57 mmol) and 18 (633mg, 2.83 mmol) 
were dissolved in DCM (6 mL) stirring at room temperature. Then TPyBOP 
(1.48 g, 2.85 mmol) and NMI (454 μL, 5.7 mmol) were added in the mixture. 
The reaction was stirred at rt until TLC-analysis showed complete conversion 
of the starting martial. Then the mixture was diluted with DCM. The organic 
phase was washed with water and brine, dried with anhydrous MgSO4, filtered 
and concentrated in vacuo. The product was purified by silica gel column chromatography. Compound 29 (800 mg, 90% 
yield) was obtained as a colorless syrup. [α]D
20 +66.3 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 738, 1029, 1070, 1171, 1208, 
1251, 1454, 1498, 1725, 2858, 2931. 1H-NMR (CDCl3, 400 MHz) δ 7.67-7.63 (m, 4 H, aromatic H), 7.41-7.06 (m, 41 H, 
aromatic H), 5.85-5.75 (m, 1 H, H-5º), 5.42-5.34 (m, 3 H, H-1a, H-1b, H-6º), 5.21-4.73 (m, 13 H), 4.59-4.50 (m, 3 H), 
4.35-3.45 (m, 22 H), 1.36 (d, J = 6.8 Hz, 1 H, CH3), 1.25 (d, J = 7.2 Hz, 1 H, CH3), 1.04 (s, 9 H, 3 CH3). 
13C-APT (CDCl3, 
100 MHz,) δ 172.78, 172.69, 155.62 (4 C=O), 138.54, 138.32, 138.26, 138.19, 136.33 (aromatic C), 135.62, 135.60 
(aromatic CH), 134.46 (C-5º), 133.20 (aromatic C), 129.86, 128.57, 128.46, 128.40, 128.35, 128.19, 128.10, 128.03, 
127.88, 127.76, 127.70, 127.66, 127.60 (aromatic CH), 117.39 (C-6º), 96.64 (C-1a), 93.00 (C-1b), 81.86 (C-5b), 80.79 
(C-5a), 79.60, 77.36, 76.12, 75.63, 74.96, 74.68, 72.22, 71.84, 69.30, 69.12, 68.71, 66.95, 63.73, 63.66, 63.50, 49.69 (2 
CHNH), 29.34 (CH3), 26.95 (3 CH3), 19.23, 18.73 (CH3). HR-MS: Calculated for C91H102N2O19Si [M+Na]
+: 1577.67383, 
found: 1577.67285. 
Synthesis of 33: A solution of 32 (600 mg, 0.38 mmol) and freshly activated 
molecular sieves 3A in freshly distilled THF (4 ml) was stirred under argon for 
30 min. After the addition of Ir(COD)(Ph2MeP)2PF6 (33 mg, 10 mol %) the 
solution turned red and the mixture was purged with H2 until the solution turned 
colourless again (5-15 seconds). After stirring under argon for 4 h, the solution 
was diluted with THF and satd aq NaHCO3. After the addition of I2 (73 mg, 0.57 
mmol), the mixture was allowed to stir overnight at room temperature. The mixture was diluted with EtOAc and washed 
with satd aq NaS2O3 and brine, respectively. The organic layer was dried over MgSO4 and concentrated in vacuo. Column 
chromatography afforded 33 (734 mg, 85%) as colorless syrup. [α]D
20 +55.9 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 737, 
1027, 1069, 1168, 1208, 1258, 1454, 1498, 1720, 2858, 2929. 1H-NMR (CDCl3, 400 MHz) δ 7.66-7.64 (m, 4 H, aromatic 
H), 7.43-7.07 (m, 41 H, aromatic H), 5.33 (d, J = 7.2 Hz, 1 H, NH), 5.26 (d, J = 7.6 Hz, 1 H, NH), 5.11-4.73 (m, 14 H, 
12 CHH, H-1a, H-1b), 4.52 (bt, 2 H, 2 CHH), 4.32-4.25 (m, 2 H, 2 CHNH), 4.17-3.99 (m, 6 H, H-5a, H-5b, H-3, 3 CHH), 
3.91-3.74 (m, 5 H, H-3, H-2º, 3 CHH), 3.67-3.61 (m, 3 H, H-2a, 2 CHH), 3.50-3.42 (m, 3 H, H-2b, H-4a, H-4b), 1.35 (d, 
J = 6.8 Hz, 1 H, CH3), 1.28 (d, J = 7.2 Hz, 1 H, CH3), 1.06 (s, 9 H, 3 CH3). 
13C-APT (CDCl3, 100 MHz,) δ 172.82, 172.65, 
155.65, 155.57 (4 C=O), 138.38, 138.15, 137.92, 137.83, 137.55, 136.29 (aromatic C), 135.65, 135.62 (aromatic CH), 
133.17, 133.09 (aromatic C), 128.71, 128.58, 128.52, 128.48, 128.43, 128.39, 128.22, 128.20, 128.18, 128.16, 127.98, 
127.95, 127.93, 127.90, 127.77, 127.73 (aromatic CH), 96.63 (C-1a), 95.90 (C-1b), 82.27 (C-5b), 80.14 (C-5a), 79.57 (C-
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2º), 77.97 (C-2b), 77.67 (C-4), 77.59 (C-4), 76.41 (C-2a), 75.95, 75.61, 75.08, 75.03, 73.81 (CH2), 69.21 (C-3b), 69.06 
(C-3a), 69.97, 63.84, 63.09, 63.03, 62.12 (CH2), 49.68 (CHNH), 49.60 (CHNH), 26.94 (3 CH3), 19.26, 18.70 (CH3), 18.57 
(CH3). HR-MS: Calculated for C88H98N2O19Si [M+Na]
+: 1537.64253, found: 1537.64262. 
Synthesis of 34: Compound 32 (610 mg, 0.4 mmol) and DMTrCl (273 mg, 0.8 
mmol) were dissolved in DCM (4 mL) stirring at room temperature. Then 
DIPEA (283 μL, 1.6 mmol) was added in the mixture. The reaction was stirred 
at rt until TLC-analysis showed complete conversion of the starting martial. 
Then the mixture was diluted with DCM. The organic phase was washed with 
water and brine, dried with anhydrous MgSO4, filtered and concentrated in 
vacuo. The product was purified by silica gel column chromatography. Compound 34 (691 mg, 95% yield) was obtained 
as a colorless syrup. [α]D
20 +118.8 (c=1, CHCl3). IR (neat, cm
-1) ν698, 738, 827, 1029, 1070, 1175, 1209, 1249, 1454, 
1508, 1607, 1724, 2931. 1H-NMR (d-acetone, 400 MHz) δ 7.74-7.68 (m, 4 H, aromatic H), 7.55-7.12 (m, 50 H, aromatic 
H), 6.89 (bd, 4 H, aromatic H), 6.82 (d, J = 7.6 Hz, 1 H, NH), 6.79 (d, J = 8.0 Hz, 1 H, NH), 5.58 (d, J = 2.8 Hz, 1 H, H-
1a), 5.25 (d, J = 2.8 Hz, 1 H, H-1b), 5.15-5.05 (m, 5 H, 5 CHH), 4.97-4.71 (m, 6 H, 2 CHH), 4.56-4.11 (m, 13 H), 3.91 
(dd, J1 = 2.8 Hz, J2 = 9.6 Hz, 1 H, H-2a), 3.82-3.66 (m, 10 H), 3.59-3.52 (m, 2 H, H-2b, H-6a), 3.34-3.31 (m, 1 H, H-6b), 
1.49-1.45 (m, 6 H, 2 CH3), 1.04 (s, 9 H, 3 CH3). 
13C-APT (d-acetone, 100 MHz,) δ 173.52, 173.41 (2 C=O), 159.55 
(aromatic C), 156.90, 156.87 (2 C=O), 146.16, 139.99, 139.74, 139.68, 138.48, 139.32, 138.03, 137.98, 136.85, 136.69 
(aromatic C), 136.40, 136.38 (aromatic CH), 134.06, 134.03 (aromatic C), 131.04, 131.00, 130.67, 130.65, 129.10, 129.07, 
129.01, 128.95, 128.83, 128.67, 128.55, 128.40, 128.33, 128.26, 128.24, 128.17, 127.58, 114.08, 114.06 (aromatic CH), 
94.97 (C-1a), 93.94 (C-1b), 87.37 (quaternary C), 82.55 (C-5a), 81.79 (C-5b), 80.87 (C-2b), 78.59 (C-4), 78.26 (C-4), 
76.90 (C-2º), 76.58 (CH2), 76.03 (C-2a), 75.86, 75.64, 75.53, 72.41 (CH2), 70.29 (C-3b), 70.11 (C-3a), 66.93, 66.90, 
64.59, 64.54, 63.86 (CH2), 55.53 (2 OCH3), 50.72 (2 CHNH), 27.39 (3 CH3), 19.73 (quaternary C), 17.97 (CH3), 17.93 
(CH3). HR-MS: Calculated for C109H116N2O21Si [M+Na]
+: 1839.77321, found: 1839.77281. 
Synthesis of 19: Compound 33 (730 mg, 0.4 mmol) was dissolved in 
THF/pyridine (1:1/v:v, 6 mL) stirring at room temperature. Then HF-pyridine (0.4 
mL) was added in the mixture. The reaction was stirred at rt until TLC-analysis 
showed complete conversion of the starting martial (10 h). Then the mixture was 
diluted with EtOAc. The organic phase was washed with water and brine, dried 
with anhydrous MgSO4, filtered and concentrated in vacuo. The product was 
purified by silica gel column chromatography. Compound 19 (548 mg, 86% yield) was obtained as a colorless syrup. 
[α]D
20 +64.0 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 751, 830, 1029, 1070, 1176, 1213, 1251, 1302, 1454, 1508, 1608, 1724, 
2928. 1H-NMR (d-acetone, 400 MHz) δ 7.49-7.10 (m, 44 H, aromatic H), 6.87-6.73 (m, 5 H, 4 aromatic H, 1 NH), 6.74 
(d, J = 7.6 Hz, 1 H, NH), 5.52 (d, J = 2.8 Hz, 1 H, H-1a), 5.26 (d, J = 2.8 Hz, 1 H, H-1b), 5.10-5.02 (m, 5 H, 5 CHH), 
4.93-4.80 (m, 4 H, 2 CHH), 4.70-4.62 (m, 3 H), 4.56-4.48 (m, 2 H), 4.42-4.21 (m, 7 H), 4.17-4.01 (m, 4 H), 3.88-3.86 
(m, 2 H), 3.75-3.47 (m, 12 H), 3.19 (dd, J1 = 5.6 Hz, J2 = 10.0 Hz, 1 H), 1.47-1.38 (m, 6 H, 2 CH3). 
13C-APT (d-acetone, 
100 MHz,) δ 173.50, 173.43 (2 C=O), 159.60, 159.58 (aromatic C), 156.99, 156.89 (2 C=O), 1146.16, 140.03, 139.77, 
139.58, 139.50, 138.07, 138.04, 136.93, 136.71 (aromatic C), 131.07, 130.99, 129.25, 129.14, 129.13, 129.09, 129.07, 
Chapter 4 
108 
129.05, 129.04, 128.99, 128.83, 128.76, 128.67, 128.64, 128.43, 128.34, 128.25, 128.19, 128.62, 114.06, 114.04 (aromatic 
CH), 95.52 (C-1a), 93.96 (C-1b), 87.35 (quaternary C), 82.63, 81.72, 80.85, 78.83, 78.59, 78.29, 76.48, 76.06, 75.86, 
75.63, 72.42, 70.34, 70.20, 66.92, 65.28, 64.32, 63.92, 63.43, 55.54 (2 OCH3), 50.78 (CHNH), 50.74 (CHNH), 17.98 (2 
CH3). HR-MS: Calculated for C93H98N2O21 [M+NH4]
+: 1596.70003, found: 1596.69828. 
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Chapter 5 
α-Selective Galactosylation Using 
TMSI/Ph3P=O Activation 
Introduction 
The construction of 1,2-cis-glycosidic linkages continues to be a major challenge in the synthesis 
of oligosaccharides and glycoconjugates.[1] Despite tremendous progress that been made over the 
years in the development of new glycosyl donors, the introduction of novel activators alongside 
the growing mechanistic insight in the underlying reaction mechanisms, there is no general 
solution to form 1,2-cis-glycosidic bonds.[2] The main reason for the lack of a general 
glycosylation procedure is the diversity of sugar substrates that leads to greatly varying results. 
The reactivity of both the glycosyl donor[3] and acceptor[4] is affected by the nature of the 
protecting groups and the orientation of the groups on the carbohydrate ring. The enormous 
variation in substitution patterns makes it difficult to translate a productive glycosylation reaction 
from one glycosylation couple to another. The use of additives to modulate glycosylation is an 
Chapter 5 
110 
attractive method to match donor and acceptor reactivity.[5] The work described in Chapters 2, 3 
and 4 has shown that additive controlled glycosylations of per-benzylated glucosyl donors can be 
used effectively for the introduction of α-(1,2)-, α-(1,3)-, α-(1,4)- and α-(1,6)- glucosyl linkages.[6] 
The stereoselective glycosylations were achieved using two glycosylation systems, the first built 
on the use of triflic acid (TfOH) activation in combination with DMF as an additive,[5b, 5k] while 
the second used trimethylsilyliodide (TMSI) as an activator and Ph3P=O as an reactivity 
moderator.[5c-e, 5l] The first system was used for secondary alcohol acceptors, while the second 
activator set was employed to glucosylate more reactive primary alcohols. The assembly of longer 
and branched oligoglucosides was accomplished by the implementation of a protecting group 
strategy that employed a single type of protecting groups to keep the reactivity of the different 
substrates as similar as possible. The triad of benzyl (Bn), para-methoxybenzyl (PMB) and 2-
methylnaphthyl (Nap) ethers was effectively exploited to discriminate the different hydroxyl 
groups on the building blocks.  
The successful synthesis of α-glucans was an incentive to explore the above described methods 
in the synthesis of α-galactans. 1,2-cis-linked galactosides exists in many natural compounds. For 
example, pectin is a complex polysaccharide that is composed of a linear chain of α-(1,4)-linked 
galacturonic acids, and it is a prominent constituent of the plant cell wall.[7] α-Galactosyl linkages 
are also frequently encountered in mammalian, bacterial and fungal polysacccharides. The 
opportunistic pathogenic fungus Asperigillus fumigatus produces galactosaminogalactans 
(GAGs), long linear polysaccharides composed of α-(1,4)-linked galactose, galactosamine and 
N-acetyl galactosamine monosaccharides, as part of a protective biofilm and the capsular 
polysaccharide of Salmonella typhi, the causative agent of typhoid fever is composed of repeating 
1,4-linked α-N-acetyl galactosaminuronic acids.[8] This Chapter was subject on the use of additive 
controlled glycosylation methodology for the construction of 1,2-cis-galactosides. 
Results and discussion 
In previous work, per-benzylated donor and acceptor building blocks were used to assemble α-
glucans and to match this approach, in this Chapter similarly protected building blocks for the 
introduction of 1,2-cis-galactosyl linkages were employed. First, attention was paid to the 
glycosylations between glucosyl- and galactosyl imidate donors 1 and 2, respectively, and 
galactosyl acceptors 3, 4 and 5 under DMF-mediated glycosylation conditions (See Table 1). The 
reactions were performed by combining the donor and acceptor with DMF in DCM, cooling to -
78oC, after which TfOH was added. After stirring for 0.5h, the reactions were warmed to 0 oC 
and allowed to proceed for 24h. 
As shown in Table 1, the glycosylation between donor 1 and acceptor 3 proceeded in 70% yield 
and good selectivity (α:β = 15:1; entry 1). The glycosylations of acceptor 4 and 5 with donor 1 
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proceeded in excellent yields, but with less stereoselectivity (α:β = 7:1 and 6:1, respectively; entry 
2 and 3). Next galactosyl imidate donor 2 was glycosylated with acceptors 3, 4 and 5. 
Disaccharide 9 was obtained in relatively poor yield and selectivity (α:β = 5:1, entry 4). 
Disaccharides 10 and 11 were obtained both with excellent yield and good selectivity (α:β = 13:1 
and 12:1, respectively; entry 5 and 6). These results indicate that, across the board, the reactions 
of the galactosyl acceptors proceed with lower selectivity under DMF/TfOH activation. Therefore, 
attention was turned to the TMSI/ Ph3P=O activation conditions, reasoning that these latter 
conditions generate intermediates that are less reactive than the intermediates generated upon 
TfOH/DMF activation, which could lead to improved stereoselectivity in the condensation 
reactions. 
Table 1. Glycosylation under TfOH/DMF activation conditions. 
 
Entry Donor Acceptor Additive Product Yielda α:βb 
1 1 3 DMF 6 70% 15:1 
2 1 4 DMF 7 95% 7:1 
3 1 5 DMF 8 95% 6:1 
4 2 3 DMF 9 55% 5:1 
5 2 4 DMF 10 95% 13:1 
6 2 5 DMF 11 98% 12:1 
a Isolated yield. b The α:β ratio was determined by 1H NMR. 
Previously, Ph3P=O has been used as an additive to modulate glycosylation selectivity by 
Mukaiyama and coworkers[5c-e], and Oka and coworkers reported α-selective ribofuranosylations 
using TMSI and Ph3P=O.[9] To be able to compare the TfOH/DMF and TMSI/Ph3P=O systems, 
the set of glycosylation reactions, summarized in Table 2 was performed. The reactions were 
performed by mixing the donor, acceptor and Ph3P=O in DCM, prior to the addition of TMSI and 
stirring for 24h at room temperature.  
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Table 2. Glycosylations under TMSI and Ph3P=O activation. 
 
Entry Donor Acceptor Additive Product Yielda α:βb 
1 1 12 Ph3P=O 17 95% >20:1 
2 1 13 Ph3P=O 18 95% >20:1 
3 1 3 Ph3P=O 6 49% >20:1 
4 1 4 Ph3P=O 7 92% >20:1 
5 1 5 Ph3P=O 8 78% >20:1 
6 1 14 Ph3P=O 21 61% >20:1 
7 1 15 Ph3P=O 22 95% >20:1 
8 1 16 Ph3P=O 23 60% >20:1 
9 2 12 Ph3P=O 19 90% 10:1 
10 2 13 Ph3P=O 20 71% 15:1 
11 2 3 Ph3P=O 9 40% 10:1 
12 2 4 Ph3P=O 10 78% 10:1 
13 2 5 Ph3P=O 11 91% 15:1 
14 2 14 Ph3P=O 24 82% >20:1 
15 2 15 Ph3P=O 25 93% 11:1 
16 2 16 Ph3P=O 26 98% >20:1 
a Isolated yield. b The α:β ratio was determined by 1H NMR. 
First, the reactions of glucosyl donor 1 were examined. In line with the results of the previous 
Chapters, the reactions with primary alcohol acceptors 12 and 13 proceeded in excellent yield 
and stereoselectivity (entry 1 and 2). Next the secondary galactosyl alcohols 3, 4 and 5 were 
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exposed to the glucosylation conditions to provide disaccharides 6, 7 and 8 with excellent 
selectivity (entries 3-5). Of note, the yield of the reaction of the C4-OH acceptor 3 (entry 3) was 
significantly lower than the reactions with the other two acceptors. The condensations with the 
secondary glucosyl acceptors 14, 15 and 16 also proceeded in a highly stereoselective manner 
(entries 6-8). While the stereoselectivity of these reactions matched the stereoselectivity of the 
TfOH/DMF mediated glucosylations (Chapter 2), the reactions proceeded more slowly (requiring 
room temperature) and with somewhat diminished yields. Next the corresponding 
galactosylations were investigated. Entry 9 and 10 show that the TMSI/Ph3P=O mediated 
galactosylations of the primary alcohol acceptors are somewhat less stereoselective than the 
corresponding glucosylations. The reactions with the secondary galactosyl acceptors 3, 4 and 5 
proceed with similar stereoselectivity. While the stereoselectivity of donor 2 with C4-OH 
galactose acceptor 3 is increased with respect to the TfOH/DMF system, the stereoselectivity of 
the reactions of the other two acceptors, 4 and 5, is somewhat poorer under the TMSI/Ph3P=O 
conditions. Finally, glucose acceptors 14, 15 and 16 were combined with donor 2 and 
TMSI/Ph3P=O activation to provide disaccharides 24, 25 and 26 in good to excellent yields. 
Disaccharides 24 and 25 were formed with excellent stereoselectivity, while disaccharide 25 was 
obtained as a 11:1 mixture of α- and β-galactosides.  
As described above, the α-(1,4)-polygalactose motif is a prominent structure in many relevant 
polysaccharides. The results in Table 1 and 2 show that the glycosylations of the galactosyl C4-
OH is more challenging than the other condensation reactions, likely as the result of the poor 
nucleophilicity of this alcohol. Therefore, the construction of the galactose-α-(1,4)-galactose was 
further investigated. Table 3 shows that conditions were screened to optimize the reaction 
between donor 2 and acceptor 3. First the glycosylation of donor 2 and acceptor 3 was explored 
without additive at 0oC. Although, the yield of this reaction was quite good, the stereoselectivity 
was poor (α:β = 3:1, entry 1). Next, the glycosylation was performed under the activation of 
TMSOTf-Ph3P=O. These conditions led to a similar yield but reduced selectivity (α:β = 2:1; entry 
2). Because the stereoselectivity of this reaction was significantly lower than the stereoselectivity 
of the TMSI-Ph3P=O mediated reaction (Table 2, entry 11), different additives were next invested 
using TMSI as promoter. Disaccharide 9 was formed with poor yield and selectivity when TBAI 
was used as an additive (entry 4). By combining Ph3P=O and TBAI the yield and α-selectivity of 
the latter reaction both increased (entry 5), although the α-selectivity of this reaction was lower 
than when solely Ph3P=O was used. The use of different phosphine oxides, Me3P=O and 
tri(pyrrolidin-1-yl)phosphine oxide (entry 6 and 7) did not lead to the desired improvement. In 
fact, when tri(pyrrolidin-1-yl)phosphine oxide was used, no disaccharide was formed at all. The 
use of Ph3P=S gave a similar selectivity as Ph3P=O, but the yield decreased to 27% (entry 8). 
Because no improvement could be found through the use of different additives, attention was 
directed to optimizing the yield for the TMSI/Ph3P=O reaction. To this end, different solvents and 
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reaction temperatures were screened. The yield and α-selectivity were decreased slightly when 
DCE was used (entry 9). While the α-selectivity increased to 12:1 when using DCM/Et2O, the 
yield dropped to 23%. Finally, the glycosylation was explored at higher temperature. Refluxing 
the reaction mixture in DCM improved the yield of the reaction to 67% while the stereoselectivity 
(α:β = 10:1) was maintained. Raising the temperature further, by refluxing the reaction mixture 
in DCE led to a poor yield and stereoselectivity. 
Table 3. Glycosylation of donor 2 and acceptor 3. 
 
Entry Promoter Additive Solvent T(oC) t(h) Yield a α:β b 
1 TfOH - DCM 0 0.5 78% 3:1 
2 TMSOTf Ph3P=O DCM rt 18 75% 2:1 
3 TMSI Ph3P=O DCM rt 24 40% 10:1 
4 TMSI TBAI DCM rt 24 23% 3:1 
5 TMSI TBAI/Ph3P=O DCM rt 24 49% 6:1 
6 TMSI Me3P=O DCM rt 24 51% 5:1 
7 TMSI  DCM rt 24 - - 
8 TMSI Ph3P=S DCM rt 24 27% 9:1 
9 TMSI Ph3P=O DCE rt 24 37% 7:1 
10 TMSI Ph3P=O DCM/Et2O rt 24 23% 12:1 
11 TMSI Ph3P=O DCM reflux 24 67% 10:1 
12 TMSI Ph3P=O DCE reflux 24 28% 3:1 
a Isolated yield. b The α:β ratio was determined by 1H NMR. 
To explore the applicability of the optimal conditions in the synthesis of an oligosaccharide, a 
linear trisaccharide was assembly as depicted in Scheme 1. First acceptor 3 was glycosylated with 
donor 27, bearing a Nap-ether at the C-4 position to form the desired disaccharide 28 (α:β = 10:1). 
Because the disaccharide could not be purified from the 1,1-linked disaccharide side product, the 
Nap-ether was removed using DDQ in DCM/H2O to provide 29. The pure α-disaccharide was 
obtained in 42% yield over two steps. Finally, disaccharide acceptor 29 was coupled with donor 
27 under the conditions established above to give the trisaccharide 30 in 64% yield and α:β = 8:1.  
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a) TMSI, Ph3P=O, DCM, reflux, 28: α:β = 10:1; 30: 64%, α:β = 8:1. b) DDQ, DCM/H2O, 29: 42% with two steps. 
Scheme 1. Synthesis of trisaccharide. 
Conclusion 
In summary, this Chapter has explored additive mediated glycosylations for the construction of 
α-glucosyl and galactosyl linkages. Because TfOH/DMF mediated glucosylations and 
galactosylations of galactosyl acceptors proceeded with lower selectivity than the systems 
explored in the previous Chapters, TMSI-Ph3P=O mediated glycosylation conditions were probed. 
It was found that the use of this activation cocktail can be used with a broad substrate scope. Both 
primary and secondary alcohol acceptors can be stereoselectively condensed with glucosyl and 
galactosyl donors. The galactosyl C4-OH proved to be a challenging alcohol to glycosylate and 
elevated temperatures were required to achieve a synthetically useful glycosylation with this 
acceptor. A linear galactosyl trisaccharide was synthesized using optimal TMSI-Ph3P=O 
mediated glycosylation conditions. 
Experimental Section 
General experimental procedures  
All reagents were of commercial grade and used as received. All moisture sensitive reactions were performed under an 
argon atmosphere. DCM used in the glycosylation reactions was dried with flamed 4Å molecular sieves before being 
used. Reactions were monitored by TLC analysis with detection by UV (254 nm) and where applicable by spraying with 
20% sulfuric acid in EtOH or with a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% 
sulfuric acid (aq.) followed by charring at ~150 °C. Column chromatography was carried out using silica gel (0.040-0.063 
mm). Size-exclusion chromatography was carried out using Sephadex LH-20. High resolution mass (HRMS) was 
performed on a Thermo Finnigan LTQ Orbitrap mass spectrometer equipped with an electrospray ion source in positive 
ion mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 °C) resolution R= 60.000 at m/z 400 
(mass range of 150-4000) and dioctylphtalate(m/z=391.28428) as lock mass, or on a Waters Spynat G2-Si(OTF) equipped 
with an electrospary ion souce in positive mode (source voltage 3.5kV) and LeuEnk (m/z = 556.2771). 1 μl of 2,5-
dihydroxybenzoic acid (2,5-DHB; Bruker Daltonics) matrix (20 mg/mL in ACN/water; 50:50 (v/v)) was applied on a 
384-MTP target plate (Bruker Daltonics, Bremen, Germany) and air-dried. Subsequently, 1 μl of xxx solution was spotted 
on the plate and the spots were left to dry prior MALDI-TOF analysis. An Ultraflextreme MALDI-TOF (Bruker 
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Daltonics), equipped with Smartbeam-II laser was used to measure the samples in reflectron positive ion mode. The 
MALDI-TOF was calibrated using a peptide calibration standard prior to measurement. 1H and 13C spectra were recorded 
on a Bruker AV 400 and Bruker AV 500 in CDCl3 or D2O. Chemical shifts (δ) are given in ppm relative to 
tetramethylsilane as internal standard (1H NMR in CDCl3) or the residual signal of the deuterated solvent. Coupling 
constants (J) are given in Hz. All 13C spectra are proton decoupled. NMR peak assignments were made using COSY and 
HSQC experiments, where applicable Clean TOCSY, HMBC and GATED experiments were used to further elucidate 
the structure. The anomeric product ratios were analyzed through integration of proton NMR signals. IR spectra were 
recorded on a Shimadzu FTIP-8300 IR spectrometer and are reported in cm Specific rotations were measured on a Propol 
automatic polarimeter or an Anton-Paar MCP 100 modular circular polarineter at 589 nm unless otherwise stated. 
Standard procedure A: A mixture of donor (1.0 eq), acceptor (0.7 eq) (donor and acceptor co-evaporated with toluene 
three times), DMF (16 eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. The 
solution was cooled to -78 ℃, after which TfOH (1.0 eq) was added. After 30 min, the mixture was placed in an ice bath. 
The reaction was stirred at 0 ℃ until TLC-analysis showed complete conversion of the acceptor. The reaction was 
quenched with Et3N, filtered and concentrated in vacuo. The products were purified by size exclusion and silica gel 
column chromatography. 
Standard procedure B: A mixture of donor (1.0 eq), acceptor (0.7 eq) (donor and acceptor co-evaporated with toluene 
three times), Ph3P=O (6 eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. Then 
TMSI (1.0 eq) was added slowly in the mixture. The reaction was stirred at room temperature until TLC-analysis indicated 
the reaction to be complete. The solution was diluted and the reaction quenched with saturated Na2S2O3. The organic 
phase was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The products 
were purified by size exclusion and silica gel column chromatography.  
Standard procedure C for deprotection of the Nap protecting group: The starting material (1 eq) was dissolved in 
DCM:H2O (10:1, 0.1 M). DDQ (1.1 eq) was added to the mixture. The reaction stirred until TLC-analysis indicated full 
consumption of the starting material (± 2h). Then the mixture was diluted with DCM and the reaction quenched with 
saturated Na2S2O3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and 
concentrated in vacuo. The product was purified by silica gel column chromatography. 
Experimental Procedures and Characterization Data of Products 
We used "a", "b" and "c" to specify the H-1 and C-13 NMR signals of sugar rings from the “reducing” to the “non-
reducing” end. 
Phenyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactopyranoside 2: IR (neat, cm-1) ν 694, 731, 751, 
1027, 1097, 1150, 1206, 1318, 1452, 1497, 1550, 1600, 1716, 2870, 3031. 1H-NMR (CDCl3, 500 
MHz, 60℃) δ 7.51-6.70 (m, aromatic H), 6.40 (bs, 1 H, H-1α), 5.59 (bs, 1 H, H-1β), 4.94-4.40 
(m), 4.19-3.87 (m), 3.46 (t), 3.67-3.50 (m). 13 C-APT (CDCl3, 125 MHz, 60℃) δ 144.05, 143.84, 
139.01, 138.90, 138.81, 138.79, 138.76, 138.51, 138.46, 138.20, 138.18, 135.38 (aromatic C), 129.47, 128.78, 128.76, 
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128.55, 128.53, 128.51, 128.47, 128.39, 128.34, 128.22, 128.19, 128.08, 127.98, 127.92, 127.89, 127.86, 127.83, 127.72, 
127.69, 127.64, 126.50, 124.29, 124.25, 120.82, 119.78, 119.58 (aromatic CH), 98.08, 97.90, 92.16, 82.44, 78.66, 78.48, 
76.12, 75.51, 75.21, 75.10, 74.97, 74.80, 73.96, 73.70, 73.65, 73.47, 73.33, 72.60, 69.97, 69.24, 68.83, 68.60. HR-MS: 
Calculated for C43H42F3O7N [M-[O(C=NPh)CF3]+OH+Na]
+: 593.2510, found:593.2516. 
Synthesis of 6: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 1 (106 mg, 0.15 mmol), 3 (45 mg, 0.1 mmol, 0.1 M in DCM), DMF (189 μL, 
2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, 
filtered and concentrated in vacuo. The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 6 (67 mg, 70% yield, α:β = 15:1) was obtained as a colorless syrup. Under condition B, 
using 1 (105 mg, 0.15 mmol), 3 (45 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI (21 μL, 0.15 
mmol). The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 6 (47 mg, 49 % 
yield, α:β > 20:1) was obtained as a colorless syrup. [α]D
20 +75.1 (c=1, CHCl3).IR (neat, cm
-1) ν697, 734, 1027, 1050, 
1093, 1359, 1454, 1497, 2923. 1H-NMR (CDCl3, 400 MHz) δ 7.41-7.09 (m, 35 H, aromatic H), 5.10 (d, J = 3.6 Hz, 1 H, 
H-1b), 4.91 (d, J = 10.8 Hz, 1 H, CHH), 4.85-4.67 (m, 9 H, 8 CHH, H-1a), 4.48 (d, J = 12.4 Hz, 1 H, CHH), 4.40 (d, J = 
10.8 Hz, 1 H, CHH),4.28-4.11 (m, 5 H, 3 CHH, H-4a, H-5b), 3.98-3.84 (m, 5 H, H-6aa, H-5a, H-4b, H-3b, H-2a), 3.73 (t, 
J = 10.0 Hz, 1 H, H-3a), 3.57 (dd, J = 3.6, 10.0 Hz, 1 H, H-2b), 3.51 (dd, J = 5.6, 9.2 Hz, 1 H, H-6ab), 3.41-3.36 (m, 4 H, 
H-6ba, OCH3), 3.06 (dd, J = 2.0, 10.4 Hz, 1 H, H-6bb). 
13C-APT (CDCl3, 100 MHz,) δ 139.02, 138.97, 138.75, 138.46, 
138.36, 138.28, 138.08 (aromatic C), 128.51, 128.48, 128.45, 128.36, 128.35, 128.19, 127.95, 127.93, 127.88, 127.82, 
127.70, 127.63, 127.59, 127.52 (aromatic CH), 98.83 (C-1b), 98.88 (C-1a), 82.30 (C-3b), 80.39 (C-2b), 77.98 (C-3a), 
77.89 (C-2a), 76.66 (C-4a), 75.54 (CH2), 75.06 (C-4b), 74.99, 74.02, 73.46, 73.40, 73.10, 72.98 (CH2), 70.80 (C-5b), 
69.45 (C-5a), 68.15 (C-6a), 67.68 (C-6b), 55.43 (OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, 
found: 1004.49243. 
Synthesis of 7: The reaction was carried out according to the standard procedure A or B. 
Under condition A, using 1 (105 mg, 0.15 mmol), 4 (45 mg, 0.1 mmol, 0.1 M in DCM), 
DMF (189 μL, 2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-0 
oC until TLC-analysis showed complete conversion of the acceptor. The reaction was 
quenched with Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 7 (91 mg, 95% yield, α:β = 7:1) was obtained as a colorless syrup. Under condition B, 
using 1 (106 mg, 0.15 mmol), 4 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI (21 μL, 0.15 
mmol). The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 7 (88 mg, 92 % 
yield, α:β > 20:1) was obtained as a colorless syrup. IR (neat, cm-1) ν 698, 737, 1027, 1050, 1096, 1274, 1356, 1454, 1497, 
1724, 2925, 3032. [α]D
20 +69.4 (c=1, CHCl3). 
1H NMR (500 MHz, CCCl3) δ 7.43-7.06 (m, 35H, aromatic H), 5.15 (d, J 
= 3.3 Hz, 1H, H-1b), 5.08 (d, J = 11.2 Hz, 1H, CHH), 4.90 (d, J = 11.0 Hz, 1H, CHH), 4.84-4.76 (m, 3H, 3 CHH), 4.72-
4.66 (m, 3H, 2 CHH, H-1a), 4.58-4.54 (m, 2H, 2 CHH), 4.48 (d, J = 11.8 Hz, 1H, CHH), 4.44 (d, J = 11.0 Hz, 1H, CHH), 
4.40-4-36 (m, 2H, 2 CHH), 4.30 (d, J = 12.1 Hz, 1H, CHH), 4.17 (bd, J = 10.1 Hz, 1H, H-5b), 4.14–4.07 (m, 2H, H-3a, 
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H-3b), 3.99 (dd, J = 10.2, 3.6 Hz, 1H, H-2a), 3.93 (bd, 1H, H-4a), 3.89-3.84 (t, J = 6.5 Hz, 1H, H-5a), 3.73 (t, J = 9.5 Hz, 
1H, H-4b), 3.65 (dd, J = 9.8, 3.4 Hz, 1H, H-2b), 3.55-3.49 (m, 3H, 2 H-6a, H-6b), 3.45-3.39 (m, 1H, H-6b), 3.32 (s, 3H, 
OCH3). 
13C NMR (125 MHz, CDCl3) δ 139.07, 138.86, 138.78, 138.31, 138.19, 138.17, 138.09 (aromatic C), 128.58, 
128.54, 128.51, 128.49, 128.45, 128.43, 128.36, 128.29, 128.23, 128.19, 128.16, 128.13, 128.11, 128.06, 127.98, 127.81, 
127.79, 127.75, 127.67, 127.62, 127.51, 127.36 (aromatic CH), 98.45 (C-1a), 96.44 (C-1b), 82.27 (C-3b), 80.30 (C-2b), 
78.09 (C-4b), 76.52 (C-3a), 75.68 (C-2a), 75.58 (CH2), 75.00 (CH2), 74.94 (C-4a), 74.88, 74.18, 73.53, 73.41, 73.33 
(CH2), 70.49 (C-5b), 69.32 (C-5a), 69.07 (C-6a), 68.25 (C-6b), 55.33 (OCH3). HR-MS: Calculated for C62H66O11 
[M+NH4]
+: 1004.49434, found: 1004.49343. 
Synthesis of 8: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 1 (105 mg, 0.15 mmol), 5 (45 mg, 0.1 mmol, 0.1 M in DCM), DMF (190 
μL, 2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, 
filtered and concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). 
Compound 8 (95 mg, 99% yield, α:β = 6:1) was obtained as a colorless syrup. Under condition B, using 1 (106 mg, 0.15 
mmol), 5 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI (21 μL, 0.15 mmol). The product 
was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 8 (76 mg, 78 % yield, α:β > 20:1) was 
obtained as a colorless syrup. IR (neat, cm-1) ν 697, 737, 1027, 1050, 1093, 1275, 1358, 1454, 1497, 1724, 2866, 2926. 
[α]D
20 +73.2 (c=1, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.37-7.20 (m, 30H), 7.12 – 7.05 (m, 5H), 4.98 (d, J = 10.5 Hz, 
1H, CHH), 4.93 (m, 2H, H-1b, H-1a), 4.86 (d, J = 11.5 Hz, 1H, CHH), 4.84 – 4.64 (m, 6H, 6 CHH), 4.56 – 4.49 (m, 3H, 
3 CHH), 4.44 (m, 2H, 2 CHH), 4.35 (dd, J1 = 10.0 Hz, J2 = 3.5 Hz, 1H, H-2a), 4.30 (d, J = 12.5 Hz, 1H, CHH), 4.13 – 
4.07 (m, 2H, H-5b, H-3b), 4.03 – 4.00 (m, 2H, H-4a, H-3a), 3.94 (t, J = 6.5, 1H, H-5a), 3.68 (t, J = 10.0 Hz, 1H, H-4b), 
3.59 – 3.56 (m, 3H, 2 H-6a, H-2b), 3.49 (dd, J1 = 11.0 Hz, J2 = 2.5 Hz, 1H, 1 H-6b), 3.44 (s, 3H, OCH3), 3.40 (dd, J1 = 
11.0 Hz, J2 = 2.0 Hz, 1H, 1 H-6b). 
13C NMR (126 MHz, CDCl3) δ 139.01, 138.89, 138.80, 138.60, 138.17, 138.08, 138.03 
(aromatic C), 128.51, 128.44, 128.42, 128.35, 128.31, 128.23, 128.18, 128.13, 128.12, 128.09, 128.01, 127.93, 127.90, 
127.86, 127.78, 127.65, 127.61, 127.59, 127.56, 127.42 (aromatic CH), 97.05 (C-1a), 94.40 (C-1b), 82.34 (C-3a), 79.35 
(C-2b), 77.83 (C-3a), 77.78 (C-4b), 75.73 (CH2), 74.80 (2 CH2, C-4a), 73.68 (CH2), 73.44 (CH2), 73.39 (CH2), 72.96 
(CH2), 71.66 (C-2a), 69.97 (C-5b), 69.39 (C-5a), 69.16 (C-6a), 68.06 (C-6b), 55.15 (OCH3). HR-MS: Calculated for 
C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49334. 
Synthesis of 9: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 2 (105 mg, 0.15 mmol), 3 (45 mg, 0.1 mmol, 0.1 M in DCM), DMF (190 μL, 
2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 9 (53 mg, 55% yield, α:β = 5:1) was obtained as a colorless syrup. Under condition B, 
using 2 (97 mg, 0.14 mmol), 3 (42 mg, 0.09 mmol, 0.1 M in DCM), Ph3P=O (240 mg, 0.86 mmol) and TMSI (20 μL, 
0.14 mmol). The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 9 (36 mg, 40 % 
α-Selective Galactosylation Using TMSI/Ph3P=O Activation 
119 
yield, α:β = 10:1) was obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1050, 1098, 1359, 1454, 1497, 2923, 
3031. [α]D
20 +34.0 (c=1, CHCl3). 
1H-NMR (CDCl3, 400 MHz) δ 7.42-7.16 (m, 35 H, aromatic H), 4.99 (d, J = 3.6 Hz, 1 
H, H-1b), 4.91-4.67 (m, 9 H, 8 CHH, H-1a), 4.60 (d, J = 12.4 Hz, 1 H, CHH), 4.41 (dd, J = 4.8, 9.2 Hz, 1 H, H-5b), 4.21 
(s, 2 H, 2 CHH), 4.13-4.05 (m, 5 H, 2 CHH, H-4a, H-4b, H-2b), 3.93-3.80 (m, 5 H, H-6aa, H-5a, H-3a, H-3b, H-2a), 3.56-
3.46 (m, 2 H, H-6ab, H-6ba), 3.36 (s, 3 H, OCH3), 3.21 (dd, J = 4.8, 8.0 Hz, 1 H, H-5b). 
13C-APT (CDCl3, 100 MHz,) δ 
139.08, 138.88, 138.79, 138.67, 138.34, 138.23 (aromatic C), 128.46, 128.41, 128.39, 128.24, 128.23, 128.16, 127.95, 
127.77, 127.69, 127.66, 127.60, 127.54, 127.48, 127.46, 127.39 (aromatic CH), 100.45 (C-1b), 98.89 (C-1a), 79.60 (C-
3b), 78.09 (C-3a), 76.66 (C-4b), 76.33 (C-4a), 77.17 (C-2b), 75.04 (CH2), 74.71 (C-2a), 74.28, 73.48, 73.28, 73.05, 72.76, 
72.37 (CH2), 69.59 (C-5a), 67.89 (C-5b), 68.25 (C-6a), 67.89 (C-6b), 55.42 (OCH3). HR-MS: Calculated for C62H66O11 
[M+NH4]
+: 1004.49434, found: 1004.49353. 
Synthesis of 10: The reaction was carried out according to the standard procedure A or B. 
Under condition A, using 2 (105 mg, 0.15 mmol), 4 (45 mg, 0.1 mmol, 0.1 M in DCM), DMF 
(190 μL, 2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-0 oC until 
TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with 
Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 
1:1). Compound 9 (91 mg, 95% yield, α:β = 13:1) was obtained as a colorless syrup. Under condition B, using 2 (106 mg, 
0.15 mmol), 4 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI (21 μL, 0.15 mmol). The 
product was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 9 (76 mg, 78 % yield, α:β > 
10:1) was obtained as a colorless syrup. IR (neat, cm-1) ν 698, 737, 1027, 1050, 1097, 1274, 1454, 1497, 1724, 2872, 
2925. [α]D
20 +72.1 (c=1, CHCl3). 
1H NMR (500 MHz, CCCl3) δ 7.34–7.11 (m, 35H, aromatic H), 5.21 (d, J = 3.5 Hz, 1H, 
H-1b), 4.98 (d, J = 11.5 Hz, 1H, CHH), 4.92 (d, J = 11.5 Hz, 1H, CHH), 4.84 (d, J = 11.5 Hz, 1H, CHH), 4.73-4.66 (m, 
4H, 4 CHH), 4.60 – 4.53 (m, 3H, 2 CHH, H-1a), 4.45 (d, J = 12.0 Hz, 1H, CHH), 4.37-4.30 (m, 5H, 4 CHH, H-5a), 4.15-
4.11 (m, 2H, H-3a, H-2b), 4.00 (dd, J = 10.5, 3.0 Hz, 1H, H-3b), 3.96 (dd, J = 10.5, 3.5 Hz, 1H, H-2a), 3.92 (bd, 2H, H-
4a, H-4b), 3.82 (t, J = 6.5 Hz, 1H, H-5b), 3.56-3.41 (m, 4H, 2 H-6a, 2 H-6b), 3.27 (s, 3H, OCH3). 
13C NMR (125 MHz, 
CDCl3) δ 139.15, 138.92, 138.82, 138.80, 138.49, 138.41, 138.25 (aromatic C), 128.47, 128.39, 128.37, 128.31, 128.15, 
128.06, 127.92, 127.78, 127.74, 127.71, 127.66, 127.61, 127.60, 127.58, 127.49, 127.34 (aromatic CH), 98.68 (C-1a), 
97.20 (C-1b), 79.13 (C-3b), 76.87 (C-2b), 76.31 (C-3a), 75.94 (C-2a), 75.21 (C-4), 75.12 (C-4), 74.97, 74.82, 74.30, 
73.46, 73.39, 73.12, 72.52 (CH2), 69.43 (C-5a), 69.34 (C-5b), 69.22 (C-6b), 68.72 (C-6a), 55.28 (OCH3). HR-MS: 
Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49331. 
Synthesis of 11: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 2 (105 mg, 0.15 mmol), 5 (45 mg, 0.1 mmol, 0.1 M in DCM), DMF (190 
μL, 2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, 
filtered and concentrated in vacuo. The product was purified by size exclusion chromatography (DCM:MeOH = 1:1). 
Compound 9 (94 mg, 98% yield, α:β = 12:1) was obtained as a colorless syrup. Under condition B, using 2 (106 mg, 0.15 
mmol), 5 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI (21 μL, 0.15 mmol). The product 
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was purified by size exclusion chromatography (DCM:MeOH = 1:1). Compound 9 (89 mg, 91 % yield, α:β = 15:1) was 
obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1027, 1052, 1096, 1276, 1454, 1497, 1724, 2870, 2919. [α]D
20 
+67.2 (c=1, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.38-7.15 (m, 35H), 4.98 (d, J = 3.5 Hz, 1H, H-1b), 4.98 (d, J = 3.5 
Hz, 1H, H-1a), 4.89 (d, J = 11.5 Hz, 1H, CHH), 4.88 (d, J = 11.5 Hz, 1H, CHH), 4.82-4.64 (m, 6H, 6 CHH), 4.56-4.48 
(m, 3H, 3 CHH), 4.41 (d, J = 11.5 Hz, 1H, CHH), 4.36 (dd, J = 10.0, 3.5 Hz, 1H, H-2a), 4.33-4.24 (m, 3H, H-5b, 2 CHH), 
4.04-3.90 (m, 5H, H-3a, H-5a, H-2b, H-3b, H-4), 3.85 (bd, 1H, H-4), 3.56 (bd, 2H, H-6a), 3.51 (bt, 1H, 1 H-6b), 3.44-
3.38 (m, 4H, 1 H-6b, OCH3). 
13C NMR (125 MHz, CDCl3) δ 139.09, 139.01, 138.94, 138.81, 138.75 (aromatic C), 128.49, 
128.43, 128.41, 128.31, 128.28, 128.20, 128.17, 128.98, 127.89, 127.82, 127.72, 127.58, 127.51, 127.48, 127.46 
(aromatic CH), 97.15 (C-1a), 94.82 (C-1b), 79.07 (C-3b), 78.03 (C-3a), 76.05 (C-2b), 75.01 (C-4), 74.92 (C-4), 74.89, 
74.62, 73.64, 73.22, 73.18, 73.01, 72.87 (CH2), 71.42 (C-2a), 69.44 (C-5a), 69.23 (C-6a), 68.83 (C-5b), 68.40 (C-6b), 
55.21 (OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49357. 
Synthesis of 17: The reaction was carried out according to the standard procedure B, using 1 (106 
mg, 0.15 mmol), 12 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI 
(20 μL, 0.14 mmol). The product was purified by size exclusion chromatography (DCM:MeOH = 
1:1). Compound 17 (93 mg, 95 % yield, α:β > 20:1) was obtained as a colorless syrup. IR (neat, 
cm-1) ν 697, 736, 1027, 1072, 1089, 1159, 1361, 1454, 1497, 2866, 2925. [α]D
20 +52.0 (c=1, 
CHCl3). 
1H-NMR (500 MHz, CDCl3) δ 7.34-7.10 (m, 35H, aromatic H), 4.99-4.89 (m, 4 H, H-1b, 3 CHH), 4.84-4.55 (m, 
9 H, CHH, H-1a), 4.46-4.39 (m, 2 H, 2 CHH), 4.01-3.94 (m, 2 H, H-3a and 3b), 3.85-3.52 (m, 9 H, H-5b, H-5a, H-4b, H-
4a, H-2b, H-6b, H-6a), 3.45 (dd, J = 9.6, J = 3.6 Hz, 1H, H-2a), 3.51 (s, 3H, OCH3). 
13C-NMR (126 MHz, CDCl3) δ 
138.86, 138.52, 138.49, 138.23, 138.02 (aromatic C), 128.49, 128.43, 128.39, 128.35, 128.08, 128.05, 127.96, 127.92, 
127.80, 127.79, 127.71, 127.70, 127.67, 127.64, 127.61, 127.58 (aromatic CH), 98.02 (C-1a), 97.32 (C-1b), 82.19 (C-3a), 
81.73 (C-3b), 80.19 (C-2), 80.03 (C-2), 77.81 (C-4), 77.66 (C-4), 75.79, 75.57, 75.03, 74.97, 73.46, 73.44, 72.44 (CH2), 
70.41 (C-5), 70.29 (C-5), 68.50 (C-6b), 66.09 (C-6a), 55.23 (OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 
1004.49434, found: 1004.493378. 
Synthesis of 18: The reaction was carried out according to the standard procedure B, using 1 
(90 mg, 0.13 mmol), 13 (39 mg, 0.08 mmol, 0.1 M in DCM), Ph3P=O (210 mg, 0.75 mmol) and 
TMSI (18 μL, 0.14 mmol). The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 18 (79 mg, 95 % yield, α:β > 20:1) was obtained as a colorless 
syrup. IR (neat, cm-1) ν 697, 734, 1029, 1073, 1156, 1206, 1362, 1454, 1497, 2866, 2915. [α]D
20 
+25.4 (c=1, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.37-7.10 (m, 35H, aromatic H), 4.98-4.58 (m, 13H, 12 CHH, H-1b), 
4.45 (bt, 2H, 2 CHH), 4.25 (d, J = 7.6 Hz, 1H, H-1a), 3.97 (t, J = 9.6 Hz, 1H, H-3b), 3.82-3.45 (m, 14H, H-2a, H-2b, H-
3a, H-4a, H-4b, H-5a, H-5b, H-6a, H-6b, OCH3). 
13C NMR (100 MHz, CDCl3) δ 138.86, 138.82, 138.69, 138.57, 138.42, 
138.18, 137.90 (aromatic C), 128.49, 128.46, 128.43, 128.38, 128.33, 128.24, 128.18, 128.14, 128.10, 128.06, 128.01, 
127.78, 127.76, 127.70, 127.66, 127.64, 127.62, 127.58, 127.53 (aromatic CH), 104.95 (C-1a), 97.26 (C-1b), 82.09 (C-
3a and 3b), 79.79 (C-2), 79.65 (C-2), 77.69 (C-4b), 775.67, 75.20, 75.00, 74.40 (CH2), 73.93 (C-4a), 73.55, 73.36, 73.18 
(CH2), 73.16 (C-5a), 70.29 (C-5b), 68.38 (C-6b), 67.04 (C-6a), 57.08 (OCH3). HR-MS: Calculated for C62H66O11 
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[M+NH4]
+: 1004.49434, found: 1004.49366. 
Synthesis of 19: The reaction was carried out according to the standard procedure B, using 2 (106 
mg, 0.15 mmol), 13 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI 
(20 μL, 0.14 mmol). The product was purified by size exclusion chromatography (DCM:MeOH 
= 1:1). Compound 19 (88 mg, 90 % yield, α:β = 10:1) was obtained as a colorless syrup. IR (neat, 
cm-1) ν 697, 734, 1029, 1056, 1077, 1098, 1206, 1362, 1454, 1497, 2870, 2916. [α]D
20 +24.3 (c=1, 
CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.20 (m, 35 H, aromatic H), 4.94-4.86 (m, 3 H, 3 CHH), 4.81-4.71 (m, 6 
H, 5 CHH, H-1b), 4.66-4.55 (m, 4 H, 4 CHH), 4.46 (d, J = 11.6 Hz, 1 H, CHH), 4.37 (d, J = 11.6 Hz, 1 H, CHH), 4.23 
(d, J = 6.1 Hz, 1 H, H-1a), 4.03 (dd, J = 3.6 Hz, J = 10.0 Hz, 1 H, H-2b), 3.97 (bd, 1 H, H-4b), 3.92 – 3.90 (m, 2 H, H-
5b, H-3b), 3.82 – 3.76 (m, 3 H, 1 H-6a, H-5a, H-2a), 3.57 – 3.48 (m, 7 H, 2 H-6b, 1 H-6a, H-a, OCH3). 
13C NMR (126 
MHz, CDCl3) δ 138.96, 138.79, 138.78, 138.68, 138.64, 137.99 (aromatic C), 128.53, 128.50, 128.44, 128.40, 128.33, 
128.31, 128.22, 128.18, 128.15, 128.09, 127.99, 127.90, 127.83, 127.71, 127.64, 127.61, 127.57, 127.49 (aromatic CH), 
104.95 (C-1a), 98.41 (C-1b), 82.14 (C-3a), 79.66 (C-2a), 79.06 (C-3b), 76.41 (C-2b), 75.17 (CH2), 74.92 (C-4b), 74.85, 
74.51 (2 CH2), 74.05 (C-4a), 73.61, 73.58 (2 CH2), 73.10 (CH2, C-5a), 72.87 (CH2), 69.47 (C-5b), 68.87 (C-6b), 66.40 
(C-6a), 57.40 (OCH3). 
Synthesis of 20: The reaction was carried out according to the standard procedure B, using 2 (106 
mg, 0.15 mmol), 12 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and TMSI 
(20 μL, 0.14 mmol). The product was purified by size exclusion chromatography (DCM:MeOH = 
1:1). Compound 20 (70 mg, 71 % yield, α:β = 15:1) was obtained as a colorless syrup. IR (neat, 
cm-1) ν 697, 737, 1027, 1096, 1159, 1275, 1359, 1454, 1497, 1724, 2876, 2919. [α]D
20 +54.5 (c=1, 
CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.12 (m, 35H, aromatic H), 5.00 (d, J = 3.6 Hz, 1H, H-1b), 4.94 (m, 2H, 2 
CHH), 4.85 (d, J = 11.0 Hz, 1H, CHH), 4.82 – 4.77 (m, 2H, 2 CHH), 4.75 – 4.66 (m, 4H, 3 CHH, H-1a), 4.61 – 4.51 (m, 
4H, 4 CHH), 4.42 (d, J = 11.8 Hz, 1H, CHH), 4.36 (d, J = 11.8 Hz, 1H, CHH), 4.03 (dd, J = 3.6 Hz, J = 9.5 Hz, 1H, H-
2b), 3.99 – 3.88 (m, 4H, H-5b, H-4a, H-3a, H-3b), 3.82 – 3.70 (m, 3H, 2 H-6a, H-5a), 3.59 (t, J = 9.3 Hz, 1H, H-4b), 3.55 
– 3.47 (m, 2H, 2 H-6b), 3.41 (dd, J = 9.6, J = 3.6 Hz, 1H, H-2a), 3.29 (s, 3H, OCH3). 
13C NMR (126 MHz, CDCl3) δ 
138.98, 138.95, 138.84, 138.81, 138.52, 138.30, 138.14 (aromatic C), 128.51, 128.48, 128.45, 128.43, 128.38, 128.36, 
128.33, 128.29, 128.27, 128.24, 128.21, 128.19, 128.13, 128.05, 128.04, 127.95, 127.89, 127.84, 127.81, 127.77, 127.75, 
127.73, 127.71, 127.67, 127.62, 127.60, 127.58, 127.54, 127.51, 127.44 (aromatic CH), 98.03 (C-1b), 97.97(C-1a), 82.17 
(C-3a), 80.27 (C-2a), 78.33 (C-3b), 78.08 (C-4b), 76.64 (C-2b), 75.77 (CH2), 75.21 (C-4a), 75.08 (CH2), 74.84 (CH2), 
73.43 (CH2), 73.41 (CH2), 72.90 (CH2), 72.62 (CH2), 70.41 (C-5a), 69.49 (C-5b), 69.03 (C-6b), 66.49 (C-6a), 55.12 
(OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49307. HR-MS: Calculated for 
C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49358. 
Synthesis of 21: The reaction was carried out according to the standard procedure B, using 
1 (102 mg, 0.14 mmol), 14 (45 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (240 mg, 0.86 mmol) 
and TMSI (20 μL, 0.14 mmol). The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 21 (60 mg, 61 % yield, α:β > 20:1) was obtained as a 
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colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1049, 1096, 1156, 1361, 1454, 1497, 2866, 2925, 3031. [α]D
20 +35.4 
(c=1, CHCl3). 
1H-NMR (CDCl3, 400 MHz) δ 7.35-7.08 (m, 35 H, aromatic H), 5.70 (d, J = 3.6Hz, 1 H, H-1b), 5.04 (d, J 
= 11.6 Hz, 1 H, CHH), 4.88 (d, J = 10.8 Hz, 1 H, CHH), 4.82-4.77 (m, 3 H, 3 CHH), 4.70 (d, J = 12.0 Hz, 1 H, CHH), 
4.61-4.46 (m, 7 H, 6 CHH, H-1a), 4.42 (d, J = 10.8 Hz, 1 H, CHH), 4.27 (d, J = 12.0 Hz, 1 H, CHH), 4.12-4.03 (m, 2 H, 
H-3a, H-4a), 3.93-3.81 (m, 3 H, H-3b, H-5a, H-6), 3.72-3.58 (m, 4 H, H-2a, H-5a, H-4b, H-5b), 3.52-3.47 (m, 2H, H-2b, 
H-6a), 3.40-3.35 (m, 4 H, OCH3, H-6b). 
13C-APT (CDCl3, 100 MHz,) δ 139.04, 138.85, 138.57, 138.25, 138.06, 138.01 
(aromatic C), 128.52, 128.41, 128.38, 128.34, 128.30, 128.12, 128.01, 127.91, 127.90, 127.79, 127.72, 127.66, 127.59, 
127.45, 127.32, 127.17, 126.84 (aromatic CH), 97.85 (C-1a), 96.72 (C-1b), 82.13 (C-3b and 3a), 80.29 (C-2a), 79.54 (C-
2b), 77.72 (C-4b), 75.63, 75.03, 74.51, 73.53, 73.46, 73.32, 73.22 (7 CH2), 72.35 (C-4a), 71.04 (C-5b), 69.60 (C-5a), 
69.09 (C-6a), 68.23 (C-6b), 55.23 (OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49331. 
Synthesis of 22: The reaction was carried out according to the standard procedure B, 
using 1 (120 mg, 0.16 mmol), 15 (51 mg, 0.11 mmol, 0.1 M in DCM), Ph3P=O (263 mg, 
0.94 mmol) and TMSI (24 μL, 0.16 mmol). The product was purified by size exclusion 
chromatography (DCM:MeOH = 1:1). Compound 22 (101 mg, 95 % yield, α:β > 20:1) 
was obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1050, 1072, 1095, 1454, 1497, 2860, 2920. [α]D
20 +53.5 
(c=1, CHCl3). 
1H NMR (400 MHz, CCCl3) δ 7.34-6.99 (m, 35H, aromatic H), 5.60 (d, J = 3.6 Hz, 1H, H-1b), 4.96-4.79 
(m, 4H, 4 CHH), 4.84-4.76 (m, 3H, 3 CHH), 4.70-4.57 (m, 6H, 5 CHH, H-1a), 4.52 (d, J = 11.2 Hz, 1H, CHH),4.46-4-
31 (m, 5H, 4 CHH, H-5b), 4.26 (t, J = 8.4 Hz, 1H, H-3a), 4.06 (t, J = 9.2 Hz, 1H, H-3b), 3.81-3.52 (m, 9H, H-2a, H-4a, 
H-5a, H-2b, H-3b, H-6a and 6b), 3.31 (s, 3H, OCH3). 
13C NMR (100 MHz, CDCl3) δ 138.87, 138.78, 138.42, 138.14, 
138.08, 137.94, 137.92 (aromatic C), 128.84, 128.48, 128.45, 128.39, 128.35, 128.28, 128.21, 128.01, 127.98, 127.90, 
127.85, 127.78, 127.75, 127.66, 127.55, 127.51, 127.31, 126.97 (aromatic CH), 97.65 (C-1a), 97.44 (C-1b), 82.37 (C-3b), 
79.70, 78.82, 78.62, 78.19, 76.71 (C-3a), 75.57, 74.90, 73.59, 73.47, 73.37 (CH2), 70.26 (C-5b), 69.54 (C-5a), 68.52 (C-
6), 68.44 (C-6), 55.11 (OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49330. 
Synthesis of 23: The reaction was carried out according to the standard procedure B, using 1 
(105 mg, 0.15 mmol), 16 (46 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) 
and TMSI (21 μL, 0.15 mmol). The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 23 (59 mg, 60 % yield, α:β > 20:1) was obtained as a 
colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1048, 1069, 1090, 1159, 1361, 1454, 1497, 2865, 2923. [α]D
20 +60.0 
(c=1, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.39-6.98 (m, 35H), 5.00-4.90 (m, 4 H, 2 CHH, H-1a and 1b), 4.86-4.76 (m, 
5 H, 5 CHH), 4.71 (d, J = 12.0 Hz, 1H, CHH), 4.60-4.42 (m, 5 H, 5 CHH), 4.32 (d, J = 12.0 Hz, 1H, CHH), 4.12-3.99 
(m, 3 H, H-3a, H-3b, H-5), 3.85 (dd, J1 = 10.0 Hz, J2 = 3.2 Hz, 1H, H-2a), 3.80-3.54 (m, 6 H, H-6, H-5, H-4a, H-4b, H-
2b), 3.55-3.45 (m, 5 H, H-6, OCH3). 
13C NMR (100 MHz, CDCl3) δ 138.82, 138.75, 138.50, 138.38, 138.20, 138.02, 
137.97 (aromatic C), 128.57, 128.49, 128.46, 128.39, 128.38, 128.25, 128.06, 127.97, 127.94, 127.77, 127.73, 127.71, 
127.69, 127.66, 127.60, 127.47 (aromatic CH), 97.40 (C-1a), 94.20 (C-1b), 82.23 (C-3b), 80.81 (C-3a), 79.06 (C-2b), 
78.03 (C-4), 77.65 (C-4), 76.33, 75.77, 75.04, 74.94 (CH2), 74.72 (C-2a), 73.58, 74.40, 72.95 (CH2), 70.28 (C-5), 70.15 
(C-5), 68.58 (C-6), 68.13 (C-6), 55.94 (OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 
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1004.49218. 
Synthesis of 24: The reaction was carried out according to the standard procedure B, using 2 
(105 mg, 0.15 mmol), 14 (45 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) 
and TMSI (20 μL, 0.14 mmol). The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 24 (78 mg, 82 % yield, α:β > 20:1) was obtained as a 
colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1046, 1098, 1206, 1274, 1359, 1454, 1497, 1724, 2868, 2923. [α]D
20 
+39.5 (c=1, CHCl3). 
1H-NMR (CDCl3, 400 MHz) δ 7.31-7.17 (m, 35 H, aromatic H), 5.77 (d, J = 3.6 Hz, 1 H, H-1b), 
4.98 (d, J = 11.6 Hz, 1 H, CHH), 4.87 (d, J = 11.6 Hz, 1 H, CHH), 4.81 (d, J = 11.6 Hz, 1 H, CHH), 4.72-4.52 (m, 9 H, 8 
CHH, H-1a), 4.42 (d, J = 12.4 Hz, 1 H, CHH), 4.29 (d, J = 11.6 Hz, 1 H, CHH), 4.22 (d, J = 11.6 Hz, 1 H, CHH), 4.07 (t, 
J = 8.8 Hz, 1 H, H-3a), 4.01-3.93 (m, 3 H, H-4a, H-4b, H-2b), 3.88-3.80 (m, 3 H, H-5a, H-5b, H-3b), 3.72-3.63 (m, 2 H, 
H-6), 3.55 (dd, J = 3.6, 9.6 Hz, 1 H, H-2b), 3.50-3.41 (m, 2 H, H-6), 3.37 (s, 3 H, OCH3), 3.21 (dd, J = 4.8, 8.0 Hz, 1 H, 
H-5b). 13C-APT (CDCl3, 100 MHz,) δ 139.04, 138.69, 138.67, 138.43, 138.33, 138.06 (aromatic C), 128.49, 128.43, 
128.40, 128.37, 128.29, 128.25, 127.98, 127.86, 127.78, 127.68, 127.59, 127.54, 127.46, 127.12, 126.81 (aromatic CH), 
97.80 (C-1a), 97.53 (C-1b), 82.11 (C-3a), 80.23 (C-2a), 79.25 (C-3b), 75.69 (C-2b), 74.85 (CH2), 74.68 (C-4b), 74.43, 
73.89, 73.49, 73.45, 73.13, 72.82 (CH2), 72.77 (C-4a), 69.93 (C-5b), 69.54 (C-5a), 69.48 (C-6), 68.74 (C-6), 55.18 (OCH3). 
HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 1004.49345. 
Synthesis of 25: The reaction was carried out according to the standard procedure B, using 
2 (105 mg, 0.15 mmol), 15 (45 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 
mmol) and TMSI (20 μL, 0.14 mmol). The product was purified by size exclusion 
chromatography (DCM:MeOH = 1:1). Compound 25 (89 mg, 93 % yield, α:β = 11:1) was 
obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1055, 1093, 1274, 1454, 1497, 1724, 2870, 2911. [α]D
20 
+52.0 (c=1, CHCl3). 
1H NMR (500 MHz, CCCl3) δ 7.34–6.98 (m, 35H, aromatic H), 5.59 (d, J = 3.2 Hz, 1H, H-1b), 4.96-
4.89 (m, 2H, 2 CHH),4.78-4.32 (m, 14H, 12 CHH, H-1a, H-5b), 4.25 (dd, J = 9.2, 8.4 Hz, 1H, H-3a), 4.07 (dd, J = 10.0, 
3.2 Hz, 1H, H-2b), 4.01 (dd, J = 10.0, 2.4 Hz, 1H, H-3b), 3.96 (bs, 1H, H-4b), 3.77-3.50 (m, 7H, 2 H-6a, 2 H-6b, H-5a, 
H-4a, H-2a), 3.23 (s, 3H, OCH3). 
13C NMR (125 MHz, CDCl3) δ 138.87, 138.78, 138.49, 138.44, 138.40, 138.35, 137.98 
(aromatic C), 128.48, 128.44, 128.42, 128.35, 128.33, 128.30, 128.28, 128.25, 128.21, 128.16, 128.00, 127.98, 127.76, 
127.57, 127.53, 127.43, 127.35, 127.22 (aromatic CH), 97.93 (C-1b), 97.83 (C-1a), 79.36 (C-3b), 79.16 (C-2a), 78.63 (C-
4a), 76.34 (C-3a), 76.07 (C-2b), 75.24 (C-4b), 74.93, 73.88, 73.79, 73.56, 73.42, 73.19, 72.68 (CH2), 69.56 (C-5a), 69.10 
(C-5b), 68.91 (C-6), 68.54 (C-6), 55.01 (OCH3). HR-MS: Calculated for C62H66O11 [M+NH4]+: 1004.49434, found: 
1004.49324. 
Synthesis of 26: The reaction was carried out according to the standard procedure B, using 2 
(105 mg, 0.15 mmol), 16 (45 mg, 0.1 mmol, 0.1 M in DCM), Ph3P=O (250 mg, 0.9 mmol) and 
TMSI (20 μL, 0.14 mmol). The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1). Compound 26 (94 mg, 98 % yield, α:β > 20:1) was obtained as a colorless 
syrup. IR (neat, cm-1) ν 697, 737, 1027, 1047, 1095, 1274, 1362, 1454, 1497, 1724, 2920, 3032. [α]D
20 +74.0 (c=1, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.44-7.08 (m, 35H), 4.98 (d, J = 3.5 Hz, 1H, H-1b), 4.92 (d, J = 3.2 Hz, 1H, H-1a), 4.90 – 
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4.59 (m, 9H, 9 CHH), 4.51-4.40 (m, 3H, 3 CHH), 4.32 (d, J = 11.8 Hz, 1H, CHH), 4.27 (d, J = 11.8 Hz, 1H, CHH), 4.15 
(t, J = 11.8, 1H, H-5b), 4.07-4.00 (m, 2H, H-3a, H-2b), 3.90 (dd, J1 = 10.0 Hz, J2 = 2.8 Hz, 1H, H-3b), 3.86 (dd, J1 = 10.0 
Hz, J2 = 3.2 Hz, 1H, H-2a), 3.78-3.55 (m, 5H, H-5a, H-4b, H-4a, H-6), 3.49-3.35 (m, 5H, H-6, OCH3). 
13C NMR (100 
MHz, CDCl3) δ138.99, 138.90, 138.88, 138.79, 138.44, 138.35, 138.09 (aromatic C), 128.55, 128.48, 128.45, 128.42, 
128.37, 128.34, 128.27, 128.26, 128.03, 127.92, 127.78, 127.73, 127.66, 127.58, 127.56, 127.52, 127.44 (aromatic CH), 
96.66 (C-1a), 94.86 (C-1b), 81.03 (C-3a), 78.86 (C-3b), 78.07 (C-4), 75.93 (C-2b), 75.68 (CH2), 75.08 (C-4), 75.05 (CH2), 
74.88 (CH2), 74.74 (C-2a), 73.63, 73.57, 73.01, 72.98, 72.95 (CH2), 70.33 (C-5a), 69.16 (C-5b), 68.77 (C-6), 68.67 (C-
6), 55.00 (OCH3). HR-MS: Calculated for C62H66O11 [M+Na]+: 1009.44973, found: 1009.44783. 
2,3,6-Tri-O-benzyl-4-O-(naphthalen-2-ylmethyl)-α/β-D-glucopyranosyl N-
phenyltrifluoroacetimidate 27: IR (neat, cm-1) ν 695, 734, 812, 909, 1027, 1097, 1152, 1208, 
1319, 1454, 1497, 1598, 1717, 2870, 2921.1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.79-6.70 (m, 
aromatic H), 6.42 (bs, 1 H, H-1α), 5.60 (bs, 1 H, H-1β), 5.06 (bd), 4.85-4.68 (m), 4.47-4.35 (m), 
4.10-3.90 (m), 3.71-3.55 (m). 13 C-APT (CDCl3, 125 MHz, 60℃) δ 143.88, 138.50, 138.49, 138.17, 136.24, 133.57, 
133.35 (aromatic C), 129.54, 128.79, 128.60, 128.54, 128.51, 128.27, 128.17, 128.12, 127.98, 127.92, 127.90, 127.87, 
127.78, 127.75, 127.72, 126.99, 126.94, 126.54, 126.49, 126.43, 126.15, 126.10, 125.99, 124.31, 120.78, 119.81, 
119.61(aromatic CH), 97.94 (C-1), 92.23 (C-1), 82.55, 78.74, 78.58, 76.21, 75.57, 75.21, 75.17, 75.03, 74.83, 73.90, 
73.71, 73.59, 73.46, 72.62, 68.83, 68.61. HR-MS: Calculated for C46H42F3O6N [M-[O(C=NPh)CF3]+OH+Na]
+: 
613.25606, found:613.25390. 
Synthesis of 28: The reaction was carried out according to the standard procedure B, using 27 
(2066 mg, 2.7 mmol), 3 (420 mg, 0.9 mmol, 0.2 M in DCM), Ph3P=O (2330 mg, 8.4 mmol) and 
TMSI (387 μL, 2.7 mmol). The product was purified by size exclusion chromatography 
(DCM:MeOH = 1:1) and silica gel column chromatography. Compound 28 (α:β = 10:1) was 
obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1050, 1098, 1454, 1497, 2872, 
2923. HR-MS: Calculated for C66H68O11 [M+NH4]+: 1054.50999, found: 1054.50946. 
Synthesis of 29: The reaction was carried out according to the general procedure C, using crude 
compound 28 (0.1 M in DCM:H2O) and DDQ (225 mg, 1.0 mmol). The product was purified by 
silica gel column chromatography. Compound 29 (340 mg, 42% yield over two steps) was 
obtained as a colorless syrup. IR (neat, cm-1) ν 697, 750, 1029, 1047, 1098, 1362, 1454, 2870, 
2925. [α]D
20 +55.1 (c=1, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.41–7.16 (m, 30 H, aromatic 
H), 5.01 (d, J = 3.6 Hz, 1 H, H-1b), 4.86 (d, J = 12.0 Hz, 1 H, CHH), 4.82-4.63 (m, 8 H, 7 CHH, H-1a), 4.35 (d, J = 12.0 
Hz, 1 H, CHH), 4.30–4.77 (m, 1 H), 4.25–4.18 (m, 4 H), 4.06 (d, J = 2.0 Hz, 1 H, H-4a), 3.97 (dd, J = 3.6 Hz, J = 10.0 
Hz, 1 H, H-2b), 3.93–3.81 (m, 5 H), 3.56–3.46 (m, 2 H), 3.36 (s, 3 H, OCH3), 3.30 (dd, J = 9.2, J = 4.0 Hz, 1 H). 
13C 
NMR (126 MHz, CDCl3) δ 138.96, 138.75, 138.53, 138.42, 138.29, 137.95 (aromatic C), 128.49, 128.44, 128.41, 128.24, 
128.06, 127.81, 127.78, 127.72, 127.68, 127.62, 127.53 (aromatic CH), 100.24 (C-1b), 98.69 (C-1a), 78.43 (C-3b), 77.75 
(C-3a), 76.46 (C-4a), 76.13 (C-2b), 75.20 (C-2a), 74.31, 73.56, 73.25, 70.04, 72.94, 71.88 (CH2), 69.70 (C-5a), 69.36 (C-
6), 68.32 (C-5b), 68.17 (C-6), 55.40 (OCH3). HR-MS: Calculated for C55H60O11 [M+NH4]+: 914.44739, found: 914.44635. 
α-Selective Galactosylation Using TMSI/Ph3P=O Activation 
125 
Synthesis of 30: The reaction was carried out according to the standard procedure B, using 
27 (130 mg, 0.17 mmol), 29 (50 mg, 0.06 mmol, 0.1 M in DCM), Ph3P=O (140 mg, 0.5 
mmol) and TMSI (25 μL, 0.17 mmol). The product was purified by size exclusion 
chromatography (DCM:MeOH = 1:1). Compound 30 (52 mg, 64 % yield, α:β = 8:1) was 
obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1029, 1047, 1096, 1206, 1331, 
1359, 1454,1497, 1724, 2860, 2923. 1H NMR (500 MHz, CDCl3) δ 7.78-7.63 (m, 4 H, 
aromatic H), 7.45-7.05 (m, 48 H, aromatic H), 5.09 (d, J = 3.6 Hz, 1H, H-1), 5.05-4.97 (m, 
2 H, CHH, H-1), 4.94-4.67 (m, 11 H, 10 CHH, H-1a), 4.56 (d, J = 12.8 Hz, 1H, 1 CHH), 4.47-4.41 (m, 2 H, 1 CHH, H-
5), 4.35-4.28 (m, 3 H, 2 CHH, H-5), 4.25-3.77 (m, 17 H), 3.57-3.49 (m, 2 H), 3.35 (s, 3 H, OCH3), 3.13-3.04 (m, 2 H). 
13C NMR (126 MHz, CDCl3) δ 139.09, 138.97, 138.92, 138.83, 138.76, 138.52, 138.47, 138.36, 138.22, 136.58, 133.32, 
133.00 (aromatic C), 128.50, 128.42, 128.40, 128.39, 128.32, 128.28, 128.23, 128.18, 128.15, 127.99, 127.89, 127.76, 
127.72, 127.68, 127.57, 127.54, 127.50, 127.47, 127.41, 127.32, 127.27, 127.20, 126.63, 126.45, 125.90, 125.71 
(aromatic CH), 100.35 (2 C-1), 98.83 (C-1a), 79.66 (C-3), 78.98 (C-3), 77.97 (C-3), 76.51, 76.21, 75.34, 75.16, 75.04, 
74.58, 74.25, 73.89, 73.40, 73.15, 73.08, 72.70, 72.62, 72.34, 72.24, 69.59, 69.20, 68.18, 67.67, 66.81, 55.41 (OCH3). 
HR-MS: Calculated for C93H96O16 [M+NH4]+: 1486.70366, found: 1486.70388. 
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Chapter 6 
Reagent Controlled Glycosylations for the 
Assembly of Well-defined Pel 
Oligosaccharides 
Introduction 
Pel is one of the exopolysaccharides that forms the biofilm surrounding Pseudomonas aeruginosa, 
an opportunistic Gram-positive pathogen that is the major cause of morbidity and mortality in 
Cystic Fibrosis patients.[1] Pel is a linear polysaccharide composed of 1,4-linked α-N-acetyl 
galactosamine (GalNAc) and α-N-acetyl glucosamine (GlcNAc) residues, present in a ±6 : 1 ratio, 
of which some of the residues have been de-acetylated to generate positively charged 
galactosamine (GalN) and glucosamine (GlcN) moieties (Figure 1).[1b] Well-defined Pel 
fragments can be used to unravel their role in biofilm formation, to study their biosynthesis and 
possibly as synthetic antigens in the development of a (semi)-synthetic vaccine against P. 
aeruginosa. Because of the random distribution of the monosaccharides in Pel, it is impossible to 
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isolate well-defined oligosaccharides from natural sources and therefore organic synthesis is 
necessary to provide these structures. 
 
Figure 1. The repeating structures of Pel. 
To assemble Pel-fragments (Figure 1), four kinds of α-bonds, α-D-GlcN-(1→4)-D-GlcN, α-D-
GlcN-(1→4)-D-GalN, α-D-GalN-(1→4)-D-GlcN and α-D-GalN-(1→4)-D-GalN, have to be 
constructed. Zhang et al. have recently reported an effective synthetic strategy to assembly 
galactosminogalactans (GAGs), fungal polysaccharides composed of 1,4-linked α-D-Gal, α-D-
GalN and α-D-GalNAc moieties.[2] For the formation of the 1,2-cis-linkage, 4,6-di-tert-
butylsilylene (4,6-O-DTBS) protected GalN-donors were used to control the selectivity.[3] This 
strategy allowed the use of galactosamine donors bearing differently masked amine 
functionalities. Galactosazide and trichloroacetyl protected GalN donors were used to combine 
GalN and GalNAc at pre-determined sites in the target GAG oligosaccharides. Of note, the 
stereodirecting capacity of the DTBS group in GalN donors effectively overrides the neighboring 
group participation by C2-particpating functionalities such as the trichloroacetamide. Thus, 
DTBS-GalN donors also represent attractive building blocks for Pel-assembly. For the 
stereoselective introduction of α-D-GlcN linkages no general solution exists, even though the 
construction of this type of glycosidic linkage has attracted significant attention,[4] as it presents 
in many important natural polysaccharides and glycoconjugates, such as heparin, heparan 
sulfate,[5] GPI anchors and various bacterial polysaccharides.[6] Additive controlled 
glycosylations have been introduced for the stereoselective construction of glycosidic linkages.[7] 
In these approaches the nature of the additive determines the reactivity of in situ formed 
glycosylating species and the reactivity of the additive can be tuned to match the reactivity of the 
glycosyl donor[8] and acceptor[9] building blocks. Chapter 2 and 3 of this Thesis have reported the 
fully stereoselective assembly of a branched α-glucan from Mycobacterium tuberculosis and α-
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(1,3)-glucans from fungi cell wall.[10] The synthetic strategy to the oligosaccharides is built on the 
use of additive controlled glycosylation reactions and the use of one single benzyl type protecting 
group (Bn, PMB, Nap). For glycosylations with relatively reactive primary alcohol acceptors, the 
trimethylsilyliodide (TMSI)-triphenylphosphine oxide (Ph3P=O) activator couple was used, 
while the condensations with the less reactive secondary alcohols required the use of the 
trifluoromethanesulfonic acid (TfOH)-dimethylformamide (DMF) pair. The successful 
construction of multiple 1,4-α-glucosidic linkages was an incentive to explore this strategy for 
the assembly of the Pel oligasaccharides. Mong and co-workers have previously described how 
formamide additives can be used for the construction of 1,2-cis-GalN3 and GlcN3 linkages. They 
introduced N-formyl-morpholine (NFM) to modulate the reactivity of tri-O-benzyl GlcN3 and 
4,6-benzylidne-GalN3 donors and showed that the glycosylations mediated by NFM proceeded 
with higher stereoselectivity than the corresponding DMF-modulated condensations.[72n] Because 
of the stronger electron withdrawing effect of the azide group with respect to a benzyl ether, 2-
azido donors are generally less reactive than their 2-O-benzyl counterparts. This lower reactivity 
can be counterbalanced by the use of a somewhat more reactive additive, explaining why NFM 
outperforms DMF in these glycosylations (See Scheme 1).  
 
Scheme 1. The relative reactivity of DMF and NFM intermediates. 
This Chapter describes a strategy to synthesize Pel oligosaccharides using additive-controlled 
glycosylations to match the reactivities of the GlcN3-donor and the Pel acceptors. Because of the 
relatively low nucleophilicity of the GlcN3-C4-OH and especially the GalN3-C4-OH, a new 
additive is introduced that generates intermediates that are more reactive than the previously 
introduced DMF and NFM-imidinium ions.  
Results and discussion 
First, attention was paid to the formation of α-D-GlcN-(1→4)-D-GlcN linkages. In line with 
previous work, solely benzyl type protecting group (PMB, Nap, Bn) were used to generate 
orthogonally protected building blocks of uniform reactivity. The synthesis of D-GlcN building 
blocks is depicted in Scheme 2 and started from D-glucosamine 1. Using the diazo transfer regent 
imidazole-1-sulfonyl azide hydrogen sulfate,[11] glucosazide was generated, which was acetylated 
and functionalized with an anomeric thiophenol group. Remove of the acetyl groups, introduction 
of a benzylidene acetal at C-4-O and C-6-O and benzylation of the remaining C-3-OH, delivered 
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the fully protected GlcN3. Regioselective opening of the benzylidene aetal and masking of the 
liberated C4-OH as a PMB-ether provided compound 4. The anomeric thio acetal in this building 
block was hydrolyzed using N-iodosuccinimide in acetone/water to liberate the anomeric 
hydroxyl group, which was then turned into the required N-phenyltrifluoroimidate donor 5. To 
obtain the first acceptor, synthon 5 was coupled with benzyl 6-hydroxyhexanoate using the TMSI-
Ph3P=O conditions to provide compound 6 in 75% yield and a 5:1 α:β ratio. Deprotection of the 
PMB-masked C4-alcohol using a catalytic amount of HCl in hexafluoroisopropanol (HFIP) 
produced acceptor 7.[12] After purification by silica gel chromatography the desired α-product was 
obtained as a single anomer.  
 
(a) BF3
.EtO2, TES, DCM, 3: 80%; (b) PMBCl, NaH, DMF, 4: 95%; (c) 1) NIS, acetone, H2O, 2) 2,2,2-trifluoro-N-
phenylacetimidoyl chloride, Cs2CO3, acetone, 5: 83% with two steps; d) TMSI, Ph3P=O, DCM, rt, 6: 75%, α:β = 5:1; (e) 
0.2 M HCl/HFIP, TES, HFIP, DCM, 7: 60%. 
Scheme 2. Synthesis of donor 5 and acceptor 7. 
With donor 5 and acceptor 7 in hand, DMF was investigated as an additive to control the 
selectivity according to previous successful experiments. Thus, donor α-D-GlcN 5, acceptor 7 and 
the additive were mixed in DCM with molecular sieves and cooled to -78oC. Next, TfOH was 
added and after stirring for 0.5h, the mixture was placed at 0 oC and allowed to stir for 24h. As 
shown in Table 1, this produced the desired disaccharide product 8 with complete α-selectivity, 
but the yield was only 32% (entry 1). Performing the reaction at room temperature did not lead 
to erosion of stereoselectivity but only marginally improved the yield (entry 2). Likely, the low 
reactivity of the azido-donor and -acceptor led to the observed poor yields and therefore NFM 
was probed as an additive.[6c] Use of this additive provided complete α-selectivity, and raised the 
yield of the condensation to 55% yield. To further improve the reaction, a more reactive additive 
was sought and N-methyl-N-phenylformamide (MPF) was explored. It was expected that the 
imidinium ion formed from this additive would be more reactive because the aniline-type nitrogen 
would be less capable of supporting the (partial) positive charge in the ion. The reaction of donor 
5 and acceptor 7 proceeded with excellent yield (91%) when performed at 0oC, and the 
disaccharide 8 was obtained with 15:1 α:β-selectivity (entry 4). Although the stereoselectivity of 
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this condensation is somewhat less than the DMF or NFM mediated glyosylations, the improved 
yield allows for an overall more productive reaction.[13]  
Table 1. Glycosylation between donor 5 and acceptor 7 under various additives. 
 
entry c(mmol/ml) additive T(oC) product yielda α:βb 
1 0.1 DMF 0 8 32% >20:1 
2 0.1 DMF rt 8 38% >20:1 
3 0.1 NFM rt 8 55% >20:1 
4 0.1 MPF 0 8 91% ~15:1 
a Isolated yield. b The α:β ratio was determined by 1H NMR. 
To probe the robustness of the MPF-mediated protocol in the synthesis of oligosaccharides, the 
assembly of an all-1,2-cis linked tetrasaccharide was explored as depicted in Scheme 3. Thus, 
donor 5 and acceptor 7 were coupled under the above identified reaction conditions to provide 
the desired disaccharide 8. The PMB was removed using a catalytic amount of HCl to give 
disaccharide acceptor 9 in 88% yield. Next, compound 9 was glycosylated with donor 5 under 
the MPF-conditions to form the desired trisaccharide 10 in 83% yield and excellent 
stereoselectivity (α:β > 19:1). Repetition of the deprotection and glycosylation reactions then 
uneventfully provided tetrasaccharide 12. The successful assembly of this tetrasaccharide 
indicates that the yield and stereoselectivity don’t decrease with the growing of the sugar chain.  
 
(a) MPF, TfOH, DCM, -78-0oC, 8: 91%, α:β = 15:1; 10: 83%, α:β > 19:1; 12: 90%, α:β > 20:1. (b) 0.2 M HCl/HFIP, TES, 
HFIP/DCM, 9: 88%; 11 78%. 
Scheme 3. Assembly of an α-glucosazide tetrasaccharide using MPF mediated glycosylations. 
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Next, attention was turned to the formation of the α-GlcN-(1→4)-GalN-linkage exploring the 
additives as described above. First donor 13 was coupled with acceptor 16 using DMF to provide 
product 20 in low yield and poor selectivity (Table 2, entry 1). The use of NFM instead of DMF 
did not improve the outcome of this glycosylation (entry 2). Likely the poor reactivity of the 
sterically encumbered GalN3-C4-OH hampers the union of the two carbohydrate building blocks. 
Table 2. Glycosylation between 2-azido Glu/Gal donors and 4-OH-2-azido Glu/Gal acceptors. 
entry donor acceptor c(mmol/ml) additive T(oC) product yielda α:βb 
1 13 16 0.1 DMF 0 20 23% 6:1 
2 13 16 0.1 NFM 0 20 24% 6:1 
3 13 16 0.1 MPF 0 20 83% 5:1 
4 13 16 0.1 MPF -10 20 43% 10:1 
5 13 16 0.2 MPF -10 20 88% 10:1 
6 14 17 0.1 MPF -10 21 88% 8:1 
7 14 18 0.1 MPF -10 22 80% 4:1 
8c 15 19 0.1 - 0 23 70% 1:0 
a Isolated yield. b The α:β ratio was determined by 1H NMR. c The reaction stirred 3 h. 
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Next, the use of MPF was explored. At 0oC, disaccharide 20 was obtained in high yield (83%), 
but with moderate α:β-selectivity (5:1). Performing the same reaction at -10oC increased the α-
selectivity (α:β = 10 : 1), but led to a relatively low yield (43%, entry 4). To increase the yield of 
the reaction, the concentration was raised from 0.1 M to 0.2 M (entry 5). This led to the formation 
of the desired compound 20 with a yield of 88% and a 10:1 α:β ratio. Having defined adequate 
conditions for the construction of α-GlcN-(1→4)-GlcN and α-GlcN-(1→4)-GalN linkages, the 
use of MPF in combination with galactosazide donor 14 was explored for the construction of the 
target α-GalN-(1→4)-GlcN and α-GalN-(1→4)-GalN linkages. Under the conditions established 
above, donor 14 was coupled with glucosyl acceptor 17 to give the disaccharide 21 in excellent 
yield and 8:1 α/β-stereo selectivity (Table 2, entry 6). Contrary disaccharide 22, formed from 
donor 14 and galactosyl acceptor 18, was obtained in poor yield and poor selectivity (α:β = 4:1, 
entry 7). Because 4,6-O-DTBS protected galactosamine donors have been shown to reliably 
provide 1,2-cis-linkages, attention was next turned to this donor type. Thus, DTBS-donor 15 was 
glycosylated with acceptor 19 at 0 oC to give the desired disaccharide 23 with completely α-
selectivity (entry 8).  
With conditions in hand to construct all Pel-cis linkages the synthesis of Pel hexasaccharides 24 
and 25 was undertaken. A [2+2+2] strategy was designed to streamline the assembly of the 
structures, building on MFP-mediated glycosylations of the GalN3-GlcN3 donor 26 (Figure 2). 
The procedure for the synthesis of the required building blocks 26 and 27 is depicted in Scheme 
4 A and B. First donor 15 was coupled with glucoazide 19 to form disaccharide 23 as a single 
anomer. Next, the silylidene ketal was cleaved with HF-pyridine, after which a benzyl ether was 
regioselectively introduced under the aegis of Taylor’s borinic acid catalyst.[14] Protection of the 
remaining C4’-OH with a naphthyl group delivered compound 30. Next the anomeric thiophenol 
group was removed using N-iodosuccinimide in acetone/water, and the resulting hydroxyl group 
turned into the desired N-phenyltrifluoroimidate functionality to provide donor 26. Acceptor 27 
was obtained from donor 15 and acceptor 7. These two building blocks were united to 
stereselectively provide disaccharide 32. Removal of the silylidene ketal and introduction of the 
C6’-O-benzyl ether as described above provided 27.   
 
Figure 2. Retrosynthesis of the target Pel hexasaccharides 24 and 25. 
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With building blocks 26 and 27, the assembly of the target hexasaccharides 24 and 25 was started 
(Scheme 4C). First, donor 26 was glycosylated with acceptor 27 using MPF as additive at -10 oC 
at a 0.2 M concentration to form tetrasaccharide 34 in 89% yield as a 10:1 α/β-mixture.  
 
(a) TfOH, DCM, 23: 70%; 32: 92%. (b) HF-pyridine, THF, 28: 98%, 33: 91%. (c) BnBr, borinic acid-catalyzed, K2CO3, 
KI, CH3CN, 60 
oC, 29: 96%; 27: 95%. (d) NapBr, NaH, DMF, 30: 93%. (e) NIS, acetone, H2O. (f) 2,2,2-trifluoro-N-
phenylacetimidoyl chloride, Cs2CO3, acetone, 26: 83% over two steps. (g) MPF, TfOH, DCM, -10 
oC, 48 h, 34: 89%, α:β 
= 10:1; 36: 91%, α:β = 10:1. (h) 0.2 M HCl/HFIP, TES, HFIP/DCM, 35: 73%. (i) H2, Pd(OH)2/C, CH3COOH, THF/H2O/t-
BuOH, 24: 76%. (k) Ac2O, NaHCO3, H2O, 25: 86%. 
Scheme 4. A: Synthesis of donor 26. B: synthesis of acceptor 27. C: Assembly of Pel fragment. 
Then the Nap ether was removed using HCl and triethylsilane in DCM/HFIP to give the 
tetrasaccharide acceptor 35. Compound 35 was treated with donor 26 under the optimal MPF-
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mediated glycosylation conditions to deliver hexasaccharide 36. Reduction of the six azides and 
removal of the benzyl ester and ethers were accomplished in a one-step reduction to give the 
compound 24, of which the amino groups were acetylated with acetic anhydride to afford the 
final compound 25. 
Conclusion 
In conclusion, an effective procedure to assemble Pel fragments containing 1,4-linked GalNAc 
and GlcNAc residues, was developed. A [2+2+2] strategy was developed for the assembly of a 
Pel-hexasaccharide in which the α-GlcN linkages were constructed in glycosylation reactions 
using MPF as an additive. MPF was reported for the first time as a moderator to introduce α-
GlcN3 linkages. The required disaccharide synthons were synthesized using a 4,6-O-DTBS 
protected galactosazide donor. To probe the ability of MPF in the synthesis of oligosaccharides, 
a linear glucosazide tetrasaccharide has also been assembled, through highly stereoselective 
glycosylation reactions, using building blocks, solely equipped with benzyl type (Bn and PMB) 
hydroxyl protecting groups. The successful synthesis reported in this Chapter show that MPF is 
a valuable addition to the “additive toolbox”, which can be used to match the reactivity of donor 
and acceptor building blocks to attain stereoselective glycosylation reactions. 
Experimental Section 
General experimental procedures 
All reagents were of commercial grade and used as received. All moisture sensitive reactions were performed under an 
argon atmosphere. DCM used in the glycosylation reactions was dried with flamed 4Å molecular sieves before being 
used. Reactions were monitored by TLC analysis with detection by UV (254 nm) and where applicable by spraying with 
20% sulfuric acid in EtOH or with a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% 
sulfuric acid (aq.) followed by charring at ~150 °C. Column chromatography was carried out using silica gel (0.040-0.063 
mm). Size-exclusion chromatography was carried out using Sephadex LH-20. 1H and 13C spectra were recorded on a 
Bruker AV 400 and Bruker AV 500 in CDCl3 or D2O. Chemical shifts (δ) are given in ppm relative to tetramethylsilane 
as internal standard (1H NMR in CDCl3) or the residual signal of the deuterated solvent. Coupling constants (J) are given 
in Hz. All 13C spectra are proton decoupled. NMR peak assignments were made using COSY and HSQC experiments, 
where applicable Clean TOCSY, HMBC and GATED experiments were used to further elucidate the structure. The 
anomeric product ratios were analyzed through integration of proton NMR signals.  
Standard procedure 
Procedure A for the glycosylation of secondary alcohols: 
A mixture of donor (1.0 eq), acceptor (0.7 eq) (donors and acceptors co-evaporated with toluene three times), MPF (16 
eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. The solution was cooled to -
78 ℃, after which TfOH (1.0 eq) was added. After 30 min, the reaction was stirred at 0 or -10 ℃ until TLC-analysis 
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showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The products were purified by size exclusion and silica gel column chromatography. 
Procedure B for the glycosylation of primary alcohols: 
A mixture of donor (1.0 eq), acceptor (0.7 eq) (donors and acceptors co-evaporated with toluene three times), Ph3P=O (6 
eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. Then TMSI (1.0 eq) was added 
slowly in the mixture. The reaction was stirred at room temperature until TLC-analysis indicated the reaction to be 
complete. The solution was diluted and the reaction quenched with saturated Na2S2O3. The organic phase was washed 
with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The products were purified by 
size exclusion and silica gel column chromatography. 
Procedure C for deprotection of the PMB and Nap protecting group: 
The starting material (1 eq) was dissolved in DCM:HFIP (1:1, 0.1 M). TES (2.0 eq) and 0.2M HCl/HFIP (0.1-1eq) were 
added to the mixture. The reaction stirred until TLC-analysis indicated full consumption of the starting material (15min-
2h). Then the mixture was diluted with DCM and the reaction quenched with saturated NaHCO3. The organic phase was 
washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified 
by silica gel column chromatography. 
Experimental Procedures and Characterization Data of Products 
For the synthesis procedure and data of known compounds 2, 3, 4 see references.[15] 
N-phenyl trifluoroacetimidate 2-N3-glucose donor 5: Compound 4 (9.1 g, 15.2 mmol) was 
dissolved in acetone:H2O (10:1, 150 mL). N-Iodosuccinimide (NIS) (6.9 g, 30.5 mmol) was 
added in one portion and the reaction was stirred at room temperature for 2 hours. The solution 
was diluted with DCM and the reaction was quenched with saturated aqueous Na2S2O3. Then the organic layer was washed 
with water and brine. The organic layer was dried with anhydrous MgSO4, filtered and concentrated in vacuo, and the 
product purified by column chromatography (pentane : ethyl acetate (EA) = 3:1). The lactol (7.2 g, 14.3 mmol) was 
obtained as colourless syrup. Next, the lactol was dissolved in acetone (150 mL). Cs2CO3 (7.0 g, 21.3 mmol) and 2,2,2-
trifluoro-N-phenylacetimidoyl chloride (3.4 mL, 21.3 mmol) were added to the solution respectively. The reaction was 
stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product was purified by column 
chromatography (pentane:EA = 40:1-20:1). Compound 5 (8.5 g, 83% over two steps, pentane:EA = 10:1, Rf = 0.45-0.55) 
was obtained as yellow syrup. IR (neat, cm-1) ν 697, 737, 1029, 1082, 1119, 1210, 1251, 1312, 1514, 1720, 2112 (N3), 
2872, 2912. 1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.38-7.20 (m, aromatic H), 7.11-7.06 (m, aromatic H), 6.82-6.78 (m, 
aromatic H), 6.37 (bs, 1 H), 5.41 (bs, 1 H), 4.92-4.80 (m), 4.74-4.69 (m), 4.60-4.48 (m), 3.96 (t, J = 10.0 Hz, 1 H), 3.90 
(bd, 1 H), 3.77-3.58 (m), 3.43 (t), 3.33 (bs, 1 H). 13 C-APT (CDCl3, 125 MHz, 60℃) δ 159.81, 159.77, 143.61, 143.49, 
138.26, 138.20, 138.11, 130.31 (aromatic C), 129.66, 128.91, 128.60, 128.57, 128.54, 128.09, 128.03, 127.96, 127.94, 
127.89, 127.84, 124.65, 124.57, 119.57, 114.22, 114.18 (aromatic CH), 96.23 (C-1), 94.35 (C-1), 83.29, 80.49, 77.70, 
77.30, 76.36, 75.68, 75.03, 74.84, 73.92, 73.80, 73.71, 68.46, 65.81, 63.45, 55.43. Calculated for C36H35F3O6N4 [M-
[O(C=NPh)CF3]+OH+Na]
+: 582.21051, found: 582.20943. 
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Synthesis of monosaccharide 6: The reaction was carried out according to the standard 
procedure B. A mixture of donor 5 (1.0 g, 1.5 mmol), benzyl 6-hydroxyhexanoate (520 mg) 
(donors and acceptors co-evaporated with toluene three times), Ph3P=O (2.6 g, 9.3 mmol) in 
dry DCM (15 mL) were stirred over fresh flame-dried molecular sieves 3A under nitrogen. Then TMSI (222 μL, 1.5 
mmol) was added slowly in the mixture. The reaction was stirred at room temperature until TLC-analysis indicated the 
reaction to be complete. The solution was diluted and the reaction quenched with saturated Na2S2O3. The organic phase 
was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The products were 
purified by silica gel column chromatography. Compound 6 (800 mg, 75% yield, α:β = 5:1, PE:EA = 8:1, Rf = 0.63) was 
obtained as a colorless syrup. IR (neat, cm-1) ν 697, 736, 1002, 1029, 1037, 1075, 1150, 1248, 1358, 1454, 1611, 1733 
(C=O), 2105 (N3), 2866, 2933. 
1H-NMR (CDCl3, 400 MHz) δ 7.40-7.21 (m, 15 H, aromatic H), 7.00 (bd, 2 H, aromatic 
H), 6.79 (bd, 2 H, aromatic H), 5.09 (s, 2 H, PhCH2), 4.90 (d, J = 3.6 Hz, 1 H, H-1a), 4.88 (s, 2 H, PhCH2),4.71 (d, J = 
10.4 Hz, 1 H, CHH), 4.63 (d, J = 12.4 Hz, 1 H, CHH), 4.49 (d, J = 12.4 Hz, 1 H, CHH), 4.43 (d, J = 10.4 Hz, 1 H, CHH), 
3.975 (t, t, J = 9.6 Hz, 1 H, H-3a), 3.79-3.63 (m, 5 H, H-2a, H-4a, H-5a, H-6a, H-1ºa), 3.47-3.37 (m, 1 H, H-1ºb), 3.33 (dd, 
1 H, J1 = 10.0 Hz, J2 = 2.0 Hz, H-2a), 2.36 (t, J = 7.6 Hz, 2H, H-5
o), 1.70-1.58 (m, 4 H, H-2º, H-4º), 1.43-1.36 (m, 2 H, 
H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.43 (C=O), 159.36, 138.09, 137.88, 130.08 (aromatic C), 129.61, 128.57, 128.50, 
128.45, 128.20, 127.99, 127.96, 127.85, 127.79, 113.87 (aromatic CH), 97.91 (C-1a), 80.22 (C-3a), 78.03 (C-4a), 75.32, 
74.79, 73.55 (CH2), 70.73 (C-5a), 68.30 (C-6a), 68.04 (C-1º), 66.13 (PhCH2), 63.37 (C-2a), 55.28 (OCH3), 34.161 (C-5º), 
29.11 (C-2º), 25.70 (C-3º), 24.68 (C-4º). HR-MS: Calculated for C41H47N3O8 [M+NH4]
+: 727.37014, found: 727.37015. 
Synthesis of monosaccharide acceptor 7: The reaction was carried out according to the standard 
procedure C. The starting material 6 (700 mg, 0.99 m mol) was dissolved in DCM:HFIP (1:1, 
0.1 M). TES (314 mL) and 0.2M HCl/HFIP (0.5 mL) were added to the mixture. The reaction 
stirred until TLC-analysis indicated full consumption of the starting material (15min). Then the mixture was diluted with 
DCM and the reaction quenched with saturated NaHCO3. The organic phase was washed with water and brine, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified by silica gel column chromatography. 
Compound 7 (350 mg, 60% yield, PE:EA = 4:1, Rf = 0.34) was obtained as a colorless syrup. [α]D
20 +59.3 (c=1, CHCl3). 
IR (neat, cm-1) ν 697, 737, 1050, 1147, 1455, 1734 (C=O), 2105 (N3), 2866, 2926, 3478. 
1H-NMR (CDCl3, 400 MHz) δ 
7.41-7.23 (m, 15 H, aromatic H), 5.10 (s, 2 H, PhCH2), 4.90 (d, J = 11.2 Hz, 1 H, CHH), 4.87 (d, J = 3.6 Hz, 1 H, H-1a), 
4.81 (d, J = 11.2 Hz, 1 H, CHH), 4.59 (d, J = 12.0 Hz, 1 H, CHH), 4.53 (d, J = 12.0 Hz, 1 H, CHH), 3.86-3.64 (m, 6 H, 
H-2a, H-3a, H-4a, H-5a, H-6a, H-1ºa), 3.47-3.41 (m, 1 H, H-1ºb), 3.25 (dd, 1 H, J1 = 10.0 Hz, J2 = 2.0 Hz, H-2a), 2.37 (t, 
J = 7.6 Hz, 2H, H-5o), 1.72-1.61 (m, 4 H, H-2º, H-4º), 1.47-1.37 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.59 
(C=O), 138.24, 137.86, 136.09 (aromatic C), 128.66, 128.63, 128.51, 128.27, 128.25, 128.14, 128.05, 127.85, 127.73, 
127.46 (aromatic CH), 98.00 (C-1a), 79.81 (C-3a), 75.04 (C-6a), 73.72 (CH2), 72.24 (c-4a), 70.24 (c-5a), 69.76 (PhCH2), 
68.07 (C-1º), 66.23 (PhCH2), 62.80 (C-2a), 34.21 (C-5º), 29.07 (C-2º), 25.74 (C-3º), 24.68 (C-4º). HR-MS: Calculated 
for C33H39O7N3 [M+NH4]
+: 607.31263, found: 607.31238. 
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Synthesis of disaccharide 8: The reaction was carried out according to the standard 
procedure A. A mixture of donor 5 (320 mg, 0.47 mmol), acceptor 7 (185 mg, 0.31 
mmol) (donors and acceptors co-evaporated with toluene three times), MPF (610 μL) 
in dry DCM (3 mL) were stirred over fresh flame-dried molecular sieves 3A under 
nitrogen. The solution was cooled to -78 ℃, after which TfOH (42 μL) was added. 
After 30 min, the reaction was stirred at -10 ℃ until TLC-analysis showed complete conversion of the acceptor. The 
reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion 
(DCM:MeOH = 1:1). Compound 8 (304 mg, 91% yield, α:β = 15:1, PE:EA = 4:1, Rf = 0.51) was obtained as a colorless 
syrup. IR (neat, cm-1) ν 697, 736, 1027, 1147, 1249, 1358, 1454, 1514, 1734 (C=O), 2103 (N3), 2866, 2928. 
1H-NMR 
(CDCl3, 400 MHz) δ 7.39-7.21 (m, 25 H, aromatic H), 7.00 (bd, 2 H, aromatic H), 6.79 (bd, 2 H, aromatic H), 5.66 (d, J 
= 4.0 Hz, 1 H, H-1b), 5.11 (s, 2 H, PhCH2), 4.98(d, J = 10.4 Hz, 1 H, CHH), 4.93 (d, J = 4.0 Hz, 1 H, H-1a), 4.89-4.82 
(m, 3 H, 3 CHH), 4.66 (d, J = 10.0 Hz, 1 H, CHH), 4.54-4.47 (m, 3 H, 3 CHH), 4.37 (d, J = 10.4 Hz, 1 H, CHH), 4.23 (d, 
J = 10.4 Hz, 1 H, CHH), 4.07 (t, J = 9.2 Hz, 1 H, H-3a), 3.98 (t, J = 9.2 Hz, 1 H, H-4a), 3.87-3.61 (m, 10 H, H-3b, H-4b, 
H-5a, H-5b, H-6a, H-6ba, OCH3), 3.54-3.44 (m, 2 H, H-6bb, H-1ºa), 3.35-3.29 (m, 3 H, H-2a, H-2b, H-1ºb), 2.38 (t, J = 7.6 
Hz, 2H, H-5o), 1.73-1.63 (m, 4 H, H-2º, H-4º), 1.46-1.38 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.53 (C=O), 
159.39, 138.22, 138.03, 137.84, 137.82, 136.17, 130.24 (aromatic C), 129.66, 128.65, 128.46, 128.42, 128.23, 128.13, 
128.00, 127.94, 127.84, 127.78, 127.64, 127.40, 113.85 (aromatic CH), 97.78 (C-1b), 97.73 (C-1a), 80.88 (C-3a), 80.33 
(C-3b), 77.82 (C-4b), 75.45, 74.73, 74.47, 73.61, 73.50 (PhCH2), 73.37 (c-4a), 71.60 (c-5b), 70.18 (C-5a), 69.09 (C-6a), 
68.23 (C-6b), 67.89 (C-1º), 66.23 (PhCH2), 63.80 (C-2), 63.42 (C-2), 55.37 (OCH3), 34.24 (C-5º), 29.15 (C-2º), 25.75 
(C-3º), 24.76 (C-4º). HR-MS: Calculated for C61H68N6O12 [M+NH4]
+: 1094.52335, found: 1094.52388. 
Synthesis of disaccharide 9: The reaction was carried out according to the standard 
procedure C. Compound 8 (200 mg, 0.18 mmol) was dissolved in DCM:HFIP (1:1, 0.1 
M). TES (60 μL) and 0.2M HCl/HFIP (100 μL) were added to the mixture. The reaction 
stirred until TLC-analysis indicated full consumption of the starting material (30 min). 
Then the mixture was diluted with DCM and the reaction quenched with saturated 
NaHCO3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated 
in vacuo. The product was purified by silica gel column chromatography. Compound 9 (152 mg, 88% yield, PE:EA = 5:1, 
Rf = 0.22) was obtained as a colorless syrup. [α]D
20 +62.9 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 736, 1029, 1043, 1146, 
1261, 1454, 1734 (C=O), 2105 (N3), 2868, 2926, 3491. 
1H-NMR (CDCl3, 400 MHz) δ 7.42-7.20 (m, 25 H, aromatic H), 
5.64 (d, J = 3.6 Hz, 1 H, H-1b), 5.11 (s, 2 H, PhCH2), 4.98 (d, J = 10.4 Hz, 1 H, CHH), 4.93 (d, J = 3.6 Hz, 1 H, H-1a), 
4.89-4.82 (m, 3 H, 3 CHH), 4.55 (d, J = 12.0 Hz, 1 H, CHH), 4.51 (d, J = 12.0 Hz, 1 H, CHH), 4.08 (dd, J1 = 8.8 Hz, J2 
= 10.0 Hz, 1 H, H-3a), 3.99 (t, J = 8.8 Hz, 1 H, H-4a), 3.86-3.65 (m, 7 H, H-3b, H-4b, H-5a, H-5b, H-6b, H-6aa), 3.53-
3.44 (m, 2 H, H-6ab, H-1ºa), 3.40-3.33 (m, 2 H, H-2a, H-1ºb), 3.24 (dd, J1 = 3.6 Hz, J2 = 10.0 Hz, 1 H, H-2b), 2.68 (bs, 1 
H, OH), 2.38 (t, J = 7.6 Hz, 2H, H-5o), 1.73-1.64 (m, 4 H, H-2º, H-4º), 1.47-1.39 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 
MHz) δ 173.56 (C=O), 138.23, 138.17, 137.79, 137.66, 136.15 (aromatic C), 128.67, 128.57, 128.54, 128.43, 128.29, 
128.17, 128.08, 127.94, 127.89, 127.83, 127.79, 127.63, 127.35 (aromatic CH), 97.73 (C-1a), 97.63 (C-1b), 80.93 (C-3a), 
79.70 (C-3b), 75.22, 74.47, 73.71, 73.40 (PhCH2), 73.12 (C-4b), 72.77 (c-4a), 70.61 (c-5b), 70.15 (C-5a), 69.93 (C-6a), 
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69.01 (C-6b), 68.23 (C-1º), 66.26 (PhCH2), 63.78 (C-2a), 62.75 (C-2b), 34.26 (C-5º), 29.15 (C-2º), 25.76 (C-3º), 24.77 
(C-4º). HR-MS: Calculated for C53H60N6O11 [M+NH4]
+: 974.46583, found: 974.46576. 
Synthesis of trisaccharide 10: The reaction was carried out according to the 
standard procedure A. A mixture of donor 5 (160 mg, 0.24 mmol), acceptor 
9 (150 mg, 0.16 mmol) (donors and acceptors co-evaporated with toluene 
three times), MPF (307 mL) in dry DCM (1.5 mL) were stirred over fresh 
flame-dried molecular sieves 3A under nitrogen. The solution was cooled 
to -78 ℃, after which TfOH (300 μL) was added. After 30 min, the reaction 
was stirred at -10 ℃ until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with 
Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 10 
(186 mg, 83% yield, α:β > 19:1, PE:EA = 4:1, Rf = 0.40) was obtained as a colorless syrup. [α]D
20 +75.8 (c=1, CHCl3). 
IR (neat, cm-1) ν 697, 736, 1029, 1147, 1249, 1359, 1454, 1514, 1734 (C=O), 2106 (N3), 2866, 2932. 
1H-NMR (CDCl3, 
400 MHz) δ 7.39-7.21 (m, 35 H, aromatic H), 7.00 (bd, 2 H, aromatic H), 6.79 (bd, 2 H, aromatic H), 5.69 (d, J = 3.6 Hz, 
1 H, H-1), 5.67 (d, J = 3.6 Hz, 1 H, H-1), 5.11 (s, 2 H, PhCH2), 5.02-4.82 (m, 7 H, 6 CHH, H-1a), 4.66 (d, J = 10.0 Hz, 1 
H, CHH), 4.56-4.46 (m, 3 H, 3 CHH), 4.39-4.33 (m, 2 H, 2 CHH), 4.26 (d, J = 12.0 Hz, 1 H, CHH), 4.18 (d, J = 12.0 Hz, 
1 H, CHH), 4.14-3.98 (m, 4 H), 3.90-3.59 (m, 11 H), 3.56-3.44 (m, 3 H), 3.37-3.24 (m, 3 H), 2.38 (t, J = 7.6 Hz, 2H, H-
5o), 1.73-1.63 (m, 4 H, H-2º, H-4º), 1.47-1.39 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.49 (C=O), 159.36, 138.27, 
138.17, 137.99, 137.79, 137.75, 137.55, 136.14, 130.25 (aromatic C), 129.61, 128.62, 128.57, 128.55, 128.42, 128.31, 
128.26, 128.13, 127.92, 127.86, 127.81, 127.70, 127.63, 127.52, 127.41, 127.33, 113.82 (aromatic CH), 97.85, 97.73, 
97.42 (C-1a, 1b and 1c), 81.04, 80.74, 79.89 (C-3a, 3b and 3c), 77.73 (C-4c), 75.26, 74.68, 74.57, 74.24, 73.57, 73.50 
(PhCH2), 72.96, 72.46 (C-4a and 4b), 71.45, 71.12, 70.16 (c-5a, 5b and 5c), 68.90, 68.65 (2 C-6), 68.24 (C-1º), 67.73 (C-
6), 66.20 (PhCH2), 63.89, 63.63, 63.13 (C-2a, 2b and 2c), 55.34 (OCH3), 34.21 (C-5º), 29.13 (C-2º), 25.73 (C-3º), 24.74 
(C-4º). HR-MS: Calculated for C81H89N9O16 [M+NH4]
+: 1461.67655, found: 1461.67594. 
Synthesis of trisaccharide acceptor 11: The reaction was carried out according 
to the standard procedure C. The starting material 10 (320 mg, 0.22 mmol) 
was dissolved in DCM:HFIP (1:1, 0.1 M). TES (71 μL) and 0.2M HCl/HFIP 
(110 μL) were added to the mixture. The reaction stirred until TLC-analysis 
indicated full consumption of the starting material (15min). Then the mixture 
was diluted with DCM and the reaction quenched with saturated NaHCO3. 
The organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. 
The product was purified by silica gel column chromatography. Compound 11 (230 mg, 78% yield) was obtained as a 
colorless syrup. [α]D
20 +51.0 (c=3mg/mL, CHCl3). IR (neat, cm
-1) ν 697, 737, 1028, 1148, 1454, 1736 (C=O), 2106 (N3), 
2866, 2926. 1H-NMR (CDCl3, 400 MHz) δ 7.42-7.17 (m, 35 H, aromatic H), 5.67-5.65 (m, 2 H, H-1b and H-1c), 5.12 (s, 
2 H, PhCH2), 5.01-4.85 (m, 7 H, 6 CHH, H-1a), 4.56 (d, J = 12.0 Hz, 1 H, CHH), 4.50 (d, J = 12.0 Hz, 1 H, CHH), 4.37-
4.32 (m, 3 H, 3 CHH), 4.22 (d, J = 12.0 Hz, 1 H, CHH), 4.14-3.99 (m, 4 H), 3.87-3.62 (m, 8 H), 3.56-3.43 (m, 3 H), 3.37-
3.30 (m, 4 H), 3.18 (dd, J1 = 3.6 Hz, J2 = 10.0 Hz, 1 H, H-2c), 2.76 (bs, 1 H, OH), 2.39 (t, J = 7.6 Hz, 2H, H-5
o), 1.74-
1.64 (m, 4 H, H-2º, H-4º), 1.47-1.41 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.56 (C=O), 138.28, 138.20, 138.17, 
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137.81, 137.61, 137.53, 136.17 (aromatic C), 138.69, 128.67, 128.61, 128.55, 128.49, 128.36, 128.31, 128.13, 128.09, 
128.00, 127.95, 127.92, 127.79, 127.73, 127.54, 127.48, 127.26 (aromatic CH), 97.78, 97.72, 97.42 (C-1a, 1b and 1c), 
81.13, 80.77, 79.14 (C-3a, 3b and 3c), 75.02, 74.59, 74.27, 73.71, 73.53, 73.38 (PhCH2), 73.04, 72.95, 72.25 (C-4a, 4b 
and 4c), 71.09, 70.31, 70.18 (c-5a, 5b and 5c), 70.02, 68.92, 68.55 (C-6a, 6b and 6c), 68.30 (C-1º), 66.26 (PhCH2), 63.93, 
63.66, 62.46 (C-2a, 2b and 2c), 34.27 (C-5º), 29.17 (C-2º), 25.77 (C-3º), 24.79 (C-4º). HR-MS: Calculated for 
C73H81N9O15 [M+NH4]
+: 1341.61904, found: 1341.61923. 
Synthesis of tetrasaccharide 12: The reaction was carried out according to 
the standard procedure A. A mixture of donor 5 (40 mg, 0.06 mmol), 
acceptor 11 (35 mg, 0.03 mmol) (donors and acceptors co-evaporated with 
toluene three times), MPF (52 μL) in dry DCM (0.3 mL) were stirred over 
fresh flame-dried molecular sieves 3A under nitrogen. The solution was 
cooled to -78 ℃, after which TfOH (5 μL) was added. After 30 min, the 
reaction was stirred at -10 ℃ until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched 
with Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). 
Compound 12 (43 mg, 90% yield, α:β > 20:1) was obtained as a colorless syrup. [α]D
20 +94.8 (c=1, CHCl3). IR (neat, cm
-
1) ν 697, 737, 1029, 1148, 1251, 1359, 1454, 1514, 1735 (C=O), 2106 (N3), 2868, 2928. 
1H-NMR (CDCl3, 400 MHz) δ 
7.42-7.15 (m, 45 H, aromatic H), 7.00 (bd, 2 H, aromatic H), 6.79 (bd, 2 H, aromatic H), 5.70-5.67 (m, 3 H, H-1b, 1c, 
1d), 5.11 (s, 2 H, PhCH2), 5.02-4.87 (m, 8 H, 7 CHH, H-1a), 4.81 (d, J = 10.4 Hz, 1 H, CHH), 4.66 (d, J = 10.4 Hz, 1 H, 
CHH), 4.54 (s, 2 H, PhCH2), 4.65 (d, J = 12.0 Hz, 1 H, CHH), 4.38-4.28 (m, 4 H, 4 CHH), 4.22-4.00 (m, 8 H), 3.90-3.59 
(m, 15 H), 3.52-3.44 (m, 3 H), 3.39-3.34 (m, 7 H), 2.38 (t, J = 7.6 Hz, 2H, H-5o), 1.73-1.64 (m, 4 H, H-2º, H-4º), 1.47-
1.38 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.54 (C=O), 159.41, 138.31, 138.23, 138.00, 137.84, 137.78, 137.55, 
136.17, 130.29 (aromatic C), 129.66, 128.66, 128.65, 128.61, 128.59, 128.48, 128.45, 128.40, 128.33, 128.30, 128.16, 
128.02, 127.98, 127.93, 127.87, 127.84, 127.74, 127.71, 127.58, 127.52, 127.43, 127.34, 113.86 (aromatic CH), 97.91, 
97.76, 97.52, 97.48 (C-1a, 1b, 1c and 1d), 80.96, 80.88, 80.79, 79.95 (C-3a, 3b, 3c and 3d), 77.76 (C-4), 75.30, 74.73, 
74.37, 74.31, 73.60, 73.56, 73.54, 73.51 (PhCH2), 73.08 (C-4), 72.38 (C-4), 72.09 (C-4), 71.48, 71.20, 71.0570.20 (c-5a, 
5b, 5c and 5d), 68.86, 68.61, 68.29 (3 C-6), 68.29 (C-1º), 67.75 (C-6), 66.25 (PhCH2), 63.81, 63.70, 63.60, 63.19 (C-2a, 
2b, 2c and 2d), 55.39 (OCH3), 34.26 (C-5º), 29.17 (C-2º), 25.77 (C-3º), 24.79 (C-4º).  
Synthesis of N-phenyl trifluoroacetimidate 2-N3-
glucose donor 13: Compound S1 (8.5 g, 15 mmol) was 
dissolved in acetone:H2O (10:1, 150 mL). N-
Iodosuccinimide (NIS) (6.7 g, 30 mmol) was added in one portion and the reaction was stirred at room temperature for 2 
hours. The solution was diluted with DCM and the reaction was quenched with saturated aqueous Na2S2O3. Then the 
organic layer was washed with water and brine. The organic layer was dried with anhydrous MgSO4, filtered and 
concentrated in vacuo, and the product purified by column chromatography (pentane : ethyl acetate (EA) = 3:1). The 
lactol (6.1 g, 13 mmol) was obtained as colorless syrup. Next, the lactol was dissolved in acetone (150 mL). Cs2CO3 (6.4 
g, 19.6 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (3.4 mL, 21.3 mmol) were added to the solution 
respectively. The reaction was stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product 
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was purified by column chromatography (pentane:EA = 40:1-20:1). Compound 13 (7.3 g, 87%) was obtained as yellow 
syrup. IR (neat, cm-1) ν 694, 734, 1027, 1073, 1116, 1150, 1208, 1312, 1361, 1452, 1490, 1497, 1598, 1717, 2110 (N3), 
2869, 3032. 1H-NMR (CDCl3, 500 MHz, 60℃) δ 7.52-6.81 (m, aromatic H), 6.37 (bs, 1 H, H-1α), 5.43 (bs, 1 H, H-1β), 
4.89-4.76 (m, CHH), 4.60-4.48 (m, CHH), 3.98 (t, J = 9.5 Hz, 1 H), 3.91 (bd, 1 H), 3.80-3.59 (m), 3.46 (t), 3.36 (bs, 1 H). 
13 C-APT (CDCl3, 125 MHz, 60℃) δ 143.61, 143.50, 138.23, 138.16, 138.14, 138.12, 138.06 (aromatic C), 129.54, 128.92, 
128.79, 128.62, 128.58, 128.54, 128.17, 128.14, 128.06, 128.04, 128.00, 127.97, 127.95, 127.91, 127.86, 126.54, 124.68, 
124.60, 120.78, 119.59 (aromatic CH), 96.24 (C-1), 94.37 (C-1), 83.28, 80.49, 77.99, 77.62, 76.33, 75.74, 75.73, 75.37, 
75.18, 73.90, 73.82, 73.74, 68.45, 65.83, 63.48. HR-MS: Calculated for C35H33F3O5N4 [M-[O(C=NPh)CF3]+OH+Na]
+: 
498.19994, found: 498.19848. 
Synthesis of N-phenyl trifluoroacetimidate 2-N3-galactose 
donor 14: Compound S2 (3.7 g, 6.0 mmol) was dissolved in 
acetone:H2O (10:1, 150 mL). N-Iodosuccinimide (NIS) (2.7 g, 
12 mmol) was added in one portion and the reaction was 
stirred at room temperature for 2 hours. The solution was diluted with DCM and the reaction was quenched with saturated 
aqueous Na2S2O3. Then the organic layer was washed with water and brine. The organic layer was dried with anhydrous 
MgSO4, filtered and concentrated in vacuo, and the product purified by column chromatography (pentane:EA = 3:1). The 
lactol was obtained as colourless syrup. Next, the lactol was dissolved in acetone. Cs2CO3 (3.0 g, 9 mmol) and 2,2,2-
trifluoro-N-phenylacetimidoyl chloride (1.5 mL, 9 mmol) were added to the solution respectively. The reaction was stirred 
overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product was purified by column 
chromatography (pentane:EA = 40:1-20:1). Compound 14 (3.3 g, 86%) was obtained as yellow syrup. IR (neat, cm-1) ν 
695, 734, 751, 986, 1027, 1153, 1316, 1364, 1454, 1490, 1497, 1590, 1717, 2114 (N3), 2870, 2915. 
1H-NMR (CDCl3, 
500 MHz, 60℃) δ 7.56-6.79 (m, aromatic H), 6.35 (bs, 1 H, H-1), 5.49 (bs, 1 H, H-1), 5.28 (d), 4.90-4.84 (m, CHH), 
4.78-4.31 (m), 4.15-3.83 (m), 3.76 (dd), 3.65-3.31 (m). 13 C-APT (CDCl3, 125 MHz, 60℃) δ 143.48, 143.36, 138.46, 
138.30, 138.25, 138.17, 138.14, 137.73, 137.69, 137.64, 137.57, 137.38, 137.33, 135.19 (aromatic C), 129.48, 128.83, 
128.67, 128.63, 128.60, 128.56, 128.48, 128.46, 128.43, 128.37, 128.34, 128.19, 128.17, 128.15, 128.14, 128.07, 128.03, 
128.00, 127.95, 127.91, 126.48, 124.46, 120.62, 119.38 (aromatic CH), 96.53 (C-1), 92.46 (C-1), 80.89, 80.69, 77.44, 
75.05, 74.93, 74.77, 74.75, 74.65, 73.81, 73.67, 73.65, 73.62, 73.53, 72.89, 72.67, 72.64, 72.46, 72.43, 72.30, 72.24, 71.90, 
69.73, 69.30, 68.74, 68.27, 68.05, 64.67, 62.24, 60.43, 59.21. HR-MS: Calculated for C35H33F3N4O5 [M+Na]
+: 669.22953, 
found: 669.22913.  
Synthesis of N-phenyl trifluoroacetimidate 2-N3-
galactose donor 15: NIS (9.15 g, 40.68 mmol) was added 
to the solution of compound S3 (18 g, 31.3 mmol) in 
Acetone/H2O (210 ml/72ml) at 0 
oC. The reaction was 
slowly warmed to room temperature and stirred until 
TLC-analysis indicated full consumption of the starting material (± 1h). Then the mixture was diluted with DCM and 
washed with saturated Na2S2O3 and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The lactol 
was purified by silica gel column chromatography (PE:EA = 4:1). Cs2CO3 was added to the solution of the lactol (10.59g, 
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24.33 mmol) in 140 ml acetone. The mixture was stirred at 0 oC for 15 minutes. Then CF3C(=NPh)Cl (6.06 g, 29.2 mmol) 
was added to the solution. which was slowly warmed to room temperature and stirred overnight. The reaction was 
quenched with Et3N and concentrated in vacuo. The product 15 was purified by silica gel column chromatography 
(PE:Et2O = 30:1 – 10:1). Compound 15 (13.3 g, a/b = 2:1, 90% yield, PE: Et2O = 10:1, Rf = 0.45-0.55) was obtained as 
white solid. a isomer: 1H-NMR (CDCl3, 400 MHz) δ 7.50 – 7.24 (m, 7H, aromatic H), 7.15 – 7.05 (m, 1H, aromatic H), 
6.84 (d, J = 7.7 Hz, 2H, aromatic H), 6.47 (bs, 1H, H-1), 4.78 (d, J = 11.4 Hz, 1H, CH2Ph), 4.69 (d, J = 11.4 Hz, 1H, 
CH2Ph), 4.63 (s, 1H, H-4), 4.22 (q, J = 12.8 Hz, 2H. H-6), 4.10 (t, J = 6.3 Hz, 1H, H-2), 3.89 (d, J = 9.5 Hz, 1H, H-3), 
3.76 (s, 1H, H-5), 1.09-1.02 (m, 18H, CH3). 
13C NMR (100 MHz, CDCl3) δ 143.29, 137.45, 128.74, 128.56, 128.01, 
127.91, 124.40, 119.35 (aromatic C/CH), 94.73 (C-1), 76.04 (C-3), 70.71 (CH2Ph), 69.89 (C-5), 69.16 (C-4), 66.76 (C-
6), 57.71 (C-2), 27.59 (CH3), 27.23 (CH3), 23.38 (C-Si), 20.73 (C-Si). b isomer: 
1H-NMR (CDCl3, 400 MHz) δ 7.48 – 
7.25 (m, 7H, aromatic H), 7.14 – 7.04 (m, 1H, aromatic H), 6.85 (d, J = 7.7 Hz, 2H, aromatic H), 5.50 (bs, 1H, H-1), 4.77 
(d, J = 11.9 Hz, 1H, CH2Ph), 4.66 (d, J = 11.9 Hz, 1H, CH2Ph), 4.43 (s, 1H, H-5), 4.19 (s, 2H, H-6), 4.02 (s, 1H, H-4), 
3.30 (s, 2H, H-2, 3), 1.15 – 1.00 (m, 18H, CH3).
 13C NMR (100 MHz, CDCl3) δ 143.45, 137.54, 128.83, 128.71, 128.17, 
127.97, 124.48, 119.42 (aromatic C/CH), 95.82 (C-1), 79.55 (C-3), 72.18 (C-2), 70.99 (CH2Ph), 68.57 (C-5), 66.84 (C-
6), 60.79 (C-4), 27.72 (CH3), 27.42 (CH3), 23.55 (C-Si), 20.89 (C-Si). HR-MS: Calculated for C29H37F3N4O5Si [M+Na]
+: 
629.2383, found: 629.2376. 
Synthesis of acceptor 16 
 
Donor 15 (620 mg, 1.0 mmol) and 2-azidoethanol (178 mg, 2.0 mmol) were dissolved in DCM, cooled to 0 oC and TfOH 
(15 μL, 0.1 mmol) was added. The reaction was stirred at 0 ℃ until TLC-analysis showed complete conversion of the 
donor. The reaction was quenched with Et3N after completed checking by TLC, filtered and concentrated in vacuo. 
Compound S11 (370 mg, 73%) was obtained with full α-selectivity. Then compound S11 was dissolved in THF. HF-
pyridine was added to the solution. After TLC-analysis showed complete consumption of the starting material, the reaction 
was quenched with saturated NaHCO3. The mixture was diluted with ethyl acetate, washed with H2O and brine, dried 
with anhydrous MgSO4, filtered, concentrated in vacuo. Crude compound S12, K2CO3, KI, and borinic acid-catalyzed 
were mixed in CH3CN, and then BnBr was added in the solution. The reaction was stirred at 60 ℃ until TLC-analysis 
showed complete conversion of the starting material. The reaction was quenched with H2O after completed checking by 
TLC, filtered and concentrated in vacuo, purified by column chromatography. Compound 16 (280 mg, 84% yield over 
two steps) was obtained as colorless syrup. [α]D
20 +89.9 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 738, 1052, 1096, 1146, 1454, 
2108 (N3), 2873, 2923, 3483. 
1H-NMR (CDCl3, 500 MHz) δ 7.40-7.28 (m, 10 H, aromatic H), 4.95 (d, J = 3.5 Hz, 1 H, 
H-1a), 4.71 (d, J = 11.5 Hz, 1 H, CHH), 4.68 (d, J = 11.5 Hz, 1 H, CHH), 4.60 (d, J = 12.0 Hz, 1 H, CHH), 4.57 (d, J = 
12.0 Hz, 1 H, CHH), 4.12 (t, J = 1.5 Hz, 1 H, H-4a), 3.98 (t, J = 6.0 Hz, 1 H, H-5a), 3.93 (dd, 1 H, J1 = 10.5 Hz, J2 = 3.0 
Hz, H-3a), 3.90-3.86 (m, 1 H, H-1ºa), 3.77-3.63 (m, 4 H, H-2a, H-6ª, H-1ºb), 3.57-3.52 (m, 1 H, H-2ºa), 3.37-3.33 (m, 1 
H, H-2ºb), 2.61 (bt, 1 H, OH), 1.21-1.18 (bt, 6 H, 2 CH3). 
13C-APT (CDCl3, 125 MHz) δ 137.94, 137.28 (aromatic C), 
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128.78, 128.58, 128.35, 128.23, 127.92, 127.83 (aromatic CH), 98.48 (C-1a), 76.02 (C-3a), 73.78, 72.13 (CH2), 69.60 (C-
6a), 69.21 (C-5a), 67.24 (C-1º), 66.83 (C-4a), 58.98 (C-2a), 50.76 (C-2º). HR-MS: Calculated for C22H26O5N6 [M+NH4]
+: 
472.23029, found: 472.23003. 
Synthesis of acceptor 17 
 
Donor 5 (820 mg, 1.2 mmol), isopropanol (200 μL, 2.6 mmol) and Ph3P=O (2 g) were dissolved in DCM (12 mL), and 
TMSI (173 μL) was added at room temperature. The reaction was stirred at rt until TLC-analysis showed complete 
conversion of the donor. The reaction was quenched with Et3N after completed checking by TLC, filtered and 
concentrated in vacuo, purified by column chromatography. Compound S13 was obtained with α:β = 5:1. Then compound 
S13 was dissolved in DCM/HFIP (1.5 mL: 1.5 mL). TES (380 μL) and 0.2M HCl/HFIP (600 μL) were added to the 
mixture. The reaction stirred until TLC-analysis indicated full consumption of the starting material (30min). Then the 
mixture was diluted with DCM and the reaction quenched with saturated NaHCO3. The organic phase was washed with 
water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified by silica gel 
column chromatography. Compound 17 (240 mg, 47% yield over two steps) was obtained as colorless syrup. [α]D
20 +83.4 
(c=1, CHCl3). IR (neat, cm
-1) ν 697, 735, 1029, 1047, 1120, 1454, 2105 (N3), 2920, 2974, 3476. 
1H-NMR (CDCl3, 400 
MHz) δ 7.40-7.20 (m, 10 H, aromatic H), 4.97 (d, J = 3.6 Hz, 1 H, H-1a), 4.88 (d, J = 11.2 Hz, 1 H, CHH), 4.78 (d, J = 
11.2 Hz, 1 H, CHH), 4.57 (d, J = 12.0 Hz, 1 H, CHH), 4.50 (d, J = 12.0 Hz, 1 H, CHH), 3.93-3.82 (m, 3 H, H-3a, H-5a, 
H-1º), 3.73-3.61 (m, 3 H, H-4a, H-6a), 3.18 (dd, 1 H, J1 = 10.0 Hz, J2 = 3.6 Hz, H-2a), 2.76 (bs, 1 H, OH), 1.23, (d, J = 
8.4 Hz, 3 H, CH3), 1.21 (d, J = 8.4 Hz, 3 H, CH3). 
13C-APT (CDCl3, 100 MHz) δ 138.20, 137.80 (aromatic C), 128.54, 
128.39, 128.00, 127.90, 127.72, 127.59 (aromatic CH), 96.37 (C-1a), 79.64 (C-3a), 74.85, 73.56 (CH2), 72.06 (C-4a), 
70.83 (C-1º), 70.12 (C-5a), 69.65 (C-6a), 62.51 (C-2a), 23.23 (CH3), 21.48 (CH3). HR-MS: Calculated for C23H29O5N3 
[M+NH4]
+: 445.24455, found: 445.24441. 
Synthesis of acceptor 18 
 
Donor 15 (2.77 g, 4.6 mmol) and isopropanol were dissolved in DCM (40 mL), cooled to 0 oC and TfOH (40 μL) was 
added. The reaction was stirred at 0 ℃ until TLC-analysis showed complete conversion of the donor. The reaction was 
quenched with Et3N after completed checking by TLC, filtered and concentrated in vacuo. Compound S14 was obtained 
with full α-selectivity. Then compound S14 was dissolved in THF (20 mL). HF-pyridine (1 mL) was added to the solution. 
After TLC-analysis showed complete consumption of the starting material, the reaction was quenched with saturated 
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NaHCO3. The mixture was diluted with ethyl acetate, washed with H2O and brine, dried with anhydrous MgSO4, filtered, 
concentrated in vacuo, purified by column chromatography. Compound S14 (1.45 g) was obtained with 94% yield over 
two steps. Then compound S14 (665 mg, 1.97 mmol), K2CO3 (293 mg), KI (327 mg), and borinic acid-catalyzed (44 mg) 
were mixed in CH3CN (20 mL), and then BnBr was added in the solution. The reaction was stirred at 60 ℃ until TLC-
analysis showed complete conversion of the starting material. The reaction was quenched with H2O after completed 
checking by TLC, filtered and concentrated in vacuo, purified by column chromatography. Compound 17 (745 mg, 80% 
yield) was obtained as colorless syrup. [α]D
20 +102.7 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 737, 1052, 1454, 2108 (N3), 
2892, 2926. 2972. 1H-NMR (CDCl3, 400 MHz) δ 7.42-7.27 (m, 10 H, aromatic H), 5.02 (d, J = 3.6 Hz, 1 H, H-1a), 4.71 
(bs, 2 H, PhCH2), 4.58 (bs, 2 H, PhCH2), 4.15 (t, J = 1.6 Hz, 1 H, H-4a), 4.01 (bt, 1 H, H-5a), 3.95-3.89 (m, 2 H, H-3a, 
H-1º), 3.76 (dd, 1 H, J1 = 10.0 Hz, J2 = 6.0 Hz, H-6aa), 3.70-3.62 (m, 2 H, H-6ab, H-2a), 2.60 (bs, 1 H, OH), 1.23 (d, 3 H, 
J = 10.4 Hz, CH3), 1.21 (d, 3 H, J = 10.4 Hz, CH3). 
13C-APT (CDCl3, 100 MHz) δ 138.03, 137.45 (aromatic C), 128.76, 
128.55, 128.29, 128.12, 127.87, 127.77 (aromatic CH), 96.68 (C-1a), 76.14 (C-3a), 73.77, 71.96 (CH2), 70.90 (C-1º), 
69.58 (C-6a), 68.73 (C-5a), 66.79 (C-4a), 59.02 (C-2a), 23.34 (CH3), 21.63 (CH3). HR-MS: Calculated for C23H29O5N3 
[M+NH4]
+: 445.24455, found: 445.24455. 
Synthesis of disaccharide 20: The reaction was carried out according to the standard 
procedure A. A mixture of donor 13 (146 mg, 0.22 mmol), acceptor 16 (50 mg, 0.11 mmol) 
(donors and acceptors co-evaporated with toluene three times), MPF (216 μL) in dry DCM 
were stirred over fresh flame-dried molecular sieves 3A under nitrogen. The solution was 
cooled to -78 ℃, after which TfOH (19 μL) was added. After 30 min, the reaction was 
stirred at -10 ℃ until TLC-analysis showed complete conversion of the acceptor. The 
reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by size exclusion 
(DCM:MeOH = 1:1). Compound 20 (86 mg, 88%, α:β = 10:1) was obtained as a colorless syrup. IR (neat, cm-1) ν 697, 
736, 1027, 1046, 1093, 1127, 1150, 1259, 1359, 1454, 2105 (N3), 2869, 2923. 
1H-NMR (CDCl3, 400 MHz) δ 7.40-7.05 
(m, 25 H, aromatic H), 4.99 (bt, 2 H, H-1a and H-1b), 4.90-4.76 (m, 3 H, 3 CHH), 4.69 (d, J = 10.8 Hz, 1 H, CHH), 4.63 
(d, J = 10.8 Hz, 1 H, CHH), 4.59-4.53 (m, 2 H, 2 CHH), 4.39 (bt, 2 H, 2 CHH), 4.31 (d, J = 2.4 Hz, 1 H), 4.13-3.49 (m, 
13 H), 3.39-3.29 (m, 2 H), 3.22 (dd, J1 = 12.4 Hz, J2 = 2.0 Hz, 1 H), 2.96 (dd, J1 = 10.8 Hz, J2 = 2.0 Hz, 1 H), 4.48 (d, J1 
= 10.8 Hz, J2 = 1.6 Hz, 1 H). 
13C-APT (CDCl3, 100 MHz) δ 138.05, 137.75, 137.654, 137.49 (aromatic C), 128.62, 128.51, 
128.42, 128.35, 128.18, 128.07, 128.06, 127.88, 127.82, 127.78, 127.75, 127.70, 127.22 (aromatic CH), 98.92 (C-1), 
98.53 (C-1), 80.15, 78.12, 75.58, 75.42, 74.91, 73.66, 73.34, 73.28, 72.00, 70.94, 69.60, 67.33, 67.26, 67.02, 64.03, 59.36, 
50.71. HR-MS: Calculated for C49H53O9N9 [M+NH4]
+: 929.43045, found: 929.43039. 
Synthesis of disaccharide 21: The reaction was carried out according to the standard procedure 
A. A mixture of donor 14 (77 mg, 0.12 mmol), acceptor 17 (34 mg, 0.08 mmol) (donors and 
acceptors co-evaporated with toluene three times), MPF (156 μL) in dry DCM were stirred over 
fresh flame-dried molecular sieves 3A under nitrogen. The solution was cooled to -78 ℃, after 
which TfOH (8 μL) was added. After 30 min, the reaction was stirred at -10 ℃ until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, 
filtered and concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 21 (62 
Reagent Controlled Glycosylations for the Assembly of Well-defined Pel Oligosaccharides 
145 
mg, 88% yield, α:β = 8:1) was obtained as a colorless syrup. [α]D
20 +85.8 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 736, 986, 
1037, 1117, 1209, 1261, 1454, 2106 (N3), 2870, 2925. 
1H-NMR (CDCl3, 400 MHz) δ 7.41-7.19 (m, 25 H, aromatic H), 
5.64 (d, J = 3.6 Hz, 1 H, H-1a), 5.03 (d, J = 3.6 Hz, 1 H, H-1b), 4.96 (d, J = 10.0 Hz, 1 H, CHH), 4.91 (d, J = 10.0 Hz, 1 
H, CHH), 4.81 (d, J = 11.2 Hz, 1 H, CHH), 4.67 (d, J = 11.2 Hz, 1 H, CHH), 4.61 (d, J = 11.2 Hz, 1 H, CHH), 4.56 (d, J 
= 12.4 Hz, 1 H, CHH), 4.48 (d, J = 11.2 Hz, 1 H, CHH), 4.44 (d, J = 12.4 Hz, 1 H, CHH), 4.29 (d, J = 11.6 Hz, 1 H, 
CHH), 4.22 (d, J = 11.6 Hz, 1 H, CHH), 4.07 (dd, J = 8.0, 10.0 Hz, 1 H, H-3b), 3.98-3.78 (m, 7 H), 3.72-3.63 (m, 2 H, 
H-6), 3.48-3.37 (m, 2 H, H-6), 3.29 (dd, J = 3.6, 10.0 Hz, 1H, H-2b), 1.28 (d, J = 6.4 Hz, 1 H, CH3), 1.24 (d, J = 6.4 Hz, 
1 H, CH3). 
13C-APT (CDCl3, 100 MHz) δ 138.44, 138.24, 137.89, 137.60 (aromatic C), 128.62, 128.57, 128.50, 128.42, 
128.37, 128.33, 128.03, 127.92, 127.89, 127.85, 127.81, 127.54, 127.45 (aromatic CH), 98.04 (C-1a), 96.16 (C-1b), 80.78 
(C-3b), 77.58 (C-3a), 74.89, 74.48 (PhCH2), 73.94 (C-2a), 73.57, 73.18 (PhCH2), 72.94 (C-4b), 72.16 (PhCH2), 71.08 (C-
4a), 70.18 (C-5b), 70.07 (C-5a), 69.51 (C-6), 68.52 (C-6), 63.63 (C-2b), 59.75 (C-1º), 23.38 (CH3), 21.65 (CH3). HR-MS: 
Calculated for C50H56O9N6 [M+NH4]
+: 902.44470, found: 902.44482. 
Synthesis of disaccharide 22: The reaction was carried out according to the standard 
procedure A. A mixture of donor 14 (77 mg, 0.12 mmol), acceptor 18 (34 mg, 0.08 mmol) 
(donors and acceptors co-evaporated with toluene three times), MPF (156 μL) in dry DCM 
were stirred over fresh flame-dried molecular sieves 3A under nitrogen. The solution was 
cooled to -78 ℃, after which TfOH (8 μL) was added. After 30 min, the reaction was stirred 
at -10 ℃ until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered 
and concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 22 (56 mg, 80% 
yield, α:β = 4:1) was obtained as a colorless syrup. IR (neat, cm-1) ν 697, 737, 1050, 1097, 1122, 1258, 1454, 2108 (N3), 
2869, 2928. 1H-NMR (CDCl3, 400 MHz) δ 7.43-7.12 (m, 25 H, aromatic H), 5.05 (d, J = 3.6 Hz, 1 H, H-1a), 4.98 (d, J = 
3.6 Hz, 1 H, H-1b), 4.88 (d, J = 12.0 Hz, 1 H, CHH), 4.80 (d, J = 10.8 Hz, 1 H, CHH), 4.72 (d, J = 11.2 Hz, 1 H, CHH), 
4.63 (d, J = 11.2 Hz, 1 H, CHH), 4.54 (bd, 3 H,3 CHH), 4.47 (d, J = 10.8 Hz, 1 H, CHH), 4.36 (dd, J = 5.2, 9.2 Hz, 1 H, 
H-5a), 4.28 (d, J = 2.8 Hz, 1 H, H-4a), 4.10 (bs, 1 H, H-4b), 4.03-3.85 (m, 8 H, H-6ba, H-5b, H-3b, H-3a, H-2b, H-2a, H-
1º), 3.60 (dd, J = 3.6, 11.2 Hz, 1H, H-2a), 3.56-3.49 (m, 2 H, H-6bb, H-6aa), 3.14-3.09 (m, 2 H, H-6ab), 1.20 (d, J = 6.0 
Hz, 1 H, CH3), 1.19 (d, J = 6.0 Hz, 1 H, CH3). 
13C-APT (CDCl3, 100 MHz) δ 138.65, 137.99, 137.70, 137.61 (aromatic 
C), 128.64, 128.58, 128.55, 128.38, 128.32, 128.16, 128.12, 128.09, 128.01, 127.90, 127.87, 127.75, 127.74, 127.64, 
127.25 (aromatic CH), 98.24 (C-1b), 96.84 (C-1a), 77.35 (C-3b), 75.94 (C-3a), 75.03, 73.67, 73.22 (PhCH2), 73.04 (C-
4b), 72.86 (C-4a), 71.91, 71.87 (PhCH2), 71.01 (C-1º), 69.37 (C-5b), 69.20 (C-5a), 67.74 (C-6a), 67.18 (C-6b), 60.35 (C-
2b), 59.51 (C-2a), 23.36 (CH3), 21.68 (CH3). HR-MS: Calculated for C50H56O9N6 [M+NH4]
+: 902.44470, found: 
902.44467. 
Synthesis of disaccharide 23: Donor 15 (5 g, 8.2 mmol) and acceptor 19 (3.32 g, 6.95 mmol) 
(donors and acceptors co-evaporated with toluene three times) were dissolved in DCM (65 
mL), cooled to 0 oC and TfOH (60 μL) was added. The reaction was stirred at 0 ℃ until 
TLC-analysis showed complete conversion of the donor. The reaction was quenched with 
Et3N after completed checking by TLC, filtered and concentrated in vacuo. Compound 23 
was obtained with full α-selectivity. Compound 23 (4.36g, 70% yield) was obtained as a 
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colorless syrup. [α]D
20 +153.3 (c=1, CHCl3). IR (neat, cm
-1) ν 651, 698, 738, 797, 826, 984, 1043, 1066, 1100, 1171, 1364, 
1473, 2107 (N3), 2859, 2933. 
1H-NMR (CDCl3, 400 MHz) δ 7.53-7.51 (m, 2 H, aromatic H), 7.44-7.22 (m, 18 H, aromatic 
H), 5.64 (d, J = 3.6 Hz, 1 H, H-1b), 5.59 (d, J = 5.2 Hz, 1 H, H-1a), 5.00 (d, J = 10.4 Hz, 1 H, CHH), 4.91 (d, J = 10.4 
Hz, 1 H, CHH), 4.73 (d, J = 11.6 Hz, 1 H, CHH), 4.63 (d, J = 11.6 Hz, 1 H, CHH), 4.43-4.37 (m, 4 H, 2 CHH, H-4b, H-
5a), 3.96-3.77 (m, 6 H, H-2a, H-2b, H-3a, H-4a, H-6), 3.72-3.64 (m, 2 H, H-3b, H-6a), 3.53 (dd, J1 = 2.0 Hz, J2 = 10.8 
Hz, 1 H, H-6b), 3.42 (s, 1 H, H-5b), 1.03 (s, 9 H, 3 CH3), 0.97 (s, 9 H, 3 CH3). 
13C-APT (CDCl3, 100 MHz) δ 137.91, 
137.78, 137.42, 133.48 (aromatic C), 132.14, 129.17, 128.62, 128.58, 128.51, 128.48, 128.00. 127.98, 127.79, 127.54 
(aromatic CH), 97.66 (C-1b), 87.10 (C-1a), 82.33 (C-3a), 75.54 (C-3b), 74.99, 73.33 (PhCH2), 72.81 (c-4a), 71.27 (c-5a), 
70.45 (PhCH2), 69.55 (C-4b), 68.89 (C-6), 67.97 (C-5b), 66.89 (C-6), 64.61 (C-2a), 58.14 (C-2b), 27.66 (3 CH3), 27.28 
(3 CH3), 23.40, 20.73. HR-MS: Calculated for C47H58N6O8SSi [M+NH4]
+: 912.41444, found: 912.41409. 
N-phenyl trifluoroacetimidate disaccharide donor 26: Compound 30 (4.15 g, 4.21 mmol) 
was dissolved in acetone:H2O (10:1, 44 mL). N-Iodosuccinimide (NIS) (2.0 g, 8.8 mmol) 
was added in one portion and the reaction was stirred at room temperature for 2 hours. 
The solution was diluted with DCM and the reaction was quenched with saturated 
aqueous Na2S2O3. Then the organic layer was washed with water and brine. The organic layer was dried with anhydrous 
MgSO4, filtered and concentrated in vacuo, and the product purified by column chromatography (pentane : ethyl acetate 
(EA) = 3:1). The lactol 31 was obtained as colourless syrup. Next, the lactol was dissolved in acetone (40 mL). Cs2CO3 
(1.9 g) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (960 μL) were added to the solution respectively. The reaction 
was stirred overnight, then quenched with Et3N, filtered and concentrated in vacuo. The product was purified by column 
chromatography (pentane:EA = 40:1-20:1). Compound 26 (3.7 g, 83% over two steps) was obtained as yellow syrup. IR 
(neat, cm-1) ν 695, 734, 818, 1027, 1116, 1209, 1312, 1454, 1489, 1497, 1717, 2107, 2870, 2918. 1H-NMR (CDCl3, 500 
MHz) δ 7.80-7.09 (m, aromatic H), 6.81 (bt, 1 H), 5.65 (dd, 1 H), 5.01-4.87 (m), 4.68-4.54 (m), 4.45-4.42 (m), 4.33-4.18 
(m), 4.03-3.41 (m). 13 C-APT (CDCl3, 125 MHz) δ 143.37, 143.22, 138.20, 138.18, 137.78, 137.58, 137.55, 137.53, 
135.58, 133.26, 133.16 (aromatic C), 128.91, 128.67, 128.53, 128.52, 128.44, 128.43, 128.28, 128.08, 128.05, 128.00, 
127.97, 127.92, 127.84, 127.81, 127.69, 127.66, 127.65, 127.55, 127.20, 127.17, 124.67, 124.56 (aromatic CH), 119.41 
(C-1), 98.34 (C-1), 98.19 (C-1), 83.55, 80.97, 77.55, 77.25, 75.51, 75.18, 75.16, 74.94, 74.89, 73.64, 73.60, 73.29, 73.21, 
73.11, 73.02, 72.76, 72.69, 72.30, 72.16, 70.42, 70.34, 68.97, 68.52, 65.80, 63.65, 59.74, 59.64. HR-MS: Calculated for 
C59H56F3N7O9 [M-[O(C=NPh)CF3]+OH+Na]
+: 910.41340, found: 910.41374. 
Synthesis of disaccharide acceptor 27: The compound 33 (865 mg, 1.0 mmol) was 
dissloved in CH3CN (10 Ml). Then BnBr (182 μL), borinic acid-catalyzed (22 mg), 
K2CO3 (148 mg), KI (166 mg), were added in the mixture. The reaction stirred at 60 
oC 
until TLC-analysis indicated full consumption of the starting material (24 h). Then the 
mixture was diluted with ethyl acetate and the reaction quenched with saturated 
NaHCO3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated 
in vacuo. The product was purified by silica gel column chromatography. Compound 27 (910 mg, 94%) was obtained as 
a colorless syrup. [α]D
20 +66.6 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 736, 1040, 1096, 1259, 1455, 1734 (C=O), 2106 (N3), 
2869, 2928. 1H-NMR (CDCl3, 400 MHz) δ 7.40-7.21 (m, 25 H, aromatic H), 5.64 (d, J = 3.6 Hz, 1 H, H-1b), 5.11 (s, 1 
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H, PhCH2), 4.96 (d, J = 10.4 Hz, 1 H, CHH), 4.91 (d, J = 3.6 Hz, 1 H, H-1a), 4.88 (d, J = 10.4 Hz, 1 H, CHH), 4.63 (bs, 
2 H, 2 CHH), 4.55 (d, J = 12.0 Hz, 1 H, CHH), 4.45 (d, J = 12.0 Hz, 1 H, CHH), 4.47-4.36 (m, 3 H, 3 CHH), 4.07-4.03 
(m, 2 H, H-3a, H-5a), 3.91-3.44 (m, 12 H), 3.32 (dd, J1 = 11.2 Hz, J2 = 3.6 Hz, 1 H, H-2a), 2.65 (s, 1 H, OH), 2.38 (t, J = 
7.6 Hz, 2H, H-5o), 1.73-1.63 (m, 4 H, H-2º, H-4º), 1.47-1.39 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.54 (C=O), 
138.32, 137.81, 137.27, 136.14 (aromatic C), 129.07, 128.72, 128.65, 128.54, 128.50, 128.39, 128.28, 128.01, 127.89, 
127.82, 127.63, 127.56, 127.32 (aromatic CH), 97.92 (C-1b), 97.68 (C-1a), 80.79 (C-3a), 76.25 (C-3b), 74.46 (PhCH2), 
73.94 (C-4a), 73.76, 73.28, 71.68 (PhCH2), 70.10 (C-4b), 69.52, 69.44 (C-6), 69.16 (C-5b), 68.20 (C-1º), 66.44 (C-5a), 
66.23 (PhCH2), 63.74 (C-2a), 58.88 (C-2b), 34.24 (C-5º), 29.13 (C-2º), 25.74 (C-3º), 24.76 (C-4º). HR-MS: Calculated 
for C53H60N6O11 [M+NH4]
+: 974.46583, found: 974.46660. 
Synthesis of disaccharide 29: Compound 23 (4.1 g, 4.6 mmol) was dissoveld in THF (40 mL) 
in a round flusk. Then HF-pyridine (1.2 mL) was added in the solution. The reaction stirred 
until TLC-analysis indicated full consumption of the starting material (30 min). Then the 
mixture was diluted with DCM and the reaction quenched with saturated NaHCO3. The 
organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The 
crude compound 28 was dissloved in CH3CN (47 mL). Then BnBr (880 μL), borinic acid-catalyzed (110 mg), K2CO3 
(710 mg), KI (800 mg) were added in the mixture. The reaction stirred at 60 oC until TLC-analysis indicated full 
consumption of the starting material (24 h). Then the mixture was diluted with ethyl acetate and the reaction quenched 
with saturated NaHCO3. The organic phase was washed with water and brine, dried with anhydrous MgSO4, filtered and 
concentrated in vacuo. The product was purified by silica gel column chromatography. Compound 29 (3.6 g, 94% yield 
with two steps) was obtained as a colorless syrup. [α]D
20 +11.7 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 737, 1029, 1046, 1077, 
1266, 2106 (N3), 2870, 2919, 3493. 
1H-NMR (CDCl3, 400 MHz) δ 7.54-7.51 (m, 2 H, aromatic H), 7.41-7.23 (m, 23 H, 
aromatic H), 5.61 (d, J = 3.6 Hz, 1 H, H-1b), 5.60 (d, J = 5.2 Hz, 1 H, H-1a), 5.00 (d, J = 10.4 Hz, 1 H, CHH), 4.94 (d, J 
= 10.4 Hz, 1 H, CHH), 4.66 (s, 2 H, PhCH2), 4.50-4.37 (m, 3 H, 2 CHH, 5a), 4.08 (s, 1 H, H-4b), 3.97-3.91 (m, 2 H, H-
2b, H-4a), 3.85-3.37 (m, 5 H), 3.66 (dd, J1 = 2.4 Hz, J2 = 10.8 Hz, 1 H, H-6b), 3.59 (dd, J1 = 5.6 Hz, J2 = 9.6 Hz, 1 H), 
3.51 (dd, J1 = 5.6 Hz, J2 = 9.6 Hz, 1 H), 2.63 (s, 1 H, OH). 
13C-APT (CDCl3, 100 MHz) δ 138.26, 137.83, 137.64, 137.24, 
133.50 (aromatic C), 132.29, 128.77, 128.63, 128.53, 128.39, 128.34, 128.08, 127.97, 127.91, 127.86, 127.85, 127.63, 
127.55 (aromatic CH), 98.17 (C-1b), 87.10 (C-1a), 82.14 (C-3a), 76.29 (C-3b), 75.14 (PhCH2), 74.36 (c-4a), 73.78, 73.19, 
71.77 (PhCH2), 71.29 (c-5a), 69.52 (C-6), 69.40 (C-6), 69.30 (C-5b), 66.47 (C-4b), 64.75 (C-2b), 58.96 (C-2a). HR-MS: 
Calculated for C46H48N6O8S [M+NH4]
+: 862.35926, found: 862.35895. 
Synthesis of thio-disaccharide 30: The compound 29 (3.83 g, 4.53 mmol) was dissloved in 
DMF (10 mL). Then NaH (544 mg) and NapBr (1.5 g) were added in the mixture. The reaction 
stirred until TLC-analysis indicated full consumption of the starting material (2 h). Then the 
mixture was diluted with ethyl acetate and the reaction quenched with ice water. The organic 
phase was washed with water and brine, dried with anhydrous MgSO4, filtered and 
concentrated in vacuo. The product was purified by silica gel column chromatography. Compound 30 (4.15 g, 93% yield) 
was obtained as a colorless syrup. [α]D
20 +208.6 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 737, 1028, 1049, 1093, 1123, 1362, 
1454, 2106 (N3), 2870. 2914. 
1H-NMR (CDCl3, 400 MHz) δ 7.80-7.11 (m, 32 H, aromatic H), 5.64 (d, J = 3.6 Hz, 1 H, 
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H-1b), 5.59 (d, J = 5.2 Hz, 1 H, H-1a), 5.01-4.89 (m, 3 H, 3 CHH), 4.70-4.62 (m, 3 H, 3 CHH), 4.50 (d, J = 12.0 Hz, 1 
H, CHH), 4.44-4.40 (m, 2 H, CHH, 5b), 4.27 (d, J = 11.6 Hz, 1 H, CHH), 4.17 (d, J = 11.6 Hz, 1 H, CHH), 4.04 (s, 1 H, 
H-4b), 3.97-3.81 (m, 6 H, H-2a, H-2b, H-3a, H-3b, H-4a, H-5a), 3.77-3.65 (m, 2 H, H-6), 3.51-3.40 (m, 2 H, H-6). 13C-
APT (CDCl3, 100 MHz) δ 138.31, 137.79, 137.60, 137.58, 135.58, 133.56, 133.24, 133.15 (aromatic C), 133.28, 129.18, 
128.67, 128.64, 128.50, 128.37, 128.27, 128.07, 127.99, 127.97, 127.93, 127.80, 127.56, 127.44, 127.20, 126.49, 126.21, 
126.09 (aromatic CH), 98.34 (C-1b), 87.13 (C-1a), 82.24 (C-3a), 77.52 (C-3b), 75.20, 74.91 (PhCH2), 74.11 (c-4a), 73.58, 
73.11 (PhCH2), 72.77 (C-4b), 72.27 (PhCH2), 71.28 (C-5b), 70.36 (C-5a), 69.42 (C-6), 68.56 (C-6), 64.80 (C-2a), 69.75 
(C-2b). HR-MS: Calculated for C57H56N6O8S [M+NH4]
+: 1002.42186, found: 1002.42125. 
Synthesis of disaccharide 32: Donor 15 (1.09 g) and acceptor 7 (790 mg) (donors and 
acceptors co-evaporated with toluene three times) were dissolved in DCM (12 mL), 
cooled to 0 oC and TfOH (12 μL) was added. The reaction was stirred at 0 ℃ until 
TLC-analysis showed complete conversion of the donor. The reaction was quenched 
with Et3N after completed checking by TLC, filtered and concentrated in vacuo. 
Compound 32 (1.24 g, 92% yield) was obtained with full α-selectivity as a colorless 
syrup. [α]D
20 +95.9 (c=1, CHCl3). IR (neat, cm
-1) ν 651, 698, 737, 765, 797, 826, 984, 1004, 1040, 1130, 1144, 1171, 1455, 
1474, 1735 (C=O), 2106 (N3), 2860, 2933. 
1H-NMR (CDCl3, 400 MHz) δ 7.44-7.24 (m, 20 H, aromatic H), 5.67 (d, J = 
3.6 Hz, 1 H, H-1b), 5.12 (s, 1 H, PhCH2), 4.96 (d, J = 10.4 Hz, 1 H, CHH), 4.92 (d, J = 3.6 Hz, 1 H, H-1a), 4.86 (d, J = 
10.4 Hz, 1 H, CHH), 4.71 (d, J = 11.6 Hz, 1 H, CHH), 4.61 (d, J = 11.6 Hz, 1 H, CHH), 4.48 (s, 2 H, PhCH2), 4.36 (d, J 
= 2.0 Hz, 1 H, H-4b), 4.06 (dd, J1 = 10 Hz, J2 = 8.4 Hz, 1 H, H-3a), 3.91-3.78 (m, 4 H), 3.74-3.45 (m, 6 H), 3.34-3.30 (m, 
2 H, H-2a, H-1ºb), 2.39 (t, J = 7.6 Hz, 2H, H-5
o), 1.74-1.64 (m, 4 H, H-2º, H-4º), 1.48-1.42 (m, 2 H, H-3º), 1.03 (s, 9 H, 
3 CH3), 0.95 (s, 9 H, 3 CH3). 
13C-APT (CDCl3, 100 MHz) δ 173.54 (C=O), 138.03, 137.85, 137.67, 136.15 (aromatic C), 
128.66, 128.56, 128.30, 128.02, 127.96, 127.92, 127.86, 127.60 (aromatic CH), 97.77 (C-1b), 97.47 (C-1a), 80.97 (C-3a), 
75.51 (C-3b), 74.25, 73.52 (PhCH2), 72.43 (c-4a), 70.45 (PhCH2), 70.11 (c-5a), 69.57 (C-4b), 69.10 (C-6), 68.25 (C-1º), 
67.90 (C-5b), 66.92 (C-6), 66.25 (PhCH2), 63.61 (C-2a), 58.13 (C-2b), 34.25 (C-5º), 29.15 (C-2º), 27.70 (3 CH3), 27.31 
(3 CH3), 25.76 (C-3º), 24.76 (C-4º), 23.44, 20.75. HR-MS: Calculated for C54H70N6O11Si [M+NH4]
+: 1024.52101, found: 
1024.52157. 
Synthesis of disaccharide 33: Compound 32 (1.16 g, 1.15 mmol) was dissoveld in THF 
(11 mL) in a round flusk. Then HF-pyridine (300 μL) was added in the solution. The 
reaction stirred until TLC-analysis indicated full consumption of the starting material 
(30 min). Then the mixture was diluted with DCM and the reaction quenched with 
saturated NaHCO3. The organic phase was washed with water and brine, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude compound 28 was dissloved in CH3CN. The product 
was purified by silica gel column chromatography. Compound 33 (910 mg, 91% yield) was obtained as a colorless syrup. 
[α]D
20 +80.6 (c=1, CHCl3). IR (neat, cm
-1) ν 698, 738, 1040, 1145, 1262, 1354, 1455, 1733 (C=O), 2106 (N3), 2872, 2932, 
3461. 1H-NMR (CDCl3, 400 MHz) δ 7.38-7.25 (m, 20 H, aromatic H), 5.65 (d, J = 3.6 Hz, 1 H, H-1b), 5.12 (s, 1 H, 
PhCH2), 4.97 (d, J = 10.4 Hz, 1 H, CHH), 4.92 (d, J = 3.6 Hz, 1 H, H-1a), 4.88 (d, J = 10.4 Hz, 1 H, CHH), 4.67-4.54 (m, 
4 H, 4 CHH), 4.05 (dd, J1 = 10.0 Hz, J2 = 8.4 Hz, 1 H, H-3a), 3.91-3.80 (m, 2 H, H-4a, H-5), 3.74-3.57 (m, 8 H), 3.51-
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3.44 (m, 1 H, H-1ºb), 3.31 (dd, J1 = 10.0 Hz, J2 = 3.6 Hz, 1 H, H-2a), 2.65 (s, 1 H, OH), 2.39 (t, J = 7.6 Hz, 2H, H-5
o), 
2.29 (s, 1 H, OH), 1.74-1.64 (m, 4 H, H-2º, H-4º), 1.47-1.40 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.58 (C=O), 
138.10, 137.79, 137.10, 136.12 (aromatic C), 128.81, 128.66, 128.57, 128.53, 128.42, 128.31, 128.29, 128.06, 127.88, 
127.80, 127.75 (aromatic CH), 97.85 (C-1b), 97.70 (C-1a), 80.77 (C-3a), 76.13 (C-3b), 74.48 (PhCH2), 73.81 (c-4a), 
73.69 (PhCH2), 71.89 (PhCH2), 70.28 (c-5b), 70.21 (C-5a), 69.06 (C-6), 68.27 (C-1º), 67.20 (C-4b), 66.27 (PhCH2), 63.78 
(C-2a), 62.93 (C-6), 58.83 (C-2b), 34.26 (C-5º), 29.15 (C-2º), 25.75 (C-3º), 24.76 (C-4º). HR-MS: Calculated for 
C46H54N6O11 [M+NH4]
+: 884.41888, found: 884.41942. 
Synthesis of tetrasaccharide 34: The reaction was carried out according to the 
standard procedure A. A mixture of donor 26 (520 mg, 0.49 mmol), acceptor 27 
(238 mg, 0.25 mmol) (donors and acceptors co-evaporated with toluene three 
times), MPF (490 μL) in dry DCM (1 mL) were stirred over fresh flame-dried 
molecular sieves 3A under nitrogen. The solution was cooled to -78 ℃, after which 
TfOH (40 μL) was added. After 30 min, the reaction was stirred at -10 ℃ until TLC-analysis showed complete conversion 
of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The product was purified by 
size exclusion (DCM:MeOH = 1:1). Compound 34 (280 mg, 89%, α:β = 10:1) was obtained as a colorless syrup. IR (neat, 
cm-1) ν 697, 736, 1028, 1096, 1258, 1319, 1356, 1454, 1497, 1731 (C=O), 2105 (N3), 2868, 2925. 
1H-NMR (CDCl3, 400 
MHz) δ 7.77-7.69 (m, 3 H, aromatic H), 7.60 (bs, 1 H, aromatic H), 7.42-7.17 (m, 48 H, aromatic H), 5.73 (d, J = 3.6 Hz, 
1 H, H-1d), 5.65 (d, J = 3.6 Hz, 1 H, H-1b), 5.10 (s, 1 H, PhCH2), 4.96-4.90 (m, 7 H), 4.74-4.48 (m, 7 H), 4.36-3.61 (m, 
22 H), 3.51-3.26 (m, 6 H), 3.20 (d, J = 10.0 Hz, 1 H), 3.03 (d, J = 10.0 Hz, 1 H), 2.36 (t, J = 7.6 Hz, 2H, H-5o), 1.71-1.61 
(m, 4 H, H-2º, H-4º), 1.45-1.37 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.38 (C=O), 138.42, 138.22, 137.70, 
137.68, 137.58, 137.54, 137.47, 136.07, 135.61, 133.14, 133.01 (aromatic C), 128.56, 128.50, 128.40, 128.38, 128.35, 
128.27, 128.25, 128.18, 128.11, 128.07, 128.00, 127.92, 127.88, 127.86, 127.78, 127.76, 127.66, 127.59, 127.41, 127.30, 
127.08, 127.01, 126.39, 126.02, 125.90 (aromatic CH), 98.74 (C-1), 98.14 (C-1), 97.75 (C-1), 97.65 (C-1), 80.97 (C-3), 
80.65 (C-3), 76.82 (C-3), 75.11 (C-3), 74.86, 74.53, 74.42 (CH2), 73.47 (C-4), 73.45, 73.32 (CH2), 73.18 (C-4), 72.86 (C-
4), 72.82 (C-4), 72.77, 72.24, 71.66 (CH2), 70.58 (C-5), 70.07 (C-5), 69.87 (C-5), 69.83 (C-5), 69.20, 68.38, 68.12, 67.87, 
66.80, 66.11 (CH2), 64.70 (C-2), 63.70 (C-2), 59.54 (C-2), 59.41 (C-2), 34.13 (C-5º), 29.04 (C-2º), 25.64 (C-3º), 24.65 
(C-4º). HR-MS: Calculated for C104H110N12O19 [M+NH4]
+: 1848.83484, found: 1848.83541. 
Synthesis of tetrasaccharide acceptor 35: The reaction was carried out according to 
the standard procedure C. Compound 34 (700 mg, 0.38 mmol) was dissolved in 
DCM:HFIP (1:1, 0.1 M). TES (304 μL, 1.91 mmol) and 0.2M HCl/HFIP (1.9 mL) 
were added to the mixture. The reaction stirred until TLC-analysis indicated full 
consumption of the starting material (15min). Then the mixture was diluted with 
DCM and the reaction quenched with saturated NaHCO3. The organic phase was washed with water and brine, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. The product was purified by silica gel column chromatography. 
Compound 35 (297mg, 73% yield) was obtained as a colorless syrup. [α]D
20 +106.7 (c=1, CHCl3). IR (neat, cm
-1) ν 696, 
737, 1040, 1100, 1261, 1454, 1735 (C=O), 2106 (N3), 2869, 2926. 
1H-NMR (CDCl3, 500 MHz) δ 7.42-7.17 (m, 45 H, 
aromatic H), 5.71 (d, J = 3.5 Hz, 1 H, H-1d), 5.65 (d, J = 3.5 Hz, 1 H, H-1b), 5.10 (s, 1 H, PhCH2), 4.95-4.89 (m, 6 H, H-
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1a, H-1c, 4 CHH), 4.72 (d, J = 12.0 Hz, 1 H, CHH), 4.68 (s, 2 H, 2 CHH), 4.57-4.48 (m, 3 H), 4.36-4.17 (m, 7 H), 4.09-
3.58 (m, 17 H), 3.51-3.30 (m, 3 H), 3.36-3.30 (m, 3 H), 3.91-3.44 (m, 12 H), 3.17 (dd, J1 = 11.5 Hz, J2 = 2.5 Hz, 1 H), 
3.02 (dd, J1 = 11.5 Hz, J2 = 2.5 Hz, 1 H), 2.66 (s, 1 H, OH), 2.37 (t, J = 7.5 Hz, 2H, H-5
o), 1.71-1.63 (m, 4 H, H-2º, H-
4º), 1.45-1.39 (m, 2 H, H-3º). 13C-APT (CDCl3, 125 MHz) δ 173.54 (C=O), 138.46, 138.32, 137.84, 137.70, 137.68, 
137.56, 137.44, 136.17 (aromatic C), 128.77, 128.67, 128.61, 128.60, 128.48, 128.30, 128.22, 128.18, 128.04, 127.93, 
127.89, 127.86, 127.81, 127.72, 127.69, 127.51, 127.48, 127.34, 127.19 (aromatic CH), 98.75 (C-1), 98.06 (C-1), 97.87 
(C-1), 97.76 (C-1), 80.92 (C-3), 80.75 (C-3), 76.11 (C-3), 75.75 (C-3), 74.54, 74.46, 73.68 (CH2), 73.58 (C-4), 73.56, 
73.44 (CH2), 73.14 (2 C-4), 73.07 71.82, 71.75 (CH2), 70.66 (C-4), 70.18 (C-5), 69.94 (C-5), 69.30, 69.14 (CH2), 68.80 
(C-5), 68.51, 68.25, 68.90 (CH2), 66.52 (C-5), 66.25 (PhCH2), 64.71 (C-2), 63.82 (C-2), 59.64 (C-2), 58.75 (C-2), 34.27 
(C-5º), 29.15 (C-2º), 25.75 (C-3º), 24.77 (C-4º). HR-MS: Calculated for C93H102N12O19 [M+NH4]
+: 1708.77224, found: 
1708.77299. 
Synthesis of hexasaccharide 36: The reaction was carried out according to the 
standard procedure A. A mixture of donor 26 (540 mg, 0.5 mmol), acceptor 35 
(360 mg, 0.21 mmol) (donors and acceptors co-evaporated with toluene three 
times), MPF (400 μL) in dry DCM (1 mL) were stirred over fresh flame-dried 
molecular sieves 3A under nitrogen. The solution was cooled to -78 ℃, after which 
TfOH (44 μL) was added. After 30 min, the reaction was stirred at -10 ℃ until 
TLC-analysis showed complete conversion of the acceptor (48 h). The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The product was purified by size exclusion (DCM:MeOH = 1:1). Compound 36 (500 mg, 91%, 
α:β = 10:1) was obtained as a colorless syrup. [α]D
20 +123.0 (c=1, CHCl3). IR (neat, cm
-1) ν 697, 736, 1039, 1099, 1261, 
1319, 1359, 1454, 1734 (C=O), 2106 (N3), 2870, 2926. 
1H-NMR (CDCl3, 400 MHz) δ 7.77-7.69 (m, 3 H, aromatic H), 
7.60 (bs, 1 H, aromatic H), 7.44-7.07 (m, 68 H, aromatic H), 5.73 (d, J = 3.6 Hz, 1 H, H-1), 5.71 (d, J = 3.2 Hz, 1 H, H-
1), 5.65 (d, J = 3.6 Hz, 1 H, H-1), 5.09 (s, 1 H, PhCH2), 4.96-4.91 (m, 9 H), 4.77-4.65 (m, 5 H), 4.58-4.48 (m, 4 H), 4.33-
3.62 (m, 37 H), 3.52-3.16 (m, 10 H), 3.05 (d, J = 10.0 Hz, 1 H), 2.99 (d, J = 10.0 Hz, 1 H), 2.36 (t, J = 7.6 Hz, 2H, H-5o), 
1.71-1.61 (m, 4 H, H-2º, H-4º), 1.45-1.37 (m, 2 H, H-3º). 13C-APT (CDCl3, 100 MHz) δ 173.40 (C=O), 138.46, 138.38, 
138.22, 137.70, 137.66, 137.61, 137.59, 137.57, 137.49, 137.45, 136.07, 135.66, 133.15, 133.02 (aromatic C), 128.56, 
128.52, 128.49, 128.48, 128.45, 128.39, 128.36, 128.28, 128.19, 128.10, 128.05, 128.01, 127.98, 127.94, 127.90, 127.86, 
127.82, 127.78, 127.77, 127.72, 127.67, 127.60, 127.42, 127.35, 127.31, 127.12, 127.11, 127.03, 127.00126.40, 126.02, 
125.90 (aromatic CH), 98.78 (C-1), 98.69 (C-1), 98.09 (C-1), 97.89 (C-1), 97.78 (C-1), 97.65 (C-1), 80.98 (C-3), 80.80 
(C-3), 80.67 (C-3), 76.93 (C-3), 76.10 (C-3), 75.67 (C-3), 74.88, 74.50, 74.40, 73.45, 73.33 (CH2), 73.26 (C-4), 73.22 (C-
4), 72.95 (CH2), 72.83 (C-4), 72.80 (CH2), 72.72 (C-4), 72.22, 71.88, 71.70 (CH2), 70.62 (C-5), 70.52 (C-5), 70.08 (C-5), 
69.85 (C-5), 69.80 (C-5), 69.60 (C-5), 69.21, 68.34, 68.13, 67.85, 66.82, 66.48, 66.12 (CH2), 64.70 (2 C-2), 63.71 (C-2), 
59.52 (C-2), 59.47 (C-2), 59.37 (C-2), 34.15 (C-5º), 29.05 (C-2º), 25.65 (C-3º), 24.66 (C-4º).  
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Synthesis of hexasaccharide 24: Compound 36 (20 mg, 0.0054 mmol) was dissolved 
in THF/H2O/tert-BuOH (2 mL/2 mL/1 mL) before a catalytic amount of Pd(OH)2/C 
was added. The reaction mixture was stirred for 3 days under a H2 atmosphere, filtered 
and concentrated in vacuo. A white powder 2 was obtained, which was purified by gel 
filtration (HW-40, 0.15M NH4OAc in H2O) to yield 1 (2 mg, 76%). 
1H-NMR (CDCl3, 
500 MHz) δ 5.40-5.35 (m, 3 H, 3 H-1), 4.85-4.81 (m, 3 H, 3 H-1), 4.13-4.06 (m, 2 H), 
3.97-3.50 (m, 35 H), 3.41-3.37 (m, 1 H), 3.15-3.08 (m, 2 H), 2.81 (dd, 2 H), 2.72-2.70 (m, 2 H), 2.06 (t, 2 H), 1.55-1.43 
(m, 5 H), 1.29-1.23 (m, 2 H). 13C-APT (CDCl3, 125 MHz) δ 99.56 (C-1), 99.50 (C-1), 99.45 (C-1), 99.22 (2 C-1), 97.44 
(C-1), 76.85, 76.66, 76.56, 76.27, 73.74, 73.33, 72.37, 72.32, 71.93, 71.14, 71.03, 70.51, 69.16, 68.81, 68.36, 68.29, 61.19, 
60.57, 60.36, 55.30, 55.29, 54.60, 51.11, 51.05, 50.95, 37.48, 28.34, 25.56, 25.43. HR-MS: Calculated for C42H78N6O27 
[M+2H+]/2: 550.25302; found: 550.25247. 
Synthesis of hexasaccharide 25: Compound 24 was dissoled in H2O. Then Ac2O and 
NaHCO3 were added in the solution. The reaction mixture was stirred for 3 days until 
TLC-analysis showed complete conversion of the acceptor. 1H-NMR (CDCl3, 500 
MHz) δ 5.36-5.34 (m, 4 H, 4 H-1), 5.27 (d, J = 4.0 Hz, 1 H, H-1), 4.79 (bt, 2 H, 2 H-
1), 4.73 (d, J = 3.0 Hz, 1 H, H-1), 4.21-4.06 (m, 5 H), 3.97-3.57 (m, 37 H), 3.40-3.35 
(m, 1 H), 2.24 (bt, 2 H), 1.97-1.91 (m, 18 H, 6 CH3), 1.80-1.74 (m, 2 H), 1.54-1.46 
(m, 4 H), 1.32-1.26 (m, 2 H). 13C-APT (CDCl3, 125 MHz) δ 180.21, 174.70, 174.69, 174.63, 174.54, 174.46 (6 C=O), 
98.22, 98.15, 96.62 (6 C-1), 77.37, 77.23, 76.10, 75.69, 75.41, 72.45, 72.40, 71.84, 71.66, 71.28, 71.15, 70.74, 70.70, 
70.39, 68.45, 68.07, 67.86, 67.58, 66.92, 61.61, 60.66, 60.31, 60.04, 54.44, 54.15, 49.93, 34.64, 28.16, 25.03, 24.38, 22.07 
(CH3), 22.03 (CH3), 22.02 (CH3), 21.92 (CH3), 21.88 (2 CH3). HR-MS: Calculated for C54H90O33N6 [M+2H
+]/2: 
676.28472; found: 676.28489. 
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Chapter 7 
Summary and Future Prospects 
Summary 
The stereoselective synthesis of glycosidic bonds is a very challenge task and there is no general 
solution for the construction of demanding glycosidic bonds, such as 1,2-cis linkages and linkages 
of 2-deoxy sugars.[1] It is tremendously difficult to design a general glycosylation strategy that 
can accommodate the varying reactivity of different donor-acceptor glycoside combinations and 
ensures a fully stereoselective glycosylation process. The introduction of nucleophilic additives 
to modulate the glycosylation reaction has been an important step forwards in this direction, as 
this opens the way to match donor and acceptor reactivity.[2] It may enable a glycosylation strategy 
that employs a single donor type, devoid of any stereodirecting protecting groups and is under 
full control of the used reagents.[3]  
To this end, this Thesis describes a strategy to synthesize 1,2-cis-oligosaccharides modulated by 
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additives, such as dimethylformamide (DMF), triphenylphosphine oxide (Ph3P=O) and N-
methyl(phenyl)formamide (MPF), using building blocks that carry solely benzyl type protecting 
groups and are therefore of uniform reactivity. These three additives were used for different 
classes of donor-acceptor combinations. The additive DMF was mainly used to modulate 
glycosylations of per-benzylated glucosyl donors and secondary alcohol acceptors. The TMSI-
Ph3P=O condition was used to glycosylate the more reactive primary alcohol acceptors. The MPF 
additive, which forms less stable anomeric imidinium ion intermediates than DMF, was used for 
donors that are somewhat less reactive, such as those in the 2-azido-2deoxy series. 
Chapter 1 provides an overview of the development of additive mediated glycosylations. Several 
additives (DMF, phosphine oxides, tetraalkyl ammonium halides) have been well studied on a 
broad scope of substrates and in a number of applications in oligosaccharide syntheses. 
Mechanistic studies have provided proof that the intermediate adducts of the additive and 
glycosyl donor play a key role in the glycosylation mechanism. Notwithstanding the initial 
successes described in Chapter 1, there still is a great demand to develop new additives and 
strategies using these reactivity modulators for the selective construction of glycosidic bonds and 
use assembly of complex and branched oligosaccharides. 
Chapter 2 describes an additive controlled glycosylation strategy to assemble branched α-
glucans (see Figure 1).[3a] The synthetic strategy builds on the use of DMF and TMSI-Ph3P=O 
controlled glycosylation reactions and the use of one single benzyl type protecting group (Bn, 
PMB, Nap). To illustrate the applicability of the strategy, a linear α-(1,4)-hexasaccharide and a 
branched α-glucan from Mycobacterium tuberculosis were assembled (Figure 1). Encouraged by 
these results, a linear α-(1,3)-glucan from the pathogenic fungus Aspergillus fumigatus was 
assembled in a fully stereoselective manner as described in Chapter 3.[3b]  
Chapter 4 further explores the methodology for the synthesis of α-(1,2)-glucans. It was observed 
that DMF-mediated glycosylations proceeded with excellent stereoselectivity to forge α-(1,2)-
glucosyl linkages of short oligosaccharides, but the construction of longer kojioligosaccharides 
was confronted with erosion of stereoselectivity, indicating a limitation of the methodology. 
Likely, the secondary structure of the larger oligosaccharide acceptors led to the decrease in 
stereoselectivity. A kojitetrasaccharide and a D-Alanine containing kojibiose glycerol phosphate 
teichoic acid building block to enable the assembly of Enterococcus faecalis LTAs, were 
synthesized (see Figure 1). 
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Figure 1. Target molecules assembled in Chapters 2, 3 and 4. 
After the successful formation of α-glucosides, the formation of α-galactosides received attention 
in Chapter 5 (see Figure 2). The stereoselective construction of the α-(1,4)-galactosides proved 
especially challenging. After screening different additives, the combination of TMSI-Ph3P=O at 
higher temperature proved effective to construct the challenging galactose-α-(1,4)-galactose 
linkage. It was also shown that the TMSI-Ph3P=O conditions can be applied to a wider substrate 
scope.  
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Figure 2. Glycosylations using the TMSI-Ph3P=O conditions developed in Chapter 5. 
A new additive, MPF, was introduced in Chapter 6 (Figure 3) for the glycosylation 2-azido-2-
deoxy building blocks, which are less reactive than their 2-O-benzyl counterparts. A linear α-
(1,4)-glucosamine tetrasaccharide was assembled to prove the utility of MPF. Next, a linear Pel 
hexasaccharide was assembled using a [2+2+2] strategy modulated by MPF. The used 
[galactosazide-α-(1,4)-glucosazide] disaccharide building blocks were synthesized using a 4,6-
O-DTBS protected galactosyl azide donor. 
 
Figure 3. Assembly of Pel fragment. 
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Future Prospects 
In additive-controlled glycosylation reactions, it has been shown that the intermediate adducts of 
the activated glycosyl donors and additives play a key role in the glycosylation mechanism and 
the reactivity of the glycosyl adducts is all important for the outcome of the glycosylation 
reactions.[4] The proposed mechanism for additive controlled glycosylations is depicted in 
Scheme 1. In this mechanism, the pool of reactive intermediates, initially formed by activation of 
the parent donor, is trapped by the nucleophilic additive to provide a mixture of α- and β-linked 
covalent additive-glycosyl donor species. Of these the more reactive β-adduct is displaced more 
rapidly which can lead to an overall α-selective glycosylation reaction. Judicious tuning of the 
reactivity of the reactive adducts is important to enable the stereoselective generation the α-linked 
products. Although spectroscopic evidence has been forwarded for the existence of the covalent 
additive-glycosyl donor adducts, detailed kinetic studies underpinning the reaction mechanism 
are missing to date.  
 
Scheme 1. The proposed reaction mechanism of additive controlled glycosylation reactions. 
To determine where the reaction mechanism lies along the SN2-SN1 continuum and how it shifts 
with changing donor structure and variation of the additive, kinetic isotope effects (KIE) can be 
studied. This technique has recently been used for a selection of glycosylation reactions, including 
the β-mannosylations and α-glucosylations developed by Crich and co-workers using 
benzylidene protected donors, [1c] the organocatalyzed glycosylations of Jacobsen [5] and the 
anionic glycosylation reactions of Bennett and co-workers [6]. The evaluation of KIEs (both 
primary 12C/13C and secondary 1H/2H effects) in a systematic series of glycosylations in which 
either the reactivity of the donor, acceptor or additive is gradually changed will provide insight 
into the origin of the stereoselectivity (or lack thereof) in these glycosylation reactions. This will 
be instructive in the future development of rationally designed additive controlled glycosylation 
reactions.  
Table 1 shows how the stereoselectivity of a per-O-benzylated glucosyl donor developed with 
gradually changing nucleophilicity of the acceptor (decreasing going from ethanol to 
monofluorethanol to difluroethanol to trifluoroethanol) for DMF-mediated and TMSI-Ph3P=O 
promoted glycosylations. The intermediate glycosyl adduct formed from TMSI-Ph3P=O is less 
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reactive than that formed under DMF-modulation. In line with the results described above, the 
less reactive TMSI-Ph3P=O conditions always gave a higher α-selectivity than the DMF-
mediated conditions but at the expense of a lower yield. The α-selectivity is increasing for both 
sets of glycosylations from ethanol to trifluoroethanol (entry 1-4, Table 1). This clearly shows the 
influence of the reactivity of the substrates on the outcome of these glycosylations. Using this set 
of acceptors to measure KIEs and establish whether and how fast the mechanism changes with 
changing nucleophilicity will underpin the limitation and substrate scope for the studied additives.   
Table 1. The influence of acceptor reactivity in glycosylations of per-O-benzylated glucosyl 
donor. 
 
Entry ROH Product 
Yield % α:β 
a b a b 
1 ethanol 27 quant quant 2.7:1 4:1 
2  28 61 42 3.5:1 5.5:1 
3 
 
29 75 73 6.7:1 15:1 
4 
 
30 62 80 13:1 18:1 
5 
 
31 94 61 >20:1 >20:1 
In Chapter 6, a new additive, MPF, is preselected for condensations of 2-azido-2-deoxy glucosyl 
donors. Although this additive was successfully used to assemble an oligo glucosamine and Pel 
oligosaccharide, Table 2 shows that the substrate scope of this method is quite narrow. The 
selectivity is significantly better for the C4-OH azidoglucose acceptor 33 and galactose acceptor 
35 than their C3-OH counterparts 34 and 36 (entry 1-2 and 3-4, Table 2). A similar trend is 
revealed for the C4-OH and C3-OH glucose and galactose acceptors (11 and 12 and 8 and 9, 
respectively). Likely this is the result of the reactivity of the MPF imidinium ion, which is too 
reactive for the C3-OH acceptors, which are more reactive than their C4-OH counterparts. For 
the more reactive acceptors the less reactive N-formylmorfoline (NMF) introduced by Mong and 
co-workers can be explored.[7] A systematic study in which these additives and DMF are 
compared side-by-side will inform on the scope and limitations of these additives. It will also be 
of interest to map how the stereoselectivity of these systems changes with varying protecting 
group pattern. The use of acyl groups is commonplace to ensure the formation of 1,2-trans-
Summary and Future Prospects  
161 
linkages. The electron-withdrawing capacity of these groups will have an effect on the reactivity 
of neighboring alcohol groups. 
Table 2. Glycosylation of 2-azido donor 32 under MPF conditions. 
 
Entry ROH product yield α:β 
1 33 37 90% 16:1 
2 34 38 78% 8:1 
3 35 39 57% 5:1 
4 36 40 63%, 2:1 
5 11 41 97% 10:1 
6 12 42 92% 3:1 
7 8 43 99% 5:1 
8 9 44 99% 1.2:1 
The synthesis of β-mannosides is an extremely challenging task because of the axially oriented 
substituent at the C2 of the donor. Several successful attempts have been reported to form β-
mannosides, including Crich’s benzylidene mannose system[8], Demchenko’s hydrogen bond 
guided β-mannosylation strategy,[9] the use of mannuronic acids, and intramolecular aglycon 
delivery (IAD) systems. An additive controlled glycosylation would offer an even more direct 
way to construct these challenging linkages. The synthesis of 1,2-cis-mannosides is completely 
different to 1,2-cis-glucosides because an equatorial β-glycosic bond needs to be formed instead 
of an axial α-bond. The glycosylation of per-benzyl mannosyl donor 45 was explored using both 
DMF and MPF mediated conditions. As shown in Scheme 2, the selectivity of both systems is 
poor, with the less reactive DMF system performing better than the more reactive MPF one. 
Therefore, new additives need be found from the “toolbox” by further studying of the relationship 
of the reactivity of the additives and the stereochemistry of this glycosylation reaction.  
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a) quant, α:β = 2:1. b) quant, α:β = 5:1. 
Scheme 2. Explorative glycosylations of mannosyl donor 45. 
Finally, the scope of the additives, described in this Thesis, should be explored further using 
various other donor glycosides, including deoxy systems (which can be found on the reactivity 
side of the spectrum) and glycuronic acids (on the low reactivity side of the spectrum). Relevant 
examples include fucosylations, rhamnosylations and xylosylations but also C2-deoxy systems 
such as found in various medically relevant bacterial glycosides and glycoconjugates (e.g. 
doxorubicin, aclarubicin and digitoxin). 
Experimental Section 
General experimental procedures 
All reagents were of commercial grade and used as received. All moisture sensitive reactions were performed under an 
argon atmosphere. DCM used in the glycosylation reactions was dried with flamed 4Å molecular sieves before being 
used. Reactions were monitored by TLC analysis with detection by UV (254 nm) and where applicable by spraying with 
20% sulfuric acid in EtOH or with a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% 
sulfuric acid (aq.) followed by charring at ~150 °C. Column chromatography was carried out using silica gel (0.040-0.063 
mm). Size-exclusion chromatography was carried out using Sephadex LH-20. 1H and 13C spectra were recorded on a 
Bruker AV 400 and Bruker AV 500 in CDCl3 or D2O. Chemical shifts (δ) are given in ppm relative to tetramethylsilane 
as internal standard (1H NMR in CDCl3) or the residual signal of the deuterated solvent. Coupling constants (J) are given 
in Hz. All 13C spectra are proton decoupled. NMR peak assignments were made using COSY and HSQC experiments, 
where applicable Clean TOCSY, HMBC and GATED experiments were used to further elucidate the structure. The 
anomeric product ratios were analyzed through integration of proton NMR signals and HPLC. HPLC analysis was 
performed over chiralpak AD column (0.46cmΦ×25cm) and eluted with hexane/isopropanol (95/5) mixture at a 1 mL/min 
flow rate and UV 254nm detector. 
Standard procedure 
Procedure A for the glycosylation of secondary alcohols: 
A mixture of donor (1.0 eq), acceptor (0.7 eq) (donors and acceptors co-evaporated with toluene three times), DMF (16 
eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. The solution was cooled to -
78 ℃, after which TfOH (1.0 eq) was added. After 30 min, the reaction was stirred at 0 or -10 ℃ until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The products were purified by size exclusion and silica gel column chromatography. 
Procedure B for the glycosylation of primary alcohols: 
A mixture of donor (1.0 eq), acceptor (0.7 eq) (donors and acceptors co-evaporated with toluene three times), Ph3P=O (6 
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eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. Then TMSI (1.0 eq) was added 
slowly in the mixture. The reaction was stirred at room temperature until TLC-analysis indicated the reaction to be 
complete. The solution was diluted and the reaction quenched with saturated Na2S2O3. The organic phase was washed 
with water and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The products were purified by 
size exclusion and silica gel column chromatography. 
Procedure C for the glycosylation of secondary alcohols: 
A mixture of donor (1.0 eq), acceptor (0.7 eq) (donors and acceptors co-evaporated with toluene three times), MPF (16 
eq) in dry DCM were stirred over fresh flame-dried molecular sieves 3A under nitrogen. The solution was cooled to -
78 ℃, after which TfOH (1.0 eq) was added. After 30 min, the reaction was stirred at 0 or -10 ℃ until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The products were purified by size exclusion. 
Experimental Procedures and Characterization Data of Products 
For the synthesis procedure and data of known compounds 6, 31, 32, 33, 35 see previous Chapter 2 and 6and 27[10], 44[11], 
46[12] see references. 
Synthesis of 27: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 6 (70 mg, 0.1 mmol, 0.1 M in DCM), ethanol (11 μL, 0.2 mmol), DMF (124 
μL) and TfOH (10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed 
complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The 
product was purified by silica gel column chromatography. Compound 27 (quant, α:β = 2.7:1) was obtained as a colorless 
syrup. Under condition B, using 6 (80 mg, 0.11 mmol, 0.1 M in DCM), ethanol (13 μL, 0.22 mmol), Ph3P=O (185 mg, 
0.66 mmol) and TMSI (15 μL, 0.11 mmol). The product was purified by silica gel column chromatography. Compound 
27 (quant, α:β > 4:1) was obtained as a colorless syrup. 
Synthesis of 28: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 6 (70 mg, 0.1 mmol, 0.1 M in DCM), 2-fluoroethanol (11 μL, 0.2 mmol), DMF 
(124 μL) and TfOH (10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. 
The product was purified by silica gel column chromatography. Compound 28 (35 mg, 61% yield, α:β = 3.5:1) was 
obtained as a colorless syrup. Under condition B, using 6 (80 mg, 0.11 mmol, 0.1 M in DCM), 2-fluoroethanol (13 μL, 
0.22 mmol), Ph3P=O (185 mg, 0.66 mmol) and TMSI (15 μL, 0.11 mmol). The product was purified by silica gel column 
chromatography. Compound 28 (27 mg, 42% yield, α:β > 5.5:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 
MHz) δ 7.37-7.11 (m, 20 H, a romatic H), 5.00 (d, J = 10.8 Hz, 1 H, CHH), 4.84-4.77 (m, 4 H), 4.67-4.59 (m, 3 H), 4.55-
4.50 (m, 1 H), 4.48-4.44 (m, 2 H), 4.00 (t, J = 9.6 Hz, 1 H), 3.90-3.56 (m, 7 H). 13C-APT (CDCl3, 100 MHz,) δ 138.95, 
138.32, 137.99 (aromatic C), 128.60, 128.53, 128.50, 128.27, 128.08, 128.06, 128.05, 127.84, 127.73 (aromatic CH), 
97.47, 83.50, 82.08, 81.81, 80.00, 77.68, 75.90, 75.23, 73.58, 73.42, 70.31, 68.48, 67.08 (d, FCH2). 
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Synthesis of 29: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 6 (70 mg, 0.1 mmol, 0.1 M in DCM), 2-difluoroethanol (11 μL, 0.2 mmol), 
DMF (124 μL) and TfOH (10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in 
vacuo. The product was purified by silica gel column chromatography. Compound 29 (45 mg, 75% yield, α:β = 6.7:1) 
was obtained as a colorless syrup. Under condition B, using 6 (80 mg, 0.11 mmol, 0.1 M in DCM), 2-difluoroethanol (13 
μL, 0.22 mmol), Ph3P=O (185 mg, 0.66 mmol) and TMSI (15 μL, 0.11 mmol). The product was purified by silica gel 
column chromatography. Compound 29 (50 mg, 73 % yield, α:β > 15:1) was obtained as a colorless syrup. 1H-NMR 
(CDCl3, 400 MHz) δ 7.34-7.11 (m, 20 H, aromatic H), 6.10-5.81 (m, 1 H, F2CH), 4.98 (d, J = 10.8 Hz, 1 H, CHH), 4.84-
4.75 (m, 4 H), 4.64-4.58 (m, 2 H), 4.48-4.44 (m, 2 H), 3.96 (t, J = 9.2 Hz, 1 H), 3.80-3.56 (m, 7 H). 13C-APT (CDCl3, 100 
MHz,) δ 138.80, 138.17, 138.14, 137.85 (aromatic C), 128.64, 128.53, 128.51, 128.24, 128.16, 128.03, 127.88, 127.76 
(aromatic CH), 114.19 (t, F2CH), 98.09, 81.85, 79.86, 77.46, 75.91, 75.26, 73.61, 73.59, 70.71, 68.31, 67.29 (t, F2CHCH2). 
Synthesis of 30: The reaction was carried out according to the standard procedure A or B. Under 
condition A, using 6 (70 mg, 0.1 mmol, 0.1 M in DCM), 2-trifluoroethanol (11 μL, 0.2 mmol), 
DMF (124 μL) and TfOH (10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-
analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in 
vacuo. The product was purified by silica gel column chromatography. Compound 30 (38 mg, 62% yield, α:β = 13:1) was 
obtained as a colorless syrup. Under condition B, using 6 (80 mg, 0.11 mmol, 0.1 M in DCM), 2-trifluoroethanol (13 μL, 
0.11 mmol), Ph3P=O (185 mg, 0.66 mmol) and TMSI (15 μL, 0.11 mmol). The product was purified by silica gel column 
chromatography. Compound 30 (56 mg, 80% yield, α:β > 18:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 
MHz) δ 7.36-7.11 (m, 20 H, aromatic H), 4.98 (d, J = 10.8 Hz, 1 H, CHH), 4.84-4.77 (m, 4 H), 4.64-4.58 (m, 2 H), 4.48-
4.44 (m, 2 H), 3.98 (t, J = 9.2 Hz, 1 H), 3.91-3.85 (m, 2 H), 3.77-3.57 (m, 5 H). 13C-APT (CDCl3, 100 MHz,) δ 138.81, 
138.15, 137.83 (aromatic C), 128.61, 128.52, 128.20, 128.11, 128.05, 128.04, 127.90, 127.76 (aromatic CH), 123.76 (q, 
F2CH), 97.92, 81.68, 79.76, 75.90, 75.29, 73.61, 73.45, 71.00, 68.21, 64.80 (q, F2CHCH2). 
Synthesis of 34 
 
Donor S1 (1200 mg, 1.7 mmol), isopropanol (265 μL, 3.4 mmol) and Ph3P=O (2.8 g) were dissolved in DCM, and TMSI 
(250 μL, 1.7 mmol) was added at room temperature. The reaction was stirred at rt until TLC-analysis showed complete 
conversion of the donor. The reaction was quenched with Et3N after completed checking by TLC, filtered and 
concentrated in vacuo. The product was purified by silica gel column chromatography. Compound S2 was obtained with 
α:β = 5:1. Next compound S2 (700 mg, 1.2 mmol) was dissolved in DCM (0.1 M), and then DDQ (300 mg) was added 
in the solution. The reaction was stirred at rt until TLC-analysis showed complete conversion of the starting material. The 
reaction was quenched with saturated Na2S2O3 after completed checking by TLC, filtered and concentrated in vacuo, 
purified by column chromatography. Compound 34 (660 g, 80% yield) was obtained as colorless syrup. 1H-NMR (CDCl3, 
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400 MHz) δ 7.36-7.21 (m, 10 H, aromatic H), 5.02 (d, J = 3.6 Hz, 1 H, H-1a), 4.71 (d, J = 11.2 Hz, 1 H, CHH), 4.66 (d, 
J = 12.0 Hz, 1 H, CHH), 4.56 (d, J = 11.2 Hz, 1 H, CHH), 4.50 (d, J = 12.0 Hz, 1 H, CHH), 4.10 (t, J = 10.4 Hz, 1 H, H-
3a), 3.93-3.84 (m, 2 H, H-5a, H-1º), 3.78 (dd, 1 H, J1 = 10.8 Hz, J2 = 3.6 Hz, H-6aa), 3.65 (dd, 1 H, J1 = 10.8 Hz, J2 = 3.6 
Hz, H-6ab), 3.58 (t, 1 H, J1 = 10.4 Hz, J2 = 3.6 Hz, H-4a), 3.13 (dd, 1 H, J1 = 10.4 Hz, J2 = 3.6 Hz, H-2a), 2.63 (bs, 1 H, 
OH), 1.21 (d, J = 8.4 Hz, 3 H, CH3), 1.20 (d, J = 8.4 Hz, 3 H, CH3). 
13C-APT (CDCl3, 100 MHz,) δ 138.12, 137.84 
(aromatic C), 128.65, 128.47, 128.06, 128.03, 127.86 (aromatic CH), 96.41 (C-1a), 78.52 (C-4a), 74.98, 73.62 (CH2), 
71.75 (C-3a), 71.00 (C-1º), 70.32 (C-5a), 68.39 (C-6a), 62.78 (C-2a), 23.29 (CH3), 21.59 (CH3). 
Synthesis of 36 
 
Donor S3 (855 mg, 1.3 mmol) and isopropanol (150 mg, 2.5 mmol) were dissolved in DCM, cooled to 0 oC and TfOH 
(11.5 μL, 0.13 mmol) was added. The reaction was stirred at 0 ℃ until TLC-analysis showed complete conversion of the 
donor. The reaction was quenched with Et3N after completed checking by TLC, filtered and concentrated in vacuo. 
Compound S4 (500 mg, 73%) was obtained with full α-selectivity. Then compound S4 (500 mg, 0.95 mmol) was 
dissolved in THF. HF-pyridine (10 eq) was added to the solution. After TLC-analysis showed complete consumption of 
the starting material, the reaction was quenched with saturated NaHCO3. The mixture was diluted with ethyl acetate, 
washed with H2O and brine, dried with anhydrous MgSO4, filtered, concentrated in vacuo. Crude compound S5 was 
dissolved in DMF, and then BnBr (1.5 eq) and NaH (5 eq) were added in the solution. The reaction was stirred at rt until 
TLC-analysis showed complete conversion of the starting material. The reaction was quenched with ice water after 
completed checking by TLC, filtered and concentrated in vacuo, purified by column chromatography. Compound S6 (442 
mg, 82% yield over two steps) was obtained as colorless syrup. Next compound S6 (442 mg, 0.78 mmol) was dissolved 
in DCM, and then DDQ was added in the solution. The reaction was stirred at rt until TLC-analysis showed complete 
conversion of the starting material. The reaction was quenched with saturated Na2S2O3 after completed checking by TLC, 
filtered and concentrated in vacuo, purified by column chromatography. Compound 36 (266 mg, 80%) was obtained as 
colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.43-7.24 (m, 10 H, aromatic H), 5.02 (d, J = 3.6 Hz, 1 H, H-1a), 4.90 (d, 
J = 11.6 Hz, 1 H, CHH), 4.73 (s, 2 H, PhCH2), 4.56 (d, J = 11.6 Hz, 1 H, CHH), 4.00-3.97 (m, 2 H, H-3a, H-4a,), 3.91-
3.85 (m, 2 H, H-5a, H-1º), 3.80 (dd, 1 H, J1 = 10.0 Hz, J2 = 3.6 Hz, H-2a), 3.74-3.70 (m, 1 H, H-6aa), 3.56-3.51 (m, 1 H, 
H-6ab), 2.07 (bs, 1 H, OH), 1.21-1.18 (bt, 6 H, 2 CH3). 
13C-APT (CDCl3, 100 MHz,) δ 137.95, 137.52 (aromatic C), 
128.53, 128.44, 128.33, 127.97, 127.94, 127.81 (aromatic CH), 96.61 (C-1a), 77.39 (C-3a), 74.49 (CH2), 73.41 (C-4a), 
72.39 (CH2), 70.74 (C-5a), 70.63 (C-1º), 62.07 (C-6a), 59.61 (C-2a), 23.20 (CH3), 21.44 (CH3). HR-MS: Calculated for 
C23H29O5N3 [M+NH4]
+: 445.24455, found: 445.24422. 
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Synthesis of 37: The reaction was carried out according to the standard procedure C. Using 
32 (78 mg, 0.12 mmol), 33 (35 mg, 0.08 mmol, 0.1 M in DCM), MPF (156 μL, 1.27 mmol) 
and TfOH (10 μL, 0.11 mmol). The reaction was stirred at -78-0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered 
and concentrated in vacuo. The products were purified by size exclusion. Compound 37 (65 
mg, 90% yield, α:β = 16:1) was obtained as a colorless syrup.1H-NMR (CDCl3, 400 MHz) δ 7.40-7.10 (m, 25 H, aromatic 
H), 5.67 (d, J = 4.0 Hz, 1 H, H-1), 5.05 (d, J = 3.6 Hz, 1 H, H-1), 5.00 (d, J = 10.4 Hz, 1 H, CHH), 4.90-4.86 (m, 3 H), 
4.74 (d, J = 10.8 Hz, 1 H, CHH), 4.55-4.43 (m, 4 H), 4.23 (d, J = 12.0 Hz, 1 H, CHH), 4.12-4.08 (m, 1 H), 4.07-3.85 (m, 
4 H), 3.79 (dd, 1 H, J1 = 10.8 Hz, J2 = 3.6 Hz), 3.70-3.62 (m, 3 H), 3.52 (bd, 1 H), 3.36-3.29 (m, 3 H), 1.28-1.24 (m, 6 H, 
2 CH3). 
13C-APT (CDCl3, 100 MHz,) δ 138.24, 138.11, 137.96, 137.93, 137.81 (aromatic C), 128.57, 128.55, 128.48, 
128.45, 128.41, 128.09, 127.97, 127.92, 127.90, 127.83, 127.74, 127.62, 127.37 (aromatic CH), 97.71 (C-1), 96.20 (C-
1), 80.79, 80.48, 78.10, 75.56, 75.04, 73.38, 73.60, 73.53, 73.46, 71.56, 71.11, 70.12, 69.15, 67.91, 63.59, 63.53, 23.37 
(CH3), 21.65 (CH3). HR-MS: Calculated for C50H56N6O9 [M+H]
+: 885.41815, found: 885.41775. 
Synthesis of 38: The reaction was carried out according to the standard procedure C. 
Using 32 (77 mg, 0.12 mmol), 34 (33 mg, 0.08 mmol, 0.1 M in DCM), DMF (156 μL, 
1.27 mmol) and TfOH (10 μL, 0.11 mmol). The reaction was stirred at -78-0 oC until 
TLC-analysis showed complete conversion of the acceptor. The reaction was quenched 
with Et3N, filtered and concentrated in vacuo. The products were purified by size 
exclusion. Compound 38 (53 mg, 78% yield, α:β = 8:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 MHz) 
δ 7.38-7.14 (m, 25 H, aromatic H), 5.55 (d, J = 3.6 Hz, 1 H, H-1), 5.05 (d, J = 4.0 Hz, 1 H, H-1), 5.00 (d, J = 10.4 Hz, 1 
H, CHH), 4.98 (d, J = 10.8 Hz, 1 H, CHH), 4.94-4.86 (m, 2 H), 4.79 (d, J = 10.8 Hz, 1 H, CHH), 4.69-4.65 (m, 2 H), 
4.55-4.42 (m, 4 H), 4.22-4.13 (m, 2 H), 4.05-4.00 (m, 1 H), 3.97-3.74 (m, 7 H), 3.66 (dd, 1 H, J1 = 10.8 Hz, J2 = 2.0 Hz), 
3.40 (dd, 1 H, J1 = 10.4 Hz, J2 = 4.0 Hz), 3.02 (dd, 1 H, J1 = 10.4 Hz, J2 = 3.6 Hz), 1.24-1.22 (m, 6 H, 2 CH3). 
13C-APT 
(CDCl3, 100 MHz,) δ 138.24, 138.07, 138.02, 138.68 (aromatic C), 128.55, 128.52, 128.49, 128.46, 128.15, 128.12, 
128.08, 127.96, 127.92, 127.83, 127.81, 127.78, 127.44 (aromatic CH), 98.77 (C-1), 96.72 (C-1), 80.15, 79.22, 78.28, 
75.80, 75.52, 75.02, 74.10, 73.74, 73.73, 71.66, 71.23, 70.37, 68.36, 68.22, 63.54, 61.32, 23.38 (CH3), 21.61 (CH3). HR-
MS: Calculated for C50H56N6O9 [M+H]
+: 885.41815, found: 885.41742. 
Synthesis of 39: The reaction was carried out according to the standard procedure C. Using 32 
(77 mg, 0.12 mmol), 35 (34 mg, 0.08 mmol, 0.1 M in DCM), DMF (156 μL, 1.27 mmol) and 
TfOH (10 μL, 0.11 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed 
complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The products were purified by size exclusion. Compound 39 (40 mg, 
57% yield, α:β = 5:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.40-
7.04 (m, 25 H, aromatic H), 5.06 (d, J = 3.6 Hz, 1 H, H-1), 4.99 (d, J = 4.0 Hz, 1 H, H-1), 4.90-4.50 (m, 8 H), 4.42-4.30 
(m, 3 H), 4.12-3.86 (m, 7 H), 3.37 (dd, 1 H, J1 = 10.8 Hz, J2 = 2.0 Hz), 3.20 (dd, 1 H, J1 = 10.4 Hz, J2 = 4.0 Hz), 2.94 (dd, 
1 H, J1 = 10.8 Hz, J2 = 2.0 Hz), 1.22-1.20 (m, 6 H, 2 CH3). 
13C-APT (CDCl3, 100 MHz,) δ 138.13, 138.11, 137.92, 137.82, 
137.60 (aromatic C), 128.81, 128.65, 128.55, 128.51, 128.45, 128.40, 128.38, 128.20, 128.17, 128.12, 127.91, 127.85, 
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127.80, 127.78, 127.67, 127.18 (aromatic CH), 98.91 (C-1), 96.83 (C-1), 80.31, 78.18, 75.82, 75.49, 74.94, 73.71, 73.52, 
73.36, 71.97, 71.06, 70.91, 69.18, 67.38, 67.08, 64.15, 59.48, 23.37 (CH3), 21.70 (CH3). HR-MS: Calculated for 
C50H56N6O9 [M+H]
+: 885.41815, found: 885.41783. 
Synthesis of 40: The reaction was carried out according to the standard procedure C. Using 
32 (77 mg, 0.12 mmol), 36 (33 mg, 0.08 mmol, 0.1 M in DCM), DMF (156 μL, 1.27 mmol) 
and TfOH (10 μL, 0.11 mmol). The reaction was stirred at -78-0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, 
filtered and concentrated in vacuo. The products were purified by size exclusion. 
Compound 40 (44 mg, 63% yield, α:β = 2:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.38-7.10 
(m, 25 H, aromatic H), 5.18 (d, J = 3.6 Hz, 1 H, H-1), 5.07-5.04 (m, 2 H), 4.84-4.75 (m, 3 H), 4.66 (d, J = 12.0 Hz, 1 H, 
CHH), 4.60-4.43 (m, 5 H), 4.17-4.02 (m), 3.95-3.78 (m), 3.73-3.47 (m), 1.21-1.19 (m, 6 H, 2 CH3). 
13C-APT (CDCl3, 100 
MHz,) δ 138.71, 138.21, 138.02, 137.94, 137.92 (aromatic C), 128.56, 128.53, 128.50, 128.42, 128.22, 128.05, 127.93, 
127.86, 127.80, 127.74 (aromatic CH), 96.69 (C-1), 96.54 (C-1), 80.58, 78.24, 75.62, 75.37, 75.19, 75.07, 74.96, 73.81, 
73.62, 73.56, 71.62, 70.73, 69.48, 68.51, 68.19, 63.98, 59.09, 23.35 (CH3), 21.54 (CH3). HR-MS: Calculated for 
C50H56N6O9 [M+H]
+: 885.41815, found: 885.41763. 
Synthesis of 41: The reaction was carried out according to the standard procedure C. Using 
32 (63 mg, 0.1 mmol), 11 (30 mg, 0.06 mmol, 0.1 M in DCM), MPF (127 μL, 1.0 mmol) and 
TfOH (10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed 
complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The products were purified by size exclusion. Compound 41 (60 mg, 
97% yield, α:β = 10:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.36-7.09 (m, 30 H, aromatic 
H), 5.74 (d, J = 4.0 Hz, 1 H, H-1), 5.11 (d, J = 10.8 Hz, 1 H, 1 CHH), 4.87-4.84 (m, 3 H), 4.77-4.73 (m, 2 H), 4.64-4.60 
(m, 2 H), 4.50-4.43 (m, 4 H), 4.24 (d, J = 12.4 Hz, 1 H, CHH), 4.08 (t, J = 9.2 Hz, 1 H, CHH), 3.94-3.63 (m, 8 H), 3.58 
(dd, 1 H, J1 = 9.2 Hz, J2 = 3.6 Hz), 3.51 (dd, 1 H, J1 = 10.8 Hz, J2 = 2.0 Hz), 3.38 (s, 3 H, OCH3), 3.33-3.27 (m, 2 H). 
13C-
APT (CDCl3, 100 MHz,) δ 138.77, 138.26, 138.18, 138.08, 138.05, 137.87 (aromatic C), 128.62, 128.57, 128.46, 128.42, 
128.31, 128.12, 127.94, 127.88, 127.83, 127.69, 127.61, 127.58, 127.37 (aromatic CH), 97.87 (C-1), 97.83 (C-1), 82.12, 
80.59, 80.25, 78.17, 75.47, 75.14, 75.05, 73.64, 73.43, 73.32, 71.50, 69.57, 69.37, 67.92, 63.41, 55.43 (CH3). HR-MS: 
Calculated for C55H59N3O10 [M+NH4]
+: 939.45387, found: 939.45366. 
Synthesis of 42: The reaction was carried out according to the standard procedure C. Using 
32 (63 mg, 0.1 mmol), 12 (30 mg, 0.06 mmol, 0.1 M in DCM), MPF (127 μL, 1.0 mmol) 
and TfOH (10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-analysis 
showed complete conversion of the acceptor. The reaction was quenched with Et3N, 
filtered and concentrated in vacuo. The products were purified by size exclusion. Compound 42 (55 mg, 92% yield, α:β 
= 3:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.36-7.09 (m, 30 H, aromatic H), 5.74 (d, J = 4.0 
Hz, 1 H, H-1), 5.11 (d, J = 10.8 Hz, 1 H, 1 CHH), 4.87-4.84 (m, 3 H), 4.77-4.73 (m, 2 H), 4.64-4.60 (m, 2 H), 4.50-4.43 
(m, 4 H), 4.24 (d, J = 12.4 Hz, 1 H, CHH), 4.08 (t, J = 9.2 Hz, 1 H, CHH), 3.94-3.63 (m, 8 H), 3.58 (dd, 1 H, J1 = 9.2 Hz, 
J2 = 3.6 Hz), 3.51 (dd, 1 H, J1 = 10.8 Hz, J2 = 2.0 Hz), 3.38 (s, 3 H, OCH3), 3.33-3.27 (m, 2 H). 
13C-APT (CDCl3, 100 
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MHz,) δ 138.77, 138.26, 138.18, 138.08, 138.05, 137.87 (aromatic C), 128.62, 128.57, 128.46, 128.42, 128.31, 128.12, 
127.94, 127.88, 127.83, 127.69, 127.61, 127.58, 127.37 (aromatic CH), 97.87 (C-1), 97.83 (C-1), 82.12, 80.59, 80.25, 
78.17, 75.47, 75.14, 75.05, 73.64, 73.43, 73.32, 71.50, 69.57, 69.37, 67.92, 63.41, 55.43 (CH3). HR-MS: Calculated for 
C55H59N3O10 [M+NH4]
+: 939.45387, found: 939.45374. 
Synthesis of 43: The reaction was carried out according to the standard procedure C. Using 32 
(63 mg, 0.1 mmol), 8 (30 mg, 0.06 mmol, 0.1 M in DCM), MPF (127 μL, 1.0 mmol) and TfOH 
(10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed complete 
conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in 
vacuo. The products were purified by size exclusion. Compound 43 (61 mg, 99% yield, α:β = 
5:1) was obtained as a colorless syrup. 1H-NMR (CDCl3, 400 MHz) δ 7.38-7.11 (m, 30 H, aromatic H), 4.94 (d, J = 3.6 
Hz, 1 H, H-1), 4.88-4.68 (m, 9 H), 4.56-4.41 (m, 4 H), 4.25-4.15 (m, 3 H), 3.93-3.83 (m, 5 H), 3.78-3.73 (m, 1 H), 3.57-
3.51 (m, 1 H), 3.38-3.34 (m, 4 H), 3.28 (dd, 1 H, J1 = 10.8 Hz, J2 = 2.0 Hz), 3.02 (dd, 1 H, J1 = 10.8 Hz, J2 = 2.0 Hz). 
13C-
APT (CDCl3, 100 MHz,) δ 138.79, 138.44, 138.26, 138.20, 137.96, 137.67 (aromatic C), 128.61, 128.57, 128.47, 128.45, 
128.40, 128.18, 128.13, 128.10, 127.91, 127.86, 127.80, 127.77, 127.59, 127.54 (aromatic CH), 98.71 (C-1), 98.61 (C-
1), 80.53, 78.24, 77.39, 75.48, 75.32, 74.98, 74.89, 73.69, 73.43, 73.28, 70.79, 68.96, 67.52, 67.36, 64.19, 55.51 (CH3). 
HR-MS: Calculated for C55H59N3O10 [M+NH4]
+: 939.45387, found: 939.45353. 
Synthesis of 44: The reaction was carried out according to the standard procedure C. Using 
32 (63 mg, 0.1 mmol), 9 (30 mg, 0.06 mmol, 0.1 M in DCM), MPF (127 μL, 1.0 mmol) and 
TfOH (10 μL, 0.1 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed 
complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The products were purified by size exclusion. Compound 44 (61 mg, 99% yield, α:β = 1.2:1) was 
obtained as a colorless syrup. HR-MS: Calculated for C55H59N3O10 [M+NH4]
+: 939.45387, found: 939.45379. 
Synthesis of 46: The reaction was carried out according to the standard procedure A and 
C. Under condition A, using 45 (106 mg, 0.15 mmol, 0.1 M in DCM), 9 (45 mg, 0.1 mmol), 
DMF (189 μL, 2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-
0 oC until TLC-analysis showed complete conversion of the acceptor. The reaction was quenched with Et3N, filtered and 
concentrated in vacuo. The products were purified by size exclusion. Compound 46 (67 mg, quent, α:β = 2:1) was obtained 
as a colorless syrup. Under condition C, using 45 (106 mg, 0.15 mmol, 0.1 M in DCM), 9 (45 mg, 0.1 mmol), MPFF (189 
μL, 2.4 mmol) and TfOH (13 μL, 1.59 mmol). The reaction was stirred at -78-0 oC until TLC-analysis showed complete 
conversion of the acceptor. The reaction was quenched with Et3N, filtered and concentrated in vacuo. The products were 
purified by size exclusion. Compound 46 (67 mg, quent, α:β = 5:1) was obtained as a colorless syrup. 
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Chinese Summary 
中文总结 
本论文围绕课题“添加剂控制的立体选择性合成1,2-顺势寡糖”，总结了博士期间的工作。
在本论文中，应用添加剂（N,N-二甲基甲酰胺（DMF），三苯基氧化膦（Ph3P=O），N-甲
基甲酰苯胺（MPF）和具有相似活性的单一芳香基团保护的单糖合成一系列顺式多糖。其
中添加剂DMF主要应用于芳香基保护的葡萄糖给体和仲醇受体之间的耦合。添加剂
Ph3P=O主要应用于活性更高的伯醇受体。而由于添加剂MPF与给体生成活性较高的中间
体，所以其主要应用于活性更低的给体与受体，例如2-叠氮去氧糖。 
在第一章中，总结了添加剂在糖苷化中的应用和发展。一些添加剂，如 DMF，氧化
膦试剂和季铵盐类添加剂，已经被广泛研究并应用于糖苷化反应中调控选择性。许多的机
理研究也已经证明添加剂与糖给体形成的中间加成物具有重要的功能。尽管在第一章描述
中有许多非常成功的添加剂，但是发展新的添加剂和糖苷化条件仍然十分重要。因为目前
仍缺乏具有普适性好且简单高效的添加剂或糖苷化方法，并且对于选择性合成多链寡糖仍
非常具有挑战性。 
 
图 1. 第二，三和四章中的目标分子。 
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第二章描述了添加剂控制下 α-葡萄寡糖的合成。结合添加剂 DMF 和 Ph3P=O，高效
选择性的合成了目标分子，并且使用单一芳香基保护基团（Bn，PMB，Nap）使底物反应
活性保持一致。应用该策略，对 α-(1,4)-直链葡萄六糖和结核杆菌衍生的支链 α-葡萄九糖
被进行了高效选择性合成。在第三章中，应用同样的策略，对衍生自病原真菌 Aspergillus 
fumigatus的 α-(1,3)-直链葡萄八糖进行了高效选择性合成。 
第四章进一步描述了 α-(1,2)-葡萄寡糖的合成。应用 DMF添加剂，对一个 α-(1,2)-葡
萄四糖和一个衍生于 Enterococcus faecalis LTAs 的含有丙氨酸的 α-(1,2)-葡萄二糖进行了
选择性合成。研究发现，在 DMF条件下，合成一些较短的 α-(1,2)-葡萄寡糖具有很高的选
择性。但是对于较长的 α-(1,2)-葡萄寡糖，选择性较差，可能由于较长的 α-(1,2)-葡萄寡糖
受体空间结构复杂导致位阻增加，降低了反应活性和选择性。 
在成功合成葡萄寡糖后，第五章转向了顺势半乳寡糖的合成研究。研究中发现，α-
(1,4)-半乳糖苷的合成非常困难。经过筛选，在高温条件下，用添加剂 TMSI-Ph3P=O调控
合成 α-(1,4)-半乳糖苷能得到较好的选择性。并且此条件具有较好的底物扩展性。 
 
图 2. 用 TMSI-Ph3P=O调控糖苷化（第五章）。 
第六章描述了一个新的添加剂 N-甲基甲酰苯胺（MPF），此添加剂用于合成活性较低
的 2-氨基去氧寡糖。在添加剂MPF调控下，对一个直链 α-(1,4)-氨基葡萄四糖进行了高效
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高选择性合成。然后，采用[2+2+2]的合成策略，在添加剂MPF调控下对直链 Pel六糖进
行选择性合成。 
 
图 3. Pel六糖分子的合成（第六章）。 
第七章对本论文进行了总结和对未来的展望。目前添加剂调控的糖苷化主要应用于 α-
糖苷的合成，期望未来发展出新的添加剂并应用于合成 β-糖苷。 
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